


**CUMULATIVE
SUPPLEMENT 7
JULY 2021**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2021

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41th EDITION

**Cumulative Supplement 7
July 2021**

CONTENTS

	<i>PAGE</i>
Contents	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT	vi
1.3 APPLICANT NAME CHANGES	vii
1.4 LEVOTHYROXINE SODIUM	viii
1.5 AVAILABILITY OF THE EDITION.....	ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xi
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

**CUMULATIVE SUPPLEMENT 7
JULY 2021**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRRA) of any changes or corrections. The DOBPRRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
AKORN INC (AKORN)	AKORN OPERATING CO LLC (AKORN)
AKORN INC (AKORN INC)	AKORN OPERATING CO LLC (AKORN)
PADDOCK LABORATORIES LLC (PADDOCK LABS LLC)	PADAGIS US LLC (PADAGIS US)

PADDICK LABORATORIES LLC (PADDICK LLC)	PADAGIS US LLC (PADAGIS US)
PERRIGO CO OF TENNESSEE INC (PERRIGO CO)	PADAGIS US LLC (PADAGIS US)
PERRIGO CO TENNESSEE INC (PERRIGO CO TENNESSEE)	PADAGIS US LLC (PADAGIS US)
PERRIGO NEW YORK INC (PERRIGO NEW YORK)	PADAGIS US LLC (PADAGIS US)
PERRIGO PHARMA INTERNATIONAL DAC (PERRIGO PHARMA INTL)	PADAGIS US LLC (PADAGIS US)
PERRIGO UK FINCO LTD PARTNERSHIP (PERRIGO UK FINCO)	PADAGIS ISRAEL PHARMACEUTICALS LTD (PADAGIS ISRAEL)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2020</u>	<u>MAR 2021</u>	<u>JUN 2021</u>	<u>SEP 2021</u>	<u>DEC 2021</u>
DRUG PRODUCTS	20478	20726	20916		
LISTED SINGLE SOURCE	2659 (13.0%)	2671 (12.9%)	2675 (12.8%)		
MULTISOURCE	17819 (87.0%)	18055 (87.1%)	18241 (87.2%)		
THERAPEUTICALLY EQUIVALENT	17746 (86.7%)	17990 (86.8%)	18175 (86.9%)		
NOT THERAPEUTICALLY EQUIVALENT	73 (0.4%)	65 (0.3%)	66 (0.3%)		
EXCEPTIONS ⁴	54 (0.3%)	54 (0.3%)	54 (0.3%)		
NEW MOLECULAR ENTITIES APPROVED	22	29	33		
NUMBER OF APPLICANTS	1185	1184	1182		

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

	TABLET;ORAL	ABIRATERONE ACETATE					
AB	AMNEAL PHARMS	500MG	A208327	002	Dec 23, 2020	Apr NEWA	
AB	QILU	500MG	A212462	002	Jun 25, 2021	Jun NEWA	

ACARBOSE

	TABLET;ORAL	ACARBOSE					
AB	EMCURE PHARMS LTD	25MG	A202271	001	Feb 07, 2012	Apr CMFD	
AB		50MG	A202271	002	Feb 07, 2012	Apr CMFD	
AB		100MG	A202271	003	Feb 07, 2012	Apr CMFD	

ACETAMINOPHEN

	POWDER;INTRAVENOUS	ACETAMINOPHEN					
+ @	MYLAN LABS LTD	1GM/VIAL	N206610	001	Jan 15, 2021	Jan NEWA	
	SOLUTION;INTRAVENOUS	ACETAMINOPHEN					
+! B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)		N204957	001	Feb 18, 2021	Feb NEWA	
+!	1GM/100ML (10MG/ML)		N204957	002	Feb 18, 2021	Feb NEWA	

ACETAMINOPHEN; BUTALBITAL

	TABLET;ORAL	BUTALBITAL AND ACETAMINOPHEN					
AA	ALVOGEN	300MG;50MG	A207635	001	Jun 05, 2017	Jun CAHN	
AA		325MG;50MG	A205120	001	Oct 30, 2015	Jun CAHN	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

	CAPSULE;ORAL	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AA	XSPIRE PHARMA	300MG;50MG;40MG	A206615	001	Aug 04, 2017	Feb CAHN	
	TABLET;ORAL	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AA	ALVOGEN	325MG;50MG;40MG	A204984	001	Jan 10, 2017	Jun CAHN	
@ GRANULES		325MG;50MG;40MG	A040864	001	Dec 01, 2008	Apr CAHN	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

	CAPSULE;ORAL	BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE					
AB	NOSTRUM LABS INC	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	Jan CAHN	

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

	CAPSULE;ORAL	TREZIX					
>D>	WRASER PHARMS LLC	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	Jul CAHN	
>A>	XSPIRE PHARMA	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	Jul CAHN	

ACETAMINOPHEN; CODEINE PHOSPHATE

	TABLET;ORAL	ACETAMINOPHEN AND CODEINE PHOSPHATE					
@ VINTAGE		300MG;15MG	A089990	001	Sep 30, 1988	Apr DISC	
@		300MG;30MG	A089805	001	Sep 30, 1988	Apr DISC	
@		300MG;60MG	A089828	001	Sep 30, 1988	Apr DISC	
AA		300MG;60MG	A089828	001	Sep 30, 1988	Apr CAHN	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

	TABLET;ORAL	ANEXSIA 5/325					
AA	! SPECGX LLC	325MG;5MG	A040409	001	Oct 20, 2000	Apr CHRS	
	ANEXSIA 7.5/325						
AA	! SPECGX LLC	325MG;7.5MG	A040405	001	Sep 08, 2000	Apr CHRS	
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	! SPECGX LLC	325MG;10MG	A040400	001	Jul 26, 2000	Apr CHRS	
	NORCO						
>D>	@ APIL	325MG;2.5MG	A040148	004	Jul 07, 2014	Apr DISC	
>A>	@	325MG;5MG	A040099	001	Jun 25, 1997	Apr DISC	
>A>	@	325MG;5MG	A040148	005	Jul 07, 2014	Apr DISC	
>A>	@	325MG;7.5MG	A040148	003	Sep 12, 2000	Apr DISC	

TABLET;ORAL

NORCO

@

325MG;10MG

A040148 001 Feb 14, 1997 Apr DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDETABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	CHARTWELL	325MG;5MG	A207834	001	Aug 15, 2019	Jan CAHN
AA		325MG;7.5MG	A207834	002	Aug 15, 2019	Jan CAHN
AA		325MG;10MG	A207834	003	Aug 15, 2019	Jan CAHN

ROXICET

@ HIKMA

325MG;5MG

A087003 001

Jan DISC

ACETAZOLAMIDECAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB	ACCORD HLTHCARE	500MG	A207659	001	Oct 18, 2018	Apr CMFD
AB	! INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Jun CAHN

TABLET;ORAL

ACETAZOLAMIDE

AB	APPCO	125MG	A211372	001	Feb 22, 2021	Feb NEWA
AB		250MG	A211372	002	Feb 22, 2021	Feb NEWA

ACETYLCYSTEINEINJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

AP	EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Apr NEWA
----	--------------	---------------------	---------	-----	--------------	----------

ACLIDINIUM BROMIDEPOWDER, METERED;INHALATION

TUDORZA PRESSAIR

+! ASTRazeneca 0.4MG/INH

N202450 001 Jul 23, 2012 Feb CAHN

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATEPOWDER, METERED;INHALATION

DUAKLIR PRESSAIR

+!	ASTRazeneca	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Jun CHRS
+		0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Jun CRLD
		0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Feb CAHN

ACYCLOVIROINTMENT;TOPICAL

ACYCLOVIR

@	ANDA REPOSITORY	5%	A206437	001	Jul 31, 2017	Jun DISC
AB	MACLEODS PHARMS LTD	5%	A212444	001	May 19, 2021	May NEWA

SUSPENSION;ORAL

ACYCLOVIR

>D> AB	VISTAPHARM	200MG/5ML	A213951	001	Jan 11, 2021	Jul DISC
>A>	@	200MG/5ML	A213951	001	Jan 11, 2021	Jul DISC
AB		200MG/5ML	A213951	001	Jan 11, 2021	Jan NEWA

ACYCLOVIR SODIUMINJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	NAMIGEN LLC	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Jun CAHN
AP	ZYDUS PHARMS	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CHRS
AP	!	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CPOT

ADAPALENE; BENZOYL PEROXIDEGEL;TOPICAL

EPIDUO FORTE

+! GALDERMA LABS 0.3%;2.5%

N207917 001 Jul 15, 2015 Feb CTEC

ADENOSINESOLUTION;INTRAVENOUS

ADENOSINE

AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Feb CMFD
AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Feb CMFD

ALPROSTADIL

	INJECTABLE; INJECTION					
	CAVERJECT					
AP	+ @ PFIZER	0.005MG/VIAL	N020379	003	Jun 27, 1996	Jan CAHN
AP	+	0.01MG/VIAL	N020379	001	Jul 06, 1995	Jan CAHN
AP	+!	0.02MG/VIAL	N020379	002	Jul 06, 1995	Jan CAHN
AP	+!	0.04MG/VIAL	N020379	004	May 19, 1997	Jan CAHN
	CAVERJECT IMPULSE					
	PFIZER	0.01MG/VIAL	N021212	001	Jun 11, 2002	Jan CAHN
		0.02MG/VIAL	N021212	002	Jun 11, 2002	Jan CAHN
	PROSTIN VR PEDIATRIC					
AP	+! PFIZER	0.5MG/ML	N018484	001		Jan CAHN

AMANTADINE HYDROCHLORIDE

	SYRUP; ORAL					
	AMANTADINE HYDROCHLORIDE					
	@ WOCKHARDT BIO AG	50MG/5ML	A075060	001	Dec 24, 1998	Jan DISC
	TABLET; ORAL					
	AMANTADINE HYDROCHLORIDE					
	@ INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017	Jan DISC
	TABLET, EXTENDED RELEASE; ORAL					
	OSMOLEX ER					
	+ ADAMAS PHARMA	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan CAHN
	+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan CAHN
	+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan CAHN
	+ @	EQ 258MG BASE	N209410	003	Feb 16, 2018	May DISC
	+!	EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan CAHN
	+ ADAMAS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan CAHN
	+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan CAHN
	+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan CAHN
	+!	EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan CAHN

AMINOCAPROIC ACID

	SOLUTION; ORAL					
	AMICAR					
AA	+! AKORN	0.25GM/ML	N015230	002		Feb CPOT
AA	+!	1.25GM/5ML	N015230	002		Feb CDFR
	AMINOCAPROIC ACID					
>D>	AA AIRIS PHARMA PVT LTD	0.25GM/ML	A213825	001	Apr 08, 2021	Jul CAHN
AA		0.25GM/ML	A213825	001	Apr 08, 2021	Apr NEWA
AA	AMNEAL	0.25GM/ML	A212780	001	Aug 23, 2019	Feb CPOT
AA		1.25GM/5ML	A212780	001	Aug 23, 2019	Feb CDFR
>A>	AA BELCHER	0.25GM/ML	A213825	001	Apr 08, 2021	Jul CAHN
AA	LEADING PHARMA LLC	0.25GM/ML	A214140	001	Jan 26, 2021	Feb CPOT
AA		1.25GM/5ML	A214140	001	Jan 26, 2021	Feb CDFR
AA	TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020	Feb CPOT
AA		1.25GM/5ML	A212494	001	Aug 11, 2020	Feb CDFR
AA	VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020	Feb CPOT
AA		1.25GM/5ML	A212814	001	Feb 26, 2020	Feb CDFR
	SYRUP; ORAL					
	AMINOCAPROIC ACID					
AA	LEADING PHARMA LLC	1.25GM/5ML	A214140	001	Jan 26, 2021	Jan NEWA
	TABLET; ORAL					
	AMINOCAPROIC ACID					
AB	EDENBRIDGE PHARMS	500MG	A212110	001	Jun 14, 2021	Jun NEWA
AB	LEADING PHARMA LLC	500MG	A213928	001	Feb 12, 2021	Feb NEWA
AB		1GM	A213928	002	Feb 12, 2021	Feb NEWA

AMIODARONE HYDROCHLORIDE

	TABLET; ORAL					
	AMIODARONE HYDROCHLORIDE					
AB	RUBICON	100MG	A078578	002	Feb 26, 2021	Feb NEWA
AB		400MG	A078578	003	Feb 26, 2021	Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE

	TABLET; ORAL					
	AMITRIPTYLINE HYDROCHLORIDE					
AB	MANKIND PHARMA	10MG	A213999	001	Feb 19, 2021	Feb NEWA
AB		25MG	A213999	002	Feb 19, 2021	Feb NEWA
AB		50MG	A213999	003	Feb 19, 2021	Feb NEWA
AB		75MG	A213999	004	Feb 19, 2021	Feb NEWA

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB		100MG	A213999	005	Feb 19, 2021	Feb NEWA
AB		150MG	A213999	006	Feb 19, 2021	Feb NEWA
@	MYLAN	10MG	A086009	002	Jun DISC	
@		25MG	A086009	003	Jun DISC	
@		50MG	A086009	001	Jun DISC	
@		75MG	A086009	004	Jun DISC	
@		100MG	A086009	005	Jun DISC	
@		150MG	A086009	006	Jun DISC	
AB	UNICHEM	10MG	A214548	001	May 19, 2021	May NEWA
AB		25MG	A214548	002	May 19, 2021	May NEWA
AB		50MG	A214548	003	May 19, 2021	May NEWA
AB		75MG	A214548	004	May 19, 2021	May NEWA
AB		100MG	A214548	005	May 19, 2021	May NEWA
AB		150MG	A214548	006	May 19, 2021	May NEWA

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

@	WOCKHARDT	EQ 2.5MG BASE	A078500	001	Sep 06, 2007	Jan DISC
@		EQ 5MG BASE	A078500	002	Sep 06, 2007	Jan DISC
@		EQ 10MG BASE	A078500	003	Sep 06, 2007	Jan DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

@	JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450	001	May 15, 2017	Jun DISC
@		EQ 5MG BASE;40MG	A207450	002	May 15, 2017	Jun DISC
@		EQ 10MG BASE;20MG	A207450	003	May 15, 2017	Jun DISC
@		EQ 10MG BASE;40MG	A207450	004	May 15, 2017	Jun DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>A>	AP	METHODIST	3.75mCi-260mCi/ML	A215083	001	Jul 09, 2021	Jul NEWA
	AP	NUKEMED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Jan CAHN

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB	CHARTWELL	250MG	A062058	001		Jun CAHN
AB		500MG	A062058	002		Jun CAHN

AMOXIL

AB	US ANTIBIOTICS	250MG	A062216	001		May CAHN
AB		500MG	A062216	004		May CAHN

FOR SUSPENSION;ORAL

AMOXIL

AB	US ANTIBIOTICS	50MG/ML	A062226	005		May CAHN
AB		125MG/5ML	A062226	001		May CAHN
+ @		200MG/5ML	N050760	001	Apr 15, 1999	May CAHN
AB		250MG/5ML	A062226	002		May CAHN
+ @		400MG/5ML	N050760	002	Apr 15, 1999	May CAHN

LAROTID

AB	US ANTIBIOTICS	125MG/5ML	A062226	003		May CAHN
AB		250MG/5ML	A062226	004		May CAHN

TABLET;ORAL

AMOXIL

+ @	US ANTIBIOTICS	500MG	N050754	002	Jul 10, 1998	May CAHN
+ @		875MG	N050754	001	Jul 10, 1998	May CAHN

TABLET, CHEWABLE;ORAL

AMOXIL

+ @	US ANTIBIOTICS	125MG	N050542	002		May CAHN
@		200MG	N050761	001	Apr 15, 1999	May CAHN
+ @		250MG	N050542	001		May CAHN
@		400MG	N050761	002	Apr 15, 1999	May CAHN

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL
 >D> LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN
 >D> @ ANI PHARMS 500MG,N/A,N/A;N/A;N/A,500MG,N/A;N/A,N/ A200218 001 Aug 30, 2013 Jul CTNA
 A,30MG
 >D> AB ! RISING 500MG,N/A,N/A;N/A;N/A,500MG,N/A;N/A,N/ A206006 001 Oct 07, 2016 Jul CTNA
 A,30MG
 >D> AB SANDOZ INC 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ A202588 001 Mar 04, 2014 Jul CTNA
 A,30MG
 >D> PREVPAC
 >D> + @ TAKEDA PHARMS USA 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ N050757 001 Dec 02, 1997 Jul CTNA
 A,30MG
 CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL
 >A> LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)
 >A> @ ANI PHARMS 500MG;500MG;30MG A200218 001 Aug 30, 2013 Jul CTNA
 >A> AB ! RISING 500MG;500MG;30MG A206006 001 Oct 07, 2016 Jul CTNA
 >A> AB SANDOZ INC 500MG;500MG;30MG A202588 001 Mar 04, 2014 Jul CTNA
 >A> PREVPAC (COPACKAGED)
 >A> + @ TAKEDA PHARMS USA 500MG;500MG;30MG N050757 001 Dec 02, 1997 Jul CTNA

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN
 + @ CUMBERLAND PHARMS 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ N050824 001 Feb 08, 2011 May DISC
 A,20MG

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL
 AMOXICILLIN AND CLAVULANATE POTASSIUM
 AB MICRO LABS LTD INDIA 200MG/5ML;EQ 28.5MG BASE/5ML A205187 001 May 21, 2021 May NEWA
 AB 400MG/5ML;EQ 57MG BASE/5ML A205187 002 May 21, 2021 May NEWA
 AUGMENTIN '125'
 AB + US ANTIBIOTICS 125MG/5ML;EQ 31.25MG BASE/5ML N050575 001 Aug 06, 1984 May CAHN
 AUGMENTIN '200'
 + @ US ANTIBIOTICS 200MG/5ML;EQ 28.5MG BASE/5ML N050725 001 May 31, 1996 May CAHN
 AUGMENTIN '250'
 AB +! US ANTIBIOTICS 250MG/5ML;EQ 62.5MG BASE/5ML N050575 002 Aug 06, 1984 May CAHN
 AUGMENTIN '400'
 + @ US ANTIBIOTICS 400MG/5ML;EQ 57MG BASE/5ML N050725 002 May 31, 1996 May CAHN
 AB + US ANTIBIOTICS 600MG/5ML;EQ 42.9MG BASE/5ML N050755 001 Jun 22, 2001 May CAHN
 TABLET;ORAL
 AUGMENTIN '250'
 + @ US ANTIBIOTICS 250MG;EQ 125MG BASE N050564 001 Aug 06, 1984 May CAHN
 AUGMENTIN '500'
 + @ US ANTIBIOTICS 500MG;EQ 125MG BASE N050564 002 Aug 06, 1984 May CAHN
 AUGMENTIN '875'
 AB + US ANTIBIOTICS 875MG;EQ 125MG BASE N050720 001 Feb 13, 1996 May CAHN
 TABLET, CHEWABLE;ORAL
 AUGMENTIN '125'
 + @ US ANTIBIOTICS 125MG;EQ 31.25MG BASE N050597 001 Jul 22, 1985 May CAHN
 AUGMENTIN '200'
 + @ US ANTIBIOTICS 200MG;EQ 28.5MG BASE N050726 001 May 31, 1996 May CAHN
 AUGMENTIN '250'
 + @ US ANTIBIOTICS 250MG;EQ 62.5MG BASE N050597 002 Jul 22, 1985 May CAHN
 AUGMENTIN '400'
 + @ US ANTIBIOTICS 400MG;EQ 57MG BASE N050726 002 May 31, 1996 May CAHN
 TABLET, EXTENDED RELEASE;ORAL
 AUGMENTIN XR
 + @ US ANTIBIOTICS 1GM;EQ 62.5MG BASE N050785 001 Sep 25, 2002 May CAHN

AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE
 AB RHODES PHARMS 2.5MG;2.5MG;2.5MG;2.5MG A213111 003 Jan 13, 2021 Jan NEWA
 AB 3.75MG;3.75MG;3.75MG;3.75MG A213111 005 Jan 13, 2021 Jan NEWA
 AB 5MG;5MG;5MG;5MG A213111 006 Jan 13, 2021 Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A213709	001	Apr 22, 2021	Apr NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213709	002	Apr 22, 2021	Apr NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A213709	003	Apr 22, 2021	Apr NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213709	004	Apr 22, 2021	Apr NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213709	005	Apr 22, 2021	Apr NEWA
AB		5MG;5MG;5MG;5MG	A213709	006	Apr 22, 2021	Apr NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213709	007	Apr 22, 2021	Apr NEWA
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A213111	001	Jan 13, 2021	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213111	002	Jan 13, 2021	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213111	004	Jan 13, 2021	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213111	007	Jan 13, 2021	Jan NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	@ GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021	Jun DISC
AA	@	5MG	A212186	001	Jan 27, 2021	Jan NEWA
AA	@	10MG	A212186	002	Jan 27, 2021	Jun DISC
AA	@ MAYNE PHARMA	10MG	A212186	002	Jan 27, 2021	Jan NEWA
AA	@ NOVAST LABS	5MG	A213898	001	Jul 14, 2020	Jan DISC
AA	@	10MG	A213898	002	Jul 14, 2020	Jan DISC
AA	SPECGX LLC	5MG	A213763	001	Aug 24, 2020	Mar DISC
AA		10MG	A213763	002	Aug 24, 2020	Mar DISC
AA	SUN PHARM INDs INC	5MG	A213583	001	Jan 22, 2021	Jan NEWA
AA		10MG	A213583	002	Jan 22, 2021	Jan NEWA
TABLET, ORALLY DISINTEGRATING;ORAL EVEKEO ODT						
>D>	+ ARBOR PHARMS LLC	2.5MG	N209905	005	Apr 16, 2021	Jul DISC
>A>	+ @	2.5MG	N209905	005	Apr 16, 2021	Jul DISC
>A>	+	2.5MG	N209905	005	Apr 16, 2021	Apr NEWA
>A>	+!	20MG	N209905	004	Jan 30, 2019	Apr CHRS

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP	@ HQ SPECLT PHARMA	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993	Mar CAHN
AP		EQ 250MG BASE/VIAL	A062772	006	Apr 15, 1993	Mar CAHN
AP		EQ 500MG BASE/VIAL	A062772	007	Apr 15, 1993	Mar CAHN
AP	@	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993	Mar CAHN
AP	@	EQ 1GM BASE/VIAL	A062772	001	Apr 15, 1993	Mar CAHN
AP	@	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993	Mar CAHN
AP	@	EQ 2GM BASE/VIAL	A062772	003	Apr 15, 1993	Mar CAHN
AP	@	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993	Mar CAHN
AP		EQ 10GM BASE/VIAL	A063142	001	Apr 15, 1993	Mar CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP	HQ SPECLT PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065176	001	Nov 30, 2005	Mar CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065176	002	Nov 30, 2005	Mar CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065188	001	Nov 25, 2005	Mar CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

	@ US ANTIBIOTICS	1MG	A090732	001	Jun 28, 2010	May CAHN
--	------------------	-----	---------	-----	--------------	----------

ANIDULAFUNGIN

POWDER;INTRAVENOUS

ERAXIS

>D>	+! VICURON	50MG/VIAL	N021632	001	Feb 17, 2006	Jul CAHN
>D>	+!	100MG/VIAL	N021632	002	Nov 14, 2006	Jul CAHN
>A>	+! VICURON HOLDINGS	50MG/VIAL	N021632	001	Feb 17, 2006	Jul CAHN
>A>	+!	100MG/VIAL	N021632	002	Nov 14, 2006	Jul CAHN

APIXABAN

TABLET;ORAL

APIXABAN

>A> AB	BRECKENRIDGE	2.5MG	A209845	001	Jul 26, 2021	Jul NEWA
>A> AB		5MG	A209845	002	Jul 26, 2021	Jul NEWA

APREMILAST

TABLET;ORAL

APREMILAST

AB	AMNEAL	10MG	A211782	001	Jun 30, 2021	Jun NEWA
AB		20MG	A211782	002	Jun 30, 2021	Jun NEWA
AB		30MG	A211782	003	Jun 30, 2021	Jun NEWA
AB	UNICHEM	10MG	A211819	001	Feb 17, 2021	Feb NFTG
AB		20MG	A211819	002	Feb 17, 2021	Feb NFTG
AB		30MG	A211819	003	Feb 17, 2021	Feb NFTG

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

AN	AXAR PHARMS INC	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Jun NFTG
AN	CIPPLA	EQ 0.015MG BASE/2ML	A207306	001	Jun 22, 2021	Jun NFTG
AN	GLENMARK PHARMS LTD	EQ 0.015MG BASE/2ML	A213132	001	Jun 22, 2021	Jun NFTG

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP	CAPLIN	50MG/50ML (1MG/ML)	A214235	001	Jan 21, 2021	Jan NFTG
	INJECTABLE;INTRAVENOUS					
	ARGATROBAN IN SODIUM CHLORIDE					
+ @	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	May DISC
	SOLUTION;INTRAVENOUS					
	ARGATROBAN IN SODIUM CHLORIDE					
+!	ACCORD HLTHCARE	50MG/50ML (1MG/ML)	N212035	001	Jun 07, 2021	Jun NEWA

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP	@ AMNEAL	1MG/ML	A210739	001	Jan 25, 2021	May DISC
		1MG/ML	A210739	001	Jan 25, 2021	Jan NEWA
	@ INGENUS PHARMS LLC	2MG/ML	A209315	002	Jan 14, 2021	Feb DISC
AP		2MG/ML	A209315	002	Jan 14, 2021	Jan NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004	Feb CAIN
----	-------------------	-----------------------------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

ASENAPINE MALEATE

TABLET;SUBLINGUAL

ASENAPINE MALEATE

>A> AB	ALEMBIC PHARMS LTD	EQ 2.5MG BASE	A206098	003	Jul 19, 2021	Jul NEWA
AB	BRECKENRIDGE	EQ 5MG BASE	A205960	003	Mar 08, 2021	Feb NEWA

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

NORGESIC

+ @ BAUSCH 385MG;30MG;25MG

N013416 003 Oct 27, 1982 May CAHN

NORGESIC FORTE

+ @ BAUSCH 770MG;60MG;50MG

N013416 004 Oct 27, 1982 May CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

>D> AB	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jul CHRS
>A>	!	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jul CHRS
>D> AB	! SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jul DISC

TABLET;ORAL CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE				
>A>	@ 325MG;200MG;16MG	A040118	001 Apr 16, 1996	Jul DISC
<u>ASPIRIN; DIPYRIDAMOLE</u>				
CAPSULE, EXTENDED RELEASE;ORAL ASPIRIN AND DIPYRIDAMOLE				
>A> AB	@ IANNETT CO INC 25MG;200MG MICRO LABS 25MG;200MG	A204552 A209929	001 Mar 20, 2019 001 Aug 11, 2021	Apr DISC Jul NEWA
<u>ASPIRIN; HYDROCODONE BITARTRATE</u>				
TABLET;ORAL HYDROCODONE BITARTRATE AND ASPIRIN				
LGM PHARMA 500MG;5MG		A205479	001 May 28, 2021	May NEWA
<u>ASPIRIN; OXYCODONE HYDROCHLORIDE</u>				
TABLET;ORAL OXYCODONE AND ASPIRIN				
>D> AA	MAYNE PHARMA INC 325MG;4.8355MG	A091670	001 Mar 16, 2011	Jul DISC
>A>	@ 325MG;4.8355MG	A091670	001 Mar 16, 2011	Jul DISC
<u>ATAZANAVIR SULFATE</u>				
CAPSULE;ORAL ATAZANAVIR SULFATE				
AB	LAURUS LABS LTD EQ 150MG BASE	A212579	001 Apr 30, 2021	Apr NEWA
AB	EQ 200MG BASE	A212579	002 Apr 30, 2021	Apr NEWA
AB	EQ 300MG BASE	A212579	003 Apr 30, 2021	Apr NEWA
<u>ATOMOXETINE HYDROCHLORIDE</u>				
CAPSULE;ORAL ATOMOXETINE HYDROCHLORIDE				
AB	HETERO LABS LTD V 10MG	A202682	001 Mar 11, 2021	Mar NEWA
AB	18MG	A202682	002 Mar 11, 2021	Mar NEWA
AB	25MG	A202682	003 Mar 11, 2021	Mar NEWA
AB	40MG	A202682	004 Mar 11, 2021	Mar NEWA
AB	60MG	A202682	005 Mar 11, 2021	Mar NEWA
AB	80MG	A202682	006 Mar 11, 2021	Mar NEWA
AB	100MG	A202682	007 Mar 11, 2021	Mar NEWA
@ MYLAN 10MG		A079021	001 Feb 18, 2021	Feb DISC
AB	10MG	A079021	001 Feb 18, 2021	Feb NEWA
AB	18MG	A079021	002 Feb 18, 2021	Feb DISC
AB	18MG	A079021	002 Feb 18, 2021	Feb NEWA
AB	25MG	A079021	003 Feb 18, 2021	Feb DISC
AB	25MG	A079021	003 Feb 18, 2021	Feb NEWA
AB	40MG	A079021	004 Feb 18, 2021	Feb DISC
AB	40MG	A079021	004 Feb 18, 2021	Feb NEWA
AB	60MG	A079021	005 Feb 18, 2021	Feb DISC
AB	60MG	A079021	005 Feb 18, 2021	Feb NEWA
AB	80MG	A079021	006 Feb 18, 2021	Feb DISC
AB	80MG	A079021	006 Feb 18, 2021	Feb NEWA
AB	100MG	A079021	007 Feb 18, 2021	Feb DISC
AB	100MG	A079021	007 Feb 18, 2021	Feb NEWA
<u>ATORVASTATIN CALCIUM</u>				
TABLET;ORAL ATORVASTATIN CALCIUM				
AB	ALKEM LABS LTD EQ 10MG BASE	A209288	001 Dec 21, 2018	Jan CAHN
AB	EQ 20MG BASE	A209288	002 Dec 21, 2018	Jan CAHN
AB	EQ 40MG BASE	A209288	003 Dec 21, 2018	Jan CAHN
AB	EQ 80MG BASE	A209288	004 Dec 21, 2018	Jan CAHN
>A> AB	DR REDDYS LABS LTD EQ 10MG BASE	A214659	001 Jul 14, 2021	Jul NEWA
>A> AB	EQ 20MG BASE	A214659	002 Jul 14, 2021	Jul NEWA
>A> AB	EQ 40MG BASE	A214659	003 Jul 14, 2021	Jul NEWA
>A> AB	EQ 80MG BASE	A214659	004 Jul 14, 2021	Jul NEWA
<u>ATORVASTATIN CALCIUM; EZETIMIBE</u>				
TABLET;ORAL EZETIMIBE AND ATORVASTATIN CALCIUM				
>D>	@ SCOV3 EQ 10MG BASE;10MG	A206084	001 Apr 26, 2017	Jul CAHN
>A>	@ EQ 10MG BASE;10MG	A206084	001 Apr 26, 2017	Jul CAHN
>D>	@ EQ 20MG BASE;10MG	A206084	002 Apr 26, 2017	Jul CAHN
>A>	@ EQ 20MG BASE;10MG	A206084	002 Apr 26, 2017	Jul CAHN

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

>D>	@	EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Jul CAHN
>A>	@	EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Jul CAHN
>D>	@	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Jul CAHN
>A>	@	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Jul CAHN
	LIPTRUZET					
+ @ ORGANON		EQ 10MG BASE;10MG	N200153	001	May 03, 2013	Feb CAHN
+ @		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	Feb CAHN
+ @		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	Feb CAHN
+ @		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	Feb CAHN

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	BIONPHARMA INC	750MG/5ML	A212918	001	Mar 30, 2021	Mar NEWA
----	----------------	-----------	---------	-----	--------------	----------

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

>A> AP	ACCORD HLTHCARE	0.25MG/5ML (0.05MG/ML)	A212868	001	Jul 26, 2021	Jul NFTG
>A> AP		0.5MG/5ML (0.1MG/ML)	A212868	002	Jul 26, 2021	Jul NFTG
>A> AP		1MG/10ML (0.1MG/ML)	A212868	003	Jul 26, 2021	Jul NEWA
>D>	+! HOSPIRA	1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Jul CTEC
>A> AP	+!	1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Jul CTEC
AP	+!	1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Mar CTEC
AP	INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	A212461	001	Oct 05, 2020	Mar CTEC
	SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL					
	ATROPINE SULFATE					
AP	ACCORD HLTHCARE	8MG/20ML (0.4MG/ML)	A213424	001	Mar 19, 2021	Mar NFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	WINDER LABS LLC	0.025MG;2.5MG	A211362	001	Jan 27, 2021	Jan NEWA
----	-----------------	---------------	---------	-----	--------------	----------

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

+ @ MYLAN		0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Jan CAHN
-----------	--	-------------------	---------	-----	--------------	----------

AVAPRITINIB

TABLET;ORAL

AYVAKIT

+ BLUEPRINT MEDICINES	25MG	N212608	004	Jun 16, 2021	Jun NEWA
+	50MG	N212608	005	Jun 16, 2021	Jun NEWA

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;INTRAVENOUS

AVYCAZ

+! ALLERGAN		EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Jan CDFR
-------------	--	------------------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

ASTEPRO

>D> AB	+! MYLAN SPECIALITY LP	EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009	Jul DISC
>A>	+ @	0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Jul DISC

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	Feb CMFD
----	------	-------------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

AZITHROMYCIN

@ MYLAN ASI		EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Feb DISC
-------------	--	--------------------	---------	-----	--------------	----------

TABLET;ORAL

AZITHROMYCIN

>D>	@ ALEMBIC PHARMS LTD	EQ 600MG BASE	A211793	001	Jan 27, 2020	Jul CMFD
>A> AB		EQ 600MG BASE	A211793	001	Jan 27, 2020	Jul CMFD
AB	YUNG SHIN PHARM	EQ 500MG BASE	A211318	001	Mar 17, 2021	Mar NEWA
AB		EQ 600MG BASE	A211068	001	May 08, 2020	Feb CMFD

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

@ XELLIA PHARMS APS

50,000 UNITS/VIAL

A203177 001 Aug 25, 2014 Jun DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

CORTISPORIN

>D> +! MONARCH PHARMS

400 UNITS/GM; 1%; EQ 3.5MG

N050168 002 May 04, 1984 Jul DISC

>A> + @

400 UNITS/GM; 1%; EQ 3.5MG

N050168 002 May 04, 1984 Jul DISC

BASE/GM; 5,000 UNITS/GM

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

AP MAIA PHARMS INC

0.05MG/ML

A210777 001 Jan 15, 2021 Jan NEWA

GABLOFEN

AP +! PIRAMAL CRITICAL

0.05MG/ML

N022462 001 Nov 19, 2010 Mar CHRS

AP +

0.05MG/ML

N022462 001 Nov 19, 2010 Mar CRLD

AP +!

0.5MG/ML

N022462 002 Nov 19, 2010 Mar CHRS

AP +

0.5MG/ML

N022462 002 Nov 19, 2010 Mar CRLD

AP +!

2MG/ML

N022462 003 Nov 19, 2010 Mar CHRS

AP +

2MG/ML

N022462 003 Nov 19, 2010 Mar CRLD

TABLET; ORAL

BACLOFEN

>A> AB AUROBINDO PHARMA LTD

10MG

A214099 001 Jul 13, 2021 Jul NEWA

>A> AB

20MG

A214099 002 Jul 13, 2021 Jul NEWA

>A> AB BEXIMCO PHARMS USA

10MG

A214114 001 Jul 16, 2021 Jul NEWA

>A> AB

20MG

A214114 002 Jul 16, 2021 Jul NEWA

AB IMPAX

5MG

A077971 003 Jul 07, 2021 Jun NEWA

AB

10MG

A077971 001 Oct 26, 2007 Jun CAHN

AB

20MG

A077971 002 Oct 26, 2007 Jun CAHN

AB INNOGENIX

5MG

A212378 003 Apr 30, 2021 Apr NEWA

AB KARTHA

5MG

A214374 001 Mar 05, 2021 Feb NEWA

AB

10MG

A214374 002 Mar 05, 2021 Feb NEWA

AB

20MG

A214374 003 Mar 05, 2021 Feb NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

+ @ UCB INC

10MG

N021589 001 Oct 30, 2003 May CRLD

+ @

20MG

N021589 002 Oct 30, 2003 May CRLD

BALOXAVIR MARBOXIL

TABLET; ORAL

XOFLUZA

+ GENENTECH INC

80MG

N210854 003 Mar 18, 2021 Mar NEWA

>A> BELUMOSUDIL MESYLATE

>A> TABLET; ORAL

>A> REZUROCK

>A> +! KADMON PHARMS LLC

EQ 200MG BASE

N214783 001 Jul 16, 2021 Jul NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

LOTENSIN

AB + VALIDUS PHARMS

5MG

N019851 001 Jun 25, 1991 Feb CAHN

AB +

10MG

N019851 002 Jun 25, 1991 Feb CAHN

AB +

20MG

N019851 003 Jun 25, 1991 Feb CAHN

AB +!

40MG

N019851 004 Jun 25, 1991 Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D> AB MYLAN

5MG; 6.25MG

A076688 001 Feb 11, 2004 Jul DISC

>A> @

5MG; 6.25MG

A076688 001 Feb 11, 2004 Jul DISC

>D> AB

10MG; 12.5MG

A076688 002 Feb 11, 2004 Jul DISC

>A> @

10MG; 12.5MG

A076688 002 Feb 11, 2004 Jul DISC

>D> AB

20MG; 12.5MG

A076688 003 Feb 11, 2004 Jul DISC

>A> @

20MG; 12.5MG

A076688 003 Feb 11, 2004 Jul DISC

>D> AB

20MG; 25MG

A076688 004 Feb 11, 2004 Jul DISC

>A> @

20MG; 25MG

A076688 004 Feb 11, 2004 Jul DISC

>D> AB SANDOZ

5MG; 6.25MG

A076631 001 Feb 11, 2004 Jul CTEC

<u>TABLET;ORAL</u>					
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLORTIAZIDE					
>A>	LOTENSIN HCT	5MG;6.25MG	A076631	001	Feb 11, 2004 Jul CTEC
AB	+ @ VALIDUS PHARMS	5MG;6.25MG	N020033	001	May 19, 1992 Feb CAHN
AB	+ !	10MG;12.5MG	N020033	002	May 19, 1992 Feb CAHN
AB	+ !	20MG;12.5MG	N020033	004	May 19, 1992 Feb CAHN
AB	+ !	20MG;25MG	N020033	003	May 19, 1992 Feb CAHN
<u>BENOXINATE HYDROCHLORIDE; FLUORESCIN SODIUM</u>					
SOLUTION/DROPS;OPHTHALMIC					
FLUORESCIN SODIUM AND BENOXINATE HYDROCHLORIDE					
+!	BAUSCH LOMB IRELAND	0.4%;0.3%	N211039	001	Mar 09, 2020 May CAHN
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE</u>					
GEL;TOPICAL					
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE					
AB	ENCUBE	5%;1.2%	A212433	001	Apr 28, 2021 Apr NEWA
AB	! PERRIGO ISRAEL	5%;1.2%	A090979	001	Jun 26, 2012 Jan CHRS
	DUAC				
AB	+ STIEFEL	5%;1.2%	N050741	001	Aug 26, 2002 Jan CHRS
>A>	<u>BENZOYL PEROXIDE; TRETINOIN</u>				
>A>	CREAM;TOPICAL				
>A>	TWYNEO				
>A>	+! SOL-GEL TECHNOLOGIES	3%;0.1%	N214902	001	Jul 26, 2021 Jul NEWA
<u>BEPOTASTINE BESILATE</u>					
SOLUTION/DROPS;OPHTHALMIC					
BEPOTASTINE BESILATE					
AT	APOTEX	1.5%	A206066	001	Mar 05, 2019 May CMFD
AT	MYLAN	1.5%	A206220	001	Mar 18, 2019 May CMFD
	BEPREVE				
AT	+! BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009 May CTEC
<u>BETAMETHASONE DIPROPIONATE</u>					
LOTION;TOPICAL					
BETAMETHASONE DIPROPIONATE					
@ PHARMGEN	EQ 0.05% BASE		A070274	001	Aug 12, 1985 May CAHN
SPRAY;TOPICAL					
SERNIVO					
+!	PRIMUS PHARMS	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016 Mar CAHN
<u>BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE</u>					
LOTION;TOPICAL					
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE					
AB	! TARO	EQ 0.05% BASE;1%	A076493	001	Jul 28, 2004 Feb CHRS
	LOTRISONE				
+ @ MERCK SHARP DOHME	EQ 0.05% BASE;1%		N020010	001	Dec 08, 2000 Feb DISC
<u>BETHANECHOL CHLORIDE</u>					
TABLET;ORAL					
BETHANECHOL CHLORIDE					
@ WOCKHARDT	5MG		A040532	001	Sep 29, 2003 Jan DISC
@	50MG		A040518	001	Sep 29, 2003 Jan DISC
<u>BEXAROTENE</u>					
CAPSULE;ORAL					
BEXAROTENE					
AB	TEVA PHARMS USA	75MG	A209931	001	Jan 14, 2021 Jan NEWA
<u>BIMATOPROST</u>					
SOLUTION/DROPS;OPHTHALMIC					
BIMATOPROST					
@ AKORN	0.03%		A203299	001	Nov 08, 2018 Feb CAHN
AT	! ALEMBIC PHARMS LTD	0.03%	A210263	001	Apr 12, 2019 Jan CHRS
AT	LUPIN LTD	0.03%	A203991	001	Feb 20, 2015 Jan CHRS

BISOPROLOL FUMARATE

TABLET;ORAL
BISOPROLOL FUMARATE

AB	UNICHEM	5MG	A078635	001	Aug 18, 2009	Apr CAHN
AB	!	10MG	A078635	002	Aug 18, 2009	Apr CAHN

BIVALIRUDIN

INJECTABLE;INTRAVENOUS
BIVALIRUDIN

AP	HAINAN POLY PHARM	250MG/VIAL	A213078	001	May 28, 2021	May NEWA
----	-------------------	------------	---------	-----	--------------	----------

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
VELCADE

+!	TAKEDA PHARMS USA	3.5MG/VIAL	N021602	001	May 13, 2003	May CAHN
----	-------------------	------------	---------	-----	--------------	----------

BOSENTAN

TABLET;ORAL
BOSENTAN

AB	ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	May CMFD
AB		125MG	A211461	002	Jan 23, 2020	May CMFD
	TRACLEER					
AB	+ ACTELION	62.5MG	N021290	001	Nov 20, 2001	Feb CAHN
AB	+!	125MG	N021290	002	Nov 20, 2001	Feb CAHN
	TABLET, FOR SUSPENSION;ORAL					
	TRACLEER					
+!	ACTELION	32MG	N209279	001	Sep 05, 2017	Feb CAHN

BRIGATINIB

TABLET;ORAL
ALUNBRIG

+!	TAKEDA PHARMS USA	30MG	N208772	001	Apr 28, 2017	May CAHN
+		90MG	N208772	002	Apr 28, 2017	May CAHN
+!		180MG	N208772	003	Oct 02, 2017	May CAHN

BRINCIDOFUVIR

SUSPENSION;ORAL
TEMBEXA

+!	CHIMERIX	10MG/ML	N214460	001	Jun 04, 2021	Jun NEWA
	TABLET;ORAL					
	TEMBEXA					
+!	CHIMERIX	100MG	N214461	001	Jun 04, 2021	Jun NEWA

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL
PARLODEL

AB	+ VALIDUS PHARMS	EQ 5MG BASE	N017962	002	Mar 01, 1982	Feb CAHN
	TABLET;ORAL					
	PARLODEL					
AB	+ VALIDUS PHARMS	EQ 2.5MG BASE	N017962	001		Feb CAHN

BUDESONIDE

CAPSULE, DELAYED RELEASE;ORAL
BUDESONIDE

AB	@ ALVOGEN	3MG	A206724	001	Nov 23, 2016	Apr CDFR
AB	AMNEAL PHARMS	3MG	A206200	001	Jul 31, 2017	Apr CDFR
AB	MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Apr CDFR
AB	MYLAN	3MG	A090410	001	May 16, 2011	Apr CDFR
AB	RISING	3MG	A207367	001	Apr 07, 2017	Apr CDFR
AB	SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Apr CDFR
AB	ZYDUS PHARMS	3MG	A206134	001	May 04, 2017	Apr CDFR

SUSPENSION;INHALATION
BUDESONIDE

AN	SUN PHARM	0.25MG/2ML	A211922	001	Apr 14, 2021	Apr NEWA
AN		0.5MG/2ML	A211922	002	Apr 14, 2021	Apr NEWA
AN		1MG/2ML	A211922	003	Apr 14, 2021	Apr NEWA

BUPIVACAINE

SOLUTION, EXTENDED RELEASE; INFILTRATION

POSIMIR

+ @ DURECT	660MG/5ML (132MG/ML)	N 204803 001 Feb 01, 2021	Mar DISC
+!	660MG/5ML (132MG/ML)	N 204803 001 Feb 01, 2021	Feb NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	HIKMA PHARMS	0.25%	A 205141 001 Feb 11, 2021	Feb NEWA
AP		0.5%	A 205141 002 Feb 11, 2021	Feb NEWA
		BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE		
AP	HIKMA PHARMS	0.25%	A 204842 001 Feb 11, 2021	Feb NEWA
AP		0.5%	A 204842 002 Feb 11, 2021	Feb NEWA
AP		0.75%	A 204842 003 Feb 11, 2021	Feb NEWA

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE; PERIARTICULAR

ZYNRELEF KIT

+!	HERON THERAPS INC	60MG/2.3ML (29.25MG/ML); 1.8MG/2.3ML	N 211988 001 May 12, 2021	Jun NEWA
+!		200MG/7ML (29.25MG/ML); 6MG/7ML (0.88MG/ML)	N 211988 002 May 12, 2021	Jun NEWA
+!		300MG/10.5ML (29.25MG/ML); 9MG/10.5ML	N 211988 003 May 12, 2021	Jun NEWA
+!		400MG/14ML (29.25MG/ML); 12MG/14ML (0.88MG/ML)	N 211988 004 May 12, 2021	Jun NEWA

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

AB	MYLAN TECHNOLOGIES	5MCG/HR	A 210162 001 May 03, 2021	Apr NEWA
AB		7.5MCG/HR	A 210162 002 May 03, 2021	Apr NEWA
AB		10MCG/HR	A 210162 003 May 03, 2021	Apr NEWA
AB		15MCG/HR	A 210162 004 May 03, 2021	Apr NEWA
AB		20MCG/HR	A 210162 005 May 03, 2021	Apr NEWA
AB	WATSON LABS TEVA	7.5MCG/HR	A 204937 005 Jun 29, 2021	Jun NEWA

BUPRENORPHINE HYDROCHLORIDE

FILM; Buccal

BUPRENORPHINE HYDROCHLORIDE

>A>	ALVOGEN	EQ 0.075MG BASE	A 211594 001 Aug 03, 2021	Jul NFTG
>A>	AB	EQ 0.15MG BASE	A 211594 002 Aug 03, 2021	Jul NFTG
>A>	AB	EQ 0.3MG BASE	A 211594 003 Aug 03, 2021	Jul NFTG
>A>	AB	EQ 0.45MG BASE	A 211594 004 Aug 03, 2021	Jul NFTG
>A>	AB	EQ 0.6MG BASE	A 211594 005 Aug 03, 2021	Jul NFTG
>A>	AB	EQ 0.75MG BASE	A 211594 006 Aug 03, 2021	Jul NFTG
>A>	AB	EQ 0.9MG BASE	A 211594 007 Aug 03, 2021	Jul NFTG

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE; EQ 0.5MG BASE	A 214930 001 Jun 15, 2021	Jun NEWA
AB		EQ 8MG BASE; EQ 2MG BASE	A 214930 002 Jun 15, 2021	Jun NEWA
>D>	@ MAYNE PHARMA INC	EQ 2MG BASE; EQ 0.5MG BASE	A 206953 001 Jul 17, 2020	Jan DISC
>D>	AB	EQ 8MG BASE; EQ 2MG BASE	A 206953 002 Jul 17, 2020	Jul DISC
>A>	@	EQ 8MG BASE; EQ 2MG BASE	A 206953 003 Jul 17, 2020	Jul DISC
AB		EQ 8MG BASE; EQ 2MG BASE	A 206953 004 Jul 17, 2020	May CMFD
>D>	@	EQ 8MG BASE; EQ 2MG BASE	A 206953 005 Jul 17, 2020	Jan DISC
>D>	RHODES PHARMS	EQ 2MG BASE; EQ 0.5MG BASE	A 205601 001 Mar 30, 2020	Jul CMFD
>A>	AB	EQ 2MG BASE; EQ 0.5MG BASE	A 205601 002 Mar 30, 2020	Jul CMFD
>D>	@	EQ 8MG BASE; EQ 2MG BASE	A 205601 003 Mar 30, 2020	Jul CMFD
>A>	AB	EQ 8MG BASE; EQ 2MG BASE	A 205601 004 Mar 30, 2020	Jul CMFD

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

+	BAUSCH	174MG	N 022108 001 Apr 23, 2008	Feb CAHN
+		348MG	N 022108 002 Apr 23, 2008	Feb CAHN
+		522MG	N 022108 003 Apr 23, 2008	Feb CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

@ TORRENT	100MG	A203969	001	Oct 31, 2014	Jan DISC
@	150MG	A203969	002	Oct 31, 2014	Jan DISC
@	200MG	A203969	003	Oct 31, 2014	Jan DISC
	WELLBUTRIN XL				
AB3 + BAUSCH	150MG	N021515	001	Aug 28, 2003	Feb CAHN
AB3 +!	300MG	N021515	002	Aug 28, 2003	Feb CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB RUBICON	5MG	A075521	001	Apr 05, 2002	Feb CMFD
AB	7.5MG	A075521	004	Mar 16, 2021	Mar NEWA
AB	10MG	A075521	002	Apr 05, 2002	Feb CMFD
AB	15MG	A075521	003	Apr 05, 2002	Feb CMFD
AB	30MG	A075521	005	Mar 16, 2021	Mar NEWA

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Feb CAHN
--------------	--------	---------	-----	--------------	----------

CABERGOLINE

TABLET;ORAL

DOSTINEX

+ @ PFIZER

0.5MG

N020664 001 Dec 23, 1996 Jan CAHN

CABOTEGRAVIR SODIUM

TABLET;ORAL

VOCABRIA

+! VII V HLTHCARE

EQ 30MG BASE

N212887 001 Jan 21, 2021 Jan NEWA

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

CABENUVA KIT

+! VII V HLTHCARE

400MG/2ML (200MG/ML);600MG/2ML
(300MG/ML)

N212888 001 Jan 21, 2021 Jan NEWA

+!

600MG/3ML (200MG/ML);900MG/3ML
(300MG/ML)

N212888 002 Jan 21, 2021 Jan NEWA

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAF CIT

>D> AP +! HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Jul CAHN
>A> AP +!	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Jul CAHN

SOLUTION;ORAL

CAF CIT

>D> AA +! HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jul CAHN
>A> AA +!	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jul CAHN

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL

CAFERGOT

>D>					
>D> AA !	SANDOZ	100MG;1MG	A084294	001	Jul DISC
>A> @		100MG;1MG	A084294	001	Jul DISC
	ERGOTAMINE TARTRATE AND CAFFEINE				
>D> AA MIKART	100MG;1MG		A040590	001	Sep 16, 2005 Jul CHRS
>A> !	100MG;1MG		A040590	001	Sep 16, 2005 Jul CHRS

ERGOTAMINE TARTRATE AND CAFFEINE

MIKART

100MG;1MG

A040590 001 Sep 16, 2005 Jul CHRS

A040590 001 Sep 16, 2005 Jul CHRS

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

AP CUSTOPHARM INC	200 IU/ML	A212416	001	May 14, 2021	May NFTG
-------------------	-----------	---------	-----	--------------	----------

CALCIUM ACETATE

TABLET;ORAL
CALCIUM ACETATE
AB ! CHARTWELL MOLECULAR 667MG A202420 001 Feb 05, 2013 Apr CHRS

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET;ORAL
ACTONEL WITH CALCIUM (COPACKAGED)
>A> + @ WARNER CHILCOTT EQ 500MG BASE;35MG N021823 001 Aug 12, 2005 Jul CPOT
TABLET, TABLET;ORAL
ACTONEL WITH CALCIUM (COPACKAGED)
>D> + @ WARNER CHILCOTT EQ 500MG BASE,N/A;N/A,35MG N021823 001 Aug 12, 2005 Jul CPOT

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS
CALCIUM GLUCONATE IN SODIUM CHLORIDE
+! HQ SPCLT PHARMA 1GM/100ML (10MG/ML) N210906 003 Jun 04, 2021 Jun NEWA

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION
CAPASTAT SULFATE
+ @ AKORN EQ 1GM BASE/VIAL N050095 001 Jun DISC

CAPTOPRIL

TABLET;ORAL
Captopril
>D> @ ANNORA PHARMA 12.5MG A074737 001 Oct 28, 1998 Jul CMFD
>A> AB 12.5MG A074737 001 Oct 28, 1998 Jul CMFD
>D> @ 25MG A074737 002 Oct 28, 1998 Jul CMFD
>A> AB 25MG A074737 002 Oct 28, 1998 Jul CMFD
>D> @ 50MG A074737 003 Oct 28, 1998 Jul CMFD
>A> AB 50MG A074737 003 Oct 28, 1998 Jul CMFD
>D> @ 100MG A074737 004 Oct 28, 1998 Jul CMFD
>A> AB 100MG A074737 004 Oct 28, 1998 Jul CMFD

CARBAMAZEPINE

TABLET, EXTENDED RELEASE;ORAL
CARBAMAZEPINE
AB CSPC OUYI 100MG A213311 001 Apr 13, 2021 Apr NEWA
AB 200MG A213311 002 Apr 13, 2021 Apr NEWA
AB 400MG A213311 003 Apr 13, 2021 Apr NEWA

CARBIDOPA; LEVODOPA

TABLET;ORAL
CARBIDOPA AND LEVODOPA
AB SCIEGEN PHARMS INC 10MG;100MG A214092 001 May 07, 2021 Apr NEWA
AB 25MG;100MG A214092 002 May 07, 2021 Apr NEWA
AB 25MG;250MG A214092 003 May 07, 2021 Apr NEWA

CARBOPLATIN

INJECTABLE;INTRAVENOUS
CARBOPLATIN
AP ! HOSPIRA 50MG/5ML (10MG/ML) A076517 001 Oct 14, 2004 Mar CHRS
AP ! 150MG/15ML (10MG/ML) A076517 002 Oct 14, 2004 Mar CHRS
AP ! 450MG/45ML (10MG/ML) A076517 003 Oct 14, 2004 Mar CHRS
AP ! 600MG/60ML (10MG/ML) A077059 001 Nov 23, 2004 Mar CHRS
AP PHARMACHEMIE BV 50MG/5ML (10MG/ML) A077269 001 Oct 14, 2004 Mar CHRS
AP 150MG/15ML (10MG/ML) A077269 002 Oct 14, 2004 Mar CHRS
AP 450MG/45ML (10MG/ML) A077269 003 Oct 14, 2004 Mar CHRS
AP 600MG/60ML (10MG/ML) A077269 004 Dec 28, 2007 Mar CHRS

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION
CARBOPROST TROMETHAMINE
AP SUNNY PHARMTECH INC EQ 0.25MG BASE/ML A213118 001 Mar 25, 2021 Mar NEWA

CARMUSTINE

INJECTABLE; INJECTION

CARMUSTINE

>A>	AP	HONG KONG	100MG/VIAL	A213460	001	Aug 02, 2021	Jul NEWA
	AP	JIANGSU HENGRUI MED	100MG/VIAL	A211202	001	Mar 12, 2021	Mar NEWA

CARVEDILOL

TABLET; ORAL

COREG

>D>	AB	+	SMITHKLINE BEECHAM	3.125MG	N020297	004	May 29, 1997	Jul CAHN
>D>	AB	+		6.25MG	N020297	003	Sep 14, 1995	Jul CAHN
>D>	AB	+!		12.5MG	N020297	002	Sep 14, 1995	Jul CAHN
>D>	AB	+		25MG	N020297	001	Sep 14, 1995	Jul CAHN
>A>	AB	+	WOODWARD	3.125MG	N020297	004	May 29, 1997	Jul CAHN
>A>	AB	+		6.25MG	N020297	003	Sep 14, 1995	Jul CAHN
>A>	AB	+!		12.5MG	N020297	002	Sep 14, 1995	Jul CAHN
>A>	AB	+		25MG	N020297	001	Sep 14, 1995	Jul CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

>D>	AB	+	SMITHKLINE BEECHAM	10MG	N022012	001	Oct 20, 2006	Jul CAHN
>D>	AB	+		20MG	N022012	002	Oct 20, 2006	Jul CAHN
>D>	AB	+!		40MG	N022012	003	Oct 20, 2006	Jul CAHN
>D>	AB	+		80MG	N022012	004	Oct 20, 2006	Jul CAHN
>A>	AB	+	WOODWARD	10MG	N022012	001	Oct 20, 2006	Jul CAHN
>A>	AB	+		20MG	N022012	002	Oct 20, 2006	Jul CAHN
>A>	AB	+!		40MG	N022012	003	Oct 20, 2006	Jul CAHN
>A>	AB	+		80MG	N022012	004	Oct 20, 2006	Jul CAHN

CASIMERSEN

SOLUTION; INTRAVENOUS

AMONDYS 45

+! SAREPTA THERAPS INC 100MG/2ML (50MG/ML)

N213026 001 Feb 25, 2021 Feb NEWA

CEFAZOLIN SODIUM

SOLUTION; INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	Mar NEWA
+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar CRLD
!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar CHRS

CEFDINIR

CAPSULE; ORAL

CEFDINIR

AB		ALKEM LABS LTD	300MG	A210220	001	Feb 19, 2021	Feb NEWA
		FOR SUSPENSION; ORAL					
		CEFDINIR					
AB		ALKEM LABS LTD	125MG/5ML	A210534	001	Feb 19, 2021	Feb NEWA
AB			250MG/5ML	A210534	002	Feb 19, 2021	Feb NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

@	ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Mar DISC
@		EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Mar DISC

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

AB		ALKEM LABS LTD	100MG/5ML	A211775	001	Feb 19, 2021	Feb NEWA
AB			200MG/5ML	A211775	002	Feb 19, 2021	Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

+	@ VALIDUS PHARMS	EQ 500MG BASE/VIAL	N050547	001		Feb CAHN
+	@	EQ 1GM BASE/VIAL	N050547	002		Feb CAHN
+	@	EQ 2GM BASE/VIAL	N050547	003		Feb CAHN

INJECTABLE; INJECTION

CLAFORAN

+ @	EQ 10GM BASE/VIAL	N 050547	004	Dec 29, 1983	Feb CAHN
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER					
@ VALIDUS PHARMS	EQ 20MG BASE/ML	N 050596	002	May 20, 1985	Feb CAHN
@	EQ 40MG BASE/ML	N 050596	004	May 20, 1985	Feb CAHN
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
@ VALIDUS PHARMS	EQ 20MG BASE/ML	N 050596	001	May 20, 1985	Feb CAHN
@	EQ 40MG BASE/ML	N 050596	003	May 20, 1985	Feb CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

@ TELIGENT	EQ 10MG BASE/ML	N 050634	001	Apr 28, 1989	Feb CAHN
+ @	EQ 20MG BASE/ML	N 050634	002	Apr 28, 1989	Feb CAHN
+ @	EQ 40MG BASE/ML	N 050634	003	Apr 28, 1989	Feb CAHN

CEFUROXIME SODIUM

INJECTABLE; INJECTION

ZINACEF

AP +! TELIGENT	EQ 1.5GM BASE/VIAL	N 050558	003	Oct 19, 1983	Feb CAHN
AP +!	EQ 7.5GM BASE/VIAL	N 050558	004	Oct 23, 1986	Feb CAHN
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS					
ZINACEF					

AB +! TELIGENT	EQ 750MG BASE/VIAL	N 050558	002	Oct 19, 1983	Feb CAHN
----------------	--------------------	----------	-----	--------------	----------

CELECOXIB

CAPSULE; ORAL

CELEBREX

AB + UPJOHN	50MG	N 020998	004	Dec 15, 2006	Apr CAHN
AB +	100MG	N 020998	001	Dec 31, 1998	Apr CAHN
AB +	200MG	N 020998	002	Dec 31, 1998	Apr CAHN
AB +!	400MG	N 020998	003	Aug 29, 2002	Apr CAHN
CELECOXIB					
@ ACIC PHARMS	200MG	A 212925	001	Dec 09, 2020	Jun DISC
@	400MG	A 212925	002	Dec 09, 2020	Jun DISC
@ JUBILANT GENERICS	50MG	A 207061	001	Apr 04, 2017	Jun DISC
@	100MG	A 207061	002	Apr 04, 2017	Jun DISC
@	200MG	A 207061	003	Apr 04, 2017	Jun DISC
@	400MG	A 207061	004	Apr 04, 2017	Jun DISC
AB UNICHEM	50MG	A 213301	001	Jan 12, 2021	Jan NEWA
AB	100MG	A 213301	002	Jan 12, 2021	Jan NEWA
AB	200MG	A 213301	003	Jan 12, 2021	Jan NEWA
AB	400MG	A 213301	004	Jan 12, 2021	Jan NEWA
AB YILING	50MG	A 211412	001	Mar 06, 2020	Jun CMFD
AB	100MG	A 211412	002	Mar 06, 2020	Jun CMFD
AB	200MG	A 211412	003	Mar 06, 2020	Jun CMFD
AB	400MG	A 211412	004	Mar 06, 2020	Jun CMFD

CENOBAIMATE

TABLET; ORAL

XCOPRI

>D> + SK LIFE	12.5MG	N 212839	001	Mar 10, 2020	Jul CHRS
>A> +!	12.5MG	N 212839	001	Mar 10, 2020	Jul CHRS
>D> +!	200MG	N 212839	006	Mar 10, 2020	Jul CHRS
>A> +	200MG	N 212839	006	Mar 10, 2020	Jul CHRS

CEPHALEXIN

CAPSULE; ORAL

KEFLEX

+ @ PRAGMA	EQ 250MG BASE	N 050405	002		May DISC
+ @	EQ 500MG BASE	N 050405	003		May DISC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

>A> AA ! PADAGIS US	5MG/5ML	A 078398	001	Jun 17, 2008	Jul CAHN
>D> AA ! PERRIGO PHARMS CO	5MG/5ML	A 078398	001	Jun 17, 2008	Jul CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

@ CHARTWELL RX	5MG	A084678	001	Apr CAHN
@	10MG	A084041	001	Apr CAHN
@	25MG	A084679	002	Apr CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB ALKEM LABS LTD	5MG;2.5MG	A214065	001	Apr 26, 2021	Apr NEWA
AB DR REDDYS	5MG;2.5MG	A214698	001	May 10, 2021	Apr NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT BAJAJ	0.12%	A075561	001	Nov 14, 2000	Feb CMFD
----------	-------	---------	-----	--------------	----------

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

GENUS	30MG/ML	A214542	001	Jun 02, 2021	May NEWA
	100MG/ML	A214542	002	Jun 02, 2021	May NEWA

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB GLENMARK PHARMS LTD	10MG	A212144	001	Mar 23, 2021	Mar NEWA
AB	25MG	A212144	002	Mar 23, 2021	Mar NEWA
AB	50MG	A212144	003	Mar 23, 2021	Mar NEWA
AB	100MG	A212144	004	Mar 23, 2021	Mar NEWA
AB	200MG	A212144	005	Mar 23, 2021	Mar NEWA
AB LANNETT CO INC	10MG	A212996	001	Jan 22, 2021	Jan NEWA
AB	25MG	A212996	002	Jan 22, 2021	Jan NEWA
AB	50MG	A212996	003	Jan 22, 2021	Jan NEWA
AB	100MG	A212996	004	Jan 22, 2021	Jan NEWA
AB	200MG	A212996	005	Jan 22, 2021	Jan NEWA
AB @ MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020	Mar DISC
AB @	25MG	A213590	002	Aug 31, 2020	Mar DISC
AB @	50MG	A213590	003	Aug 31, 2020	Mar DISC
AB @	100MG	A213590	004	Aug 31, 2020	Mar DISC
AB @	200MG	A213590	005	Aug 31, 2020	Mar DISC

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

@ RISING	100MG	A088725	001	Aug 31, 1984	Jan CAHN
@	250MG	A088726	001	Aug 31, 1984	Jan CAHN

CHLORTHALIDONE

TABLET;ORAL

THALITONE

BX + CASPER PHARMA LLC	15MG	N019574	001	Dec 20, 1988	May CMFD
BX +!	25MG	N019574	002	Feb 12, 1992	May CMFD

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

>A> AA HAVIX	250MG	A215158	001	Jul 29, 2021	Jul NEWA
>D> ! MIKART	250MG	A207483	001	Jun 24, 2016	Jul CTEC
>A> AA !	250MG	A207483	001	Jun 24, 2016	Jul CTEC
AB PAR PHARM INC	375MG	A212743	002	Apr 29, 2021	Apr NEWA

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB TAGI	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Feb NEWA
AB	EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Feb NEWA
LOCOLEST LIGHT					
@ CHARTWELL RX	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Apr CAHN
@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Apr CAHN

CHOLINE FENOFOBRATE

CAPSULE, DELAYED RELEASE;ORAL
 FENOFOBRIC ACID
 @ YICHANG HUMANWELL EQ 45MG FENOFOBRIC ACID A212562 001 Dec 23, 2020 Jun DISC
 @ EQ 135MG FENOFOBRIC ACID A212562 002 Dec 23, 2020 Jun DISC

CICLESONIDE

SPRAY, METERED;NASAL
 OMNARIS
 +! COVIS 0.05MG/SPRAY N022004 001 Oct 20, 2006 May CPOT

CICLOPIROX

GEL;TOPICAL
 CICLOPIROX
 AB +! ALVOGEN 0.77% N020519 001 Jul 21, 1997 Jun CAHN
 SOLUTION;TOPICAL
 CICLOPIROX
 @ AKORN 8% A078975 001 Feb 17, 2010 Apr DISC
 AT RISING 8% A078124 001 Sep 18, 2007 May CAHN
 SUSPENSION;TOPICAL
 CICLOPIROX
 >A> AB PERRIGO ISRAEL 0.77% A077676 001 Dec 15, 2006 Jul CAHN
 >D> AB PERRIGO NEW YORK 0.77% A077676 001 Dec 15, 2006 Jul CAHN

CILOSTAZOL

TABLET;ORAL
 CILOSTAZOL
 @ EPIC PHARMA LLC 50MG A077022 002 Mar 11, 2005 Jan CMS1
 @ NOSTRUM LABS INC 50MG A077708 001 Sep 28, 2009 Mar DISC
 AB 50MG A077708 001 Sep 28, 2009 Jan CAHN
 @ 100MG A077708 002 Sep 28, 2009 Mar DISC
 AB 100MG A077708 002 Sep 28, 2009 Jan CAHN

CIMETIDINE

TABLET;ORAL
 CIMETIDINE
 @ NOVITIUM PHARMA 300MG A074340 001 Jun 23, 1995 Feb CAHN
 @ 400MG A074340 002 Jun 23, 1995 Feb CAHN
 @ 800MG A074339 001 Jun 23, 1995 Feb CAHN

CIPROFLOXACIN

INJECTABLE, SUSPENSION;OTIC
 OTIPRIO
 +! ALK ABELLO 6% (60MG/ML) N207986 001 Dec 10, 2015 Jun CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION
 CISATRACURIUM BESYLATE
 >D> AP SAGENT PHARMS INC EQ 2MG BASE/ML A201851 001 Nov 06, 2020 Jul DISC
 >A> @ EQ 2MG BASE/ML A201851 001 Nov 06, 2020 Jul DISC
 @ ZYDUS PHARMS EQ 2MG BASE/ML A213527 001 Aug 31, 2020 Feb DISC

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL
 IDKIT:HP
 >D> +! EXALENZ BIOSCIENCE N/A, 4GM; 75MG, N/A N021314 001 Dec 17, 2002 Jul CPOT
 >A> +! 4GM; 75MG N021314 001 Dec 17, 2002 Jul CPOT

CLARITHROMYCIN

TABLET;ORAL
 CLARITHROMYCIN
 @ WOCKHARDT 250MG A065266 001 May 31, 2006 Jan DISC
 @ 500MG A065266 002 May 31, 2006 Jan DISC

CLASCOTERONE

CREAM;TOPICAL
 WINLEVI
 + @ CASSIOPEA SPA 1% N213433 001 Aug 26, 2020 Mar DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL
CLEOCIN HYDROCHLORIDE

AB	+	PFIZER	EQ 75MG BASE	N 050162	001	Feb CAHN
AB	+		EQ 150MG BASE	N 050162	002	Feb CAHN
AB	+!		EQ 300MG BASE	N 050162	003	Apr 14, 1988 Feb CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL
CLEOCIN

AA	!	PFIZER	EQ 75MG BASE/5ML	A 062644	001	Apr 07, 1986 Feb CAHN
----	---	--------	------------------	----------	-----	-----------------------

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL
CLEOCIN

AB	@	PFIZER	EQ 2% BASE	N 050680	001	Aug 11, 1992 Feb CAHN
AB	+!		EQ 2% BASE	N 050680	002	Mar 02, 1998 Feb CAHN

GEL;TOPICAL
CLEOCIN T

AB	+!	PFIZER	EQ 1% BASE	N 050615	001	Jan 07, 1987 Feb CAHN
----	----	--------	------------	----------	-----	-----------------------

CLINDAMYCIN PHOSPHATE

AB	ENCUBE	EQ 1% BASE	A 212438	001	Mar 11, 2021 Mar NEWA
AB	GLENMARK PHARMS LTD	EQ 1% BASE	A 214251	001	Feb 10, 2021 Jan NEWA

INJECTABLE;INJECTION
CLEOCIN PHOSPHATE

AP	PFIZER	EQ 150MG BASE/ML	A 062803	001	Oct 16, 1987 Feb CAHN
AP	+!	EQ 150MG BASE/ML	N 050441	001	Feb CAHN

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @	PFIZER	EQ 6MG BASE/ML	N 050639	001	Aug 30, 1989 Feb CAHN
+ @		EQ 12MG BASE/ML	N 050639	002	Aug 30, 1989 Feb CAHN
+ @		EQ 18MG BASE/ML	N 050639	003	Apr 10, 1991 Feb CAHN

CLINDAMYCIN PHOSPHATE

>A> AP	ALMAJECT	EQ 150MG BASE/ML	A 062800	001	Jul 24, 1987 Jul CAHN	
>A>	@	EQ 150MG BASE/ML	A 062801	001	Jul 24, 1987 Jul CAHN	
>A> AP		EQ 150MG BASE/ML	A 062943	001	Sep 29, 1988 Jul CAHN	
>D> AP	ALVOGEN	EQ 150MG BASE/ML	A 062800	001	Jul 24, 1987 Jul CAHN	
>D>	@	EQ 150MG BASE/ML	A 062801	001	Jul 24, 1987 Jul CAHN	
>D> AP		EQ 150MG BASE/ML	A 062943	001	Sep 29, 1988 Jul CAHN	
	@ MYLAN LABS LTD	EQ 150MG BASE/ML	A 204748	001	Oct 10, 2017 Jan DISC	
	LOTION;TOPICAL CLEOCIN T					
AB	+!	PFIZER	EQ 1% BASE	N 050600	001	May 31, 1989 Feb CAHN
	CLINDAMYCIN PHOSPHATE					
AB	TARO PHARMS	EQ 1% BASE	A 214526	001	Jun 28, 2021 Jun NEWA	
	SOLUTION;TOPICAL CLEOCIN T					
+ @	PFIZER	EQ 1% BASE	N 050537	001	Feb CAHN	
+ @	PHARMACIA AND UPJOHN	EQ 1% BASE	N 050537	001	Jan DISC	
	SUPPOSITORY;VAGINAL CLEOCIN					
+!	PFIZER	100MG	N 050767	001	Aug 13, 1999 Feb CAHN	
	SWAB;TOPICAL CLEOCIN					
+ @	PFIZER	EQ 1% BASE	N 050537	002	Feb 22, 1994 Mar DISC	
AT	+!		EQ 1% BASE	N 050537	002	Feb 22, 1994 Feb CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL
ZIANA

AB	+!	BAUSCH	1.2%;0.025%	N 050802	001	Nov 07, 2006 May CAHN
----	----	--------	-------------	----------	-----	-----------------------

CLOBAZAM

SUSPENSION;ORAL
CLOBAZAM

AB	ALKEM LABS LTD	2.5MG/ML	A 213039	001	May 06, 2021 Apr NEWA
>D>	@ TARO	2.5MG/ML	A 210978	001	Apr 15, 2019 Jul CMFD
>A> AB		2.5MG/ML	A 210978	001	Apr 15, 2019 Jul CMFD

TABLET;ORAL
CLOBAZAM

@ CELLTRION	10MG	A 211959	001	Dec 09, 2020 Jun DISC
-------------	------	----------	-----	-----------------------

TABLET;ORAL

CLOBAZAM

	@	20MG	A211959	002	Dec 09, 2020	Jun DISC
	@ LANNETT CO INC	10MG	A212092	001	Oct 30, 2019	Mar DISC
	@	20MG	A212092	002	Oct 30, 2019	Mar DISC
AB	MSN	10MG	A213404	001	May 11, 2021	Apr NEWA
AB		20MG	A213404	002	May 11, 2021	Apr NEWA

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	GLASSHOUSE PHARMS	0.05%	A211207	001	Mar 26, 2021	Mar NEWA
	IMPOYZ		N209483	001	Nov 28, 2017	Mar CAHN
+!	PRIMUS PHARMS	0.025%				
	OINTMENT;TOPICAL					
	CLOBETASOL PROPIONATE					
	@ TORRENT	0.05%	A212926	001	Oct 25, 2019	Jan DISC
	SHAMPOO;TOPICAL					
	CLOBETASOL PROPIONATE					
AB	AMNEAL	0.05%	A214895	001	Jun 14, 2021	Jun NEWA
AB	TARO PHARMS	0.05%	A214867	001	Mar 25, 2021	Mar NEWA
	SOLUTION;TOPICAL					
	CLOBETASOL PROPIONATE					
AT	PRINSTON INC	0.05%	A213139	001	Feb 08, 2021	Jan NEWA
	SPRAY;TOPICAL					
	CLOBETASOL PROPIONATE					
	@ AKORN	0.05%	A207218	001	Apr 28, 2017	Apr DISC

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP	MEITHEAL	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jan CAHN
	@ NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

>A> AB	ALEMBIC PHARMS LTD	25MG	A211822	001	Aug 04, 2021	Jul NEWA
>A> AB		50MG	A211822	002	Aug 04, 2021	Jul NEWA
>A> AB		75MG	A211822	003	Aug 04, 2021	Jul NEWA
AB	VGYAAN	25MG	A213221	001	Jun 22, 2020	May CMFD
AB		50MG	A213221	002	Jun 22, 2020	May CMFD
AB		75MG	A213221	003	Jun 22, 2020	May CMFD

CLONIDINE

SYSTEM;TRANSDERMAL

CATAPRES-TTS-1

AB	+	LAVIPHARM	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan CAHN
AB	+	TECHNOMED	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan CAHN
		CATAPRES-TTS-2					
AB	+	LAVIPHARM	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan CAHN
AB	+	TECHNOMED	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan CAHN
		CATAPRES-TTS-3					
AB	+!	LAVIPHARM	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan CAHN
AB	+!	TECHNOMED	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP	! HIKMA FARMACEUTICA	5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Mar CHRS
	DURAACLON					
+ @ MYLAN INSTITUTIONAL		5MG/10ML (0.5MG/ML)	N020615	002	Apr 27, 1999	Mar DISC

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020	Feb CMFD
AB		EQ 300MG BASE	A213351	002	Jul 17, 2020	Feb CMFD

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

TRANXENE

+ @ RECORDATI RARE	3.75MG	N 017105	001	May CRLD
+ @	7.5MG	N 017105	002	May CRLD
+ @	15MG	N 017105	003	May CRLD

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB AUROLIFE PHARMA LLC	3.75MG	A 071858	002	Jul 17, 1987	Jan CAHN
AB	7.5MG	A 071858	003	Jul 17, 1987	Jan CAHN
AB !	15MG	A 071858	001	Jul 17, 1987	Jan CAHN
TRANXENE					
+ @ RECORDATI RARE	3.75MG	N 017105	006		May CRLD
TRANXENE SD					
+ @ RECORDATI RARE	11.25MG	N 017105	005		May CRLD
+ @	22.5MG	N 017105	004		May CRLD

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA AKORN	10MG/5ML;5MG/5ML;6.25MG/5ML	A 040674	001	Dec 23, 2014	Feb CAHN
----------	-----------------------------	----------	-----	--------------	----------

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

GLENMARK PHARMS LTD	1.875GM/PACKET	A 202190	001	Jul 16, 2018	Feb CTEC
@ WATSON LABS INC	1.875GM/PACKET	A 202178	001	Sep 01, 2020	Feb DISC
@	3.75GM/PACKET	A 202178	002	Sep 01, 2020	Feb DISC

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

@ WATSON LABS INC	625MG	A 200830	001	Sep 02, 2020	Feb DISC
-------------------	-------	----------	-----	--------------	----------

COlestipol HYDROCHLORIDE

GRANULE;ORAL

COlestid

AB + PFIZER	5GM/SCOOPFUL	N 017563	003	Sep 22, 1995	Feb CAHN
AB +!	5GM/PACKET	N 017563	004	Sep 22, 1995	Feb CAHN
FLAVORED COlestid					
+ PFIZER	5GM/PACKET	N 017563	001		Feb CAHN
+	5GM/SCOOPFUL	N 017563	002		Feb CAHN
TABLET;ORAL					
COlestid					
AB +! PFIZER	1GM	N 020222	001	Jul 19, 1994	Feb CAHN

CROTAMITON

CREAM;TOPICAL

EURAX

+ @ JOURNEY	10%	N 006927	001		Jan CAHN
LOTION;TOPICAL					
EURAX					
AT +! JOURNEY	10%	N 009112	003		Jan CAHN

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

SOLUTION;INTRAVENOUS

TRALEMENT

+! AM REGENT	(1ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML	N 209376	001	Jul 02, 2020	Jan CPOT
+!	(5ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML	N 209376	002	Dec 02, 2020	Jan NEWA
>A> +!	(1ML) EQ 0.06MG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG BASE/ML;EQ 1MG BASE/ML	N 209376	003	Jun 30, 2021	Jul NEWA

CYCLOSPORINE

EMULSION;OPHTHALMIC

VERKAZIA

+! SANTEN	0.1%	N 214965	001	Jun 23, 2021	Jun NEWA
-----------	------	----------	-----	--------------	----------

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA QUAGEN 4MG A212491 001 Feb 24, 2021 Feb NEWA

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE;ORAL

PROCYSB

> HORIZON EQ 25MG BASE N203389 001 Apr 30, 2013 May CAHN
+! EQ 75MG BASE N203389 002 Apr 30, 2013 May CAHNCYTARABINE

INJECTABLE;INJECTION

CYTARABINE

@ MYLAN LABS LTD 20MG/ML

A200914 001 Dec 13, 2011 May DISC

DABIGATRAN ETEXILATE MESYLATE

>D>	PELLET;ORAL					
>D>	PRADAXA					
>D>	+ BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021	Jul CDFR
	+	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021	Jun NEWA
>D>	+	EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021	Jul CDFR
	+	EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021	Jun NEWA
>D>	+	EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021	Jul CDFR
	+	EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021	Jun NEWA
>D>	+	EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021	Jul CDFR
	+	EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021	Jun NEWA
>D>	+	EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021	Jul CDFR
	+	EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021	Jun NEWA
>D>	+!	EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021	Jul CDFR
	+!	EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021	Jun NEWA
>A>	PELLETS;ORAL					
>A>	PRADAXA					
>A>	+ BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021	Jul CDFR
>A>	+	EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021	Jul CDFR
>A>	+	EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021	Jul CDFR
>A>	+	EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021	Jul CDFR
>A>	+	EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021	Jul CDFR
>A>	+!	EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021	Jul CDFR

DACTINOMYCIN

INJECTABLE;INJECTION

DACTINOMYCIN

AP	AUROMEDICS PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan CAHN
>A>	@ HIKMA	0.5MG/VIAL	A090304	001	Mar 16, 2010	Jul CAHN
AP	MEITHEAL	0.5MG/VIAL	A213463	001	Nov 13, 2020	Feb CAHN
>D>	@ WEST-WARD PHARMS INT	0.5MG/VIAL	A090304	001	Mar 16, 2010	Jul CAHN

DAPSONE

TABLET;ORAL

DAPSONE

AB ALVOGEN 25MG A205429 001 Jan 07, 2016 Jun CAHN
AB 100MG A205429 002 Jan 07, 2016 Jun CAHNDAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

AP	HISUN PHARM HANGZHOU	500MG/VIAL	A212250	001	Apr 21, 2021	Apr NEWA
AP	HONG KONG	500MG/VIAL	A213623	001	Jun 29, 2021	Jun NEWA
+!	HOSPIRA INC	350MG/VIAL	N210282	001	Jun 21, 2021	Jun NEWA
+!		500MG/VIAL	N210282	002	Jun 21, 2021	Jun NEWA

POWDER;IV (INFUSION)

DAPTOMYCIN

AP	@ DR REDDYS	350MG/VIAL	A211403	001	Aug 31, 2020	May DISC
AP	HONG KONG	350MG/VIAL	A213786	001	Jun 29, 2021	Jun NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

@ JUBILANT GENERICS	EQ 7.5MG BASE
@	EQ 15MG BASE

A205550	001	Oct 12, 2016	Jun DISC
A205550	002	Oct 12, 2016	Jun DISC

DASIGLUCAGON HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS

ZEGALOGUE

+! ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	May CAHN
+!	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Mar NEWA
ZEGALOGUE (AUTOINJECTOR)					
+! ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	May CAHN
+!	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Mar NEWA

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DAUNORUBICIN HYDROCHLORIDE

>A> AP	+! HIKMA	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Jul CAHN
>D> AP	+! WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Jul CAHN

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

>D>	@ APOTEX	50MG/VIAL	A205539	001	Nov 23, 2020	Jul CMFD
	@	50MG/VIAL	A205539	001	Nov 23, 2020	May DISC
	@ CIPLA	50MG/VIAL	A208601	001	Nov 16, 2017	May DISC
>A> AP	GLAND	50MG/VIAL	A205539	001	Nov 23, 2020	Jul CMFD
AP	HONG KONG	50MG/VIAL	A212959	001	Jul 02, 2021	Jun NEWA
AP	QILU	50MG/VIAL	A212826	001	Apr 12, 2021	Apr NEWA

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

>A> AB	AMNEAL	90MG	A214194	003	Aug 02, 2021	Jul NEWA
AB		180MG	A214194	001	Feb 09, 2021	Jan NEWA
AB		360MG	A214194	002	Feb 09, 2021	Jan NEWA
AB	AUCTA	90MG	A214559	001	Mar 09, 2021	Feb NEWA
AB		180MG	A214559	002	Mar 09, 2021	Feb NEWA
AB		360MG	A214559	003	Mar 09, 2021	Feb NEWA
AB	MSN	180MG	A214650	001	Mar 17, 2021	Mar NEWA
AB		360MG	A214650	002	Mar 17, 2021	Mar NEWA

TABLET;ORAL

DEFERASIROX

AB	ANNORA PHARMA	90MG	A214341	001	May 14, 2021	May NEWA
AB		180MG	A214341	002	May 14, 2021	May NEWA
AB		360MG	A214341	003	May 14, 2021	May NEWA
AB	CELLTRION	90MG	A212669	001	May 27, 2021	May NEWA
AB		180MG	A212669	002	May 27, 2021	May NEWA
AB		360MG	A212669	003	May 27, 2021	May NEWA

DEFERIPRONE

TABLET;ORAL

DEFERIPRONE

AB	HIKMA	500MG	A213239	001	Mar 29, 2021	Mar NEWA
	FERRIPROX					
AB	+! CHIESI	500MG	N021825	001	Oct 14, 2011	Mar CTEC

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS

DEOXYCHOLIC ACID

AP	SLAYBACK PHARMA LLC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Mar NFTG
----	---------------------	--------------------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	10MG	A209785	001	Jul 07, 2021	Jun NEWA
AB		25MG	A209785	002	Jul 07, 2021	Jun NEWA
AB		50MG	A209785	003	Jul 07, 2021	Jun NEWA
AB		75MG	A209785	004	Jul 07, 2021	Jun NEWA
AB		100MG	A209785	005	Jul 07, 2021	Jun NEWA
AB		150MG	A209785	006	Jul 07, 2021	Jun NEWA
	NORPRAMIN					
AB	+ VALIDUS PHARMS	10MG	N014399	007	Feb 11, 1982	Feb CAHN
AB	+	25MG	N014399	001		Feb CAHN
AB	+	50MG	N014399	003		Feb CAHN
AB	+	75MG	N014399	004		Feb CAHN
AB	+!	100MG	N014399	005		Feb CAHN
AB	+	150MG	N014399	006		Feb CAHN

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX-D 12 HOUR

+! ORGANON 2.5MG;120MG

N021313 001 Feb 01, 2006 Jun CAHN

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

NOCTIVA

+ @ ROIVANT 0.00083MG/SPRAY
+ @ 0.00166MG/SPRAYN201656 001 Mar 03, 2017 Feb CAHN
N201656 002 Mar 03, 2017 Feb CAHNDESOGESTREL; ETHINYLN ESTRADIOL

TABLET; ORAL-21

ORTHO-CEPT

+ @ JANSSEN PHARMS 0.15MG;0.03MG

N020301 001 Dec 14, 1992 May CRLD

TABLET; ORAL-28

ORTHO-CEPT

+ @ JANSSEN PHARMS 0.15MG;0.03MG

N020301 002 Dec 14, 1992 May CRLD

DESONIDE

GEL; TOPICAL

DESONATE

+ @ LEO PHARMA AS 0.05%

N021844 001 Oct 20, 2006 Mar DISC

DESONIDE

! CINTEX SVCS 0.05%
0.05%A202470 001 May 11, 2020 Mar CHRS
A202470 001 May 11, 2020 Mar CTECDESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

@ AKORN 0.05%

A203787 001 Jan 06, 2017 Apr DISC

@ 0.25%

A203234 001 Jun 12, 2015 Apr DISC

>A> AB PERRIGO ISRAEL 0.25%

A076510 001 Jul 01, 2003 Jul CAHN

>D> AB PERRIGO NEW YORK 0.25%

A076510 001 Jul 01, 2003 Jul CAHN

OINTMENT; TOPICAL

DESOXIMETASONE

AB ! GLENMARK GENERICS 0.25%

A202838 001 Sep 20, 2013 Apr CHRS

TOPICORT

@ TARO PHARM INDs LTD 0.25%

A074286 001 Jun 07, 1996 Apr DISC

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

BP ALVOGEN 0.5MG
BP 0.75MG
BP 4MG
BP 6MG
BP ! HIKMA 1MG
BP ! 2MGA088481 002 Apr 28, 1983 Jun CAHN
A088481 003 Apr 28, 1983 Jun CAHN
A088481 004 Apr 28, 1983 Jun CAHN
A088481 001 Nov 28, 1983 Jun CAHN
A088306 001 Sep 15, 1983 Apr CHRS
A087916 001 Aug 26, 1982 Apr CHRS

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

>A> AP GLAND PHARMA LTD EQ 4MG PHOSPHATE/ML A215654 001 Aug 04, 2021 Jul NEWA

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRAMYCIN AND DEXAMETHASONE

>A> AB AMNEAL 0.1%;0.3% A212991 001 Jul 15, 2021 Jul NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP GLAND EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A202126 001 Aug 20, 2015 May CAHN

>A> AP HIKMA EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A205046 001 Apr 26, 2017 Jul CAHN

AP HONG KONG EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A204843 001 Jan 18, 2019 Jun CMFD

>D> AP WEST-WARD PHARMS INT EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A205046 001 Apr 26, 2017 Jul CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

>D> AB MYLAN 5MG A204266 001 Aug 25, 2015 Jul DISC

>A> @ 5MG A204266 001 Aug 25, 2015 Jul DISC

>D> AB 10MG A204266 002 Aug 25, 2015 Jul DISC

>A> @ 10MG A204266 002 Aug 25, 2015 Jul DISC

>D> AB 15MG A204266 003 Aug 25, 2015 Jul DISC

>A> @ 15MG A204266 003 Aug 25, 2015 Jul DISC

>D> AB 20MG A204266 004 Dec 21, 2015 Jul DISC

>A> @ 20MG A204266 004 Dec 21, 2015 Jul DISC

>D> AB 25MG A204266 005 May 04, 2021 Jul DISC

>A> @ 25MG A204266 005 May 04, 2021 Jul DISC

AB 25MG A204266 005 May 04, 2021 Apr NEWA

>D> AB 30MG A202580 001 Aug 28, 2013 Jul CAHN

>A> @ 30MG A202580 001 Aug 28, 2013 Jul CAHN

>D> AB 35MG A204266 006 May 04, 2021 Jul DISC

>A> @ 35MG A204266 006 May 04, 2021 Jul DISC

AB 35MG A204266 006 May 04, 2021 Apr NEWA

>D> AB 40MG A204266 007 Aug 25, 2015 Jul DISC

>A> @ 40MG A204266 007 Aug 25, 2015 Jul DISC

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE;ORAL

AZSTARYS

+ COMMAVE THERAP EQ 5.2MG BASE;EQ 26.1MG BASE N212994 001 May 07, 2021 May NEWA

+ EQ 7.8MG BASE;EQ 39.2MG BASE N212994 002 May 07, 2021 May NEWA

+! EQ 10.4MG BASE;EQ 52.3MG BASE N212994 003 May 07, 2021 May NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP AUROMEDICS PHARMA EQ 250MG BASE/VIAL A200752 001 Oct 19, 2011 Jan CAHN

AP EQ 500MG BASE/VIAL A200752 002 Oct 19, 2011 Jan CAHN

ZINECARD

AP +! PFIZER EQ 250MG BASE/VIAL N020212 001 May 26, 1995 Mar CAHN

AP +! EQ 500MG BASE/VIAL N020212 002 May 26, 1995 Mar CAHN

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA ARBOR PHARMS LLC 2.5MG A090533 001 Oct 25, 2011 May CTEC

AA 7.5MG A090533 003 Oct 25, 2011 May CTEC

AA 15MG A090533 005 Oct 25, 2011 May CTEC

AA 20MG A090533 006 Oct 25, 2011 May CTEC

AA 30MG A090533 007 Oct 25, 2011 May CTEC

AA WINDER LABS LLC 2.5MG A212160 001 Jun 07, 2021 May NEWA

AA 5MG A212160 002 Jun 07, 2021 May NEWA

AA 7.5MG A212160 003 Jun 07, 2021 May NEWA

AA 10MG A212160 004 Jun 07, 2021 May NEWA

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	15MG	A212160	005	Jun 07, 2021	May NEWA
AA	20MG	A212160	006	Jun 07, 2021	May NEWA
AA	30MG	A212160	007	Jun 07, 2021	May NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%

@ FRESENIUS KABI USA	5GM/100ML;75MG/100ML	A212346	001	Sep 10, 2020	Mar DISC
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%					
@ FRESENIUS KABI USA	5GM/100ML;150MG/100ML	A212346	002	Sep 10, 2020	Mar DISC

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003		Mar CTEC
-------------------	-----------------------	---------	-----	--	----------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

>A>	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Jul NFTG
AP	FRESENIUS KABI USA	5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Feb NEWA
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
>A> AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Jul NFTG
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Feb NEWA
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Feb NFTG
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP	FRESENIUS KABI USA	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Feb NEWA
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Feb NEWA
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Feb NFTG

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	2.5GM/100ML;450MG/100ML	A211190	001	Dec 20, 2019	May CMFD
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
AP	FRESENIUS KABI USA	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	May CMFD
@	5GM/100ML;300MG/100ML		A211194	001	Aug 26, 2020	Feb DISC
AP	+! ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001		May CTEC
+!	5GM/100ML;300MG/100ML		N017799	001		Feb CTEC
DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP	FRESENIUS KABI USA	5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020	May CMFD
@	5GM/100ML;450MG/100ML		A211276	001	Sep 15, 2020	Mar DISC
DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP	FRESENIUS KABI USA	5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020	May CMFD
@	5GM/100ML;900MG/100ML		A211211	001	Sep 14, 2020	Mar DISC

DICLOFENAC POTASSIUM

TABLET; ORAL

CATALFLAM

>A>	AMICI	25MG	A076561	002	Jul 21, 2021	Jul NEWA
AB		50MG	A076561	001	Mar 18, 2004	May CTNA

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB	! TARO SOLARAZE	3%	A206298	001	Apr 28, 2016	Mar CHRS
+ @ FOUGERA PHARMS	3%		N021005	001	Oct 16, 2000	Mar DISC

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT	AKORN	1.5%	A206655	001	Jan 28, 2021	Jan NEWA
@ RISING	1.5%		A206715	001	Aug 07, 2017	May CAHN

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

@ MICRO LABS	50MG	A074986	001	Feb 26, 1999	Feb CAHN
@	75MG	A074986	002	Feb 26, 1999	Feb CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

>A> AB	MICRO LABS	50MG;0.2MG
>A> AB		75MG;0.2MG

A204355	001	Jul 15, 2021	Jul NEWA
A204355	002	Jul 15, 2021	Jul NEWA

DICLOXA CILLIN SODIUM

CAPSULE;ORAL

DICLOXA CILLIN SODIUM

@ SANDOZ	EQ 125MG BASE	A061454	002	Jan DISC
@	EQ 250MG BASE	A061454	001	Jan DISC
@	EQ 500MG BASE	A061454	003	Jan DISC
TEVA	EQ 250MG BASE	A062286	001	Jun 03, 1982 Jan CTEC
!	EQ 500MG BASE	A062286	002	Jun 03, 1982 Jan CTEC
AB !	EQ 500MG BASE	A062286	002	Jun 03, 1982 Jan CHRS

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

AP	PRA XGEN	10MG/ML	A212058	001	Apr 26, 2019	Jun CAHN
AA	SYRUP;ORAL	DICYCLOMINE HYDROCHLORIDE	A214721	001	Apr 23, 2021	Apr NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

@ AUROBINDO PHARMA	125MG	A090094	001	Sep 24, 2008	Jan DISC
@	200MG	A090094	002	Sep 24, 2008	Jan DISC
@	250MG	A090094	003	Sep 24, 2008	Jan DISC
@	400MG	A090094	004	Sep 24, 2008	Jan DISC

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

BX !	ANJ PHARMS	0.05%	A076263	001	Dec 20, 2002	Apr CAHN
OINTMENT;TOPICAL	DIFLORASONE DIACETATE	@ AKORN	A206572	001	Jul 24, 2015	Apr DISC

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DIFLUPREDNATE

>A> AB	CIPLA	0.05%	A211776	001	Aug 09, 2021	Jul NFTG
--------	-------	-------	---------	-----	--------------	----------

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

AP	PROVEPHARM SAS	1MG/ML	A212046	001	Jan 07, 2020	Jan CAHN
----	----------------	--------	---------	-----	--------------	----------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB1	GLENMARK PHARMS LTD	60MG	A212317	001	Mar 22, 2021	Mar NEWA
AB1		90MG	A212317	002	Mar 22, 2021	Mar NEWA
AB1		120MG	A212317	003	Mar 22, 2021	Mar NEWA
AB1	MYLAN	60MG	A074910	001	May 02, 1997	Mar CTEC
AB1		90MG	A074910	002	May 02, 1997	Mar CTEC
AB1 !		120MG	A074910	003	May 02, 1997	Mar CTEC

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

@ INTL MEDICATION	5MG/ML	A075749	001	Nov 21, 2001	Jan DISC
-------------------	--------	---------	-----	--------------	----------

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

>A> AB	LUPIN	120MG	A210226	001	Oct 05, 2020	Jul CAHN
>A> AB		240MG	A210226	002	Oct 05, 2020	Jul CAHN
>D> AB	LUPIN ATLANTIS	120MG	A210226	001	Oct 05, 2020	Jul CAHN
>D> AB		240MG	A210226	002	Oct 05, 2020	Jul CAHN
AB	PHARMATHEN	120MG	A210436	001	Mar 26, 2021	Mar NEWA

CAPSULE, DELAYED RELEASE;ORAL DIMETHYL FUMARATE							
AB		240MG	A210436	002	Mar 26, 2021	Mar NEWA	
	@ ZYDUS PHARMS	120MG	A210538	001	Sep 24, 2020	Feb DISC	
	@	240MG	A210538	002	Sep 24, 2020	Feb DISC	
	TECFIDERA						
AB	+	BIOGEN INC	120MG	N204063	001	Mar 27, 2013	Apr CAHN
AB	+		240MG	N204063	002	Mar 27, 2013	Apr CAHN
<u>DINOPROSTONE</u>							
GEL;ENDOCERVICAL PREPIDIL							
+!	PFIZER	0.5MG/3GM	N019617	001	Dec 09, 1992	Jan CAHN	
SUPPOSITORY;VAGINAL PROSTIN E2							
+!	PFIZER	20MG	N017810	001		Jan CAHN	
<u>DIPYRIDAMOLE</u>							
TABLET;ORAL DIPYRIDAMOLE							
AB	OXFORD PHARMS	25MG	A040542	001	Apr 21, 2006	Jan CMFD	
AB		50MG	A040542	002	Apr 21, 2006	Jan CMFD	
AB		75MG	A040542	003	Apr 21, 2006	Jan CMFD	
<u>DIROXIMEL FUMARATE</u>							
CAPSULE, DELAYED RELEASE;ORAL VUMERTY							
+!	BIOGEN INC	231MG	N211855	001	Oct 29, 2019	Apr CAHN	
<u>DISOPYRAMIDE PHOSPHATE</u>							
CAPSULE;ORAL DISOPYRAMIDE PHOSPHATE							
@	MAYNE PHARMA	EQ 100MG BASE	A070173	001	May 31, 1985	Feb DISC	
@		EQ 150MG BASE	A070173	002	May 31, 1985	Feb DISC	
<u>DIVALPROEX SODIUM</u>							
CAPSULE, DELAYED REL PELLETS;ORAL DIVALPROEX SODIUM							
@	TEVA PHARMS USA	EQ 125MG VALPROIC ACID	A211505	001	Nov 17, 2020	May DISC	
TABLET, DELAYED RELEASE;ORAL DIVALPROEX SODIUM							
@	ANCHEN PHARMS	EQ 500MG VALPROIC ACID	A078411	001	Nov 03, 2008	May DISC	
TABLET, EXTENDED RELEASE;ORAL DIVALPROEX SODIUM							
AB	AMTA	EQ 250MG VALPROIC ACID	A214462	001	Mar 15, 2021	Mar NEWA	
AB		EQ 500MG VALPROIC ACID	A214462	002	Mar 15, 2021	Mar NEWA	
<u>DOCETAXEL</u>							
INJECTABLE;INJECTION DOCETAXEL							
AP	EUGIA PHARMA	20MG/2ML (10MG/ML)	A214575	001	Jun 25, 2021	Jun NEWA	
AP		80MG/8ML (10MG/ML)	A214575	002	Jun 25, 2021	Jun NEWA	
AP		160MG/16ML (10MG/ML)	A214575	003	Jun 25, 2021	Jun NEWA	
AP	GLAND PHARMA LTD	20MG/2ML (10MG/ML)	A213510	001	Jul 01, 2021	Jun NEWA	
AP		80MG/8ML (10MG/ML)	A213510	002	Jul 01, 2021	Jun NEWA	
AP		160MG/16ML (10MG/ML)	A213510	003	Jul 01, 2021	Jun NEWA	
AP	HIKMA	20MG/ML (20MG/ML)	A204490	001	Jan 14, 2021	Jan NEWA	
AP		80MG/4ML (20MG/ML)	A204490	002	Jan 14, 2021	Jan NEWA	
AP	HONG KONG	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Jun CMFD	
AP		80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Jun CMFD	
AP		160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Jun CMFD	
AP	@ INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Apr DISC	
AP	+!	SHILPA	N205934	001	Dec 22, 2015	Apr CHRS	
AP	+	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Apr CRLD	
AP		20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jan CAHN	
AP	+	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Apr CHRS	
AP	+	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Apr CRLD	
AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jan CAHN	
AP	+	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Apr CHRS	
AP	+	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Apr CRLD	
AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jan CAHN	

DOFETILIDE

CAPSULE;ORAL						
DOFETILIDE						
@ RICONPHARMA LLC	0.125MG		A212410	001	Dec 27, 2019	Feb DISC
@	0.25MG		A212410	002	Dec 27, 2019	Feb DISC
@	0.5MG		A212410	003	Dec 27, 2019	Feb DISC

DOLASETRON MESYLATE

INJECTABLE; INJECTION						
ANZEMET						
+ @ VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)		N020624	002	Sep 11, 1997	Feb CAHN
+ @	100MG/5ML (20MG/ML)		N020624	001	Sep 11, 1997	Feb CAHN
@	500MG/25ML (20MG/ML)		N020624	003	Dec 11, 2001	Feb CAHN
TABLET;ORAL						
ANZEMET						
+ @ VALIDUS PHARMS	50MG		N020623	001	Sep 11, 1997	Feb CAHN
+ @	100MG		N020623	002	Sep 11, 1997	Feb CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC						
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE						
AT ALEMBIC PHARMS LTD	EQ 2% BASE;EQ 0.5% BASE		A213099	001	May 04, 2021	Apr NEWA
AT AUROBINDO PHARMA LTD	EQ 2% BASE;EQ 0.5% BASE		A207629	001	May 14, 2021	May NEWA
AT FDC LTD	EQ 2% BASE;EQ 0.5% BASE		A205295	001	Jun 13, 2019	Feb CMFD

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION					
DOPRAM					
>D> AP +! HIKMA	20MG/ML		N014879	001	Jul CAHN
>A> AP +!	20MG/ML		N014879	001	Jul CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL						
DOXAZOSIN MESYLATE						
>D> AB MYLAN	EQ 1MG BASE		A075509	001	Oct 19, 2000	Jul DISC
>A> @	EQ 1MG BASE		A075509	001	Oct 19, 2000	Jul DISC
>D> AB	EQ 2MG BASE		A075509	002	Oct 19, 2000	Jul DISC
>A> @	EQ 2MG BASE		A075509	002	Oct 19, 2000	Jul DISC
>D> AB	EQ 4MG BASE		A075509	003	Oct 19, 2000	Jul DISC
>A> @	EQ 4MG BASE		A075509	003	Oct 19, 2000	Jul DISC
>D> AB	EQ 8MG BASE		A075509	004	Oct 19, 2000	Jul DISC
>A> @	EQ 8MG BASE		A075509	004	Oct 19, 2000	Jul DISC

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL						
DOXEPIN HYDROCHLORIDE						
AB ALEMBIC PHARMS LTD	EQ 10MG BASE		A215076	001	Apr 21, 2021	Apr NEWA
AB	EQ 25MG BASE		A215076	002	Apr 21, 2021	Apr NEWA
AB	EQ 50MG BASE		A215076	003	Apr 21, 2021	Apr NEWA
AB	EQ 75MG BASE		A215076	004	Apr 21, 2021	Apr NEWA
AB	EQ 100MG BASE		A215076	005	Apr 21, 2021	Apr NEWA
AB APPCO	EQ 10MG BASE		A214908	001	Apr 01, 2021	Mar NEWA
AB	EQ 25MG BASE		A214908	002	Apr 01, 2021	Mar NEWA
AB	EQ 50MG BASE		A214908	003	Apr 01, 2021	Mar NEWA
AB	EQ 75MG BASE		A214908	004	Apr 01, 2021	Mar NEWA
AB	EQ 100MG BASE		A214908	005	Apr 01, 2021	Mar NEWA
AB LEADING PHARMA LLC	EQ 10MG BASE		A211619	001	Mar 09, 2021	Feb NEWA
AB	EQ 25MG BASE		A211619	002	Mar 09, 2021	Feb NEWA
AB	EQ 50MG BASE		A211619	003	Mar 09, 2021	Feb NEWA
AB	EQ 75MG BASE		A211619	004	Mar 09, 2021	Feb NEWA
AB	EQ 100MG BASE		A211619	005	Mar 09, 2021	Feb NEWA
AB	EQ 150MG BASE		A211618	001	Mar 01, 2021	Feb NEWA

TABLET;ORAL						
DOXEPIN HYDROCHLORIDE						
@ PAR PHARM INC	EQ 3MG BASE		A202510	001	Jul 24, 2020	Jan DISC
@	EQ 6MG BASE		A202510	002	Jul 24, 2020	Jan DISC
AB RK PHARMA	EQ 3MG BASE		A202337	001	Jan 20, 2016	Jan CAHN
AB	EQ 6MG BASE		A202337	002	Jan 20, 2016	Jan CAHN

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB	AJANTA PHARMA LTD	100MG	A214391	001	Feb 18, 2021	Feb NFTG
AB		200MG	A214391	002	Feb 18, 2021	Feb NFTG
AB		300MG	A214391	003	Feb 18, 2021	Feb NFTG
AB	ALKEM LABS LTD	100MG	A213911	001	Feb 18, 2021	Feb NFTG
AB		200MG	A213911	002	Feb 18, 2021	Feb NFTG
AB		300MG	A213911	003	Feb 18, 2021	Feb NFTG
>A>	AB	ANNORA	A211726	002	Aug 09, 2021	Jul NEWA
>A>	AB		A211726	003	Aug 09, 2021	Jul NEWA
AB		300MG	A211726	001	Feb 18, 2021	Feb NFTG
AB	AUROBINDO PHARMA LTD	100MG	A214387	001	Feb 18, 2021	Feb NFTG
AB		200MG	A214387	002	Feb 18, 2021	Feb NFTG
AB		300MG	A214387	003	Feb 18, 2021	Feb NFTG
AB	BIONPHARMA INC	100MG	A213033	001	Apr 28, 2021	May CAHN
AB		200MG	A213033	002	Apr 28, 2021	May CAHN
AB		300MG	A213033	003	Apr 28, 2021	May CAHN
AB	BLUEPHARMA	100MG	A214543	001	May 05, 2021	Apr NEWA
AB		200MG	A214543	002	May 05, 2021	Apr NEWA
AB		300MG	A214543	003	May 05, 2021	Apr NEWA
AB	HIKMA	100MG	A212835	001	Feb 18, 2021	Feb NFTG
AB		200MG	A212835	002	Feb 18, 2021	Feb NFTG
AB		300MG	A212835	003	Feb 18, 2021	Feb NFTG
AB	LUPIN PHARMS	100MG	A211652	001	Feb 18, 2021	Feb NFTG
AB		200MG	A211652	002	Feb 18, 2021	Feb NFTG
AB		300MG	A211652	003	Feb 18, 2021	Feb NFTG
AB	MSN PHARMS INC	100MG	A211741	001	Feb 18, 2021	Feb NFTG
AB		200MG	A211741	002	Feb 18, 2021	Feb NFTG
AB		300MG	A211741	003	Feb 18, 2021	Feb NFTG
AB	MYLAN API	100MG	A213033	001	Apr 28, 2021	Apr NEWA
AB		200MG	A213033	002	Apr 28, 2021	Apr NEWA
AB		300MG	A213033	003	Apr 28, 2021	Apr NEWA
AB	SCIEGEN PHARMS INC	100MG	A214017	001	Feb 18, 2021	Feb NFTG
AB		200MG	A214017	002	Feb 18, 2021	Feb NFTG
AB		300MG	A214017	003	Feb 18, 2021	Feb NFTG
AB	SUN PHARM	100MG	A214384	001	Feb 18, 2021	Feb NFTG
AB		200MG	A214384	002	Feb 18, 2021	Feb NFTG
AB		300MG	A214384	003	Feb 18, 2021	Feb NFTG
AB	TASMAN PHARMA	100MG	A213661	001	Feb 18, 2021	Feb NFTG
AB		200MG	A213661	002	Feb 18, 2021	Feb NFTG
AB		300MG	A213661	003	Feb 18, 2021	Feb NFTG
AB	TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021	Feb NFTG
AB		200MG	A213162	002	Feb 18, 2021	Feb NFTG
AB		300MG	A213162	003	Feb 18, 2021	Feb NFTG
AB	TRIS PHARMA INC	100MG	A214543	001	May 05, 2021	Jun CAHN
AB		200MG	A214543	002	May 05, 2021	Jun CAHN
AB		300MG	A214543	003	May 05, 2021	Jun CAHN
AB	ZYDUS PHARMS	100MG	A211818	001	Feb 18, 2021	Feb NFTG
AB		200MG	A211818	002	Feb 18, 2021	Feb NFTG
AB		300MG	A211818	003	Feb 18, 2021	Feb NFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr CDFR
+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr CDFR
+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr CDFR
+!		EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr CDFR

DULOXETINE HYDROCHLORIDE

AB	SUNSHINE	EQ 20MG BASE	A212328	001	Feb 11, 2021	Feb NEWA
AB		EQ 30MG BASE	A212328	002	Feb 11, 2021	Feb NEWA
AB		EQ 60MG BASE	A212328	003	Feb 11, 2021	Feb NEWA

DUTASTERIDE

CAPSULE;ORAL

AVODART

>D>	AB	+! GLAXOSMITHKLINE	0.5MG	N021319	001	Nov 20, 2001	Jul CAHN
>A>	AB	+! WOODWARD	0.5MG	N021319	001	Nov 20, 2001	Jul CAHN
		DUTASTERIDE					
		@ NOSTRUM LABS INC	0.5MG	A204705	001	Nov 20, 2015	Apr CAHN

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

JALYN

>D>	AB	+!	GLAXOSMITHKLINE	0.5MG;0.4MG	N 022460	001	Jun 14, 2010	Jul CAHN
>A>	AB	+!	WOODWARD	0.5MG;0.4MG	N 022460	001	Jun 14, 2010	Jul CAHN

DYDROGESTERONE

TABLET;ORAL

GYNOREST

>D>	@	SOLVAY	5MG	N 017388	001	Jul CRLD
>A>	@		5MG	N 017388	001	Jul CRLD
>D>	@		10MG	N 017388	002	Jul CRLD
>A>	@		10MG	N 017388	002	Jul CRLD

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

+! RESILIA PHARMS 1%

N 205175 001 Oct 24, 2013 Feb CAHN

EDETADE CALCIUM DISODIUM

INJECTABLE;INJECTION

CALCIUM DISODIUM VERSENATE

+! BAUSCH 200MG/ML

N 008922 001 May CAHN

TABLET;ORAL

CALCIUM DISODIUM VERSENATE

@ BAUSCH 500MG

N 008922 002 May CAHN

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

AB STRIDES PHARMA 600MG

A 078509 001 Jun 16, 2021 Jun NEWA

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+ @ AUROBINDO PHARMA LTD 600MG;300MG;300MG

N 022343 001 Aug 15, 2018 Feb DISC

EFINACONAZOLE

SOLUTION;TOPICAL

EFINACONAZOLE

AB	ACRUX DDS	10%	A 211969	001	Jun 21, 2021	Jun NEWA
AB	AUROBINDO PHARMA LTD	10%	A 212066	001	Mar 29, 2021	Mar NEWA
AB	TEVA PHARMS USA	10%	A 211827	001	Dec 16, 2020	Feb CTEC
	JUBLIA					
AB	+! BAUSCH	10%	N 203567	001	Jun 06, 2014	Feb CTEC

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

TABLET;ORAL

TRIKAFTA (COPACKAGED)

+ VERTEX PHARMS INC 50MG,37.5MG,25MG; 75MG

N 212273 002 Jun 08, 2021 Jun NEWA

+! 100MG,75MG,50MG; 150MG

N 212273 001 Oct 21, 2019 Jun CPOT

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	APOTEX	200MG;300MG	A 208740	001	Jun 16, 2021	Jun NEWA
AB	CIPLA	200MG;300MG	A 090958	001	Apr 02, 2021	Mar NEWA
AB	LAURUS LABS LTD	200MG;300MG	A 212114	001	Jul 26, 2019	Jan CMFD
AB	LUPIN LTD	200MG;300MG	A 204131	001	Jun 04, 2021	May NEWA
AB	MACLEODS PHARMS LTD	200MG;300MG	A 203442	001	May 15, 2020	Feb CMFD
AB	MYLAN	200MG;300MG	A 206436	001	Apr 09, 2018	Feb CMFD
AB	STRIDES PHARMA	200MG;300MG	A 091055	001	Jan 13, 2021	Jan NEWA
AB	ZYDUS PHARMS	100MG;150MG	A 212689	002	Jul 01, 2021	Jun NEWA
AB		133MG;200MG	A 212689	003	Jul 01, 2021	Jun NEWA
AB		167MG;250MG	A 212689	004	Jul 01, 2021	Jun NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL

>A> ENALAPRIL MALEATE
 >A> AB BIONPHARMA INC 1MG/ML A212408 001 Aug 10, 2021 Jul NFTG

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>D> AB MYLAN 5MG;12.5MG A075624 001 Sep 18, 2001 Jul DISC
 >A> @ 5MG;12.5MG A075624 001 Sep 18, 2001 Jul DISC
 >D> AB 10MG;25MG A075624 002 Sep 18, 2001 Jul DISC
 >A> @ 10MG;25MG A075624 002 Sep 18, 2001 Jul DISC

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

AB ACTAVIS LABS FL INC 40MG A209614 001 May 14, 2021 May NFTG

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

REZIPRES

+! ETON	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun CAHN
+ @	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun DISC
+!	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun CAHN
+ @	47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun DISC
+!	47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun CAHN
+! SINTETICA SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun NEWA
+!	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun NEWA
+!	47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun NEWA

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

AP AUROBINDO PHARMA LTD 50MG/ML (50MG/ML) A214579 001 Jun 14, 2021 Jun NEWA

EPLERENONE

TABLET;ORAL

EPLERENONE

AB CHARTWELL RX	25MG	A078482	001	Jul 30, 2008	Apr CAHN
AB	50MG	A078482	002	Jul 30, 2008	Apr CAHN
@ PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Feb DISC
@	50MG	A212765	002	Aug 10, 2020	Feb DISC
INSPIRA					
AB + UPJOHN	25MG	N021437	001	Sep 27, 2002	Apr CAHN
AB +!	50MG	N021437	002	Sep 27, 2002	Apr CAHN
@	100MG	N021437	003	Sep 27, 2002	Apr CAHN

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

AP2 SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb CTEC
AP EQ 0.5MG BASE/VIAL		A210473	001	Jan 15, 2021	Jan NFTG
AP2 EQ 1.5MG BASE/VIAL		A210473	002	Jan 15, 2021	Feb CTEC
AP EQ 1.5MG BASE/VIAL		A210473	002	Jan 15, 2021	Jan NFTG
AP1 TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Feb CTEC
AP1	EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Feb CTEC
FLOLAN					
AP1 +! GLAXOSMITHKLINE LLC	EQ 0.5MG BASE/VIAL	N020444	001	Sep 20, 1995	Feb CTEC
AP1 +!	EQ 1.5MG BASE/VIAL	N020444	002	Sep 20, 1995	Feb CTEC
VELETRI					
AP2 +! ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CAHN
AP2 +!	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb CAHN
AP2 +! ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CHRS
AP2 +	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CTEC
AP2 +!	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb CTEC

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

AP !	MYLAN LABS LTD	2MG/ML	A203258	001	Jul 20, 2018	Apr CHRS
AP !		75MG/100ML	A203258	002	Jul 20, 2018	Apr CHRS
	INTEGRILIN					
+ @	SCHERING	2MG/ML	N020718	001	May 18, 1998	Apr DISC
+ @		75MG/100ML	N020718	002	May 18, 1998	Apr DISC

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

AA +!	VALIDUS PHARMS	50,000 IU	N003444	001		Feb CAHN
-------	----------------	-----------	---------	-----	--	----------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

>A> AB	ALEMBIC PHARMS LTD	EQ 25MG BASE	A214719	001	Jul 08, 2021	Jul NEWA
>A> AB		EQ 100MG BASE	A214719	002	Jul 08, 2021	Jul NEWA
>A> AB		EQ 150MG BASE	A214719	003	Jul 08, 2021	Jul NEWA
AB	MSN	EQ 25MG BASE	A214366	001	May 10, 2021	Apr NEWA
AB		EQ 100MG BASE	A214366	002	May 10, 2021	Apr NEWA
AB		EQ 150MG BASE	A214366	003	May 10, 2021	Apr NEWA

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP	GLAND PHARMA LTD	EQ 1GM BASE/VIAL	A212040	001	Mar 26, 2021	Mar NEWA
----	------------------	------------------	---------	-----	--------------	----------

ERYTHROMYCIN

SOLUTION; TOPICAL

ERYTHRA-DERM

AT	SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Apr CMFD
	TABLET; ORAL					

ERYTHROMYCIN

AB	ORANGE	250MG	A213628	001	Jun 28, 2021	Jun NEWA
AB		500MG	A213628	002	Jun 28, 2021	Jun NEWA
AB	TEVA PHARMS USA INC	250MG	A214549	001	Feb 11, 2021	Feb NEWA
AB		500MG	A214549	002	Feb 11, 2021	Feb NEWA

TABLET, DELAYED RELEASE; ORAL

ERYTHROMYCIN

>A> AB	TORRENT	250MG	A211975	001	Jul 26, 2021	Jul NEWA
		500MG	A211975	002	Jul 26, 2021	Jul NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@ PAR PHARM INC	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	May DISC
@	EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	May DISC

ESLICARBAZEPINE ACETATE

TABLET; ORAL

ESLICARBAZEPINE ACETATE

AB	DR REDDYS LABS LTD	200MG	A211238	001	Jun 29, 2021	Jun NFTG
AB		400MG	A211238	002	Jun 29, 2021	Jun NFTG
AB		600MG	A211238	003	Jun 29, 2021	Jun NFTG
AB		800MG	A211238	004	Jun 29, 2021	Jun NFTG

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

@ AMTA	EQ 20MG BASE	A213859	001	Nov 18, 2020	May DISC	
@	EQ 40MG BASE	A213859	002	Nov 18, 2020	May DISC	
AB	ETHYPHARM	EQ 20MG BASE	A090841	001	Mar 31, 2021	Mar NEWA
AB		EQ 40MG BASE	A090841	002	Mar 31, 2021	Mar NEWA
AB	GRAVITI PHARMS	EQ 20MG BASE	A213486	001	Mar 19, 2021	Mar NEWA
AB		EQ 40MG BASE	A213486	002	Mar 19, 2021	Mar NEWA
AB	INDCHEMIE HEALTH	EQ 40MG BASE	A210559	002	Feb 26, 2021	Feb NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

>A> AB	MYLAN	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Jul NEWA
>A> AB		EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Jul NEWA

ESTRADIOL

CREAM;VAGINAL
ESTRADIOL

>A> AB	PRASCO LABS LLC	0.01%	A212313	001	Jul 15, 2021	Jul NEWA
--------	-----------------	-------	---------	-----	--------------	----------

FILM, EXTENDED RELEASE;TRANSDERMAL

>D>	ALORA					
>D> BX	ALLERGAN	0.025MG/24HR	N020655	004	Apr 05, 2002	Jul DISC
>A>	@	0.025MG/24HR	N020655	004	Apr 05, 2002	Jul DISC
>D> BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Jul DISC
>A>	@	0.05MG/24HR	N020655	001	Dec 20, 1996	Jul DISC
>D> BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Jul DISC
>A>	@	0.075MG/24HR	N020655	002	Dec 20, 1996	Jul DISC
>D> BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Jul DISC
>A>	@	0.1MG/24HR	N020655	003	Dec 20, 1996	Jul DISC
		INSERT, EXTENDED RELEASE;VAGINAL				
		ESTRING				
+!	PFIZER	0.0075MG/24HR	N020472	001	Apr 26, 1996	Jan CAHN

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION
DEPO-ESTRADIOL

@ PFIZER	1MG/ML	A085470	001		Mar CAHN
@	3MG/ML	A085470	002		Mar CAHN
!	5MG/ML	A085470	003		Mar CAHN

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

TABLET;ORAL
MYFEMBREE

+! MYOVANT SCIENCES	1MG;0.5MG;40MG	N214846	001	May 26, 2021	May NEWA
---------------------	----------------	---------	-----	--------------	----------

ESTROPIPATE

TABLET;ORAL
OGEN .625
@ PFIZER 0.75MG
OGEN 1.25
@ PFIZER 1.5MG
OGEN 2.5
@ PFIZER 3MG
OGEN 5
PFIZER 6MG

A083220	001		Jan CAHN
A083220	002		Jan CAHN
A083220	003		Jan CAHN
A083220	004		Jan CAHN

ESZOPICLONE

TABLET;ORAL
ESZOPICLONE
@ NOSTRUM LABS INC 1MG
@ 2MG
@ 3MG

A203087	001	May 08, 2019	Jan CAHN
A203087	002	May 08, 2019	Jan CAHN
A203087	003	May 08, 2019	Jan CAHN

ETHACRYNIC ACID

TABLET;ORAL
ETHACRYNIC ACID

AB	ALVOGEN	25MG	A205709	001	Jul 24, 2018	Jun CAHN
----	---------	------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL
ETHINYL ESTRADIOL; ETONOGESTREL

AB	TEVA PHARMS USA INC	0.015MG/24HR;0.12MG/24HR	A204305	001	Jan 13, 2021	Jan NEWA
----	---------------------	--------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL
ETHINYL ESTRADIOL AND NORELGESTROMIN

AB	AMNEAL	0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Feb NEWA
----	--------	--------------------------	---------	-----	--------------	----------

AB	XULANE					
----	--------	--	--	--	--	--

AB	! MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb CTEC
----	----------------------	--------------------------	---------	-----	--------------	----------

ETHINYLMESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

>D>	NORINYL 1+35 21-DAY					
>D> AB	ALLERGAN	0.035MG;1MG	N017565	001	Jul	DISC
>A>	@	0.035MG;1MG	N017565	001	Jul	DISC
	TABLET; ORAL-28					
>D>	NORINYL 1+35 28-DAY					
>D> AB	ALLERGAN	0.035MG;1MG	N017565	002	Jul	DISC
>A>	@	0.035MG;1MG	N017565	002	Jul	DISC

ETHINYLMESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

GEMMILY

AB	XIROMED	0.02MG;1MG	A213317	001	Nov 09,	2020	Mar CAHN
	NORETHINDRONE ACETATE AND ETHINYLMESTRADIOL AND FERROUS FUMARATE						
>A> AB	AMNEAL PHARMS	0.02MG;1MG	A214292	001	Jul 20,	2021	Jul NEWA
	TABLET; ORAL-21						
>D>	GILDESS 1/20						
>D> AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24,	2012	Jul DISC
>A>	@	0.02MG;1MG	A077077	002	Jul 24,	2012	Jul DISC
	TABLET; ORAL-28						
>D>	GILDESS FE 1/20						
>D> AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	001	May 20,	2005	Jul DISC
>A>	@	0.02MG;1MG	A077077	001	May 20,	2005	Jul DISC

ETODOLAC

TABLET; ORAL

ETODOLAC

>D> AB	BAYSHORE PHARMS LLC	400MG	A210704	001	Dec 16,	2020	Jul DISC
>A>	@	400MG	A210704	001	Dec 16,	2020	Jul DISC
>D> AB		500MG	A210704	002	Dec 16,	2020	Jul DISC
>A>	@	500MG	A210704	002	Dec 16,	2020	Jul DISC

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

>D>	@ CAPLIN	2MG/ML	A215028	001	Dec 18,	2020	Jul CMFD
>A> AP		2MG/ML	A215028	001	Dec 18,	2020	Jul CMFD
	@	2MG/ML	A215028	001	Dec 18,	2020	Jun DISC

ETRAVIRINE

TABLET; ORAL

ETRAVIRINE

>D> AB	AMNEAL	25MG	A214196	001	Jun 14,	2021	Jul DISC
>A>	@	25MG	A214196	001	Jun 14,	2021	Jul DISC
AB		25MG	A214196	001	Jun 14,	2021	Jun NFTG
AB		100MG	A214196	002	Jun 14,	2021	Jun NFTG
AB		200MG	A214196	003	Jun 14,	2021	Jun NFTG
	INTELENCE						
>D> AB	+ JANSSEN R AND D	25MG	N022187	003	Mar 26,	2012	Jul CTEC
>A>	+	25MG	N022187	003	Mar 26,	2012	Jul CTEC

EVEROLIMUS

TABLET; ORAL

AFINITOR

AB	+ NOVARTIS	10MG	N022334	002	Mar 30,	2009	Feb CTEC
	EVEROLIMUS						
	@ BIOCON PHARMA	2.5MG	A214182	001	Feb 11,	2021	Feb DISC
AB		2.5MG	A214182	001	Feb 11,	2021	Feb NEWA
	@	5MG	A214182	002	Feb 11,	2021	Feb DISC
AB		5MG	A214182	002	Feb 11,	2021	Feb NEWA
	@	7.5MG	A214182	003	Feb 11,	2021	Feb DISC
AB		7.5MG	A214182	003	Feb 11,	2021	Feb NEWA
	@	10MG	A214182	004	Feb 11,	2021	Feb DISC
AB		10MG	A214182	004	Feb 11,	2021	Feb NEWA
AB	BRECKENRIDGE	0.25MG	A205432	001	May 20,	2021	May NEWA
AB		0.5MG	A205432	002	May 20,	2021	May NEWA
AB		0.75MG	A205432	003	May 20,	2021	May NEWA
AB		2.5MG	A205426	001	Mar 05,	2021	Feb NEWA
AB		5MG	A205426	002	Mar 05,	2021	Feb NEWA
AB		7.5MG	A205426	003	Mar 05,	2021	Feb NEWA

	TABLET;ORAL EVEROLIMUS				
AB		10MG		A205426	004 Mar 05, 2021 Feb NEWA
	<u>EXEMESTANE</u>				
	TABLET;ORAL AROMASIN				
AB	+! PFIZER	25MG		N020753	001 Oct 21, 1999 Mar CAHN
	<u>EXENATIDE SYNTHETIC</u>				
	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS BYDUREON				
	+ @ ASTRAZENECA AB	2MG/VIAL		N022200	001 Jan 27, 2012 Feb DISC
	BYDUREON PEN				
	+ @ ASTRAZENECA AB	2MG		N022200	002 Feb 28, 2014 Feb DISC
	<u>EZETIMIBE</u>				
	TABLET;ORAL ZETIA				
AB	+! ORGANON	10MG		N021445	001 Oct 25, 2002 Feb CAHN
	<u>EZETIMIBE; ROSUVASTATIN CALCIUM</u>				
	TABLET;ORAL ROSZET				
	+ ALTHERA PHARMS	10MG;EQ 5MG BASE		N213072	001 Mar 23, 2021 Mar NEWA
	+ @	10MG;EQ 5MG BASE		N213072	001 Mar 23, 2021 Mar NEWA
	+ @	10MG;EQ 10MG BASE		N213072	002 Mar 23, 2021 Mar NEWA
	+ @	10MG;EQ 10MG BASE		N213072	002 Mar 23, 2021 Mar NEWA
	+ @	10MG;EQ 20MG BASE		N213072	003 Mar 23, 2021 Mar NEWA
	+ @	10MG;EQ 20MG BASE		N213072	003 Mar 23, 2021 Mar NEWA
	+! @	10MG;EQ 40MG BASE		N213072	004 Mar 23, 2021 Mar NEWA
	+! @	10MG;EQ 40MG BASE		N213072	004 Mar 23, 2021 Mar NEWA
	<u>EZETIMIBE; SIMVASTATIN</u>				
	TABLET;ORAL EZETIMIBE AND SIMVASTATIN				
>D> AB	ANI PHARMS	10MG;10MG		A201890	001 Apr 26, 2017 Jul DISC
>A>	@	10MG;10MG		A201890	001 Apr 26, 2017 Jul DISC
>D> AB		10MG;20MG		A201890	002 Apr 26, 2017 Jul DISC
>A>	@	10MG;20MG		A201890	002 Apr 26, 2017 Jul DISC
>D> AB		10MG;40MG		A201890	003 Apr 26, 2017 Jul DISC
>A>	@	10MG;40MG		A201890	003 Apr 26, 2017 Jul DISC
>D> AB		10MG;80MG		A201890	004 Apr 26, 2017 Jul DISC
>A>	@	10MG;80MG		A201890	004 Apr 26, 2017 Jul DISC
	@ MYLAN	10MG;10MG		A200082	001 Dec 17, 2020 Jan DISC
	@	10MG;20MG		A200082	002 Dec 17, 2020 Jan DISC
	@	10MG;40MG		A200082	003 Dec 17, 2020 Jan DISC
	@	10MG;80MG		A200082	004 Dec 17, 2020 Jan DISC
	VYTORIN				
AB	+ ORGANON	10MG;10MG		N021687	001 Jul 23, 2004 Feb CAHN
AB	+	10MG;20MG		N021687	002 Jul 23, 2004 Feb CAHN
AB	+	10MG;40MG		N021687	003 Jul 23, 2004 Feb CAHN
AB	+!	10MG;80MG		N021687	004 Jul 23, 2004 Feb CAHN
	<u>FAMOTIDINE</u>				
	FOR SUSPENSION;ORAL FAMOTIDINE				
AB	AKORN	40MG/5ML		A201995	001 May 30, 2014 Feb CAHN
AB	NOVITIUM PHARMA	40MG/5ML		A215043	001 Apr 20, 2021 Apr NEWA
	<u>FAMOTIDINE; IBUPROFEN</u>				
	TABLET;ORAL IBUPROFEN AND FAMOTIDINE				
>A>					
>A> AB	ALKEM LABS LTD	26.6MG;800MG		A211890	001 Aug 03, 2021 Jul NFTG
	<u>FELODIPINE</u>				
	TABLET, EXTENDED RELEASE;ORAL FELODIPINE				
	@ JUBILANT GENERICS	2.5MG		A203983	001 Aug 19, 2016 Jun DISC
	@	5MG		A203983	002 Aug 19, 2016 Jun DISC
	@	10MG		A203983	003 Aug 19, 2016 Jun DISC

<u>FENOFIBRATE</u>					
TABLET; ORAL					
FENOFIBRATE					
AB	AUSTARPHARMA	48MG	A208476	001	Feb 10, 2021
AB		145MG	A208476	002	Feb 10, 2021
<u>FENOPROFEN CALCIUM</u>					
CAPSULE; ORAL					
FENOPROFEN CALCIUM					
@ RISING		EQ 200MG BASE	A072394	001	Oct 17, 1988
@		EQ 300MG BASE	A072395	001	Oct 17, 1988
<u>FENTANYL CITRATE</u>					
INJECTABLE; INJECTION					
FENTANYL CITRATE					
AP	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020
@		EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020
<u>FERRIC CARBOXYMALTPOSE</u>					
SOLUTION; INTRAVENOUS					
INJECTAFER					
+!	AM REGENT	1GM IRON/20ML (50MG IRON/ML)	N203565	003	Apr 28, 2021
<u>FERRIC MALTOL</u>					
CAPSULE; ORAL					
ACCRUFER					
+!	SHIELD TX	30MG IRON	N212320	001	Jul 25, 2019
<u>FERRIC OXYHYDROXIDE</u>					
INJECTABLE; INJECTION					
DEXFERRUM					
@ AM REGENT		EQ 50MG IRON/ML	N040024	001	Feb 23, 1996
FERRILECIT					
AB	+! SANOFI AVENTIS US	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	N020955	001	Feb 18, 1999
AB	+!	62.5MG/5ML	N020955	001	Feb 18, 1999
INFED					
BP	+! ALLERGAN	EQ 100MG IRON/2ML (EQ 50MG IRON/ML)	N017441	001	
IRON DEXTRAN					
@ SANOFI AVENTIS US		EQ 50MG IRON/ML	N010787	002	
PROFERDEX					
@ NEW RIVER		EQ 50MG IRON/ML	N017807	001	
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE					
AB	WEST-WARD PHARMS INT	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	A078215	001	Mar 31, 2011
AB		62.5MG/5ML	A078215	001	Mar 31, 2011
INJECTABLE; INTRAVENOUS					
VENOFER					
+ AM REGENT		EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N021135	002	Mar 20, 2005
+		EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005
@		EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)	N021135	005	Mar 29, 2013
@		EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013
@		EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)	N021135	003	Mar 29, 2005
@		EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005
+		EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	N021135	001	Nov 06, 2000
+		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000
+		EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N021135	004	Feb 09, 2007
+		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007
TABLET, CHEWABLE; ORAL					
VELPHORO					
+! VIFOR FRESENIUS		EQ 500MG IRON	N205109	001	Nov 27, 2013
+!		500MG	N205109	001	Nov 27, 2013

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

AB	+! COVIS	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Mar CAHN
AB	SANDOZ INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	A206604	001	Jan 15, 2021	Jan NFTG

FEXINIDAZOLE

TABLET; ORAL

FEXINIDAZOLE

>A>	+! SANOFI	600MG	N214429	001	Jul 16, 2021	Jul CAHN
-----	-----------	-------	---------	-----	--------------	----------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

@ ACTAVIS TOTOWA TEVA 5MG

A077914 001 Mar 28, 2007 May DISC

>A>	<u>FINERENONE</u>
-----	-------------------

TABLET; ORAL

KERENDIA

>A>	+ BAYER HLTHCARE	10MG	N215341	001	Jul 09, 2021	Jul NEWA
>A>	+!	20MG	N215341	002	Jul 09, 2021	Jul NEWA

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

AB	@ APOTEX	EQ 0.5MG BASE	A207993	001	Dec 18, 2020	Jun DISC
	DR REDDYS	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Feb NEWA
AB	@ MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan DISC
	@ ZYDUS PHARMS	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan NEWA

A207994 001 Oct 14, 2020 Mar DISC

FLECAINIDE ACETATE

TABLET; ORAL

TAMBOCOR

+ @ ALVOGEN	50MG	N018830	004	Aug 23, 1988	Jun CAHN
+ @	100MG	N018830	001	Oct 31, 1985	Jun CAHN
+ @	150MG	N018830	003	Jun 03, 1988	Jun CAHN
@	200MG	N018830	002	Oct 31, 1985	Jun CAHN
+ @ CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Jan DISC
+ @	100MG	N018830	001	Oct 31, 1985	Jan DISC
+ @	150MG	N018830	003	Jun 03, 1988	Jan DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	CARDINAL HEALTH 414	20-500mCi/ML	A203603	002	Sep 27, 2018	Mar NEWA
	NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015	Jan CAHN
AP	PHARMALOGIC HLDGS	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan CAHN
AP	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar CTEC

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Mar CMFD
AP		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Mar CMFD

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

>D> AT	AKORN	0.01%	A091514	001	Jun 25, 2015	Jul DISC
>A>	@	0.01%	A091514	001	Jun 25, 2015	Jul DISC
AT	SOLARIS PHARMA CORP	0.01%	A212760	001	Apr 02, 2021	Mar NEWA
AT		0.01%	A212761	001	Apr 02, 2021	Mar NEWA

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

>D> AT	AKORN	0.01%	A202705	001	Sep 09, 2016	Jul DISC
>A>	@	0.01%	A202705	001	Sep 09, 2016	Jul DISC
AT	SOLARIS PHARMA CORP	0.01%	A212762	001	Apr 02, 2021	Mar NEWA

AT	OIL/DROPS;OTIC FLUOCINOLONE ACETONIDE TASMAN PHARMA	0.01%	A213264	001	Feb 05, 2021	Jan NEWA
<u>FLUOCINONIDE</u>						
	CREAM;TOPICAL LIDEX					
	+ @ ALVOGEN LIDEX-E	0.05%	N016908	002		Jun CAHN
AB2	+ ALVOGEN VANOS	0.05%	N016908	003		Jun CAHN
AB	+! BAUSCH GEL;TOPICAL FLUOCINONIDE	0.1%	N021758	001	Feb 11, 2005	May CAHN
AB	+ ALVOGEN OINTMENT;TOPICAL LIDEX	0.05%	N017373	001		Jun CAHN
AB	+ ALVOGEN SOLUTION;TOPICAL LIDEX	0.05%	N016909	002		Jun CAHN
AT	+ ALVOGEN	0.05%	N018849	001	Apr 06, 1984	Jun CAHN
<u>FLUOROURACIL</u>						
	INJECTABLE;INJECTION FLUOROURACIL					
AP	FRESENIUS KABI USA	500MG/10ML (50MG/ML)	A040279	002	Sep 30, 1998	May CHRS
AP		1GM/20ML (50MG/ML)	A040279	001	Sep 30, 1998	May CHRS
AP		2.5GM/50ML (50MG/ML)	A040278	001	Sep 30, 1998	May CHRS
AP		5GM/100ML (50MG/ML)	A040278	002	Sep 30, 1998	May CHRS
	@ NOVAST LABS	5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019	Mar CPOT
AP	TEVA PHARMS USA	500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000	May CHRS
<u>FLUOXETINE HYDROCHLORIDE</u>						
	CAPSULE;ORAL FLUOXETINE HYDROCHLORIDE					
	@ ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020	Feb DISC
	@	EQ 20MG BASE	A202729	002	Aug 27, 2020	Feb DISC
	@	EQ 40MG BASE	A202729	003	Aug 27, 2020	Feb DISC
	@ GRANULES	EQ 10MG BASE	A078143	001	Jan 16, 2008	Jun CAHN
	@	EQ 20MG BASE	A078143	002	Jan 16, 2008	Jun CAHN
	@	EQ 40MG BASE	A078143	003	Jan 16, 2008	Jun CAHN
	TABLET;ORAL FLUOXETINE HYDROCHLORIDE					
>D> AB	DR REDDYS LABS LTD	EQ 20MG BASE	A076006	002	Apr 23, 2018	Jul CHRS
>A> AB	!	EQ 20MG BASE	A076006	002	Apr 23, 2018	Jul CHRS
>D> AB	MYLAN	EQ 10MG BASE	A075755	001	Aug 02, 2001	Jul DISC
>A>	@	EQ 10MG BASE	A075755	001	Aug 02, 2001	Jul DISC
>D> AB	!	EQ 20MG BASE	A075755	002	Aug 02, 2001	Jul DISC
>A>	@	EQ 20MG BASE	A075755	002	Aug 02, 2001	Jul DISC
	TORRENT	EQ 10MG BASE	A206937	001	Oct 21, 2016	Mar CHRS
	!	EQ 20MG BASE	A206937	002	Oct 21, 2016	Mar CHRS
AB	UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	May CAHN
AB		EQ 20MG BASE	A211696	002	Jan 30, 2019	May CAHN
	SARAFEM					
+ @ APIL		EQ 10MG BASE	N021860	001	May 19, 2006	Mar DISC
+ @		EQ 20MG BASE	N021860	003	May 19, 2006	Mar DISC
<u>FLUOXYMESTERONE</u>						
	TABLET;ORAL FLUOXYMESTERONE					
	@ UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983	Jan DISC
<u>FLUPHENAZINE HYDROCHLORIDE</u>						
	TABLET;ORAL FLUPHENAZINE HYDROCHLORIDE					
AB	CEROVENE INC	1MG	A214534	001	Jan 07, 2021	Jan NEWA
AB		2.5MG	A214534	002	Jan 07, 2021	Jan NEWA
AB		5MG	A214534	003	Jan 07, 2021	Jan NEWA
AB		10MG	A214534	004	Jan 07, 2021	Jan NEWA
AB	NOVITIUM PHARMA	1MG	A214674	001	Mar 01, 2021	Feb NEWA
AB		2.5MG	A214674	002	Mar 01, 2021	Feb NEWA
AB		5MG	A214674	003	Mar 01, 2021	Feb NEWA

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB		10MG	A214674	004	Mar 01, 2021	Feb NEWA
AB	ZYDUS	1MG	A214552	001	May 27, 2021	May NEWA
AB		2.5MG	A214552	002	May 27, 2021	May NEWA
AB		5MG	A214552	003	May 27, 2021	May NEWA
AB		10MG	A214552	004	May 27, 2021	May NEWA

FLURBIPROFEN SODIUM

SOLUTION/DROPS;OPHTHALMIC

FLURBIPROFEN SODIUM

! BAUSCH AND LOMB	0.03%	A074447	001	Jan 04, 1995	Jan CHRS
	0.03%	A074447	001	Jan 04, 1995	Jan CTEC
OCUFEN					
+ @ ALLERGAN	0.03%	N019404	001	Dec 31, 1986	Jan DISC

FLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

@ CIPLA	125MG	A075780	001	Sep 19, 2001	Mar DISC
! PAR PHARM	125MG	A075298	001	Sep 18, 2001	Mar CHRS
	125MG	A075298	001	Sep 18, 2001	Mar CTEC
! WAYLIS THERAP	125MG	A075298	001	Sep 18, 2001	Jun CAHN

FLUTICASONE PROPIONATE

OINTMENT;TOPICAL

FLUTICASONE PROPIONATE

>A> AB	! PERRIGO ISRAEL	0.005%	A076668	001	May 14, 2004	Jul CAHN
>D> AB	! PERRIGO NEW YORK	0.005%	A076668	001	May 14, 2004	Jul CAHN
	POWDER;INHALATION					
	ARMONAIR RESPICLICK					

>A> + TEVA PHARM 0.03MG/INH N208798 007 Jul 09, 2021 Jul NEWA

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

AB	BEIJING	EQ 80MG BASE	A209397	001	Apr 26, 2021	Apr NEWA
----	---------	--------------	---------	-----	--------------	----------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

@ BIONPHARMA INC	100MG	A212182	002	Sep 16, 2020	Feb DISC
------------------	-------	---------	-----	--------------	----------

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

AN	TEVA PHARMS USA INC	0.02MG/2ML	A091141	001	Jun 22, 2021	Jun NFTG
----	---------------------	------------	---------	-----	--------------	----------

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

DULERA

+ ORGANON	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019	Jun CAHN
+!	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010	Jun CAHN
+!	0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010	Jun CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

>A> AP	ASPIRO	EQ 150MG BASE/VIAL	A214616	001	Jul 29, 2021	Jul NEWA
AP	AUROBINDO PHARMA LTD	EQ 150MG BASE/VIAL	A210625	001	Jan 12, 2021	Jan NEWA
	@ MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019	Mar DISC
AP	PRAXGEN	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Jun CAHN

FOSCARNET SODIUM

INJECTABLE;INJECTION

FOSCARNET SODIUM

AP	FRESENIUS KABI USA	2.4GM/100ML	A212483	001	Jan 29, 2021	Jan NEWA
AP	GLAND PHARMA LTD	2.4GM/100ML	A213001	001	Apr 21, 2021	Apr NEWA
	FOSCAVIR					
AP	+! CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Jan CTEC

FOSDENOPTERIN HYDROBROMIDE

POWDER; INTRAVENOUS
NULIBRY
+! ORIGIN EQ 9.5MG BASE/VIAL N214018 001 Feb 26, 2021 Feb NEWA

>D> FOSPHENYTOIN SODIUM
>D> SOLUTION; INTRAVENOUS
>D> SESQUIENT
>D> +! SEDOR PHARMS LLC EQ 100MG PHENYTOIN NA/2ML (EQ 50MG N210864 001 Nov 05, 2020 Jul DISC
PHENYTOIN NA/ML)
>A> + @ EQ 100MG PHENYTOIN NA/2ML (EQ 50MG N210864 001 Nov 05, 2020 Jul DISC
PHENYTOIN NA/ML)
>D> +! EQ 500MG PHENYTOIN NA/10ML (EQ N210864 002 Nov 05, 2020 Jul DISC
50MG PHENYTOIN NA/ML)
>A> + @ EQ 500MG PHENYTOIN NA/10ML (EQ N210864 002 Nov 05, 2020 Jul DISC
50MG PHENYTOIN NA/ML)

FULVESTRANT

INJECTABLE; INTRAMUSCULAR
FULVESTRANT
AO APOTEX 50MG/ML A211730 001 Jun 11, 2021 Jun NEWA
AO AUROMEDICS PHARMA 50MG/ML A208811 001 Jul 23, 2019 Jan CAHN
>A> AO ZYDUS PHARMS 50MG/ML A215234 001 Jul 29, 2021 Jul NEWA

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE
AP ACCORD HLTHCARE 10MG/ML A070017 001 Dec 15, 1986 Apr CMFD
AP ATHENEX INC 10MG/ML A214766 001 Jan 27, 2021 Jan NEWA
>D> @ HIKMA 10MG/ML N018267 001 Jul CAHN
>A> @ 10MG/ML N018267 001 Jul CAHN
@ 10MG/ML N018267 001 Jun CAHN
TABLET; ORAL
LASIX
AB + VALIDUS PHARMS 20MG N016273 002 Feb CAHN
AB + 40MG N016273 001 Feb CAHN
AB +! 80MG N016273 003 Feb CAHN

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN
AB ASCENT PHARMS INC 100MG A214956 001 May 10, 2021 Apr NEWA
AB 300MG A214956 002 May 10, 2021 Apr NEWA
AB 400MG A214956 003 May 10, 2021 Apr NEWA
AB GRAVITI PHARMS 100MG A207099 001 Mar 24, 2017 Jun CAHN
AB 300MG A207099 002 Mar 24, 2017 Jun CAHN
AB 400MG A207099 003 Mar 24, 2017 Jun CAHN
AB ZHEJIANG YONGTAI 100MG A213603 001 Aug 17, 2020 Apr CMFD
@ 100MG A213603 001 Aug 17, 2020 Feb DISC
AB 300MG A213603 002 Aug 17, 2020 Apr CMFD
@ 300MG A213603 002 Aug 17, 2020 Feb DISC
AB 400MG A213603 003 Aug 17, 2020 Apr CMFD
@ 400MG A213603 003 Aug 17, 2020 Feb DISC

GALANTAMINE HYDROBROMIDE

TABLET; ORAL
GALANTAMINE HYDROBROMIDE
AB ! YABAO PHARM EQ 4MG BASE A077604 001 Feb 06, 2009 May CHRS
RAZADYNE
+ @ JANSSEN PHARMS EQ 4MG BASE N021169 001 Feb 28, 2001 May DISC
+ @ EQ 8MG BASE N021169 002 Feb 28, 2001 May DISC
+ @ EQ 12MG BASE N021169 003 Feb 28, 2001 May DISC

GANCICLOVIR SODIUM

INJECTABLE; INJECTION
>D> CYTOVENE
>D> AP +! CHEPLAPHARM EQ 500MG BASE/VIAL N019661 001 Jun 23, 1989 Jul DISC
>A> + @ EQ 500MG BASE/VIAL N019661 001 Jun 23, 1989 Jul DISC
GANCICLOVIR SODIUM
>D> AP PHARMASCIENCE INC EQ 500MG BASE/VIAL A207645 001 Dec 08, 2017 Jul CHRS
>A> AP ! EQ 500MG BASE/VIAL A207645 001 Dec 08, 2017 Jul CHRS
>D> @ WEST-WARD PHARMS INT EQ 500MG BASE/VIAL A076222 001 Jul 16, 2003 Jul CMFD

INJECTABLE; INJECTION
GANCICLOVIR SODIUM

>A> AP EQ 500MG BASE/VIAL A076222 001 Jul 16, 2003 Jul CMFD

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
GATIFLOXACIN

AT AKORN 0.5% A203189 001 Sep 03, 2014 Feb CAHN
@ MYLAN 0.5% A206446 001 Jun 08, 2018 Jun DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP HIKMA INTL PHARMS	EQ 200MG BASE/VIAL	A206617 001 Jun 25, 2021 Jun NEWA
AP	EQ 1GM BASE/VIAL	A206617 002 Jun 25, 2021 Jun NEWA
AP ! JIANGSU HANSON PHARM	EQ 200MG BASE/VIAL	A202485 001 May 07, 2013 Feb CHRS
AP !	EQ 1GM BASE/VIAL	A202485 002 May 07, 2013 Feb CHRS
AP MEITHEAL	200MG/5.26ML (38MG/ML)	A212129 001 Dec 11, 2020 Jan CAHN
AP	1GM/26.3ML (38MG/ML)	A212129 002 Dec 11, 2020 Jan CAHN
AP	2GM/52.6ML (38MG/ML)	A212129 003 Dec 11, 2020 Jan CAHN
GEMZAR		
+ @ LILLY	EQ 200MG BASE/VIAL	N020509 001 May 15, 1996 Feb DISC
+ @	EQ 1GM BASE/VIAL	N020509 002 May 15, 1996 Feb DISC

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

AB ASCENT PHARMS INC 600MG A214603 001 Jan 13, 2021 Jan NEWA

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE

@ HIKMA	EQ 10MG BASE/ML	A062251 002 Jun CAHN
@	EQ 40MG BASE/ML	A062251 001 Jun CAHN

GLECAPREVIR; PIBRENTASVIR

PELLETS; ORAL
MAVYRET

+! ABBVIE INC 50MG; 20MG/ PACKET N215110 001 Jun 10, 2021 Jun NEWA

GLYBURIDE

TABLET; ORAL
GLYNASE

AB + Pfizer	1.5MG	N020051 001 Mar 04, 1992 Feb CAHN
AB +	3MG	N020051 002 Mar 04, 1992 Feb CAHN
+ @	4.5MG	N020051 003 Sep 24, 1993 Feb CAHN
AB +!	6MG	N020051 004 Sep 24, 1993 Feb CAHN
MICRONASE		
+ @ Pfizer	1.25MG	N017498 001 May 01, 1984 Feb CAHN
@	2.5MG	N017498 002 May 01, 1984 Feb CAHN
+ @	5MG	N017498 003 May 01, 1984 Feb CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP ATHENEX INC	0.2MG/ML	A210083 001 Feb 21, 2020 Jan CAHN
AP HONG KONG	0.2MG/ML	A212802 001 Jul 06, 2021 Jun NEWA
AP XIROMED	0.2MG/ML	A212227 001 Mar 04, 2021 Feb NEWA

ROBINUL

>D> + @ HIKMA	0.2MG/ML	N017558 001 Jul CAHN
>A> + @	0.2MG/ML	N017558 001 Jul CAHN

SOLUTION; ORAL

>A> GLYCOPYRROLATE		
>A> AA PAR PHARM INC	1MG/5ML	A204438 001 Aug 09, 2021 Jul NFTG

TABLET; ORAL

ROBINUL

AA + CASPER PHARMA LLC	1MG	N012827 001 Jun CMFD
ROBINUL FORTE		
AA + CASPER PHARMA LLC	2MG	N012827 002 Jun CMFD

GLYCOPYRRONIUM TOSYLATE

CLOTH;TOPICAL

QBREXZA

+! JOURNEY

EQ 2.4% BASE

N210361 001 Jun 28, 2018 May CAHN

GONADORELIN HYDROCHLORIDE

INJECTABLE;INJECTION

FACTREL

>A>	@ HIKMA	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Jul CAHN
>A>	@	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Jul CAHN
>A>	@	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Jul CAHN
>D>	@ WEST-WARD PHARMS INT	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Jul CAHN
>D>	@	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Jul CAHN
>D>	@	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Jul CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION;ORAL

GRANISOL

@ INTRA SANA LABS

EQ 2MG BASE/10ML

A078334 001 Feb 28, 2008 Jan CAHN

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB	! AMNEAL PHARM	EQ 2MG BASE	A075109	002	Nov 25, 1998	Jan CHRS
	@ MYLAN	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jan DISC
	@	EQ 2MG BASE	A074796	002	Jan 27, 1997	Jan DISC
AB	UNICHEM	EQ 1MG BASE	A214689	001	Mar 03, 2021	Feb NEWA
AB		EQ 2MG BASE	A214689	002	Mar 03, 2021	Feb NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	GUANFACINE HYDROCHLORIDE					
	@ YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May DISC
	@	EQ 2MG BASE	A213428	002	Nov 25, 2020	May DISC
	@	EQ 3MG BASE	A213428	003	Nov 25, 2020	May DISC
	@	EQ 4MG BASE	A213428	004	Nov 25, 2020	May DISC

HALCINONIDE

SOLUTION;TOPICAL

HALOG

+! SUN PHARM INDs INC 0.1%

N017823 001

Apr CRLD

HALOBETASOL PROPIONATE

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

AB	@ COSETTE	0.05%	A077721	001	Sep 07, 2006	Mar DISC
AB	! PERRIGO ISRAEL	0.05%	A076872	001	Dec 16, 2004	Mar CHRS
	ULTRAVATE					
	+ @ SUN PHARM INDs INC	0.05%	N019968	001	Dec 17, 1990	Mar DISC

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Apr CMFD
AB		5MG	A071131	001	Feb 17, 1987	Apr CMFD
AB		10MG	A071132	001	May 12, 1987	Apr CMFD

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

>A> AO	HONG KONG	EQ 50MG BASE/ML	A214507	001	Jul 26, 2021	Jul NEWA
>A> AO		EQ 100MG BASE/ML	A214507	002	Jul 26, 2021	Jul NEWA

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALDOL

+ @ ORTHO MCNEIL

EQ 2MG BASE/ML

N015922 001

Mar CRLD

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

@ BE PHARMS	1,000 UNITS/ML	A214804	001	Dec 29, 2020	Jun DISC
@	10,000 UNITS/ML	A214839	001	Dec 29, 2020	Jun DISC
>D> AP +! HIKMA	1,000 UNITS/ML	N017037	001		Jul CAHN
>A> AP +!	1,000 UNITS/ML	N017037	001		Jul CAHN
>D> AP +!	5,000 UNITS/ML	N017037	002		Jul CAHN
>A> AP +!	5,000 UNITS/ML	N017037	002		Jul CAHN
>D> @	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jul CAHN
>A> @	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jul CAHN
>D> AP +!	10,000 UNITS/ML	N017037	003		Jul CAHN
>A> AP +!	10,000 UNITS/ML	N017037	003		Jul CAHN
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP FRESENIUS KABI USA	200 UNITS/100ML	A212441	001	Jul 24, 2020	Apr CMFD
@	200 UNITS/100ML	A212441	001	Jul 24, 2020	Jan DISC
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP FRESENIUS KABI USA	200 UNITS/100ML	A212441	002	Jul 24, 2020	Apr CMFD
@	200 UNITS/100ML	A212441	002	Jul 24, 2020	Jan DISC
HEPARIN SODIUM PRESERVATIVE FREE					
@ SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014	Apr DISC

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA UPSHER SMITH LABS	10MG	A209251	001	Jul 09, 2018	May CAHN
AA	25MG	A209251	002	Jul 09, 2018	May CAHN
AA	50MG	A209251	003	Jul 09, 2018	May CAHN
AA	100MG	A209251	004	Jul 09, 2018	May CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

MICROZIDE

AB +! TEVA BRANDED PHARM	12.5MG	N020504	001	Dec 27, 1996	Mar CAHN
--------------------------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

ZESTORETIC

AB + ALMATICA	12.5MG; 10MG	N019888	003	Nov 18, 1993	Jan CAHN
AB +!	12.5MG; 20MG	N019888	001	Sep 20, 1990	Jan CAHN
AB +!	25MG; 20MG	N019888	002	Jul 20, 1989	Jan CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB JUBILANT CADISTA	12.5MG; 50MG	A201845	001	Sep 18, 2012	Jun CAHN
AB	12.5MG; 100MG	A201845	002	Sep 18, 2012	Jun CAHN
AB	25MG; 100MG	A201845	003	Sep 18, 2012	Jun CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

+ @ CONCORDIA	12.5MG; EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun DISC
+ @	12.5MG; EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun DISC
+ @	12.5MG; EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB + VALIDUS PHARMS	25MG; 50MG	N018303	001	Dec 31, 1984	Feb CAHN
+ @	25MG; 100MG	N018303	002	Dec 31, 1984	Feb CAHN
+ @	50MG; 100MG	N018303	003	Dec 31, 1984	Feb CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A> @ ANI PHARMS	25MG; 40MG	A070705	002	Oct 01, 1986	Jul CMS1
------------------	------------	---------	-----	--------------	----------

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL
ZOHYDRO ER

AB	+!	RECRO GAINESVILLE	10MG	N 202880	001	Oct 25, 2013	May CAHN
AB	+		15MG	N 202880	002	Oct 25, 2013	May CAHN
AB	+		20MG	N 202880	003	Oct 25, 2013	May CAHN
AB	+		30MG	N 202880	004	Oct 25, 2013	May CAHN
AB	+		40MG	N 202880	005	Oct 25, 2013	May CAHN
AB	+		50MG	N 202880	006	Oct 25, 2013	May CAHN

TABLET, EXTENDED RELEASE;ORAL
HYDROCODONE BITARTRATE

AB		ALVOGEN PINE BROOK	20MG	A 208269	001	Mar 01, 2021	Feb NFTG
AB			30MG	A 208269	002	Mar 01, 2021	Feb NFTG
AB			40MG	A 208269	003	Mar 01, 2021	Feb NFTG
AB			60MG	A 208269	004	Mar 01, 2021	Feb NFTG
AB			80MG	A 208269	005	Mar 01, 2021	Feb NFTG
AB			100MG	A 208269	006	Mar 01, 2021	Feb NFTG
AB			120MG	A 208269	007	Mar 01, 2021	Feb NFTG

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB		NOSTRUM LABS INC	5MG;200MG	A 077727	001	Nov 06, 2006	Jan CAHN
AB			7.5MG;200MG	A 077723	001	Nov 06, 2006	Jan CAHN
			10MG;200MG	A 077723	002	Nov 06, 2006	Mar CTEC
AB			10MG;200MG	A 077723	002	Nov 06, 2006	Jan CAHN
		REPREXAIN					
	@	AMNEAL PHARMS NY	2.5MG;200MG	A 076642	003	Oct 19, 2007	Mar DISC
	@		10MG;200MG	A 076642	004	Oct 19, 2007	Mar DISC

HYDROCORTISONE

CREAM;TOPICAL

SYNACORT

@ BAUSCH	0.5%	A 087459	001	May CAHN
@	1%	A 087458	001	May CAHN
@	2.5%	A 087457	001	May CAHN

ENEMA;RECTAL

COLOCORT

AB		CHARTWELL	100MG/60ML	A 075172	001	Dec 03, 1999	Apr CAHN
----	--	-----------	------------	----------	-----	--------------	----------

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL

CORTISPORIN

>D>							
>D>	+!	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N 050218	001	Aug 09, 1985	Jul DISC
>A>	+ @		0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N 050218	001	Aug 09, 1985	Jul DISC

HYDROCORTISONE PROBUTATE

CREAM;TOPICAL

PANDEL

+!	ANI PHARMS	0.1%	N 020453	001	Feb 28, 1997	Apr CAHN
----	------------	------	----------	-----	--------------	----------

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

HYDROCORTONE

+ @	MERCK	EQ 50MG BASE/ML	N 012052	001		
-----	-------	-----------------	----------	-----	--	--

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

AB		COSETTE	0.2%	A 213724	001	Feb 11, 2021	Feb NEWA
----	--	---------	------	----------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDE

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

@ LANNETT CO INC	2MG	A 077471	002	Dec 09, 2009	Mar DISC
@	4MG	A 077471	003	Dec 09, 2009	Mar DISC
@	8MG	A 077471	001	Dec 09, 2009	Mar DISC

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

>D> AB	HAVIX	200MG	A212902	001	May 14, 2020	Jul CAHN
>A> AB	SENORES PHARMS	200MG	A212902	001	May 14, 2020	Jul CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR

MAKENA

AP1	+! COVIS	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Mar CAHN
	MAKENA PRESERVATIVE FREE					
AP	+! COVIS	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Mar CAHN
	SOLUTION;SUBCUTANEOUS					
	MAKENA (AUTOINJECTOR)					
	+! COVIS	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Mar CAHN

HYDROXYUREA

TABLET;ORAL

SIKLOS

+! ADDMEDICA SAS 1GM

N208843 002 Dec 21, 2017 Mar CHRS

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB	PRINSTON INC	10MG	A040580	003	May 27, 2005	Feb CMS1
AB		25MG	A040580	002	May 27, 2005	Feb CMS1

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

AP	NANG KUANG PHARM CO	EQ 3MG BASE/3ML	A204329	001	Jun 16, 2021	Jun NEWA
----	---------------------	-----------------	---------	-----	--------------	----------

IBREXAFUNGERP CITRATE

TABLET;ORAL

BREXAFAEMME

+! SCYNEXIS EQ 150MG BASE

N214900 001 Jun 01, 2021 Jun NEWA

IBRUTINIB

CAPSULE;ORAL

IBRUTINIB

>D> AB	ZYDUS	70MG	A211344	001	Mar 31, 2021	Jul DISC
>A>	@	70MG	A211344	001	Mar 31, 2021	Jul DISC
AB		70MG	A211344	001	Mar 31, 2021	Mar NFTG
>D> AB		140MG	A211344	002	Mar 31, 2021	Jul DISC
>A>	@	140MG	A211344	002	Mar 31, 2021	Jul DISC
AB		140MG	A211344	002	Mar 31, 2021	Mar NFTG
	IMBRUVICA					
>D> AB	+ PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017	Jul CTEC
>A>	+	70MG	N205552	002	Dec 20, 2017	Jul CTEC
>D> AB	+!	140MG	N205552	001	Nov 13, 2013	Jul CTEC
>A>	+!	140MG	N205552	001	Nov 13, 2013	Jul CTEC

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

>D> AB	L PERRIGO CO	100MG/5ML	A076925	001	Sep 23, 2004	Jul CAHN
>A> AB	PADAGIS US	100MG/5ML	A076925	001	Sep 23, 2004	Jul CAHN

TABLET;ORAL

IBUPROFEN

>A> AB	L PERRIGO CO	400MG	A077114	001	Jul 18, 2005	Jul CAHN
>A> AB		600MG	A077114	002	Jul 18, 2005	Jul CAHN
>A> AB		800MG	A077114	003	Jul 18, 2005	Jul CAHN
>D> AB	PERRIGO PHARMS CO	400MG	A077114	001	Jul 18, 2005	Jul CAHN
>D> AB		600MG	A077114	002	Jul 18, 2005	Jul CAHN
>D> AB		800MG	A077114	003	Jul 18, 2005	Jul CAHN
	@ VINTAGE PHARMS	400MG	A071644	001	Feb 01, 1988	Feb DISC

IBUTILIDE FUMARATE

INJECTABLE; INJECTION
CORVERT
AP +! PFIZER 0.1MG/ML N020491 001 Dec 28, 1995 Feb CAHN

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS
ICATIBANT ACETATE
AP @ DR REDDYS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A213054 001 Oct 05, 2020 May DISC
GLENMARK PHARMS LTD EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A213222 001 May 21, 2021 May NEWA

ICOSAPENT ETHYL

CAPSULE; ORAL
ICOSAPENT ETHYL
AB APOTEX 1GM A209437 001 Jun 30, 2021 Jun NEWA
@ TEVA PHARMS USA 500MG A209525 001 Sep 11, 2020 Mar DISC
@ VASCEPA 1GM A209525 002 Sep 11, 2020 Mar DISC
+ AMARIN PHARMS 500MG N202057 002 Feb 16, 2017 Mar CTEC

ILOPROST

SOLUTION; INHALATION
VENTAVIS
+! ACTELION 10MCG/ML (10MCG/ML) N021779 002 Dec 08, 2005 Feb CAHN
@ 20MCG/2ML (10MCG/ML) N021779 001 Dec 29, 2004 Feb CAHN
+! 20MCG/ML (20MCG/ML) N021779 003 Aug 07, 2009 Feb CAHN

IMIQUIMOD

CREAM; TOPICAL
IMIQUIMOD
AB TARO 3.75% A205971 001 Jan 26, 2021 Jan NFTG

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE
>D> AB ANI PHARMS 2.5MG A074299 001 Jul 27, 1995 Jul CHRS
>A> AB ! 2.5MG A074299 001 Jul 27, 1995 Jul CHRS
>D> AB MYLAN 1.25MG A074461 002 Mar 26, 1997 Jul DISC
>A> @ 1.25MG A074461 002 Mar 26, 1997 Jul DISC
>D> AB ! 2.5MG A074461 001 Mar 27, 1996 Jul DISC
>A> @ 2.5MG A074461 001 Mar 27, 1996 Jul DISC

INDOCYANINE GREEN

INJECTABLE; INJECTION
INDOCYANINE GREEN
AP RENEW PHARMS 25MG/VIAL A040811 001 Nov 21, 2007 Jun CAHN

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN
@ JUBILANT GENERICS 25MG A205215 001 Aug 25, 2017 Jan DISC
@ 50MG A205215 002 Aug 25, 2017 Jan DISC
TIVORBEX
+ @ GENUS 20MG N204768 001 Feb 24, 2014 Apr DISC
+ @ 40MG N204768 002 Feb 24, 2014 Apr DISC
CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN
@ AUROBINDO PHARMA LTD 75MG A204243 001 Dec 27, 2016 Jan DISC
@ JUBILANT GENERICS 75MG A202706 001 Oct 05, 2015 Jun DISC

INFIGRATINIB PHOSPHATE

CAPSULE; ORAL
TRUSELTIQ
+ QED THERAP 25MG N214622 001 May 28, 2021 May NEWA
+! 100MG N214622 002 May 28, 2021 May NEWA

TOPAMIDOL

INJECTABLE; INJECTION

ISOVUE-300	61%	N018735	002	Dec 31, 1985	Jan CTEC
+! BRACCO ISOVUE-370	76%	N018735	003	Dec 31, 1985	Jan CTEC
+! BRACCO SCANLUX-300	76%	A090394	001	Jun 18, 2010	Jan DISC
@ SANOCHEMIA CORP USA SCANLUX-370	61%	A090394	002	Jun 18, 2010	Jan DISC
@ SANOCHEMIA CORP USA	76%				

IRBESARTAN

TABLET; ORAL

IRBESARTAN					
@ US ANTIBIOTICS	75MG	A203161	001	Sep 27, 2012	May CAHN
@	150MG	A203161	002	Sep 27, 2012	May CAHN
@	300MG	A203161	003	Sep 27, 2012	May CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE					
@ US ANTIBIOTICS	40MG/2ML (20MG/ML)	A078953	001	Apr 15, 2010	May CAHN
@	100MG/5ML (20MG/ML)	A078953	002	Apr 15, 2010	May CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE					
AP AMRING PHARMS	0.2MG/ML	A211237	001	May 19, 2021	May NEWA
AP MICRO LABS	0.2MG/ML	A210845	001	Feb 16, 2021	Feb NEWA

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM					
AB1 MYLAN PHARMS INC	10MG	A075945	001	Nov 08, 2002	Mar CTEC
AB1	20MG	A075945	002	Nov 08, 2002	Mar CTEC
AB1	40MG	A075945	003	Nov 08, 2002	Mar CTEC
CLARAVIS					
AB1 TEVA PHARMS USA	10MG	A076356	001	Apr 11, 2003	Mar CTEC
AB1	20MG	A076135	002	Apr 11, 2003	Mar CTEC
AB1	30MG	A076135	003	May 11, 2006	Mar CTEC
AB1 !	40MG	A076135	001	Apr 11, 2003	Mar CTEC
ISOTRETINOIN					
AB2 ACTAVIS LABS FL	10MG	A205063	001	Mar 31, 2021	Mar NFTG
AB2	20MG	A205063	002	Mar 31, 2021	Mar NFTG
AB2	25MG	A205063	003	Mar 31, 2021	Mar NFTG
AB2	30MG	A205063	004	Mar 31, 2021	Mar NFTG
AB2	35MG	A205063	005	Mar 31, 2021	Mar NFTG
AB2	40MG	A205063	006	Mar 31, 2021	Mar NFTG
AB1 AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017	Mar CTEC
AB1	20MG	A207792	002	Sep 29, 2017	Mar CTEC
AB1	30MG	A207792	003	Sep 29, 2017	Mar CTEC
AB1	40MG	A207792	004	Sep 29, 2017	Mar CTEC
AB2 UPSHER SMITH LABS	40MG	A213571	001	Apr 12, 2021	Apr NEWA
MYORISAN					
AB1 DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	Mar CTEC
AB1	20MG	A076485	002	Jan 19, 2012	Mar CTEC
AB1	30MG	A076485	004	Aug 25, 2015	Mar CTEC
AB1	40MG	A076485	003	Jan 19, 2012	Mar CTEC
ZENATANE					
AB1 DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013	Mar CTEC
AB1	20MG	A202099	002	Mar 25, 2013	Mar CTEC
AB1	30MG	A202099	004	Feb 23, 2015	Mar CTEC
AB1	40MG	A202099	003	Mar 25, 2013	Mar CTEC

ITRACONAZOLE

TABLET; ORAL

ONMEL					
+ @ SEBELA IRELAND LTD	200MG	N022484	001	Apr 29, 2010	Apr DISC

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET;ORAL

SYMDEKO (COPACKAGED)

>A>	+ VERTEX PHARMS INC	75MG;75MG, 50MG	N210491	002	Jun 21, 2019	Jul CPOT
>A>	+!	150MG;150MG, 100MG	N210491	001	Feb 12, 2018	Jul CPOT
	TABLET, TABLET;ORAL					
	SYMDEKO (COPACKAGED)					
>D>	+ VERTEX PHARMS INC	75MG,N/A;75MG, 50MG	N210491	002	Jun 21, 2019	Jul CPOT
>D>	+!	150MG,N/A;150MG, 100MG	N210491	001	Feb 12, 2018	Jul CPOT

IVOSIDENIB

TABLET;ORAL

TIBSOVO

+! SERVIER

250MG

N211192 001 Jul 20, 2018 Apr CAHN

IXAZOMIB CITRATE

CAPSULE;ORAL

NINLARO

+ TAKEDA PHARMS USA

EQ 2.3MG BASE

N208462 001 Nov 20, 2015 May CAHN

+

EQ 3MG BASE

N208462 002 Nov 20, 2015 May CAHN

+!

EQ 4MG BASE

N208462 003 Nov 20, 2015 May CAHN

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

KETAMINE HYDROCHLORIDE

AP	AUROMEDICS PHARMA	EQ 10MG BASE/ML	A076092	001	Sep 30, 2008	Jan CAHN
AP		EQ 50MG BASE/ML	A076092	002	Dec 28, 2001	Jan CAHN
AP		EQ 100MG BASE/ML	A076092	003	Oct 25, 2002	Jan CAHN

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL

KETOCONAZOLE

AT	XIROMED	2%	A213601	001	May 21, 2021	May NEWA
AB	CREAM;TOPICAL					
	KETOCONAZOLE					
AB	ENCUBE	2%	A212443	001	May 20, 2021	May NEWA
	TABLET;ORAL					
	KETOCONAZOLE					
	@ MYLAN	200MG	A075597	001	Dec 23, 1999	Mar DISC

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

>D> AB	HERITAGE PHARMS INC	75MG	A074014	003	Jan 29, 1993	Jul CTEC
>A>	!	75MG	A074014	003	Jan 29, 1993	Jul CTEC
	@ RISING	50MG	A074024	001	Dec 29, 1995	Jan CAHN
	@	75MG	A074024	002	Dec 29, 1995	Jan CAHN
>D> AB	! TEVA	75MG	A073517	001	Dec 22, 1992	Jul DISC
>A>	@	75MG	A073517	001	Dec 22, 1992	Jul DISC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

@	AUROBINDO PHARMA LTD	15MG/ML	A212939	001	Oct 20, 2020	Apr DISC
@		30MG/ML	A212939	002	Oct 20, 2020	Apr DISC
@	HOSPIRA	15MG/ML	A074993	001	Jan 27, 1999	Mar DISC
	SOLUTION/DROPS;OPHTHALMIC					
	KETOROLAC TROMETHAMINE					
@	AUROBINDO PHARMA LTD	0.5%	A205190	001	Dec 03, 2020	Jun DISC

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP	BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002	Mar CMFD
	TABLET;ORAL					
	LABETALOL HYDROCHLORIDE					
>D> AB	PAR FORM	200MG	A200908	002	Jul 10, 2012	Jul CHRS
>A> AB	!	200MG	A200908	002	Jul 10, 2012	Jul CHRS
	TRANDATE					
>A>	+ @ ALVOGEN	100MG	N018716	001	May 24, 1985	Jul DISC

TABLET;ORAL
TRANDATE

>A>	+ @	200MG	N 018716	002	Aug 01, 1984	Jul DISC
>A>	+ @	300MG	N 018716	003	Aug 01, 1984	Jul DISC
>A>	+ @	400MG	N 018716	004	Aug 01, 1984	Jul CAHN
>D> AB	+ CNTY LINE PHARMS	100MG	N 018716	001	May 24, 1985	Jul DISC
>D> AB	+!	200MG	N 018716	002	Aug 01, 1984	Jul DISC
AB	+!	200MG	N 018716	002	Aug 01, 1984	Apr CHRS
>D> AB	+	300MG	N 018716	003	Aug 01, 1984	Jul DISC
>D>	+ @	400MG	N 018716	004	Aug 01, 1984	Jul CAHN

LACTULOSE

SOLUTION;ORAL
LACTULOSE

AA	TORRENT	10GM/15ML	A 207786	001	Jun 11, 2018	Jun CMFD
	SOLUTION;ORAL, RECTAL					
	LACTULOSE					
AA	TORRENT	10GM/15ML	A 203762	001	Mar 27, 2015	Jun CMFD

LAMIVUDINE

TABLET;ORAL
LAMIVUDINE

AB	CENTAUR PHARMS PVT	150MG	A 203586	001	Nov 21, 2016	Jun CAHN
----	--------------------	-------	----------	-----	--------------	----------

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+ @ AUROBINDO PHARMA LTD 300MG;300MG

N 022344 001 May 15, 2018 Feb DISC

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

@ GRANULES	25MG	A 078982	001	Jan 27, 2009	Jun CAHN
@	100MG	A 078982	002	Jan 27, 2009	Jun CAHN
@	150MG	A 078982	003	Jan 27, 2009	Jun CAHN
@	200MG	A 078982	004	Jan 27, 2009	Jun CAHN

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

@ JUBILANT GENERICS	5MG	A 200220	001	Feb 28, 2011	Jun DISC
@	25MG	A 200220	002	Feb 28, 2011	Jun DISC

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

>A> AB	ACTAVIS ELIZABETH	250MG	A 200672	006	Nov 13, 2013	Jul CMS1
	TABLET, ORALLY DISINTEGRATING;ORAL					
	LAMOTRIGINE					
AB	AJANTA PHARMA LTD	25MG	A 213271	001	Jan 19, 2021	Jan NEWA
AB		50MG	A 213271	002	Jan 19, 2021	Jan NEWA
AB		100MG	A 213271	003	Jan 19, 2021	Jan NEWA
AB		200MG	A 213271	004	Jan 19, 2021	Jan NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
PREVACID

+ @ TAKEDA PHARMS USA 15MG

N 020406 001 May 10, 1995 Jun DISC

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE

AB	DR REDDYS LABS LTD	15MG	A 210465	001	Feb 01, 2021	Jan NEWA
		30MG	A 210465	002	Feb 01, 2021	Jan NEWA

LASMIDITAN SUCCINATE

TABLET;ORAL

REYVOW

+ ELI LILLY AND CO	EQ 50MG BASE	N 211280	001	Jan 31, 2020	May CPOT
+	EQ 100MG BASE	N 211280	002	Jan 31, 2020	May CHRS
+!	EQ 100MG BASE	N 211280	002	Jan 31, 2020	May CPOT
+!	EQ 200MG BASE	N 211280	003	Dec 18, 2020	May CHRS
+	EQ 200MG BASE	N 211280	003	Dec 18, 2020	May CPOT

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

AB	AET PHARMA	10MG	A213497	001	May 10, 2021	Jun CAHN
AB		20MG	A213497	002	May 10, 2021	Jun CAHN
AB	AUROBINDO PHARMA LTD	10MG	A213652	001	Mar 29, 2021	Mar NEWA
AB		20MG	A213652	002	Mar 29, 2021	Mar NEWA
AB	AXUNIO	10MG	A213497	001	May 10, 2021	Apr NEWA
AB		20MG	A213497	002	May 10, 2021	Apr NEWA

LENALIDOMIDE

CAPSULE; ORAL

LENALIDOMIDE

>A>	AB	ARROW INTL	5MG	A201452	001	May 21, 2021	Jul CAHN
>A>	AB		10MG	A201452	002	May 21, 2021	Jul CAHN
>A>	AB		15MG	A201452	003	May 21, 2021	Jul CAHN
>A>	AB		25MG	A201452	004	May 21, 2021	Jul CAHN
>D>	AB	NATCO PHARMA LTD	5MG	A201452	001	May 21, 2021	Jul CAHN
	AB		5MG	A201452	001	May 21, 2021	May NFTG
>D>	AB		10MG	A201452	002	May 21, 2021	Jul CAHN
	AB		10MG	A201452	002	May 21, 2021	May NFTG
>D>	AB		15MG	A201452	003	May 21, 2021	Jul CAHN
	AB		15MG	A201452	003	May 21, 2021	May NFTG
>D>	AB		25MG	A201452	004	May 21, 2021	Jul CAHN
	AB		25MG	A201452	004	May 21, 2021	May NFTG

LETROZOLE

TABLET; ORAL

LETROZOLE

© APOTEX INC

2.5MG

A091303 001 Apr 19, 2012 Jan DISC

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET; ORAL

KISQALI F

NOVARTIS

2.5MG; EO 200MG BASE

N209935 001 May 04, 2017 Jul CPOT

>D> +! NOVARTIS 2.5MG,N/A;N/A,EQ 200MG BASE N209935 001 May 04, 2017 Jul CPOT
TABLET, TABLET;ORAL
KISQALI FEMARA CO-PACK (COPACKAGED)

LEUCOVORIN CALCIUM

**INJECTABLE; INJECTION
LEUCOVORIN CALCIUM**

>A> AP !	HIKMA	EQ 50MG BASE/VIAL	A089384	001	Sep 14, 1987	Jul CAHN
>A> AP !		EQ 100MG BASE/VIAL	A089717	001	Mar 28, 1988	Jul CAHN
>D> AP !	WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL	A089384	001	Sep 14, 1987	Jul CAHN
>D> AP !		EQ 100MG BASE/VIAL	A089717	001	Mar 28, 1988	Jul CAHN
TABLET;ORAL						
LEUCOVORIN CALCIUM						
AB	EPIC PHARMA LLC	EQ 10MG BASE	A074544	003	May 19, 2021	May NEWA
AB		EQ 15MG BASE	A074544	004	May 19, 2021	May NEWA

LEUPROLIDE MESYLATE

EMULSION; SUBCUTANEOUS
CAMCEVI KIT
1 L FORESEE PHARMS

+! FORESEE PHARMS EQ 4ZMG BASE

NZ11488 001 May 25, 2021 May NEWA

LEVETIRACETAM

LEVETIRACETAM
9. TURILANT GENERICS

SUBTAN GENERICS		500MG/5ML (100MG/ML)	A206838	001	Jan 02, 2016	Jan DISC
LEVETIRACETAM IN SODIUM CHLORIDE						
AP	AUROBINDO PHARMA LTD	1GM/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Feb CPOT
AP		1.5GM/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Feb CPOT
AP	GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Feb CPOT
AP		1.5GM/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Feb CDFR
AP	+! HQ SPECIALITY PHARMA	1GM/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Feb CPOT
AP	+! HQ SPECIALITY PHARMA	1.5GM/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Feb CPOT
AP	NEXUS PHARMS	1GM/100ML (10MG/ML)	A213532	002	Jul 06, 2020	Feb CPOT
AP		1.5GM/100ML (15MG/ML)	A213532	003	Jul 06, 2020	Feb CPOT

	SOLUTION;ORAL LEVETIRACETAM						
AA	AKORN	100MG/ML		A090601	001	Feb 28, 2012	Feb CAHN
	TABLET;ORAL LEVETIRACETAM						
	@ NOSTRUM LABS INC	250MG		A090511	001	Aug 18, 2011	Mar DISC
AB		250MG		A090511	001	Aug 18, 2011	Jan CAHN
	@	500MG		A090511	002	Aug 18, 2011	Mar DISC
AB		500MG		A090511	002	Aug 18, 2011	Jan CAHN
	@	750MG		A090511	003	Aug 18, 2011	Mar DISC
AB		750MG		A090511	003	Aug 18, 2011	Jan CAHN
	@	1GM		A090511	004	Aug 18, 2011	Mar DISC
AB		1GM		A090511	004	Aug 18, 2011	Jan CAHN
AB	SCIEGEN PHARMS INC	750MG		A215069	001	Jun 11, 2021	Jun NEWA
AB		1GM		A215069	002	Jun 11, 2021	Jun NEWA
	TABLET, EXTENDED RELEASE;ORAL ELEPSIA XR						
	+ TRIPPOINT	1GM		N204417	001	Dec 20, 2018	Jan CAHN
	+!	1.5GM		N204417	002	Dec 20, 2018	Jan CAHN
	LEVETIRACETAM						
AB	OVERSEAS	750MG		A212688	001	Jun 11, 2020	May CMFD
	<u>LEVOBUNOLOL HYDROCHLORIDE</u>						
	SOLUTION/DROPS;OPHTHALMIC AKBETA						
>D> AT	AKORN	0.25%		A074779	001	Oct 29, 1996	Jul DISC
>A>	@	0.25%		A074779	001	Oct 29, 1996	Jul DISC
>D> AT		0.5%		A074780	001	Oct 29, 1996	Jul DISC
>A>	@	0.5%		A074780	001	Oct 29, 1996	Jul DISC
	BETAGAN						
	+ @ ALLERGAN	0.25%		N019814	001	Jun 28, 1989	Jun DISC
	<u>LEVO CETIRIZINE DIHYDROCHLORIDE</u>						
	SOLUTION;ORAL LEVO CETIRIZINE DIHYDROCHLORIDE						
>D> AA	! L PERRIGO CO	2.5MG/5ML		A091263	001	Nov 07, 2011	Jul CAHN
>A> AA	! PADAGIS US XYZAL	2.5MG/5ML		A091263	001	Nov 07, 2011	Jul CAHN
	+ @ SANOFI	2.5MG/5ML		N022157	001	Jan 28, 2008	Apr DISC
	TABLET;ORAL LEVO CETIRIZINE DIHYDROCHLORIDE						
AB	! GLENMARK GENERICS	5MG		A090385	001	Feb 24, 2011	Apr CHRS
	@ GRANULES	5MG		A090486	001	Mar 26, 2013	Apr CAHN
	@ NEOPHARMA	5MG		A204323	001	Dec 20, 2016	Mar DISC
	@ US ANTIBIOTICS XYZAL	5MG		A204323	001	Dec 20, 2016	May CAHN
	+ @ SANOFI	5MG		N022064	001	May 25, 2007	Apr DISC
	<u>LEVOFLOXACIN</u>						
	TABLET;ORAL LEVOFLOXACIN						
AB	CADILA	250MG		A077652	001	Sep 07, 2012	Jun CAHN
AB		500MG		A077652	002	Sep 07, 2012	Jun CAHN
AB		750MG		A077652	003	Sep 07, 2012	Jun CAHN
	@ JUBILANT GENERICS	250MG		A203613	001	Jun 19, 2015	Jun DISC
	@	500MG		A203613	002	Jun 19, 2015	Jun DISC
	<u>LEVOLEUCOVORIN CALCIUM</u>						
	POWDER;INTRAVENOUS LEVOLEUCOVORIN CALCIUM						
>A> AP	HIKMA	EQ 50MG BASE/VIAL		A206263	001	Jun 16, 2016	Jul CAHN
>D> AP	WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL		A206263	001	Jun 16, 2016	Jul CAHN
	<u>LEVORPHANOL TARTRATE</u>						
	TABLET;ORAL LEVORPHANOL TARTRATE						
>A>	NOVITIUM PHARMA	1MG		A213479	003	Jul 20, 2021	Jul NEWA
AB		3MG		A213479	002	Jan 12, 2021	Jan NEWA
AB	! SENTYNL THERAPS INC	3MG		A074278	003	Jun 18, 2018	Jan CTEC
AB	SUN PHARM INDs INC	2MG		A213906	001	Jun 17, 2021	Jun NEWA

LEVOTHYROXINE SODIUM

	CAPSULE;ORAL						
	LEVOTHYROXINE SODIUM						
>D> AB	@ TEVA PHARMS USA INC	0.075MG	A211369	001	Oct 28, 2020	Apr DISC	
>A>	@	0.088MG	A213256	001	Jan 06, 2021	Jul DISC	
>D> AB	@	0.088MG	A213256	001	Jan 06, 2021	Jul DISC	
>A>	@	0.1MG	A213256	002	Jan 06, 2021	Jul DISC	
AB	@	0.1MG	A213256	002	Jan 06, 2021	Jul DISC	
>D> AB		0.112MG	A211369	003	Apr 16, 2021	Apr NFTG	
>D> AB		0.125MG	A213256	003	Jan 06, 2021	Jul DISC	
>A>	@	0.125MG	A213256	003	Jan 06, 2021	Jul DISC	
	@	0.15MG	A211369	002	Oct 28, 2020	Apr DISC	
	TIROSINT						
+ INSTITUT BIOCHIMIQUE		0.075MG	N021924	004	Oct 13, 2006	Apr CTEC	
+ INSTITUT BIOCHIMIQUE		0.15MG	N021924	007	Oct 13, 2006	Apr CTEC	
	POWDER; INTRAVENOUS						
	LEVOTHYROXINE SODIUM						
@ DR REDDYS		100MCG/VIAL	A208837	001	Mar 27, 2020	Feb DISC	
	SOLUTION; INTRAVENOUS						
	LEVOTHYROXINE SODIUM						
+! CUSTOPHARM INC		100MCG/ML	N214253	001	May 17, 2021	May NEWA	
	SOLUTION; ORAL						
	THYQUIDITY						
+! VISTAPHARM		100MCG/5ML	N214047	001	Nov 30, 2020	Apr CAHN	
	TIROSINT-SOL						
+ INSTITUT BIOCHIMIQUE		37.5MCG/ML	N206977	013	Jan 13, 2021	Jan NEWA	
+ INSTITUT BIOCHIMIQUE		44MCG/ML	N206977	014	Jan 13, 2021	Jan NEWA	
+ INSTITUT BIOCHIMIQUE		62.5MCG/ML	N206977	015	Jan 13, 2021	Jan NEWA	

LIDOCAINE

	OINTMENT;TOPICAL					
	LIDOCAINE					
AT	QUAGEN	5%	A212695	001	Apr 20, 2021	Apr NEWA
	@ RISING	5%	A208604	001	Sep 20, 2017	May CAHN
	PATCH;TOPICAL					
	LIDOCAINE					
AB	NAL PHARM	5%	A205882	001	Apr 29, 2021	Apr NEWA
	@ NOVEN PHARMS INC	5%	A203265	001	Dec 01, 2020	Jun DISC

LIDOCAINE HYDROCHLORIDE

	JELLY;TOPICAL					
	XYLOCAINE					
+ @ AKORN		2%	N008816	001		Jan DISC
	SOLUTION;ORAL					
	LIDOCAINE HYDROCHLORIDE VISCOUS					
AT	LANNETT CO INC	2%	A040708	001	Feb 27, 2007	Jan CMFD

LIDOCAINE; PRILOCaine

	CREAM;TOPICAL					
	LIDOCAINE AND PRILOCaine					
>A> AB	ACRUX DDS PTY	2.5%;2.5%	A212482	001	Jul 27, 2021	Jul NEWA

LINACLOTIDE

	CAPSULE;ORAL					
	LINACLOTIDE					
AB	@ MYLAN	145MCG	A209564	001	Feb 09, 2021	Feb DISC
	@	145MCG	A209564	001	Feb 09, 2021	Jan NFTG
AB	@	290MCG	A209564	002	Feb 09, 2021	Feb DISC
	LINZESS		A209564	002	Feb 09, 2021	Jan NFTG
+! ALLERGAN		145MCG	N202811	001	Aug 30, 2012	Feb CTEC
+!		290MCG	N202811	002	Aug 30, 2012	Feb CTEC

LINCOMYCIN HYDROCHLORIDE

	INJECTABLE;INJECTION					
	LINCOCIN					
AP	+! PFIZER	EQ 300MG BASE/ML	N050317	001		Feb CAHN
	LINCOMYCIN HYDROCHLORIDE					
AP	PRAZGEN	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Mar NEWA

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

AB	ZYDUS	EQ 0.005MG BASE	A214803	001	Jan 22, 2021	Jan NEWA
AB		EQ 0.025MG BASE	A214803	002	Jan 22, 2021	Jan NEWA
AB		EQ 0.05MG BASE	A214803	003	Jan 22, 2021	Jan NEWA

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB	YILING	20MG	A208920	001	Mar 04, 2021	Feb NEWA
AB		30MG	A208920	002	Mar 04, 2021	Feb NEWA
AB		40MG	A208920	003	Mar 04, 2021	Feb NEWA

LOPINAVIR; RITONAVIR

TABLET;ORAL

LOPINAVIR AND RITONAVIR

AB	HETERO LABS LTD III	100MG;25MG	A091677	001	Jun 04, 2021	May NFTG
AB		200MG;50MG	A091677	002	Jun 04, 2021	May NFTG

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM

AA	AKORN	2MG/ML	A200169	001	Jan 30, 2012	Feb CAHN
	INJECTABLE; INJECTION					
	ATIVAN					
>D> AP	+! HIKMA	2MG/ML	N018140	001		Jul CAHN
>A> AP	+!	2MG/ML	N018140	001		Jul CAHN
>D> AP	+!	4MG/ML	N018140	002		Jul CAHN
>A> AP	+!	4MG/ML	N018140	002		Jul CAHN

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

>D>	@ HIKMA	25MG	A077459	001	Oct 06, 2010	Jul CMFD
>A> AB		25MG	A077459	001	Oct 06, 2010	Jul CMFD
>D>	@	50MG	A077459	002	Oct 06, 2010	Jul CMFD
>A> AB		50MG	A077459	002	Oct 06, 2010	Jul CMFD
>D>	@	100MG	A077459	003	Oct 06, 2010	Jul CMFD
>A> AB		100MG	A077459	003	Oct 06, 2010	Jul CMFD
	JUBILANT CADISTA	25MG	A201170	001	Sep 18, 2012	Jun CAHN
		50MG	A201170	002	Sep 18, 2012	Jun CAHN
AB		100MG	A201170	003	Sep 18, 2012	Jun CAHN

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEPREDNOL ETABONATE

AB	AKORN	0.5%	A212080	001	Feb 10, 2021	Jan NFTG
	SUSPENSION/DROPS;OPHTHALMIC					
	LOTEPREDNOL ETABONATE					
AB	SUN PHARM	0.5%	A212450	001	Feb 26, 2021	Feb NEWA

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

>D> AB	MYLAN	EQ 5MG BASE	A076762	001	Nov 01, 2004	Jul DISC
>A>	@	EQ 5MG BASE	A076762	001	Nov 01, 2004	Jul DISC
>D> AB		EQ 10MG BASE	A076762	002	Nov 01, 2004	Jul DISC
>A>	@	EQ 10MG BASE	A076762	002	Nov 01, 2004	Jul DISC
>D> AB		EQ 25MG BASE	A076762	003	Nov 01, 2004	Jul DISC
>A>	@	EQ 25MG BASE	A076762	003	Nov 01, 2004	Jul DISC
>D> AB		EQ 50MG BASE	A076762	004	Nov 01, 2004	Jul DISC
>A>	@	EQ 50MG BASE	A076762	004	Nov 01, 2004	Jul DISC

LULICONAZOLE

CREAM;TOPICAL

LUZU

+! BAUSCH

1%

N204153 001 Nov 14, 2013 May CAHN

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	20MG	A213248	001	May 13, 2021	May NEWA
AB		40MG	A213248	002	May 13, 2021	May NEWA
AB		60MG	A213248	003	May 13, 2021	May NEWA
AB		80MG	A213248	004	May 13, 2021	May NEWA
AB		120MG	A213248	005	May 13, 2021	May NEWA
AB	WATSON LABS TEVA	20MG	A208016	001	Feb 02, 2021	Jan NEWA
AB		40MG	A208016	002	Feb 02, 2021	Jan NEWA
AB		60MG	A208016	003	Feb 02, 2021	Jan NEWA
AB		80MG	A208016	004	Feb 02, 2021	Jan NEWA
AB		120MG	A208016	005	Feb 02, 2021	Jan NEWA

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

AP	B BRAUN MEDICAL INC	2GM/50ML (40MG/ML)	A207967	001	Apr 26, 2021	Apr NEWA
AP		4GM/100ML (40MG/ML)	A207967	002	Apr 26, 2021	Apr NEWA
AP		4GM/50ML (80MG/ML)	A207967	003	Apr 26, 2021	Apr NEWA
	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE CORP	1GM/100ML	A211965	001	Aug 11, 2020	Feb CMFD
	MAGNESIUM SULFATE IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	Feb CMFD
AP		4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	Feb CMFD
AP		4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	Feb CMFD

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

>D>	@ HERITAGE PHARMA	50MG	A072163	001	Jun 01, 1988	Jun CAHN
	MYLAN	25MG	A072285	002	Oct 03, 1988	Jul DISC
>A>	@	25MG	A072285	002	Oct 03, 1988	Jul DISC
>D>	!	50MG	A072285	001	Oct 03, 1988	Jul DISC
>A>	@	50MG	A072285	001	Oct 03, 1988	Jul DISC
>D>		75MG	A072285	003	Oct 03, 1988	Jul DISC
>A>	@	75MG	A072285	003	Oct 03, 1988	Jul DISC

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

	+ @ PFIZER	100MG/ML	N 012541	002	Mar CAHN
AB	+!	150MG/ML	N 020246	001	Oct 29, 1992
	+ @	400MG/ML	N 012541	003	May DISC
	+!	400MG/ML	N 012541	003	Mar CAHN
	INJECTABLE;SUBCUTANEOUS DEPO-SUBQ PROVERA 104				
	+! PFIZER	104MG/0.65ML	N 021583	001	Dec 17, 2004
	TABLET;ORAL PROVERA				
AB	+ PFIZER	2.5MG	N 011839	001	Mar CAHN
AB	+	5MG	N 011839	003	Mar CAHN
AB	+!	10MG	N 011839	004	Mar CAHN

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

@ STRIDES PHARMA 250MG A209209 001 Sep 18, 2020 Mar DISC

MELOXICAM

CAPSULE; ORAL

MELOXICAM

AB	LUPIN LTD	5MG	A209487	001	Jun 01, 2020	Feb CTEC
AB	!	10MG	A209487	002	Jun 01, 2020	Feb CTEC
AB	NOVITIUM PHARMA	5MG	A211398	001	Mar 09, 2021	Feb NEWA
AB		10MG	A211398	002	Mar 09, 2021	Feb NEWA

MELPHALAN

TABLET;ORAL

MELPHALAN

! ALVOGEN

2MG

A207809 001 Mar 22, 2017 Jan CAHN

MELPHALAN FLUFENAMIDE

POWDER;INTRAVENOUS

PEPAXTO

+! ONCOPEPTIDES AB

20MG/VIAL

N214383 001 Feb 26, 2021 Feb NEWA

MELPHALAN FLUFENAMIDE HYDROCHLORIDE

POWDER;INTRAVENOUS

PEPAXTO

+! ONCOPEPTIDES AB

EQ 20MG BASE/VIAL

N214383 001 Feb 26, 2021 Mar CPOT

+!

20MG/VIAL

N214383 001 Feb 26, 2021 Mar CAIN

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

ALKERAN

+ @ APOTEX

EQ 50MG BASE/VIAL

N020207 001 Nov 18, 1992 Jan DISC

MELPHALAN HYDROCHLORIDE

>A> AP	ALMAJECT	EQ 50MG BASE/VIAL	A204817 001 May 17, 2019	Jul CAHN
>D> AP	ALVOGEN	EQ 50MG BASE/VIAL	A204817 001 May 17, 2019	Jul CAHN
>A> AP	HIKMA	EQ 50MG BASE/VIAL	A090303 001 Oct 28, 2010	Jul CAHN
AP	HONG KONG	EQ 50MG BASE/VIAL	A212960 001 May 28, 2021	May NEWA
>D> AP	WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL	A090303 001 Oct 28, 2010	Jul CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

>A> AB	AUROBINDO PHARMA LTD	7MG	A214651 001 Aug 09, 2021	Jul NEWA
>A> AB		14MG	A214651 002 Aug 09, 2021	Jul NEWA
>A> AB		21MG	A214651 003 Aug 09, 2021	Jul NEWA
>A> AB		28MG	A214651 004 Aug 09, 2021	Jul NEWA
>D> AB	MYLAN	7MG	A206032 001 Sep 28, 2016	Jul DISC
>A>	@	7MG	A206032 001 Sep 28, 2016	Jul DISC
>D> AB		14MG	A206032 002 Sep 28, 2016	Jul DISC
>A>	@	14MG	A206032 002 Sep 28, 2016	Jul DISC
>D> AB		21MG	A206032 003 Sep 28, 2016	Jul DISC
>A>	@	21MG	A206032 003 Sep 28, 2016	Jul DISC
>D> AB		28MG	A206032 004 Sep 28, 2016	Jul DISC
>A>	@	28MG	A206032 004 Sep 28, 2016	Jul DISC
AB	YICHANG HUMANWELL	7MG	A211100 001 Apr 02, 2021	Mar NEWA
AB		14MG	A211100 002 Apr 02, 2021	Mar NEWA
AB		21MG	A211100 003 Apr 02, 2021	Mar NEWA
AB		28MG	A211100 004 Apr 02, 2021	Mar NEWA

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA	SETON PHARMS	2MG/ML	A210319 001 Aug 31, 2020	May CAHN	
TABLET;ORAL					
MEMANTINE HYDROCHLORIDE					
@ JUBILANT GENERICS			5MG	A091585 001 Oct 13, 2015	Jun DISC
@			10MG	A091585 002 Oct 13, 2015	Jun DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

@ VALIDUS PHARMS

25MG/ML

N005010 007

Feb CAHN

@

50MG/ML

N005010 002

Feb CAHN

@

75MG/ML

N005010 009

Feb CAHN

@

100MG/ML

N005010 003

Feb CAHN

SYRUP;ORAL

DEMEROL

@ VALIDUS PHARMS

50MG/5ML

N005010 005

Feb CAHN

TABLET;ORAL

DEMEROL

+ @ VALIDUS PHARMS

50MG

N005010 001

Feb CAHN

+

@

100MG

N005010 004

Feb CAHN

TABLET;ORAL

METHOCARBAMOL

AA	@ AUROBINDO PHARMA LTD	750MG GRANULATION TECH	A213967 001 Aug 12, 2020 A212623 001 Apr 30, 2021	Feb DISC Apr NEWA
AA		750MG	A212623 002 Apr 30, 2021	Apr NEWA
AA	MLV	500MG	A212623 001 Apr 30, 2021	Jun CAHN
AA		750MG	A212623 002 Apr 30, 2021	Jun CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM

>A> AP	! HIKMA	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341 001 Sep 16, 1986	Jul CAHN
>A>	!	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342 001 Sep 16, 1986	Jul CAHN
>D> AP	! WEST-WARD PHARMS INT	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341 001 Sep 16, 1986	Jul CAHN
>D>	!	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342 001 Sep 16, 1986	Jul CAHN
		METHOTREXATE SODIUM PRESERVATIVE FREE		
>A> AP	! HIKMA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340 001 Sep 16, 1986	Jul CAHN
>A> AP	!	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343 001 Sep 16, 1986	Jul CAHN
	@ MYLAN LABS LTD	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529 004 Mar 29, 2012	May DISC
>D> AP	! WEST-WARD PHARMS INT	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340 001 Sep 16, 1986	Jul CAHN
>D> AP	!	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343 001 Sep 16, 1986	Jul CAHN

TABLET;ORAL

METHOTREXATE SODIUM

AB	LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787 001 Apr 23, 2021	Apr NEWA
----	--------------------	---------------	--------------------------	----------

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB	RISING	0.2MG	A211919 001 Jan 15, 2021	Jan NEWA
----	--------	-------	--------------------------	----------

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	ASCENT PHARMS INC	5MG/5ML	A207417 001 Jan 29, 2021	Jan NEWA
AA		10MG/5ML	A207417 002 Jan 29, 2021	Jan NEWA
	@ LANNETT CO INC	5MG/5ML	A207414 001 Dec 16, 2020	Jan DISC
	@	10MG/5ML	A207414 002 Dec 16, 2020	Jan DISC

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@ ALVOGEN	5MG	A206840 001 Sep 15, 2016	Jun CAHN
@	10MG	A206840 002 Sep 15, 2016	Jun CAHN
@	20MG	A206840 003 Sep 15, 2016	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ALVOGEN	10MG	A204772 001 Feb 29, 2016	Jun CAHN
AB		20MG	A204772 002 Feb 29, 2016	Jun CAHN

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

AB	PRAXGEN	4MG	A212262 001 Jun 27, 2019	Feb CAHN
----	---------	-----	--------------------------	----------

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	GENEYORK PHARMS	EQ 40MG BASE/VIAL	A212396 001 Apr 20, 2021	Apr NEWA
AP		EQ 125MG BASE/VIAL	A212396 002 Apr 20, 2021	Apr NEWA
AP		EQ 500MG BASE/VIAL	A212396 003 Apr 20, 2021	Apr NEWA
AP		EQ 1GM BASE/VIAL	A212396 004 Apr 20, 2021	Apr NEWA
AP		EQ 2GM BASE/VIAL	A212396 005 Apr 20, 2021	Apr NEWA
AP	TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A212396 001 Apr 20, 2021	May CAHN
AP		EQ 125MG BASE/VIAL	A212396 002 Apr 20, 2021	May CAHN
AP		EQ 500MG BASE/VIAL	A212396 003 Apr 20, 2021	May CAHN
AP		EQ 1GM BASE/VIAL	A212396 004 Apr 20, 2021	May CAHN
AP		EQ 2GM BASE/VIAL	A212396 005 Apr 20, 2021	May CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

REGLAN

>A>	@ HIKMA	EQ 5MG BASE/ML	N 017862	001	Jul CAHN
>A>	@	EQ 10MG BASE/ML	N 017862	004	May 28, 1987 Jul CAHN
>D>	@ WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N 017862	001	Jul CAHN
>D>	@	EQ 10MG BASE/ML	N 017862	004	May 28, 1987 Jul CAHN

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	BAYSHORE PHARMS LLC	2.5MG	A 214799	001	Mar 30, 2021	Mar NEWA
AB		5MG	A 214799	002	Mar 30, 2021	Mar NEWA
AB		10MG	A 214799	003	Mar 30, 2021	Mar NEWA
AB	INNOGENIX	2.5MG	A 213827	001	Mar 30, 2021	Mar NEWA
AB		5MG	A 213827	002	Mar 30, 2021	Mar NEWA
AB		10MG	A 213827	003	Mar 30, 2021	Mar NEWA
AB	! SANDOZ	5MG	A 076466	001	Dec 19, 2003	May CHRS
AB	!	10MG	A 076466	002	Dec 19, 2003	May CHRS
	ZAROXOLYN					
+ @	LANNETT CO INC	2.5MG	N 017386	001		May DISC
+ @		5MG	N 017386	002		May DISC
+ @		10MG	N 017386	003		May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A 204161	001	Nov 25, 2016	May CMFD
AB		EQ 50MG TARTRATE	A 204161	002	Nov 25, 2016	May CMFD
AB		EQ 100MG TARTRATE	A 204161	003	Nov 25, 2016	May CMFD
AB		EQ 200MG TARTRATE	A 204161	004	Nov 25, 2016	May CMFD
AB	YICHANG HUMANWELL	EQ 100MG TARTRATE	A 213854	001	Feb 12, 2021	Feb NEWA
AB		EQ 200MG TARTRATE	A 213854	002	Feb 12, 2021	Feb NEWA

METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR

AB	+ VALIDUS PHARMS	50MG	N 017963	001		Feb CAHN
AB	+	100MG	N 017963	002		Feb CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB	RICONPHARMA LLC	150MG	A 214352	001	Jan 25, 2021	Jan NEWA
AB		200MG	A 214352	002	Jan 25, 2021	Jan NEWA
AB		250MG	A 214352	003	Jan 25, 2021	Jan NEWA

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

>A> AP	HIKMA	EQ 50MG BASE/VIAL	A 213261	001	Jul 09, 2021	Jul NEWA
>A> AP		EQ 100MG BASE/VIAL	A 213261	002	Jul 09, 2021	Jul NEWA
>A> AP	JIANGSU HANSOH PHARM	EQ 50MG BASE/VIAL	A 213363	001	Jul 09, 2021	Jul NEWA
>A> AP		EQ 100MG BASE/VIAL	A 213363	002	Jul 09, 2021	Jul NEWA
AP	XELLIA PHARMS APS	EQ 50MG BASE/VIAL	A 211713	001	Jun 02, 2021	May NEWA
AP		EQ 100MG BASE/VIAL	A 211713	002	Jun 02, 2021	May NEWA

POWDER; INTRAVENOUS

MICAFUNGIN

+!	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	N 212156	001	Jun 16, 2021	Jun NEWA
+!		EQ 100MG BASE/VIAL	N 212156	002	Jun 16, 2021	Jun NEWA
>A>	+! TEVA PHARMS USA INC	EQ 50MG BASE/VIAL	N 212125	001	Jul 30, 2021	Jul NEWA
>A>	+!	EQ 100MG BASE/VIAL	N 212125	002	Jul 30, 2021	Jul NEWA

MIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

+!	INFORLIFE	50MG/50ML (1MG/ML)	N 211844	001	Mar 22, 2021	Mar NEWA
+!		100MG/100ML (1MG/ML)	N 211844	002	Mar 22, 2021	Mar NEWA

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	2.5MG	A214734	001	Jan 21, 2021	Jan NEWA
AB		5MG	A214734	002	Jan 21, 2021	Jan NEWA
AB		10MG	A214734	003	Jan 21, 2021	Jan NEWA

MIGLITOL

TABLET;ORAL

GLYSET

AB	+! PFIZER	25MG	N020682	001	Dec 18, 1996	Feb CAHN
AB	+	50MG	N020682	002	Dec 18, 1996	Feb CAHN
AB	+	100MG	N020682	003	Dec 18, 1996	Feb CAHN

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP	CAPLIN	EQ 1MG BASE/ML	A214380	001	Apr 16, 2021	Apr NEWA
----	--------	----------------	---------	-----	--------------	----------

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

+!	VYNNE	EQ 4% BASE	N212379	001	Oct 18, 2019	Mar CAHN
+!	ZILXI	EQ 1.5% BASE	N213690	001	May 28, 2020	Mar CAHN

CAPSULE;ORAL

DYNACIN

AB	ALVOGEN	EQ 50MG BASE	A063067	003	Aug 14, 1990	Jun CAHN
AB		EQ 75MG BASE	A063067	002	Sep 15, 1999	Jun CAHN
AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	Jun CAHN

INJECTABLE;INJECTION

MINOCIN

+! REMPEX EQ 100MG BASE/VIAL

N050444 001 May CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

@	BARR LABS INC	EQ 65MG BASE	A065485	004	May 18, 2012	May DISC
@		EQ 80MG BASE	A065485	007	Apr 26, 2017	May DISC
@		EQ 105MG BASE	A065485	008	Apr 26, 2017	May DISC
@		EQ 115MG BASE	A065485	005	May 18, 2012	May DISC
	SOLODYN					
+ @	BAUSCH	EQ 45MG BASE	N050808	001	May 08, 2006	May CAHN
AB	+	EQ 55MG BASE	N050808	008	Aug 27, 2010	May CAHN
AB	+	EQ 65MG BASE	N050808	004	Jul 23, 2009	May CAHN
AB	+	EQ 80MG BASE	N050808	007	Aug 27, 2010	May CAHN
+ @		EQ 90MG BASE	N050808	002	May 08, 2006	May CAHN
AB	+	EQ 105MG BASE	N050808	006	Aug 27, 2010	May CAHN
AB	+	EQ 115MG BASE	N050808	005	Jul 23, 2009	May CAHN
+ @		EQ 135MG BASE	N050808	003	May 08, 2006	May CAHN

MINOXIDIL

TABLET;ORAL

LONITEN

+ @ PFIZER 2.5MG

N018154 001 Feb CAHN

+ @ 10MG

N018154 003 Feb CAHN

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MYRBETRIQ GRANULES

+! APGDI 8MG/ML

N213801 001 Mar 25, 2021 Mar NEWA

MODAFINIL

TABLET;ORAL

MODAFINIL

>D> AB	MYLAN PHARMS INC	100MG	A076594	001	Jul 16, 2012	Jul DISC
>A>	@	100MG	A076594	001	Jul 16, 2012	Jul DISC
>D> AB		200MG	A076594	002	Jul 16, 2012	Jul DISC
>A>	@	200MG	A076594	002	Jul 16, 2012	Jul DISC

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION ASMANEX HFA			
+ ORGANON	0.05MG/INH	N 205641	003 Aug 12, 2019 Jun CAHN
+ !	0.10MG/INH	N 205641	001 Apr 25, 2014 Jun CAHN
+ !	0.20MG/INH	N 205641	002 Apr 25, 2014 Jun CAHN
OINTMENT; TOPICAL MOMETASONE FUROATE			
@ TORRENT	0.1%	A 207899	001 Jul 13, 2018 Jan DISC
POWDER; INHALATION ASMANEX TWISTHALER			
+ ORGANON	0.11MG/INH	N 021067	002 Feb 01, 2008 Jun CAHN
+ !	0.22MG/INH	N 021067	001 Mar 30, 2005 Jun CAHN
SPRAY, METERED; NASAL MOMETASONE FUROATE			
AB ! APOTEX INC	0.05MG/SPRAY	A 091161	001 Mar 22, 2016 May CHRS
NASONEX			
+ @ ORGANON	0.05MG/SPRAY	N 020762	001 Oct 01, 1997 May DISC
AB + !	0.05MG/SPRAY	N 020762	001 Oct 01, 1997 Feb CAHN

MONTELUKAST SODIUM

TABLET; ORAL MONTELUKAST SODIUM			
>D> AB	AJANTA PHARMA LTD	EQ 10MG BASE	A 203432 001 Jul 31, 2015 Jul DISC
>A>	@	EQ 10MG BASE	A 203432 001 Jul 31, 2015 Jul DISC
TABLET, CHEWABLE; ORAL MONTELUKAST SODIUM			
>D> AB	AJANTA PHARMA LTD	EQ 4MG BASE	A 203328 001 Jul 31, 2015 Jul DISC
>A>	@	EQ 4MG BASE	A 203328 001 Jul 31, 2015 Jul DISC
>D> AB		EQ 5MG BASE	A 203328 002 Jul 31, 2015 Jul DISC
>A>	@	EQ 5MG BASE	A 203328 002 Jul 31, 2015 Jul DISC
>D> AB	HIKMA	EQ 4MG BASE	A 091128 001 Aug 03, 2012 Jul DISC
>A>	@	EQ 4MG BASE	A 091128 001 Aug 03, 2012 Jul DISC
>D> AB		EQ 5MG BASE	A 091128 002 Aug 03, 2012 Jul DISC
>A>	@	EQ 5MG BASE	A 091128 002 Aug 03, 2012 Jul DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL KADIAN			
+ @ ALLERGAN	40MG	N 020616	009 Jul 09, 2012 May DISC
+ @	70MG	N 020616	010 Jul 09, 2012 May DISC
+ @	130MG	N 020616	011 Jul 09, 2012 May DISC
+ @	150MG	N 020616	012 Jul 09, 2012 May DISC
+ @	200MG	N 020616	007 Feb 27, 2007 May DISC
MORPHINE SULFATE			
>A> AB	IMPAX LABS INC	40MG	A 200411 007 Jul 25, 2018 May CTEC
	NORTEC DEV ASSOC	20MG	A 203158 001 Aug 04, 2021 Jul NEWA
>A> AB		30MG	A 203158 002 Aug 04, 2021 Jul NEWA
>A> AB		50MG	A 203158 003 Aug 04, 2021 Jul NEWA
>A> AB		60MG	A 203158 004 Aug 04, 2021 Jul NEWA
>A> AB		80MG	A 203158 005 Aug 04, 2021 Jul NEWA
>A> AB		100MG	A 203158 006 Aug 04, 2021 Jul NEWA
INJECTABLE; INJECTION MORPHINE SULFATE			
+! HOSPIRA INC	50MG/ML	N 202515	006 Apr 29, 2021 Apr NEWA
	INTL MEDICATION SYS	1MG/ML	A 202861 001 Apr 29, 2021 Apr NFTG
SOLUTION; ORAL MORPHINE SULFATE			
@ ANI PHARMS	10MG/5ML	A 205509	001 Apr 17, 2018 Jan DISC
@	20MG/5ML	A 205509	002 Apr 17, 2018 Jan DISC
@	100MG/5ML	A 205509	003 Apr 17, 2018 Jan DISC
AA WINDER LABS LLC	10MG/5ML	A 211454	001 Feb 12, 2021 Feb NEWA
AA	20MG/5ML	A 211454	002 Feb 12, 2021 Feb NEWA
AA	100MG/5ML	A 211454	003 Feb 12, 2021 Feb NEWA
TABLET; ORAL MORPHINE SULFATE			
AB UPSHER SMITH LABS	15MG	A 210610	001 Jul 22, 2019 May CAHN
AB	30MG	A 210610	002 Jul 22, 2019 May CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT1 UPSHER SMITH LABS EQ 0.5% BASE

A212616 001 Feb 10, 2021 Jan NEWA

MYCOPHENOLATE MOFETIL

SUSPENSION;ORAL
MYCOPHENOLATE MOFETIL

>A> AB LANNETT CO INC 200MG/ML

A214525 001 Jul 29, 2021 Jul NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP AMNEAL 500MG/VIAL
AP MEITHEAL 500MG/VIAL
AP NANJING KING-FRIEND 500MG/VIAL

A211374 001 Mar 05, 2021 Feb NEWA
A212130 001 Jan 15, 2021 Jan CAHN
A212130 001 Jan 15, 2021 Jan NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL
MYCOPHENOLIC ACID

AB AMTA 180MG
AB 360MG

A214376 001 Feb 10, 2021 Jan NEWA
A214376 002 Feb 10, 2021 Jan NEWA

NABUMETONE

TABLET;ORAL
NABUMETONE

AB ANNORA PHARMA 500MG
AB 750MG

A090445 001 Jan 12, 2011 Mar CAHN
A090445 002 Jan 12, 2011 Mar CAHN

NADOLOL

TABLET;ORAL
NADOLOL

@ NOVAST LABS 20MG
@ 40MG
@ 80MG
AB VGYAAN 20MG
AB 40MG
AB 80MG

A210786 001 Jun 01, 2018 May DISC
A210786 002 Jun 01, 2018 May DISC
A210786 003 Jun 01, 2018 May DISC
A212856 001 Sep 13, 2019 May CMFD
A212856 002 Sep 13, 2019 May CMFD
A212856 003 Sep 13, 2019 May CMFD

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION
NALOXONE HYDROCHLORIDE

AP AUROBINDO PHARMA LTD 1MG/ML
>D> AP BAXTER HLTHCARE CORP 0.4MG/ML
>A> @ 0.4MG/ML
AP 0.4MG/ML

A213279 001 Jan 14, 2021 Jan NEWA
A214785 001 Jan 29, 2021 Jul DISC
A214785 001 Jan 29, 2021 Jul DISC
A214785 001 Jan 29, 2021 Jan NEWA

SPRAY;NASAL
KLOXXADO
+! HIKMA 8MG/SPRAY

N212045 001 Apr 29, 2021 Apr NEWA

NALTREXONE HYDROCHLORIDE

TABLET;ORAL
REVIA

>D> @ TEVA WOMENS 50MG
>A> + @ 50MG

N018932 001 Nov 20, 1984 Jul CRLD
N018932 001 Nov 20, 1984 Jul CRLD

NAPROXEN

SUSPENSION;ORAL
NAPROXEN

AB NOVITIUM PHARMA 25MG/ML
TABLET;ORAL
NAPROXEN
AB GRANULES 250MG
AB 375MG
AB 500MG
>A> AB L PERRIGO CO 250MG
>A> AB 375MG
>A> AB 500MG
>D> AB PERRIGO PHARMS CO 250MG
>D> AB 375MG
>D> AB 500MG

A211910 001 Mar 10, 2021 Feb NEWA
A074140 001 Dec 21, 1993 Feb CMFD
A074140 002 Dec 21, 1993 Feb CMFD
A074140 003 Dec 21, 1993 Feb CMFD
A077339 001 Apr 27, 2005 Jul CAHN
A077339 002 Apr 27, 2005 Jul CAHN
A077339 003 Apr 27, 2005 Jul CAHN
A077339 001 Apr 27, 2005 Jul CAHN
A077339 002 Apr 27, 2005 Jul CAHN
A077339 003 Apr 27, 2005 Jul CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

>D>	@	ANI PHARMS	EQ 2.5MG BASE	A203659	001	Apr 16,	2015	Jul	CMFD
>A> AB			EQ 2.5MG BASE	A203659	001	Apr 16,	2015	Jul	CMFD
>D>	@		EQ 5MG BASE	A203659	002	Apr 16,	2015	Jul	CMFD
>A> AB			EQ 5MG BASE	A203659	002	Apr 16,	2015	Jul	CMFD
>D>	@		EQ 10MG BASE	A203659	003	Apr 16,	2015	Jul	CMFD
>A> AB			EQ 10MG BASE	A203659	003	Apr 16,	2015	Jul	CMFD
>D>	@		EQ 20MG BASE	A203659	004	Apr 16,	2015	Jul	CMFD
>A> AB			EQ 20MG BASE	A203659	004	Apr 16,	2015	Jul	CMFD
>D>	@	INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29,	2015	Jul	CMFD
>A> AB			EQ 2.5MG BASE	A203828	001	Jul 29,	2015	Jul	CMFD
>D>	@		EQ 5MG BASE	A203828	002	Jul 29,	2015	Jul	CMFD
>A> AB			EQ 5MG BASE	A203828	002	Jul 29,	2015	Jul	CMFD
>D>	@		EQ 10MG BASE	A203828	003	Jul 29,	2015	Jul	CMFD
>A> AB			EQ 10MG BASE	A203828	003	Jul 29,	2015	Jul	CMFD
>D>	@		EQ 20MG BASE	A203828	004	Jul 29,	2015	Jul	CMFD
>A> AB			EQ 20MG BASE	A203828	004	Jul 29,	2015	Jul	CMFD

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP	CAPLIN	5MG/10ML (0.5MG/ML)	A213074	001	Apr 20, 2021	Apr	NEWA
AP		10MG/10ML (1MG/ML)	A213074	002	Apr 20, 2021	Apr	NEWA
AP	HONG KONG	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Mar	NEWA
AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Mar	NEWA
AP	MEITHEAL	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Apr	CAHN
AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Apr	CAHN

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

@ JUBILANT GENERICS 500MG A209156 001 May 14, 2018 Jun DISC
@ 750MG A209156 002 May 14, 2018 Jun DISC
@ 1GM A209156 003 May 14, 2018 Jun DISC

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAT.

NICARDIPINE HYDROCHLORIDE

AB	ANI PHARMS	20MG	A074670	001	Oct 28, 1996	May CMFD
AB		30MG	A074670	002	Oct 28, 1996	May CMFD
AB	EPIC PHARMA	20MG	A074928	001	Mar 19, 1998	May CTEC
AB	!	30MG	A074928	002	Mar 19, 1998	May CTEC
INJECTABLE; INJECTION						
NICARDIPINE HYDROCHLORIDE						
AP	AM REGENT	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Apr CTEC
!		25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Feb CHRS
AP	AUROBINDO PHARMA LTD	25MG/10ML (2.5MG/ML)	A211121	001	Apr 08, 2021	Apr NEWA
AP	SUN PHARM	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009	Jun CMFD
@		25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009	Jun CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPIINE

>A>	AB1	AUROBINDO PHARMA LTD	30MG		A213361	001	Jul 19,	2021	Jul	NEWA
>A>	AB1		60MG		A213361	002	Jul 19,	2021	Jul	NEWA
>A>	AB1		90MG		A213361	003	Jul 19,	2021	Jul	NEWA
		@ ELITE	90MG		A212016	001	Nov 18,	2020	Jun	DISC
>D>	AB1	MYLAN	30MG		A201071	001	Dec 03,	2010	Jul	DISC
>A>		@	30MG		A201071	001	Dec 03,	2010	Jul	DISC
>D>	AB1		60MG		A201071	002	Dec 03,	2010	Jul	DISC
>A>		@	60MG		A201071	002	Dec 03,	2010	Jul	DISC
>D>	AB1		90MG		A201071	003	Dec 03,	2010	Jul	DISC
>A>		@	90MG		A201071	003	Dec 03,	2010	Jul	DISC
		@ PAR PHARM	30MG		A077899	001	Dec 13,	2006	Apr	DISC
		@	60MG		A077899	002	Dec 13,	2006	Apr	DISC
		@	90MG		A077899	003	May 25,	2012	Apr	DISC

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

! MYLAN 20MG
30MGA079051 001 Jul 25, 2008 Jan CHRS
A079051 002 Jul 25, 2008 Jan CHRSNITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

AB ALEMBIC PHARMS LTD 25MG
AB 50MG
AB 100MGA211935 001 Jun 25, 2021 Jun NEWA
A211935 002 Jun 25, 2021 Jun NEWA
A211935 003 Jun 25, 2021 Jun NEWANITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>D> AB MYLAN 75MG;25MG
>A> @ 75MG;25MGA076648 001 Mar 22, 2004 Jul DISC
A076648 001 Mar 22, 2004 Jul DISCNITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

MINITRAN

@ BAUSCH 0.4MG/HR

A089773 001 Aug 30, 1996 May CAHN

POWDER;SUBLINGUAL

GONITRO

>D> + @ POHL BOSKAMP 0.4MG/PACKET
>A> +! 0.4MG/PACKET
+ @ 0.4MG/PACKETN208424 001 Jun 08, 2016 Jul CMFD
N208424 001 Jun 08, 2016 Jul CMFD
N208424 001 Jun 08, 2016 Jun DISCTABLET;SUBLINGUAL
NITROGLYCERINAB RUBICON 0.3MG
AB 0.4MG
AB 0.6MGA209779 001 May 03, 2021 Apr NEWA
A209779 002 May 03, 2021 Apr NEWA
A209779 003 May 03, 2021 Apr NEWANOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP ANDERSEN GLOBAL EQ 1MG BASE/ML
AP BRECKENRIDGE EQ 1MG BASE/ML
AP GLAND PHARMA LTD EQ 1MG BASE/ML
AP SUN PHARM EQ 1MG BASE/MLA214455 001 Jan 22, 2021 Jan NEWA
A214455 001 Jan 22, 2021 Mar CAHN
A214323 001 May 06, 2021 Apr NEWA
A211980 001 Jan 29, 2021 Jan NEWA

>D> SOLUTION;INTRAVENOUS

>D> NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

>D> +! BAXTER HLTHCARE CORP EQ 4MG BASE/250ML (EQ 16MCG
BASE/ML)

N214313 001 Jan 15, 2021 Jul DISC

>A> + @ EQ 4MG BASE/250ML (EQ 16MCG
BASE/ML)

N214313 001 Jan 15, 2021 Jul DISC

+!
EQ 4MG BASE/250ML (EQ 16MCG
BASE/ML)

N214313 001 Jan 15, 2021 Jan NEWA

>D> +!
EQ 8MG BASE/250ML (EQ 32MCG
BASE/ML)

N214313 002 Jan 15, 2021 Jul DISC

>A> + @
EQ 8MG BASE/250ML (EQ 32MCG
BASE/ML)

N214313 002 Jan 15, 2021 Jul DISC

+!
EQ 8MG BASE/250ML (EQ 32MCG
BASE/ML)

N214313 002 Jan 15, 2021 Jan NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB ZYDUS EQ 10MG BASE
AB EQ 50MG BASE
AB EQ 75MG BASEA213441 001 Feb 24, 2021 Feb NEWA
A213441 003 Feb 24, 2021 Feb NEWA
A213441 004 Feb 24, 2021 Feb NEWANYSTATIN

CREAM;TOPICAL

NYSTATIN

>A> AT MACLEODS PHARMS LTD 100,000 UNITS/GM

A213566 001 Aug 10, 2021 Jul NEWA

OINTMENT;TOPICAL

NYSTATIN

AT MACLEODS PHARMS LTD 100,000 UNITS/GM

A213826 001 Jan 14, 2021 Jan NEWA

	POWDER;TOPICAL NYSTATIN						
>D> AT	NESHER PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	Jul CAHN	
>A> AT	ZYDUS PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	Jul CAHN	
	SUSPENSION;ORAL NYSTATIN						
AA	NIVAGEN PHARMS INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jun CAHN	
	<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>						
	CREAM;TOPICAL NYSTATIN AND TRIAMCINOLONE ACETONIDE						
AT	ALEOR DERMACEUTICALS	100,000 UNITS/GM;0.1%	A214090	001	Mar 31, 2021	Mar NEWA	
>A>	<u>ODEVIXIBAT</u>						
>A>	CAPSULE;ORAL BYLVAY						
>A>	+ ALBIREO	0.4MG	N215498	002	Jul 20, 2021	Jul NEWA	
>A>	+!	1.2MG	N215498	004	Jul 20, 2021	Jul NEWA	
>A>	CAPSULE, PELLETS;ORAL BYLVAY						
>A>	+ ALBIREO	0.2MG	N215498	001	Jul 20, 2021	Jul NEWA	
>A>	+!	0.6MG	N215498	003	Jul 20, 2021	Jul NEWA	
	<u>OFLOXACIN</u>						
	SOLUTION/DROPS;OPHTHALMIC OFLOXACIN						
	@ ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Jun CAHN	
	@	0.3%	A076830	001	Aug 31, 2004	Jan DISC	
	SOLUTION/DROPS;OTIC OFLOXACIN						
	@ ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Jun CAHN	
	TABLET;ORAL FLOXIN						
	+ @ JANSSEN PHARMS	200MG	N019735	001	Dec 28, 1990	Jan CRLD	
	+ @	300MG	N019735	002	Dec 28, 1990	Jan CRLD	
	+ @	400MG	N019735	003	Dec 28, 1990	Jan CRLD	
	OFLOXACIN						
AB	LARKEN LABS	400MG	A076093	003	Sep 02, 2003	May CMFD	
	<u>OLANZAPINE</u>						
	TABLET;ORAL OLANZAPINE						
>D> AB	HISUN PHARM HANGZHOU	2.5MG	A206924	001	Dec 31, 2020	Jul DISC	
>A>	@	2.5MG	A206924	001	Dec 31, 2020	Jul DISC	
	AB	2.5MG	A206924	001	Dec 31, 2020	Feb CAHN	
>D> AB		5MG	A206924	002	Dec 31, 2020	Jul DISC	
>A>	@	5MG	A206924	002	Dec 31, 2020	Jul DISC	
	AB	5MG	A206924	002	Dec 31, 2020	Feb CAHN	
>D> AB		7.5MG	A206924	003	Dec 31, 2020	Jul DISC	
>A>	@	7.5MG	A206924	003	Dec 31, 2020	Jul DISC	
	AB	7.5MG	A206924	003	Dec 31, 2020	Feb CAHN	
>D> AB		10MG	A206924	004	Dec 31, 2020	Jul DISC	
>A>	@	10MG	A206924	004	Dec 31, 2020	Jul DISC	
	AB	10MG	A206924	004	Dec 31, 2020	Feb CAHN	
>D> AB		15MG	A206924	005	Dec 31, 2020	Jul DISC	
>A>	@	15MG	A206924	005	Dec 31, 2020	Jul DISC	
	AB	15MG	A206924	005	Dec 31, 2020	Feb CAHN	
>D> AB		20MG	A206924	006	Dec 31, 2020	Jul DISC	
>A>	@	20MG	A206924	006	Dec 31, 2020	Jul DISC	
	AB	20MG	A206924	006	Dec 31, 2020	Feb CAHN	
	TABLET, ORALLY DISINTEGRATING;ORAL OLANZAPINE						
>D> AB	HISUN PHARM HANGZHOU	5MG	A206892	001	Dec 31, 2020	Jul DISC	
>A>	@	5MG	A206892	001	Dec 31, 2020	Jul DISC	
	AB	5MG	A206892	001	Dec 31, 2020	Feb CAHN	
>D> AB		10MG	A206892	002	Dec 31, 2020	Jul DISC	
>A>	@	10MG	A206892	002	Dec 31, 2020	Jul DISC	
	AB	10MG	A206892	002	Dec 31, 2020	Feb CAHN	
>D> AB		15MG	A206892	003	Dec 31, 2020	Jul DISC	
>A>	@	15MG	A206892	003	Dec 31, 2020	Jul DISC	
	AB	15MG	A206892	003	Dec 31, 2020	Feb CAHN	
>D> AB		20MG	A206892	004	Dec 31, 2020	Jul DISC	

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

>A>	@	20MG	A206892	004	Dec 31, 2020	Jul DISC
AB		20MG	A206892	004	Dec 31, 2020	Feb CAHN

OLANZAPINE; SAMIDORPHAN L-MALATE

TABLET;ORAL

LYBALVI

+! ALKERMES INC	5MG;EQ 10MG BASE	N213378	001	May 28, 2021	May NEWA
+	10MG;EQ 10MG BASE	N213378	002	May 28, 2021	May NEWA
+	15MG;EQ 10MG BASE	N213378	003	May 28, 2021	May NEWA
+	20MG;EQ 10MG BASE	N213378	004	May 28, 2021	May NEWA

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

>D> AB	MYLAN	5MG	A078276	001	Oct 26, 2016	Jul DISC
>A>	@	5MG	A078276	001	Oct 26, 2016	Jul DISC
>D> AB		20MG	A078276	002	Oct 26, 2016	Jul DISC
>A>	@	20MG	A078276	002	Oct 26, 2016	Jul DISC
>D> AB		40MG	A078276	003	Oct 26, 2016	Jul DISC
>A>	@	40MG	A078276	003	Oct 26, 2016	Jul DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>D> AT	AKORN	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Mar CTEC
>A>	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Jul CTEC
>D> AT		EQ 0.1% BASE	A206306	001	Dec 07, 2015	Jul CTEC
>A>	WOCKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jul DISC
	@	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jul DISC

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB	AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Mar CMFD
	@	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

LOVAZA

AB	+! WOODWARD	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb CAHN
----	-------------	------------------------------------------------------------------------------	---------	-----	--------------	----------

ONDANSETRON

FILM;ORAL

ZUPLENZ

+! @ AQUESTIVE	4MG	N022524	001	Jul 02, 2010	Feb CAHN
+ @	8MG	N022524	002	Jul 02, 2010	Feb CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

@ HOSPIRA	EQ 2MG BASE/ML	A077840	001	Jan 19, 2007	Jun DISC
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
@ EMCURE PHARMS LTD	EQ 2MG BASE/ML	A078945	001	Jan 03, 2013	May DISC

ORITAVANCIN DIPHOSPHATE

POWDER;INTRAVENOUS

KIMYRSA

+! MELINTA THERAP	EQ 1.2GM BASE/VIAL	N214155	001	Mar 12, 2021	Mar NEWA
ORBACTIV					
+! MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	May CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL

NORFLEX

+ @ BAUSCH	100MG	N012157	001		May CAHN
ORPHENADRINE CITRATE					
@ IMPAX PHARMS	100MG	A040368	001	Jun 23, 2000	Jan DISC

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	@ MYLAN	EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan DISC
	@	EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan NEWA
AB	@	EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan DISC
	@	EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan NEWA
AB	@	EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan DISC
	@	EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan NEWA

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

@ CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	May DISC
@	100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	May DISC

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

>A> AB	AKORN	300MG/5ML	A211420	001	Jul 09, 2021	Jul NEWA
AB	GLASSHOUSE PHARMS	300MG/5ML	A212428	001	Jun 21, 2021	Jun NEWA

OXICONAZOLE NITRATE

LOTION;TOPICAL

OXISTAT

+! ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr CAHN
---------------	------------	---------	-----	--------------	----------

OXYBUTYNIN CHLORIDE

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB	APPCO	5MG	A209025	001	Dec 21, 2017	Jan CAHN
	@ STRIDES PHARMA	5MG	A208165	001	Dec 17, 2020	Jun DISC

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

@ LANNETT CO INC	5MG	A203823	001	Aug 01, 2014	Apr DISC
------------------	-----	---------	-----	--------------	----------

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA	QUAGEN	5MG/5ML	A213761	001	Jun 02, 2021	May NEWA
AA		100MG/5ML	A213761	002	Jun 02, 2021	May NEWA

TABLET;ORAL

OXAYDO

+ ZYLA	5MG	N202080	001	Jun 17, 2011	Mar CRLD
+	7.5MG	N202080	002	Jun 17, 2011	Mar CRLD

OXYCODONE HYDROCHLORIDE

AB	ALVOGEN	5MG	A202116	001	Dec 30, 2011	Apr CAHN
AB		15MG	A202116	002	Dec 30, 2011	Apr CAHN
AB		30MG	A202116	003	Dec 30, 2011	Apr CAHN

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

+ @ MYLAN SPECIALITY LP	50MG	N016848	001		Apr DISC
-------------------------	------	---------	-----	--	----------

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

>A> AP	+! HIKMA	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Jul CAHN
>A> AP	+!	100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Jul CAHN
>D> AP	+! WEST-WARD PHARMS INT	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Jul CAHN
>D> AP	+!	100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Jul CAHN

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

+ CELGENE INTL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	May CPOT
+	EQ 0.46MG BASE	N209899	002	Mar 25, 2020	May CPOT
+!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	May CPOT

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	ACCORD HLTHCARE @ MYLAN LABS LTD	6MG/ML 6MG/ML	A205720 001 Aug 17, 2018 A091540 001 Sep 29, 2011	May CMFD Mar DISC
----	-------------------------------------	------------------	------------------------------------------------------	----------------------

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

>D> AP	+ JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264 001 Jul 31, 2009	Jul CTEC
>A> AB	+	39MG/0.25ML (39MG/0.25ML)	N022264 001 Jul 31, 2009	Jul CTEC
>D> AP	+	78MG/0.5ML (78MG/0.5ML)	N022264 002 Jul 31, 2009	Jul CTEC
>A> AB	+	78MG/0.5ML (78MG/0.5ML)	N022264 002 Jul 31, 2009	Jul CTEC
>D> AP	+	117MG/0.75ML (117MG/0.75ML)	N022264 003 Jul 31, 2009	Jul CTEC
>A> AB	+	117MG/0.75ML (117MG/0.75ML)	N022264 003 Jul 31, 2009	Jul CTEC
>D> AP	+!	156MG/ML (156MG/ML)	N022264 004 Jul 31, 2009	Jul CTEC
>A> AB	+!	156MG/ML (156MG/ML)	N022264 004 Jul 31, 2009	Jul CTEC
>D> AP	+	234MG/1.5ML (156MG/ML)	N022264 005 Jul 31, 2009	Jul CTEC
>A> AB	+	234MG/1.5ML (156MG/ML)	N022264 005 Jul 31, 2009	Jul CTEC
		PALIPERIDONE PALMITATE		
>D> AP	TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149 001 Jul 06, 2021	Jul CTEC
>A> AB	AP	39MG/0.25ML (39MG/0.25ML)	A211149 001 Jul 06, 2021	Jul CTEC
	AP	39MG/0.25ML (39MG/0.25ML)	A211149 001 Jul 06, 2021	Jun NFTG
>D> AP	AP	78MG/0.5ML (78MG/0.5ML)	A211149 002 Jul 06, 2021	Jul CTEC
>A> AB	AP	78MG/0.5ML (78MG/0.5ML)	A211149 002 Jul 06, 2021	Jul CTEC
	AP	78MG/0.5ML (78MG/0.5ML)	A211149 002 Jul 06, 2021	Jun NFTG
>D> AP	AP	117MG/0.75ML (117MG/0.75ML)	A211149 003 Jul 06, 2021	Jul CTEC
>A> AB	AP	117MG/0.75ML (117MG/0.75ML)	A211149 003 Jul 06, 2021	Jul CTEC
	AP	117MG/0.75ML (117MG/0.75ML)	A211149 003 Jul 06, 2021	Jun NFTG
>D> AP	AP	156MG/ML (156MG/ML)	A211149 004 Jul 06, 2021	Jul CTEC
>A> AB	AP	156MG/ML (156MG/ML)	A211149 004 Jul 06, 2021	Jul CTEC
	AP	156MG/ML (156MG/ML)	A211149 004 Jul 06, 2021	Jun NFTG
>D> AP	AP	234MG/1.5ML (156MG/ML)	A211149 005 Jul 06, 2021	Jul CTEC
>A> AB	AP	234MG/1.5ML (156MG/ML)	A211149 005 Jul 06, 2021	Jul CTEC
	AP	234MG/1.5ML (156MG/ML)	A211149 005 Jul 06, 2021	Jun NFTG

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

+ @ HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372 002 Feb 29, 2008	Apr DISC
+ @	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372 001 Jul 25, 2003	Apr DISC

PALONOSETRON HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615 001 Mar 15, 2021	Mar NEWA
AP	! DR REDDYS LABS LTD	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533 002 Apr 21, 2016	Apr CHRS
	EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951 001 Jun 29, 2021	Jun NEWA
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951 002 Jun 29, 2021	Jun NEWA
	@ HOSPIRA INC	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005 002 Sep 19, 2018	Apr DISC
	@ QILU	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648 002 Sep 19, 2018	Apr DISC
	@ TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713 002 Mar 23, 2018	Apr DISC

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

+ @ FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109 001 Nov 21, 2017	May DISC
------------------------	-------------------------------------------	--------------------------	----------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

>A> AP	+! HIKMA	30MG/10ML (3MG/ML)	N021113 001 Mar 04, 2002	Jul CAHN
>A> AP	+!	90MG/10ML (9MG/ML)	N021113 002 Mar 04, 2002	Jul CAHN
>D> AP	+! WEST-WARD PHARMS INT	30MG/10ML (3MG/ML)	N021113 001 Mar 04, 2002	Jul CAHN
>D> AP	+!	90MG/10ML (9MG/ML)	N021113 002 Mar 04, 2002	Jul CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

@ JUBILANT GENERICS EQ 20MG BASE
@ EQ 40MG BASEA090901 001 Aug 30, 2011 Jun DISC
A090901 002 Aug 30, 2011 Jun DISCPAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

AB	CSPC OUYI	EQ 12.5MG BASE	A213485 001 Feb 16, 2021	Feb NEWA
AB		EQ 25MG BASE	A213485 002 Feb 16, 2021	Feb NEWA
AB		EQ 37.5MG BASE	A213485 003 Feb 16, 2021	Feb NEWA
>A> AB	SINOOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612 001 Aug 11, 2021	Jul NEWA
>A> AB		EQ 25MG BASE	A213612 002 Aug 11, 2021	Jul NEWA

PATIROMER SORBITEX CALCIUM

POWDER;ORAL

VELTASSA

+ VIFOR PHARMA EQ 8.4GM BASE/PACKET
+ EQ 16.8GM BASE/PACKET
+! EQ 25.2GM BASE/PACKETN205739 001 Oct 21, 2015 Jun CAHN
N205739 002 Oct 21, 2015 Jun CAHN
N205739 003 Oct 21, 2015 Jun CAHNPEGCETACOPLAN

SOLUTION;SUBCUTANEOUS

EMPAVELI

+! APELLIS PHARMS 1080MG/20ML (54MG/ML)

N215014 001 May 14, 2021 May NEWA

PEMETREXED

SOLUTION;INTRAVENOUS

PEMETREXED

+ @ ACTAVIS LLC 100MG/4ML (25MG/ML)
+ @ 500MG/20ML (25MG/ML)
+ @ 1GM/40ML (25MG/ML)N208419 001 Aug 21, 2020 Jan DISC
N208419 002 Aug 21, 2020 Jan DISC
N208419 003 Aug 21, 2020 Jan DISCPENICILLIN G POTASSIUM

INJECTABLE;INJECTION

PENICILLIN G POTASSIUM

AP	HQ SPECLT PHARMA	1,000,000 UNITS/VIAL	A065149 001 Jul 23, 2009	Mar CAHN
AP		5,000,000 UNITS/VIAL	A065149 002 Jul 23, 2009	Mar CAHN
AP		20,000,000 UNITS/VIAL	A065149 003 Jul 23, 2009	Mar CAHN

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

PENICILLIN V POTASSIUM

@ DAVA PHARMS INC EQ 125MG BASE/5ML
@ EQ 250MG BASE/5ML

PENICILLIN-VK
TEVA EQ 125MG BASE/5ML
! EQ 250MG BASE/5MLA062981 001 Feb 10, 1989 Mar DISC
A062981 002 Feb 10, 1989 Mar DISC

A060456 001 Mar CTEC
A060456 002 Mar CTECPENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION

PENTAMIDINE ISETHIONATE

AP EMCURE PHARMS LTD 300MG/VIAL

A213806 001 Jan 07, 2021 Jan NEWA

PENTOXIFYLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIL

@ UPSHER SMITH LABS 400MG
TRENTAL
+ @ VALIDUS PHARMS 400MGA074962 001 Mar 31, 1999 May DISC
N018631 001 Aug 30, 1984 Feb CAHNPERAMPANEL

TABLET;ORAL

FYCOMPRA

+ EISAI INC 2MG
+ 4MG
+ 6MG
+ 8MG
+ 10MG
+! 12MGN202834 001 Oct 22, 2012 Jun CTEC
N202834 002 Oct 22, 2012 Jun CTEC
N202834 003 Oct 22, 2012 Jun CTEC
N202834 004 Oct 22, 2012 Jun CTEC
N202834 005 Oct 22, 2012 Jun CTEC
N202834 006 Oct 22, 2012 Jun CTEC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

BIORPHEN

+! ETON PHARMS	0.5MG/5ML (0.1MG/ML)
+ @	10MG/ML (10MG/ML)
+!	10MG/ML (10MG/ML)

N212909	001	Oct 21, 2019	Feb CPOT
N212909	002	Mar 11, 2021	Apr DISC
N212909	002	Mar 11, 2021	Mar NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP2	AUROBINDO PHARMA LTD	10MG/ML (10MG/ML)
>D>	@ CAPLIN	10MG/ML (10MG/ML)
>A> AP1		10MG/ML (10MG/ML)
>D>	@	50MG/5ML (10MG/ML)
>A> AP1		50MG/5ML (10MG/ML)
>D>	@	100MG/10ML (10MG/ML)
>A> AP1		100MG/10ML (10MG/ML)
AP1	GLAND PHARMA LTD	10MG/ML (10MG/ML)
AP2	+! HIKMA	10MG/ML (10MG/ML)
AP2	+!	50MG/5ML (10MG/ML)
AP2	+!	100MG/10ML (10MG/ML)
AP1	PROVEPHARM SAS	10MG/ML (10MG/ML)
AP1		50MG/5ML (10MG/ML)
AP1		100MG/10ML (10MG/ML)

A210696	001	Jan 07, 2021	Jan NEWA
A213318	001	Jun 11, 2020	Jul CMFD
A213318	001	Jun 11, 2020	Jul CMFD
A213318	002	Jun 11, 2020	Jul CMFD
A213318	002	Jun 11, 2020	Jul CMFD
A213318	003	Jun 11, 2020	Jul CMFD
A213318	003	Jun 11, 2020	Jul CMFD
A211920	003	Apr 08, 2021	Apr NEWA
N203826	001	Dec 20, 2012	Jan CAHN
N203826	002	Jun 19, 2019	Jan CAHN
N203826	003	Jun 19, 2019	Jan CAHN
A211081	001	Jul 17, 2020	Jan CAHN
A211081	002	Jul 17, 2020	Jan CAHN
A211081	003	Jul 17, 2020	Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	AKORN	5MG/5ML; 6.25MG/5ML
----	-------	---------------------

A040675	001	Dec 23, 2014	Feb CAHN
---------	-----	--------------	----------

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+! INTL MEDICATION	1MG/0.5ML
----	--------------------	-----------

A083722	001		May CRLD
---------	-----	--	----------

PIFLUUFOLASTAT F-18

SOLUTION; INTRAVENOUS

PYLARIFY

+! PROGENICS PHARMS INC	50ML (1-80mCi/ML)
-------------------------	-------------------

N214793	001	May 26, 2021	May NEWA
---------	-----	--------------	----------

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	ANNORA PHARMA	EQ 15MG BASE
AB		EQ 30MG BASE
AB		EQ 45MG BASE
AB	SHUANGCHENG	EQ 15MG BASE
AB		EQ 30MG BASE
AB		EQ 45MG BASE

A204133	001	Apr 07, 2014	Jan CAHN
A204133	002	Apr 07, 2014	Jan CAHN
A204133	003	Apr 07, 2014	Jan CAHN
A210165	001	Jan 22, 2021	Jan NEWA
A210165	002	Jan 22, 2021	Jan NEWA
A210165	003	Jan 22, 2021	Jan NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

@ MYLAN LABS LTD	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	
@	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	
>D> AP	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	
>A>	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	
AP	PROVEPHARM SAS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL
AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL
AP		EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL
AP	SAGENT PHARMS INC	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL

A065458	001	Aug 15, 2014	Apr DISC
A065458	002	Aug 15, 2014	Mar DISC
A065458	003	Aug 15, 2014	Jul DISC
A065458	003	Aug 15, 2014	Jul DISC
A207847	001	Jan 13, 2017	Jan CAHN
A207847	002	Jan 13, 2017	Jan CAHN
A207848	002	Jan 13, 2017	Jan CAHN
A207847	003	Jan 13, 2017	Jan CAHN
A207848	001	May 11, 2018	Jan CAHN
A208674	001	Feb 16, 2021	Feb NEWA
A208674	002	Feb 16, 2021	Feb NEWA
A208674	003	Feb 16, 2021	Feb NEWA

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A208675 001 Feb 16, 2021	Feb NEWA
>A>	AP SANDOZ INC	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A203557 002 Jul 08, 2021	Jul NEWA
AP	! WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996 001 Mar 22, 2017	Jan CHRS
AP	!	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996 002 Mar 22, 2017	Jan CHRS
AP	!	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996 003 Mar 22, 2017	Jan CHRS
AP	!	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146 001 Mar 17, 2017	Jan CHRS
	ZOSYN			
+ @	WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N050684 001 Oct 22, 1993	Jan DISC
+ @		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N050684 002 Oct 22, 1993	Jan DISC
+ @		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N050684 003 Oct 22, 1993	Jan DISC
+ @		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N050684 004 Oct 22, 1993	Jan DISC

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

@ BAUSCH

EQ 0.2MG BASE/INH

N020014 001 Nov 30, 1992 May CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB NOSTRUM LABS INC 10MG A074118 002 Jun 15, 1993 Jan CMS1

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYXIN B SULFATE

@ GLAND

AP ! XELLIA PHARMS APS EQ 500,000 UNITS BASE/VIAL A207322 001 Apr 14, 2016 May DISC

AP ! XELLIA PHARMS APS EQ 500,000 UNITS BASE/VIAL A202766 001 Jan 15, 2014 May CHRS

POMALIDOMIDE

CAPSULE; ORAL

POMALIDOMIDE

@ BRECKENRIDGE

1MG

A210111 001 Oct 30, 2020 Feb DISC

@

2MG

A210111 002 Oct 30, 2020 Feb DISC

@

3MG

A210111 003 Oct 30, 2020 Feb DISC

@

4MG

A210111 004 Oct 30, 2020 Feb DISC

@ EUGIA PHARMA

1MG

A210249 001 Oct 30, 2020 Apr DISC

@

2MG

A210249 002 Oct 30, 2020 Apr DISC

@

3MG

A210249 003 Oct 30, 2020 Apr DISC

@

4MG

A210249 004 Oct 30, 2020 Apr DISC

POMALYST

+ CELGENE

1MG

N204026 001 Feb 08, 2013 Apr CTEC

+

2MG

N204026 002 Feb 08, 2013 Apr CTEC

+

3MG

N204026 003 Feb 08, 2013 Apr CTEC

+ !

4MG

N204026 004 Feb 08, 2013 Apr CTEC

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

+ TAKEDA PHARMS USA

EQ 10MG BASE

N203469 004 Dec 18, 2020 May CAHN

+

EQ 15MG BASE

N203469 001 Dec 14, 2012 May CAHN

+

EQ 30MG BASE

N203469 003 Apr 23, 2015 May CAHN

+ !

EQ 45MG BASE

N203469 002 Dec 14, 2012 May CAHN

PONESIMOD

TABLET; ORAL

PONVORY

+ JANSSEN PHARMS

2MG

N213498 001 Mar 18, 2021 Mar NEWA

+

3MG

N213498 002 Mar 18, 2021 Mar NEWA

+

4MG

N213498 003 Mar 18, 2021 Mar NEWA

+

5MG

N213498 004 Mar 18, 2021 Mar NEWA

+

6MG

N213498 005 Mar 18, 2021 Mar NEWA

+

7MG

N213498 006 Mar 18, 2021 Mar NEWA

TABLET;ORAL
PONVORY

+	8MG	N213498	007	Mar 18, 2021	Mar NEWA
+	9MG	N213498	008	Mar 18, 2021	Mar NEWA
+	10MG	N213498	009	Mar 18, 2021	Mar NEWA
+!	20MG	N213498	010	Mar 18, 2021	Mar NEWA

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL
NOXAFIL POWDERMIX KIT

+!	MSD MERCK CO	300MG	N214770	001	May 31, 2021	May NEWA
----	--------------	-------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE;ORAL
POSACONAZOLE

AB	AET PHARMA	100MG	A213454	001	Feb 01, 2021	Jan NEWA
----	------------	-------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB	GRANULES	8MEQ	A214686	001	Feb 16, 2021	Feb NEWA
AB		10MEQ	A214686	002	Feb 16, 2021	Feb NEWA

FOR SOLUTION;ORAL
POTASSIUM CHLORIDE

AA	STRIDES PHARMA	20MEQ	A211667	001	Mar 11, 2021	Mar NEWA
----	----------------	-------	---------	-----	--------------	----------

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ

@	FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Mar DISC
@		746MG/100ML	A211087	002	Sep 09, 2020	Mar DISC

AP	NEXUS PHARMS	14.9MG/ML	A214727	001	Mar 18, 2021	Mar NFTG
AP		745MG/100ML	A214727	002	Mar 18, 2021	Mar NFTG

POTASSIUM CHLORIDE 20MEQ

@	FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Mar DISC
AP		1.49GM/100ML	A211087	005	May 07, 2021	Apr NEWA

AP	NEXUS PHARMS	29.8MG/ML	A214727	003	Mar 18, 2021	Mar NFTG
AP		1.49GM/100ML	A214727	004	Mar 18, 2021	Mar NFTG

POTASSIUM CHLORIDE 40MEQ

@	FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar DISC
AP	NEXUS PHARMS	2.98GM/100ML	A214727	005	Mar 18, 2021	Mar NFTG

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA	GRANULES	20MEQ/15ML	A213392	001	Jan 29, 2021	Jan NEWA
AA		40MEQ/15ML	A213392	002	Jan 29, 2021	Jan NEWA
AA	SAPTALIS PHARMS	20MEQ/15ML	A211648	001	May 21, 2021	May NEWA
AA		40MEQ/15ML	A211648	002	May 21, 2021	May NEWA

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

>D>	AB1	AMTA	10MEQ	A214395	001	Jan 28, 2021	Jul DISC
>A>		@	10MEQ	A214395	001	Jan 28, 2021	Jul DISC

AB1 10MEQ

>D>	AB1		20MEQ	A214395	002	Jan 28, 2021	Jul DISC
>A>		@	20MEQ	A214395	002	Jan 28, 2021	Jul DISC

AB1 20MEQ

AB1	AUROBINDO PHARMA LTD	10MEQ	A214728	001	Mar 31, 2021	Mar NEWA
AB1		15MEQ	A214728	002	Mar 31, 2021	Mar NEWA

AB1		20MEQ	A214728	003	Mar 31, 2021	Mar NEWA
AB1	@ CENTAUR PHARMS PVT	10MEQ	A213588	001	Aug 21, 2020	Mar DISC

@ CENTAUR PHARMS PVT 10MEQ

AB1		20MEQ	A213588	002	Aug 21, 2020	Mar DISC
-----	--	-------	---------	-----	--------------	----------

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

+!	BAXTER HLTHCARE	150MG/100ML; 450MG/100ML	N017648	005	Nov 26, 2002	Mar CTNA
+!		150MG/100ML; 450MG/100ML	N017648	005	Nov 26, 2002	Mar CTEC

@ FRESENIUS KABI USA 150MG/100ML; 450MG/100ML

+!	BAXTER HLTHCARE	POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%	A212347	001	Sep 17, 2020	Mar DISC
+!			A212347	001	Sep 17, 2020	Mar DISC

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%

AP	+!	BAXTER HLTHCARE	150MG/100ML; 900MG/100ML	N017648	001	Mar CTNA
AP	+!		150MG/100ML; 900MG/100ML	N017648	001	Mar CHRS

AP	FRESENIUS KABI USA	150MG/100ML; 900MG/100ML	A212347	003	Jun 02, 2021	May NEWA
AP		POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%	A212347	003	Jun 02, 2021	May NEWA

+! BAXTER HLTHCARE 300MG/100ML; 900MG/100ML

+!		300MG/100ML; 900MG/100ML	N017648	002	Mar CHRS
+!		300MG/100ML; 900MG/100ML	N017648	002	Mar CTEC

+! @ FRESENIUS KABI USA 300MG/100ML; 900MG/100ML

+!		300MG/100ML; 900MG/100ML	A212347	002	Sep 17, 2020	Mar DISC
----	--	--------------------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%
© BAXTER HLTHCARE 75MG/100ML; 900MG/100ML

N 017648 004

Mar CTNA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

AB	ASCENT PHARMS INC	5MEQ	A214420	001	Feb 05, 2021	Jan NEWA
AB		10MEQ	A214420	002	Feb 05, 2021	Jan NEWA
AB		15MEQ	A214420	003	Feb 05, 2021	Jan NEWA
AB	BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Apr CMFD
AB	@	10MEQ	A212799	001	Jun 29, 2020	Feb DISC
AB		15MEQ	A212799	002	Jun 29, 2020	Apr CMFD
AB	@	15MEQ	A212799	002	Jun 29, 2020	Feb DISC
AB	EYWA	5MEQ	A214426	001	Feb 19, 2021	Feb NEWA
AB		10MEQ	A214426	002	Feb 19, 2021	Feb NEWA
AB		15MEQ	A214426	003	Feb 19, 2021	Feb NEWA

PRALSETINIB

CAPSULE; ORAL

GAVRETO

+! GENENTECH INC 100MG

N 213721 001 Sep 04, 2020 Mar CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>D>	AB	NOSTRUM LABS INC	0.125MG	A091450	001	Oct 08, 2010	Jul	DISC
>A>		@	0.125MG	A091450	001	Oct 08, 2010	Jul	DISC
	AB		0.125MG	A091450	001	Oct 08, 2010	Apr	CAHN
>D>	AB		0.25MG	A091450	002	Oct 08, 2010	Jul	DISC
>A>		@	0.25MG	A091450	002	Oct 08, 2010	Jul	DISC
	AB		0.25MG	A091450	002	Oct 08, 2010	Apr	CAHN
>D>	AB		0.5MG	A091450	003	Oct 08, 2010	Jul	DISC
>A>		@	0.5MG	A091450	003	Oct 08, 2010	Jul	DISC
	AB		0.5MG	A091450	003	Oct 08, 2010	Apr	CAHN
>D>	AB		1MG	A091450	004	Oct 08, 2010	Jul	DISC
>A>		@	1MG	A091450	004	Oct 08, 2010	Jul	DISC
	AB		1MG	A091450	004	Oct 08, 2010	Apr	CAHN
>D>	AB		1.5MG	A091450	005	Oct 08, 2010	Jul	DISC
>A>		@	1.5MG	A091450	005	Oct 08, 2010	Jul	DISC
	AB		1.5MG	A091450	005	Oct 08, 2010	Apr	CAHN

PRAMIPEXOLE DIHYDRO

XIAMEN

<u>PRASUGREL HYDROCHLORIDE</u>									
TABLET; ORAL									
PRASUGREL									
	@ DR REDDYS LABS LTD	EQ 5MG BASE		A205926	001	Jul 07, 2020	Jan	DISC	
	@	EQ 10MG BASE		A205926	002	Jul 07, 2020	Jan	DISC	
>A> AB	PANACEA	EQ 5MG BASE		A205897	001	Oct 16, 2017	Jul	CAHN	
>A> AB		EQ 10MG BASE		A205897	002	Oct 16, 2017	Jul	CAHN	
>D> AB	PANACEA BIOTEC LTD	EQ 5MG BASE		A205897	001	Oct 16, 2017	Jul	CAHN	
>D> AB		EQ 10MG BASE		A205897	002	Oct 16, 2017	Jul	CAHN	

DRAVASTATIN SODIUM

TABLE II. OBAT

PRAVACHOT

PRAVACHOL							
+ @	BRISTOL MYERS SQUIBB	20MG	N019898	003	Oct 31, 1991	Jun	DISC
+ @		40MG	N019898	004	Mar 22, 1993	Jun	DISC
+ @		80MG	N019898	008	Dec 18, 2001	Jun	DISC
PRAVASTATIN SODIUM							
AB	BIOCON PHARMA	10MG	A209869	001	Apr 13, 2018	Jan	CAHN
AB		20MG	A209869	002	Apr 13, 2018	Jan	CAHN
AB		40MG	A209869	003	Apr 13, 2018	Jan	CAHN
AB		80MG	A209869	004	Apr 13, 2018	Jan	CAHN
	@ HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018	Jan	DISC
	@	40MG	A206061	002	Nov 23, 2018	Jan	DISC
	@	80MG	A206061	003	Nov 23, 2018	Jan	DISC
AB	! TEVA PHARMS	80MG	A077793	001	Jan 15, 2008	Jun	CHRS

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

AB	ANI PHARMS	EQ 1MG BASE	A072577	002	May 16, 1989	Feb CMFD
AB		EQ 2MG BASE	A072577	001	May 16, 1989	Feb CMFD
AB		EQ 5MG BASE	A072577	003	May 16, 1989	Feb CMFD

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Mar CMFD
	TABLET;ORAL					
	PREDNISOLONE					

@ RISING

5MG

A084773

001

Jan CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

@ BAUSCH EQ 15MG BASE/5ML

A075250

001

Jul 12, 2002

May CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

ORAPRED ODT

>D> AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Jul CTEC
>A>	+		EQ 10MG BASE	N021959	001	Jun 01, 2006	Jul CTEC
>D> AB	+		EQ 15MG BASE	N021959	002	Jun 01, 2006	Jul CTEC
>A>	+		EQ 15MG BASE	N021959	002	Jun 01, 2006	Jul CTEC
>D> AB	+!		EQ 30MG BASE	N021959	003	Jun 01, 2006	Jul CTEC
>A>	+!		EQ 30MG BASE	N021959	003	Jun 01, 2006	Jul CTEC
		PREDNISOLONE SODIUM PHOSPHATE					
>D> AB		MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Jul DISC
>A>	@		EQ 10MG BASE	A202179	001	Apr 10, 2013	Jul DISC
>D> AB			EQ 15MG BASE	A202179	002	Apr 10, 2013	Jul DISC
>A>	@		EQ 15MG BASE	A202179	002	Apr 10, 2013	Jul DISC
>D> AB			EQ 30MG BASE	A202179	003	Apr 10, 2013	Jul DISC
>A>	@		EQ 30MG BASE	A202179	003	Apr 10, 2013	Jul DISC

PREDNISONE

TABLET;ORAL

PREDNISONE

AB		NOVITIUM PHARMA	1MG	A215246	001	Jul 06, 2021	Jun NEWA
	@ RISING		10MG	A089983	001	Jan 12, 1989	Jan CAHN
	@		20MG	A085813	001		Jan CAHN
	@		50MG	A089984	001	Jan 12, 1989	Jan CAHN
AB		STRIDES PHARMA	10MG	A208412	001	Feb 11, 2021	Feb NEWA
AB			20MG	A208412	002	Feb 11, 2021	Feb NEWA
		PREDNISONE TABLET, DELAYED RELEASE;ORAL					
		RAYOS					
	+	HORIZON	1MG	N202020	001	Jul 26, 2012	Apr CAHN
	+		2MG	N202020	002	Jul 26, 2012	Apr CAHN
	+		5MG	N202020	003	Jul 26, 2012	Apr CAHN

PREGABALIN

CAPSULE;ORAL

LYRICA

AB	+	UPJOHN	25MG	N021446	001	Dec 30, 2004	Apr CAHN
AB	+		50MG	N021446	002	Dec 30, 2004	Apr CAHN
AB	+		75MG	N021446	003	Dec 30, 2004	Apr CAHN
AB	+		100MG	N021446	004	Dec 30, 2004	Apr CAHN
AB	+		150MG	N021446	005	Dec 30, 2004	Apr CAHN
AB	+		200MG	N021446	006	Dec 30, 2004	Apr CAHN
AB	+		225MG	N021446	007	Dec 30, 2004	Apr CAHN
AB	+		300MG	N021446	008	Dec 30, 2004	Apr CAHN
		PREGABALIN					
AB		ALKEM LABS LTD	25MG	A207799	007	Sep 30, 2019	Feb CMS1
AB			50MG	A207799	008	Sep 30, 2019	Feb CMS1
AB		APOTEX	25MG	A211685	001	Jul 07, 2021	Jun NEWA
AB			50MG	A211685	002	Jul 07, 2021	Jun NEWA
AB			75MG	A211685	003	Jul 07, 2021	Jun NEWA
AB			100MG	A211685	004	Jul 07, 2021	Jun NEWA
AB			150MG	A211685	005	Jul 07, 2021	Jun NEWA
AB			200MG	A211685	006	Jul 07, 2021	Jun NEWA
AB			225MG	A211685	007	Jul 07, 2021	Jun NEWA

CAPSULE;ORAL
PREGABALIN

AB		300MG	A211685	008	Jul 07, 2021	Jun NEWA
>A> AB	CHANGZHOU PHARM	50MG	A214322	001	Jul 15, 2021	Jul NEWA
>A> AB		75MG	A214322	002	Jul 15, 2021	Jul NEWA
>A> AB		100MG	A214322	003	Jul 15, 2021	Jul NEWA
>A> AB		150MG	A214322	004	Jul 15, 2021	Jul NEWA
>A> AB		200MG	A214322	005	Jul 15, 2021	Jul NEWA
>A> AB		225MG	A214322	006	Jul 15, 2021	Jul NEWA
>A> AB		300MG	A214322	007	Jul 15, 2021	Jul NEWA

SOLUTION;ORAL
LYRICA

AA	+! UPJOHN	20MG/ML	N022488	001	Jan 04, 2010	Apr CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	LYRICA CR					
AB	+ UPJOHN	82.5MG	N209501	001	Oct 11, 2017	Apr CAHN
AB	+	165MG	N209501	002	Oct 11, 2017	Apr CAHN
AB	+!	330MG	N209501	003	Oct 11, 2017	Apr CAHN
	PREGABALIN					
AB	ALVOGEN	82.5MG	A211687	001	Jul 06, 2021	Jun NEWA
AB		165MG	A211687	002	Jul 06, 2021	Jun NEWA
AB		330MG	A211687	003	Jul 06, 2021	Jun NEWA
AB	ALVOGEN PINE BROOK	82.5MG	A211593	001	Apr 13, 2021	Apr NFTG
AB		165MG	A211593	002	Apr 13, 2021	Apr NFTG
AB		330MG	A211593	003	Apr 13, 2021	Apr NFTG
AB	APOTEX	165MG	A213313	001	Apr 13, 2021	Apr NFTG
AB		330MG	A213313	002	Apr 13, 2021	Apr NFTG
AB	MSN	82.5MG	A213226	001	Apr 13, 2021	Apr NFTG
AB		165MG	A213226	002	Apr 13, 2021	Apr NFTG
AB		330MG	A213226	003	Apr 13, 2021	Apr NFTG
AB	MYLAN	82.5MG	A211948	001	Apr 13, 2021	Apr NFTG
AB		330MG	A211431	001	Jul 02, 2021	Jun NEWA
AB	SUN PHARM	82.5MG	A211889	001	Apr 13, 2021	Apr NFTG
AB		165MG	A211889	002	Apr 13, 2021	Apr NFTG
AB		330MG	A211889	003	Apr 13, 2021	Apr NFTG

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	CAPLIN	EQ 5MG BASE/ML	A214379	001	Apr 22, 2021	Apr NEWA
>A>	@ HIKMA	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jul CAHN
>A> AP		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jul CAHN
>D>	@ WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jul CAHN
>D> AP		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jul CAHN

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE

>A> AA	@ AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009	Feb DISC
	QUAGEN	6.25MG/5ML	A213890	001	Jul 12, 2021	Jul NEWA

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

>D> AB	MYLAN	225MG	A203803	001	Apr 29, 2016	Jul DISC
>A>	@	225MG	A203803	001	Apr 29, 2016	Jul DISC
>D> AB		325MG	A203803	002	Apr 29, 2016	Jul DISC
>A>	@	325MG	A203803	002	Apr 29, 2016	Jul DISC
>D> AB		425MG	A203803	003	Apr 29, 2016	Jul DISC
>A>	@	425MG	A203803	003	Apr 29, 2016	Jul DISC
AB	ZYDUS	225MG	A214184	001	Apr 21, 2021	Apr NEWA
AB		325MG	A214184	002	Apr 21, 2021	Apr NEWA
AB		425MG	A214184	003	Apr 21, 2021	Apr NEWA

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

@ HIKMA	15MG	A080927	002			Apr DISC
---------	------	---------	-----	--	--	----------

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

@ WATSON LABS 60MG

A070178 002 Apr 23, 2018 Apr DISC

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

BD QUAGEN 50MG

A080154 001 Mar CMFD

PROTAMINE SULFATE

INJECTABLE;INJECTION

PROTAMINE SULFATE

>A>	@ HIKMA	10MG/ML	A089474	001	Nov 05, 1986	Jul CAHN
>A>	@	10MG/ML	A089475	001	Nov 05, 1986	Jul CAHN
>D>	@ WEST-WARD PHARMS INT	10MG/ML	A089474	001	Nov 05, 1986	Jul CAHN
>D>	@	10MG/ML	A089475	001	Nov 05, 1986	Jul CAHN

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

AB NOVITIUM PHARMA 500MG

A080157 001 Apr CMFD

PYRIMETHAMINE

TABLET;ORAL

PYRIMETHAMINE

>A> AB	FERA PHARMS LLC	25MG	A211271	001	Jul 27, 2021	Jul NEWA
--------	-----------------	------	---------	-----	--------------	----------

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

@ JUBILANT GENERICS EQ 25MG BASE

A203150 001 Nov 26, 2013 Jun DISC

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

@ ANCHEN PHARMS EQ 150MG BASE

A090757 001 Dec 01, 2017 Jun DISC

@ EQ 200MG BASE

A090757 002 Dec 01, 2017 Jun DISC

@ EQ 300MG BASE

A090757 003 Dec 01, 2017 Jun DISC

@ EQ 400MG BASE

A090757 004 Dec 01, 2017 Jun DISC

@ MYLAN EQ 50MG BASE

A202228 001 Feb 02, 2021 Feb DISC

AB EQ 50MG BASE

A202228 001 Feb 02, 2021 Jan NEWA

@ EQ 150MG BASE

A202228 002 Feb 02, 2021 Feb DISC

AB EQ 150MG BASE

A202228 002 Feb 02, 2021 Jan NEWA

@ EQ 200MG BASE

A202228 003 Feb 02, 2021 Feb DISC

AB EQ 200MG BASE

A202228 003 Feb 02, 2021 Jan NEWA

@ EQ 300MG BASE

A202228 004 Feb 02, 2021 Feb DISC

AB EQ 300MG BASE

A202228 004 Feb 02, 2021 Jan NEWA

@ EQ 400MG BASE

A202228 005 Feb 02, 2021 Feb DISC

AB EQ 400MG BASE

A202228 005 Feb 02, 2021 Jan NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

@ RISING 324MG

A089894 001 Dec 15, 1988 Jan CAHN

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

>D>	+ @ EISAI INC	10MG	N020973	001	May 29, 2002	Jul CAHN
>D> AB	+!	20MG	N020973	002	Aug 19, 1999	Jul CAHN
>A>	+ @ WOODWARD	10MG	N020973	001	May 29, 2002	Jul CAHN
>A> AB	+!	20MG	N020973	002	Aug 19, 1999	Jul CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD EQ 150MG BASE

A211058 001 Jul 16, 2018 Jun DISC

@ EQ 300MG BASE

A211058 002 Jul 16, 2018 Jun DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD EQ 15MG BASE/ML

A090623 001 Jul 28, 2010 Jun DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ WOCKHARDT LTD	EQ 150MG BASE
@	EQ 300MG BASE

A075208	001	Dec 17, 1998	Jan DISC
A075208	002	Dec 17, 1998	Jan DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB	ACCORD HLTHCARE	500MG	A212930	001	May 18, 2021	May NEWA
AB		1GM	A212930	002	May 18, 2021	May NEWA
@	AMNEAL	500MG	A207690	001	Mar 11, 2021	Apr DISC
AB		500MG	A207690	001	Mar 11, 2021	Mar NEWA
@		1GM	A207690	002	Mar 11, 2021	Apr DISC
AB		1GM	A207690	002	Mar 11, 2021	Mar NEWA
AB	GRAVITI PHARMS	500MG	A212889	001	Jan 28, 2021	Jan NEWA
AB		1GM	A212889	002	Jan 28, 2021	Jan NEWA
AB	PRAZGEN	500MG	A212781	001	Mar 23, 2020	Feb CAHN
AB		1GM	A212781	002	Mar 23, 2020	Feb CAHN

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

>A> AB	PADAGIS US	0.5MG	A201189	001	Jul 17, 2013	Jul CAHN
>A> AB		0.5MG	A201189	001	Jul 17, 2013	Jul CAHN
>A> AB		1MG	A201189	002	Jan 22, 2014	Jul CAHN
>A> AB		1MG	A201189	002	Jan 22, 2014	Jul CAHN
>A> AB		2MG	A201189	003	Jan 22, 2014	Jul CAHN
>A> AB		2MG	A201189	003	Jan 22, 2014	Jul CAHN
>D> AB	PADDICK LABS LLC	0.5MG	A201189	001	Jul 17, 2013	Jul CAHN
>D> AB		1MG	A201189	002	Jan 22, 2014	Jul CAHN
>D> AB		2MG	A201189	003	Jan 22, 2014	Jul CAHN

RILUZOLE

FILM;ORAL

EXSERVAN

+!	MITSUBISHI HOLDINGS	50MG
----	---------------------	------

N212640	001	Nov 22, 2019	Feb CAHN
---------	-----	--------------	----------

RIMEGEPEANT SULFATETABLET, ORALLY DISINTEGRATING;ORAL
NURTEC ODT

>A>	+! BIOHAVEN IRELAND	EQ 75MG BASE	N212728	001	Feb 27, 2020	Jul CAHN
>D>	+! BIOHAVEN PHARM	EQ 75MG BASE	N212728	001	Feb 27, 2020	Jul CAHN

RISPERIDONETABLET, ORALLY DISINTEGRATING;ORAL
RISPERDAL

+ @ JANSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003	Feb DISC
+ @	1MG	N021444	002	Apr 02, 2003	Feb DISC
+ @	2MG	N021444	003	Apr 02, 2003	Feb DISC
+ @	3MG	N021444	004	Dec 23, 2004	Feb DISC
+ @	4MG	N021444	005	Dec 23, 2004	Feb DISC

RISPERIDONE

AB	! JUBILANT GENERICS	1MG	A090839	002	Nov 04, 2011	Feb CHRS
----	---------------------	-----	---------	-----	--------------	----------

RITONAVIR

CAPSULE;ORAL

RITONAVIR

@ HIKMA	100MG
---------	-------

A205801	001	Dec 03, 2020	Mar DISC
---------	-----	--------------	----------

RIZATRIPTAN BENZOATETABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

@ JUBILANT GENERICS	EQ 5MG BASE	A203334	001	Oct 16, 2015	Jun DISC	
@	EQ 10MG BASE	A203334	002	Oct 16, 2015	Jun DISC	
>A> AB	PANACEA	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jul CAHN
>A> AB		EQ 10MG BASE	A204722	002	Jan 11, 2017	Jul CAHN
>D> AB	PANACEA BIOTEC LTD	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jul CAHN
>D> AB		EQ 10MG BASE	A204722	002	Jan 11, 2017	Jul CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

REQUIP

>D>	AB	+!	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Jul DISC	
>A>		+	@	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Jul DISC	
>D>	AB	+		EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Jul DISC	
>A>		+	@	EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Jul DISC	
>D>	AB	+		EQ 1MG BASE	N020658	003	Sep 19, 1997	Jul DISC	
>A>		+	@	EQ 1MG BASE	N020658	003	Sep 19, 1997	Jul DISC	
>D>	AB	+		EQ 2MG BASE	N020658	004	Sep 19, 1997	Jul DISC	
>A>		+	@	EQ 2MG BASE	N020658	004	Sep 19, 1997	Jul DISC	
>D>	AB	+		EQ 3MG BASE	N020658	006	Jan 27, 1999	Jul DISC	
>A>		+	@	EQ 3MG BASE	N020658	006	Jan 27, 1999	Jul DISC	
>D>	AB	+		EQ 4MG BASE	N020658	007	Jan 27, 1999	Jul DISC	
>A>		+	@	EQ 4MG BASE	N020658	007	Jan 27, 1999	Jul DISC	
>D>	AB	+		EQ 5MG BASE	N020658	005	Sep 19, 1997	Jul DISC	
>A>		+	@	EQ 5MG BASE	N020658	005	Sep 19, 1997	Jul DISC	
				ROPINIROLE HYDROCHLORIDE					
>D>	AB		PRINSTON INC	EQ 0.25MG BASE	A078110	001	May 05, 2008	Jul CHRS	
>A>	AB	!		EQ 0.25MG BASE	A078110	001	May 05, 2008	Jul CHRS	
				TABLET, EXTENDED RELEASE;ORAL					
				REQUIP XL					
				+ @ GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Jun DISC
AB		+			EQ 2MG BASE	N022008	001	Jun 13, 2008	Jun CHRS
				+ @	EQ 6MG BASE	N022008	006	Apr 10, 2009	Jun DISC
				+ @	EQ 12MG BASE	N022008	005	Oct 31, 2008	Jun DISC
				ROPINIROLE HYDROCHLORIDE					
AB		!	DR REDDYS LABS LTD	EQ 2MG BASE	A201576	001	Jun 06, 2012	Jun CHRS	

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

+ @	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	Mar CRLD
+ @		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Mar CRLD
ROPIVACAINE HYDROCHLORIDE						
@	MYLAN ASI	150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Jan DISC
@		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Jan DISC

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

>D>		+	SB PHARMCO	EQ 2MG BASE	N021071	002	May 25, 1999	Jul CAHN
>D>		+		EQ 4MG BASE	N021071	003	May 25, 1999	Jul CAHN
>D>		+	@	EQ 8MG BASE	N021071	004	May 25, 1999	Jul CAHN
>A>		+	WOODWARD	EQ 2MG BASE	N021071	002	May 25, 1999	Jul CAHN
>A>		+		EQ 4MG BASE	N021071	003	May 25, 1999	Jul CAHN
>A>		+	@	EQ 8MG BASE	N021071	004	May 25, 1999	Jul CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB		+	IPR	EQ 5MG BASE	N021366	002	Aug 12, 2003	Apr CPOT
AB		+		EQ 10MG BASE	N021366	003	Aug 12, 2003	Apr CPOT
AB		+	!	EQ 40MG BASE	N021366	005	Aug 12, 2003	Apr CPOT
ROSVUASTATIN CALCIUM								
AB			ACCORD HLTHCARE	EQ 5MG BASE	A206434	001	Oct 31, 2016	Apr CPOT
AB				EQ 10MG BASE	A206434	002	Oct 31, 2016	Apr CPOT
AB				EQ 20MG BASE	A206434	003	Oct 31, 2016	Apr CPOT
AB				EQ 40MG BASE	A206434	004	Oct 31, 2016	Apr CPOT
AB			ALKEM LABS LTD	EQ 5MG BASE	A206465	001	Mar 21, 2017	Apr CPOT
AB				EQ 10MG BASE	A206465	002	Mar 21, 2017	Apr CPOT
AB				EQ 20MG BASE	A206465	003	Mar 21, 2017	Apr CPOT
AB				EQ 40MG BASE	A206465	004	Mar 21, 2017	Apr CPOT
AB			ALLIED	EQ 5MG BASE	A079168	001	Jul 19, 2016	Apr CPOT
AB				EQ 10MG BASE	A079168	002	Jul 19, 2016	Apr CPOT
AB				EQ 20MG BASE	A079168	003	Jul 19, 2016	Apr CPOT
AB				EQ 40MG BASE	A079168	004	Jul 19, 2016	Apr CPOT
		@	AMNEAL PHARMS CO	EQ 5MG BASE	A208850	001	Oct 16, 2018	Apr CPOT
		@		EQ 10MG BASE	A208850	002	Oct 16, 2018	Apr CPOT
		@		EQ 20MG BASE	A208850	003	Oct 16, 2018	Apr CPOT
		@		EQ 40MG BASE	A208850	004	Oct 16, 2018	Apr CPOT
		@	APOTEX INC	EQ 5MG BASE	A079145	001	Jul 19, 2016	Apr CPOT

TABLET;ORAL

ROSUVASTATIN CALCIUM

	@	EQ 10MG BASE	A079145	002	Jul 19, 2016	Apr CPOT
	@	EQ 20MG BASE	A079145	003	Jul 19, 2016	Apr CPOT
	@	EQ 40MG BASE	A079145	004	Jul 19, 2016	Apr CPOT
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A079170	001	Jul 19, 2016	Apr CPOT
AB		EQ 10MG BASE	A079170	002	Jul 19, 2016	Apr CPOT
AB		EQ 20MG BASE	A079170	003	Jul 19, 2016	Apr CPOT
AB		EQ 40MG BASE	A079170	004	Jul 19, 2016	Apr CPOT
>D> AB	BIOCON LTD	EQ 5MG BASE	A207752	001	Oct 31, 2016	Jul CAHN
AB		EQ 5MG BASE	A207752	001	Oct 31, 2016	Apr CPOT
>D> AB		EQ 10MG BASE	A207752	002	Oct 31, 2016	Jul CAHN
AB		EQ 10MG BASE	A207752	002	Oct 31, 2016	Apr CPOT
>D> AB		EQ 20MG BASE	A207752	003	Oct 31, 2016	Jul CAHN
AB		EQ 20MG BASE	A207752	003	Oct 31, 2016	Apr CPOT
>D> AB		EQ 40MG BASE	A207752	004	Oct 31, 2016	Jul CAHN
AB		EQ 40MG BASE	A207752	004	Oct 31, 2016	Apr CPOT
>A> AB	BIOCON PHARMA	EQ 5MG BASE	A207752	001	Oct 31, 2016	Jul CAHN
>A> AB		EQ 10MG BASE	A207752	002	Oct 31, 2016	Jul CAHN
>A> AB		EQ 20MG BASE	A207752	003	Oct 31, 2016	Jul CAHN
>A> AB		EQ 40MG BASE	A207752	004	Oct 31, 2016	Jul CAHN
AB	CADILA PHARMS LTD	EQ 5MG BASE	A207453	001	Nov 23, 2016	Apr CPOT
AB		EQ 10MG BASE	A207453	002	Nov 23, 2016	Apr CPOT
AB		EQ 20MG BASE	A207453	003	Nov 23, 2016	Apr CPOT
AB		EQ 40MG BASE	A207453	004	Nov 23, 2016	Apr CPOT
AB	CHANGZHOU PHARM	EQ 5MG BASE	A207408	001	Oct 31, 2016	Apr CPOT
AB		EQ 10MG BASE	A207408	002	Oct 31, 2016	Apr CPOT
AB		EQ 20MG BASE	A207408	003	Oct 31, 2016	Apr CPOT
AB		EQ 40MG BASE	A207408	004	Oct 31, 2016	Apr CPOT
AB	GLENMARK PHARMS	EQ 5MG BASE	A079172	001	Jul 19, 2016	Apr CPOT
AB		EQ 10MG BASE	A079172	002	Jul 19, 2016	Apr CPOT
AB		EQ 20MG BASE	A079172	003	Jul 19, 2016	Apr CPOT
AB		EQ 40MG BASE	A079172	004	Jul 19, 2016	Apr CPOT
AB	HETERO LABS LTD V	EQ 5MG BASE	A207616	001	Oct 31, 2016	Apr CPOT
AB		EQ 10MG BASE	A207616	002	Oct 31, 2016	Apr CPOT
AB		EQ 20MG BASE	A207616	003	Oct 31, 2016	Apr CPOT
AB		EQ 40MG BASE	A207616	004	Oct 31, 2016	Apr CPOT
	@ INVENTIA	EQ 5MG BASE	A207653	001	Feb 05, 2021	May DISC
AB		EQ 5MG BASE	A207653	001	Feb 05, 2021	Apr CPOT
AB		5MG	A207653	001	Feb 05, 2021	Jan NEWA
	@	EQ 10MG BASE	A207653	002	Feb 05, 2021	May DISC
AB		EQ 10MG BASE	A207653	002	Feb 05, 2021	Apr CPOT
AB		10MG	A207653	002	Feb 05, 2021	Jan NEWA
	@	EQ 20MG BASE	A207653	003	Feb 05, 2021	May DISC
AB		EQ 20MG BASE	A207653	003	Feb 05, 2021	Apr CPOT
AB		20MG	A207653	003	Feb 05, 2021	Jan NEWA
	@	EQ 40MG BASE	A207653	004	Feb 05, 2021	May DISC
AB		EQ 40MG BASE	A207653	004	Feb 05, 2021	Apr CPOT
AB		40MG	A207653	004	Feb 05, 2021	Jan NEWA
AB	LUPIN	EQ 5MG BASE	A205587	001	Jul 31, 2017	Apr CPOT
AB		EQ 10MG BASE	A205587	002	Jul 31, 2017	Apr CPOT
AB		EQ 20MG BASE	A205587	003	Jul 31, 2017	Apr CPOT
AB		EQ 40MG BASE	A205587	004	Jul 31, 2017	Apr CPOT
AB	MSN	EQ 5MG BASE	A208898	001	Nov 22, 2017	Apr CPOT
AB		EQ 10MG BASE	A208898	002	Nov 22, 2017	Apr CPOT
AB		EQ 20MG BASE	A208898	003	Nov 22, 2017	Apr CPOT
AB		EQ 40MG BASE	A208898	004	Nov 22, 2017	Apr CPOT
	@ MYLAN	EQ 5MG BASE	A079161	001	Jul 19, 2016	Apr CPOT
	@	EQ 10MG BASE	A079161	002	Jul 19, 2016	Apr CPOT
	@	EQ 20MG BASE	A079161	003	Jul 19, 2016	Apr CPOT
	@	EQ 40MG BASE	A079161	004	Jul 19, 2016	Apr CPOT
AB	RENATA	EQ 5MG BASE	A207062	001	Oct 31, 2016	Apr CPOT
AB		EQ 10MG BASE	A207062	002	Oct 31, 2016	Apr CPOT
AB		EQ 20MG BASE	A207062	003	Oct 31, 2016	Apr CPOT
AB		EQ 40MG BASE	A207062	004	Oct 31, 2016	Apr CPOT
AB	SANDOZ INC	EQ 5MG BASE	A079171	001	Jul 19, 2016	Apr CPOT
AB		EQ 10MG BASE	A079171	002	Jul 19, 2016	Apr CPOT
AB		EQ 20MG BASE	A079171	003	Jul 19, 2016	Apr CPOT
AB		EQ 40MG BASE	A079171	004	Jul 19, 2016	Apr CPOT
	@ SCIEGEN PHARMS INC	EQ 5MG BASE	A206381	001	Apr 24, 2019	Apr CPOT
	@	EQ 10MG BASE	A206381	002	Apr 24, 2019	Apr CPOT
	@	EQ 20MG BASE	A206381	003	Apr 24, 2019	Apr CPOT
	@	EQ 40MG BASE	A206381	004	Apr 24, 2019	Apr CPOT
AB	SHANDONG	EQ 5MG BASE	A207375	001	May 07, 2019	Apr CPOT

TABLET;ORAL
ROSUVASTATIN CALCIUM

AB		EQ 10MG BASE	A207375	002	May 07, 2019	Apr CPOT
AB		EQ 20MG BASE	A207375	003	May 07, 2019	Apr CPOT
AB		EQ 40MG BASE	A207375	004	May 07, 2019	Apr CPOT
AB	SUN PHARM	EQ 5MG BASE	A079169	001	Jul 19, 2016	Apr CPOT
AB		EQ 10MG BASE	A079169	002	Jul 19, 2016	Apr CPOT
AB		EQ 20MG BASE	A079169	003	Jul 19, 2016	Apr CPOT
AB		EQ 40MG BASE	A079169	004	Jul 19, 2016	Apr CPOT
	@ SUNSHINE	EQ 5MG BASE	A210667	001	Apr 01, 2020	Apr CPOT
	@	EQ 10MG BASE	A210667	002	Apr 01, 2020	Apr CPOT
	@	EQ 20MG BASE	A210667	003	Apr 01, 2020	Apr CPOT
	@	EQ 40MG BASE	A210667	004	Apr 01, 2020	Apr CPOT
	@ TEVA PHARMS USA	EQ 5MG BASE	A079166	001	Jul 19, 2016	Apr CPOT
	@	EQ 10MG BASE	A079166	002	Jul 19, 2016	Apr CPOT
	@	EQ 20MG BASE	A079166	003	Jul 19, 2016	Apr CPOT
	@	EQ 40MG BASE	A079166	004	Jul 19, 2016	Apr CPOT
AB	TORRENT	EQ 5MG BASE	A201619	001	Oct 31, 2016	Apr CPOT
AB		EQ 10MG BASE	A201619	002	Oct 31, 2016	Apr CPOT
AB		EQ 20MG BASE	A201619	003	Oct 31, 2016	Apr CPOT
AB		EQ 40MG BASE	A201619	004	Oct 31, 2016	Apr CPOT
	@ UMEDICA LABS PVT LTD	EQ 5MG BASE	A207626	001	Apr 09, 2019	Apr CPOT
	@	EQ 10MG BASE	A207626	002	Apr 09, 2019	Apr CPOT
	@	EQ 20MG BASE	A207626	003	Apr 09, 2019	Apr CPOT
	@	EQ 40MG BASE	A207626	004	Apr 09, 2019	Apr CPOT
AB	WATSON LABS INC	EQ 5MG BASE	A079167	001	Apr 29, 2016	Apr CPOT
AB		EQ 10MG BASE	A079167	002	Apr 29, 2016	Apr CPOT
AB		EQ 20MG BASE	A079167	003	Apr 29, 2016	Apr CPOT
AB		EQ 40MG BASE	A079167	004	Apr 29, 2016	Apr CPOT
AB	ZHEJIANG YONGTAI	EQ 5MG BASE	A212059	001	Nov 04, 2019	Apr CPOT
AB		5MG	A212059	001	Nov 04, 2019	Feb CMFD
AB		EQ 10MG BASE	A212059	002	Nov 04, 2019	Apr CPOT
AB		10MG	A212059	002	Nov 04, 2019	Feb CMFD
AB		EQ 20MG BASE	A212059	003	Nov 04, 2019	Apr CPOT
AB		20MG	A212059	003	Nov 04, 2019	Feb CMFD
AB		EQ 40MG BASE	A212059	004	Nov 04, 2019	Apr CPOT
AB		40MG	A212059	004	Nov 04, 2019	Feb CMFD
	@ ZYDUS PHARMS	EQ 5MG BASE	A206513	001	Mar 01, 2019	Apr CPOT
	@	EQ 10MG BASE	A206513	002	Mar 01, 2019	Apr CPOT
	@	EQ 20MG BASE	A206513	003	Mar 01, 2019	Apr CPOT
	@	EQ 40MG BASE	A206513	004	Mar 01, 2019	Apr CPOT

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

AB	ALKEM LABS LTD	40MG/ML	A213410	001	Feb 23, 2021	Feb NEWA
	TABLET;ORAL					
	RUFINAMIDE					
AB	HETERO LABS LTD III	200MG	A204993	001	May 11, 2021	Apr NEWA
AB		400MG	A204993	002	May 11, 2021	Apr NEWA
AB	MYLAN	200MG	A205095	001	May 16, 2016	May CMFD
AB		400MG	A205095	002	May 16, 2016	May CMFD

SAFINAMIDE MESYLATE

TABLET;ORAL

XADAGO

>D>	+	MDD US	50MG	N207145	001	Mar 21, 2017	Jul CPOT
>A>	+		EQ 50MG BASE	N207145	001	Mar 21, 2017	Jul CPOT
>D>	+	!	100MG	N207145	002	Mar 21, 2017	Jul CPOT
>A>	+	!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Jul CPOT

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

SAPROPTERIN DIHYDROCHLORIDE

AB	DR REDDYS	100MG/PACKET	A209452	001	Mar 30, 2021	Mar NEWA
	TABLET;ORAL					
	SAPROPTERIN DIHYDROCHLORIDE					
AB	DR REDDYS	100MG	A207685	001	Jun 15, 2021	Jun NEWA

SCOPOLAMINE

SYSTEM;TRANSDERMAL

SCOPOLAMINE

>A> AB	PADAGIS US	1MG/72HR	A078830	001	Jan 30, 2015	Jul CAHN
>D> AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Jul CAHN
	TRANSDERM SCOP					
AB	+! BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Mar CAHN

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

SELEGILINE HYDROCHLORIDE

AB	NOVITIUM PHARMA	5MG	A075352	001	Nov 30, 1998	Apr CMFD
----	-----------------	-----	---------	-----	--------------	----------

SELENIOS ACID

SOLUTION;INTRAVENOUS

SELENIOS ACID

+! AM REGENT	EQ 60MCG BASE/ML (EQ 60MCG BASE/ML)	N209379	002	Jan 25, 2021	Jan NEWA
--------------	----------------------------------------	---------	-----	--------------	----------

SELEXIPAG

>A>	POWDER;INTRAVENOUS					
>A>	UPTRAVI					
>A>	+! ACTELION	1.8MG/VIAL	N214275	001	Jul 29, 2021	Jul NEWA
	TABLET;ORAL					
	UPTRAVI					
+ ATELION	0.2MG	N207947	001	Dec 21, 2015	Feb CAHN	
+!	0.4MG	N207947	002	Dec 21, 2015	Feb CAHN	
+	0.6MG	N207947	003	Dec 21, 2015	Feb CAHN	
+	0.8MG	N207947	004	Dec 21, 2015	Feb CAHN	
+	1MG	N207947	005	Dec 21, 2015	Feb CAHN	
+	1.2MG	N207947	006	Dec 21, 2015	Feb CAHN	
+	1.4MG	N207947	007	Dec 21, 2015	Feb CAHN	
+	1.6MG	N207947	008	Dec 21, 2015	Feb CAHN	

SELINEXOR

TABLET;ORAL

XPOVIO

+ KARYOPHARM THERAPS	40MG	N212306	002	Apr 15, 2021	Apr NEWA
+ 50MG		N212306	003	Apr 15, 2021	Apr NEWA
+ 60MG		N212306	004	Apr 15, 2021	Apr NEWA

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS

WEGOVTY

+! NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N215256	001	Jun 04, 2021	Jun NEWA
+!	0.5MG/0.5ML (0.5MG/0.5ML)	N215256	002	Jun 04, 2021	Jun NEWA
+!	1MG/0.5ML (1MG/0.5ML)	N215256	003	Jun 04, 2021	Jun NEWA
+!	1.7MG/0.75ML (1.7MG/0.75ML)	N215256	004	Jun 04, 2021	Jun NEWA
+!	2.4MG/0.75ML (2.4MG/0.75ML)	N215256	005	Jun 04, 2021	Jun NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB	ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jan CMFD
AB		EQ 50MG BASE	A076881	002	Feb 06, 2007	Jan CMFD
AB		EQ 100MG BASE	A076881	003	Feb 06, 2007	Jan CMFD
AB	ASCENT PHARMS INC	EQ 25MG BASE	A214790	001	May 03, 2021	Apr NEWA
AB		EQ 50MG BASE	A214790	002	May 03, 2021	Apr NEWA
AB		EQ 100MG BASE	A214790	003	May 03, 2021	Apr NEWA
AB	GRANULES	EQ 25MG BASE	A078403	001	Jan 08, 2008	May CAHN
AB		EQ 50MG BASE	A078403	002	Jan 08, 2008	May CAHN
AB		EQ 100MG BASE	A078403	003	Jan 08, 2008	May CAHN
AB	SCIEGEN PHARMS INC	EQ 25MG BASE	A076442	001	Apr 30, 2007	Apr CMFD
AB		EQ 50MG BASE	A076442	002	Apr 30, 2007	Apr CMFD
AB		EQ 100MG BASE	A076442	003	Apr 30, 2007	Apr CMFD

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

AB	BIONPHARMA INC	800MG/PACKET	A209374	001	May 17, 2021	May NEWA
AB	TABLET;ORAL					
	SEVELAMER CARBONATE					

AB	ANXIN	800MG	A212970	001	Apr 09, 2020	Mar CMFD
AB	LUPIN LTD	800MG	A204600	001	Jan 14, 2021	Jan NEWA

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

SEVELAMER HYDROCHLORIDE

AB	LUPIN LTD	400MG	A213145	001	Jun 16, 2021	Jun NEWA
AB		800MG	A213145	002	Jun 16, 2021	Jun NEWA

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

SILDENAFIL CITRATE

AB	APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Apr NEWA
AB	HETERO LABS LTD V	EQ 10MG BASE/ML	A213014	001	May 11, 2021	Apr NEWA
AB	TABLET;ORAL					
	SILDENAFIL CITRATE					
AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Mar CAHN
AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Mar CAHN
AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Mar CAHN
AB	UMEDICA LABS PVT LTD	EQ 25MG BASE	A209302	003	Jun 15, 2021	Jun NEWA
@	WATSON LABS INC	EQ 25MG BASE	A202506	001	Nov 25, 2020	May DISC
@		EQ 50MG BASE	A202506	002	Nov 25, 2020	May DISC
@		EQ 100MG BASE	A202506	003	Nov 25, 2020	May DISC

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

AB	BIOCON PHARMA	5MG	A078034	001	Dec 20, 2006	Mar CAHN
AB		10MG	A078034	002	Dec 20, 2006	Mar CAHN
AB		20MG	A078034	003	Dec 20, 2006	Mar CAHN
AB		40MG	A078034	004	Dec 20, 2006	Mar CAHN
AB		80MG	A078034	005	Dec 20, 2006	Mar CAHN
AB	HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Apr CMFD
AB		20MG	A206557	002	Nov 13, 2017	Apr CMFD
AB		40MG	A206557	003	Nov 13, 2017	Apr CMFD
AB		80MG	A206557	004	Nov 13, 2017	Apr CMFD
AB	! LUPIN ZOCOR	80MG	A078103	004	May 11, 2007	Jun CHRS
AB	+ ORGANON	5MG	N019766	001	Dec 23, 1991	Feb CAHN
AB	+	10MG	N019766	002	Dec 23, 1991	Feb CAHN
AB	+	20MG	N019766	003	Dec 23, 1991	Feb CAHN
AB	+	40MG	N019766	004	Dec 23, 1991	Feb CAHN
AB	+ @	80MG	N019766	005	Jul 10, 1998	Jun DISC
AB	+!	80MG	N019766	005	Jul 10, 1998	Feb CAHN

SINECATECHINS

OINTMENT;TOPICAL

VEREGEN

+!	ANI PHARMS	15%	N021902	001	Oct 31, 2006	Apr CAHN
----	------------	-----	---------	-----	--------------	----------

SIROLIMUS

TABLET;ORAL

SIROLIMUS

AB	ALKEM LABS LTD	0.5MG	A214753	001	Mar 12, 2021	Mar NEWA
AB		1MG	A214753	002	Mar 12, 2021	Mar NEWA
AB		2MG	A214753	003	Mar 12, 2021	Mar NEWA

SODIUM ACETATE

INJECTABLE;INJECTION

SODIUM ACETATE

AP	MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Apr NFTG
----	--------------	---------	---------	-----	--------------	----------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; INTRAVENOUS

SODIUM PHENYLACETATE AND SODIUM BENZOATE

+! MAIA PHARMS INC 10%;10% (2GM/20ML;2GM/20ML)

N215025 001 Jun 10, 2021 Jun NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

>A>	HIKMA	9MG/ML	A201833	001	Sep 24, 2013	Jul CAHN
>A> AP		9MG/ML	A201850	001	Jan 20, 2012	Jul CAHN
>D>	WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013	Jul CAHN
>D> AP		9MG/ML	A201850	001	Jan 20, 2012	Jul CAHN
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	@ JUBILANT CADISTA	9MG/ML	A203352	001	May 18, 2016	Jun DISC
	SODIUM CHLORIDE 23.4%					
	FRESENIUS KABI USA	234MG/ML	A212248	001	Apr 28, 2021	Apr NFTG
	SOLUTION; INTRAVENOUS					
	SODIUM CHLORIDE 14.6%					
	FRESENIUS KABI USA	50MEQ/20ML (2.5MEQ/ML)	A212070	001	Apr 28, 2021	Apr NFTG
AP		100MEQ/40ML (2.5MEQ/ML)	A212070	002	Apr 28, 2021	Apr NFTG
	SOLUTION FOR SLUSH; IRRIGATION					
	SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER					
>D>	BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985	Jul CHRS
>A>	+!	900MG/100ML	N019319	002	May 17, 1985	Jul CHRS

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

AP NUKEMED 10-200mCi/ML A203912 001 Apr 22, 2015 Jan CAHN

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

>A> AP	@ AUROBINDO PHARMA LTD	25MG/ML	A211934	001	Dec 10, 2020	Jun DISC
	BE PHARMS	25MG/ML	A214971	001	Jul 12, 2021	Jul NEWA

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB	NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Jan CMFD
AB	+! SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Jan CTEC

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KIONEX

AA	ANI PHARMS	454GM/BOT	A040029	001	Feb 06, 1998	Mar CAHN
AA	L PERRIGO CO	454GM/BOT	A040029	001	Feb 06, 1998	Mar CAHN
	SUSPENSION; ORAL, RECTAL					
	KIONEX					
	@ ANI PHARMS	15GM/60ML	A040028	001	Sep 17, 2007	Mar CAHN
	@ L PERRIGO CO	15GM/60ML	A040028	001	Sep 17, 2007	Mar CAHN
	SODIUM POLYSTYRENE SULFONATE					
	@ ANI PHARMS	15GM/60ML	A090590	001	May 13, 2011	Mar CAHN
	@ L PERRIGO CO	15GM/60ML	A090590	001	May 13, 2011	Mar CAHN

SOFOSBUVIR; VELPATASVIR

PELLETS; ORAL

EPCLUSA

+	GILEAD SCIENCES INC	150MG;37.5MG/PACKET	N214187	001	Jun 10, 2021	Jun NEWA
+		200MG;50MG/PACKET	N214187	002	Jun 10, 2021	Jun NEWA

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

	@ AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019	Jun DISC
	@ ZYDUS PHARMS	10MG	A205483	002	May 20, 2019	Jun DISC
		5MG	A207721	001	Oct 19, 2020	Mar DISC
	@	10MG	A207721	002	Oct 19, 2020	Mar DISC

SORAFENIB TOSYLATE

TABLET;ORAL
NEXAVAR
+! BAYER HLTHCARE EQ 200MG BASE N021923 001 Dec 20, 2005 May CTEC
SORAFENIB TOSYLATE
@ TEVA PHARMS USA INC EQ 200MG BASE A209567 001 Nov 12, 2020 May DISC

SOTALOL HYDROCHLORIDE

TABLET;ORAL
SOTALOL HYDROCHLORIDE
@ MYLAN 80MG A077616 001 Feb 07, 2007 Feb DISC
@ 120MG A077616 002 Feb 07, 2007 Feb DISC
@ 160MG A077616 003 Feb 07, 2007 Feb DISC

SOTORASIE

TABLET;ORAL
LUMAKRAS
+! AMGEN INC 120MG N214665 001 May 28, 2021 May NEWA

STERILE WATER FOR INJECTION

LIQUID;N/A
STERILE WATER FOR INJECTION
>A> AP HIKMA 100% (10ML) A206369 001 Sep 02, 2015 Jul CAHN
>A> @ 100% (20ML) A206369 002 Sep 02, 2015 Jul CAHN
>D> AP ! NEPHRON 100% (5ML) A211222 001 Feb 10, 2021 Jan NEWA
>D> AP WEST-WARD PHARMS INT 100% (10ML) A206369 001 Sep 02, 2015 Jul CAHN
>D> @ 100% (20ML) A206369 002 Sep 02, 2015 Jul CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION
SUCCINYLCHOLINE CHLORIDE
AP ACCORD HLTHCARE 20MG/ML A213705 001 May 20, 2020 Mar CMFD
AP HIKMA 20MG/ML A213229 001 Jun 12, 2020 Apr CMFD
@ 20MG/ML A213229 001 Jun 12, 2020 Feb DISC
AP SAGENT PHARMS INC 20MG/ML A215022 001 Mar 29, 2021 Mar NEWA

SULFAMETHOXAZOLE

TABLET;ORAL
SULFAMETHOXAZOLE
@ RISING 500MG A085844 001 Jan CAHN

SULFASALAZINE

TABLET;ORAL
AZULFIDINE
AB +! PFIZER 500MG N007073 001 Mar CAHN
SULFASALAZINE
AB CHARTWELL 500MG A080197 001 Jun CMFD
TABLET, DELAYED RELEASE;ORAL
AZULFIDINE EN-TABS
AB +! PFIZER 500MG N007073 002 Apr 06, 1983 Mar CAHN

SULFISOXAZOLE

TABLET;ORAL
SULFISOXAZOLE
@ RISING 500MG A085628 001 Jan CAHN

SUMATRIPTAN

SPRAY;NASAL
SUMATRIPTAN
AB CIPLA 20MG/SPRAY A214209 001 Feb 22, 2021 Feb NEWA
AB FLORIDA 20MG/SPRAY A208967 001 Feb 17, 2021 Mar CAHN
AB PHARMASERVE NW 20MG/SPRAY A208967 001 Feb 17, 2021 Feb NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE
>A> AP CAPLIN EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A213998 001 Jul 13, 2021 Jul NEWA
@ MYLAN ASI EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090314 001 Jun 10, 2010 May DISC
@ EQ 6MG BASE/0.5ML (EQ 12MG A090641 001 Jul 28, 2010 Jan DISC

INJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

(BASE/ML)

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

@ CONCORD BIOTECH LTD

PANACEA

EQ 0.5MG BASE

A213112 001 Nov 10, 2020

Apr DISC

EQ 0.5MG BASE

A090802 001 Sep 28, 2012

Jul CAHN

EQ 1MG BASE

A090802 002 Sep 28, 2012

Jul CAHN

EQ 5MG BASE

A090802 003 Sep 28, 2012

Jul CAHN

>D> AB PANACEA BIOTEC LTD EQ 0.5MG BASE

A090802 001 Sep 28, 2012

Jul CAHN

>D> AB EQ 1MG BASE

A090802 002 Sep 28, 2012

Jul CAHN

>D> AB EQ 5MG BASE

A090802 003 Sep 28, 2012

Jul CAHN

TADALAFIL

TABLET;ORAL

CIALIS

AB1 + LILLY 2.5MG

N021368 004 Jan 07, 2008

Feb CTEC

AB1 + 5MG

N021368 001 Nov 21, 2003

Feb CTEC

AB1 + 10MG

N021368 002 Nov 21, 2003

Feb CTEC

Tadalafil

AB1 ACCORD HLTHCARE 2.5MG

A209167 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A209167 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A209167 003 Oct 23, 2019

Feb CTEC

AB1 AJANTA PHARMA LTD 2.5MG

A209654 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A209654 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A209654 003 Mar 26, 2019

Feb CTEC

AB1 ALEMBIC PHARMS LTD 2.5MG

A204809 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A204809 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A204809 003 Mar 26, 2019

Feb CTEC

AB1 AMNEAL PHARMS CO 2.5MG

A209744 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A209744 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A209744 003 Mar 26, 2019

Feb CTEC

AB1 AUROBINDO PHARMA LTD 2.5MG

A206285 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A206285 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A206285 003 Mar 26, 2019

Feb CTEC

AB1 CIPLA 2.5MG

A209539 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A209539 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A209539 003 Mar 26, 2019

Feb CTEC

AB1 DR REDDYS LABS LTD 2.5MG

A210069 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A210069 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A210069 003 Mar 26, 2019

Feb CTEC

@ GLENMARK PHARMS LTD

2.5MG

A210716 001 Dec 29, 2020

Feb DISC

@ 5MG

A210716 002 Dec 29, 2020

Feb DISC

@ 10MG

A210716 003 Dec 29, 2020

Feb DISC

@ 20MG

A210716 004 Dec 29, 2020

Feb DISC

AB1 HETERO LABS LTD III 2.5MG

A209908 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A209908 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A209908 003 Mar 26, 2019

Feb CTEC

AB1 LUPIN LTD 2.5MG

A210567 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A210567 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A210567 003 Mar 26, 2019

Feb CTEC

AB1 MACLEODS PHARMS LTD 2.5MG

A207244 001 Oct 07, 2019

Feb CTEC

AB1 5MG

A207244 002 Oct 07, 2019

Feb CTEC

AB1 10MG

A207244 003 Oct 07, 2019

Feb CTEC

AB1 MYLAN 2.5MG

A206956 001 Apr 29, 2019

Feb CTEC

AB1 5MG

A206957 001 Apr 29, 2019

Feb CTEC

AB1 10MG

A206956 002 Apr 29, 2019

Feb CTEC

AB1 QILU 2.5MG

A210420 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A210420 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A210420 003 Mar 26, 2019

Feb CTEC

AB1 SUN PHARM 2.5MG

A208934 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A208934 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A208934 003 Mar 26, 2019

Feb CTEC

AB1 SUNSHINE 2.5MG

A211335 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A211335 002 Mar 26, 2019

Feb CTEC

AB1 10MG

A211335 003 Mar 26, 2019

Feb CTEC

AB1 TEVA PHARMS USA 2.5MG

A090141 001 May 22, 2018

Feb CTEC

AB1 5MG

A090141 002 May 22, 2018

Feb CTEC

AB1 10MG

A090141 003 May 22, 2018

Feb CTEC

AB1 TORRENT 2.5MG

A211839 001 Mar 26, 2019

Feb CTEC

AB1 5MG

A211839 002 Mar 26, 2019

Feb CTEC

TABLET;ORAL
TADALAFIL

AB1		10MG	A211839	003	Mar 26, 2019	Feb CTEC
AB1	UMEDICA LABS PVT LTD	2.5MG	A211298	001	Oct 23, 2020	Feb CTEC
AB1		5MG	A211298	002	Oct 23, 2020	Feb CTEC
AB1		10MG	A211298	003	Oct 23, 2020	Feb CTEC
AB1	UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A209250	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A209250	003	Mar 26, 2019	Feb CTEC
AB1	YANGLING BUCHANG	2.5MG	A208824	001	Oct 27, 2020	Feb CTEC
AB1		5MG	A208824	002	Oct 27, 2020	Feb CTEC
AB1		10MG	A208824	003	Oct 27, 2020	Feb CTEC
AB1	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A206693	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A206693	003	Mar 26, 2019	Feb CTEC

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL
TAMSULOSIN HYDROCHLORIDE

@ ANCHEN PHARMS 0.4MG

A202010 001 Jan 04, 2013 Jun DISC

TAVABOROLE

SOLUTION;TOPICAL
TAVABOROLE

AB	CIPLA	5%	A212224	001	Feb 09, 2021	Jan NEWA
AB	FLATWING	5%	A211963	001	Feb 03, 2021	Feb CPOT
AB		5.0%	A211963	001	Feb 03, 2021	Jan NEWA
AB	IDENTIRX	5%	A211963	001	Feb 03, 2021	Feb CAHN
AB	LUPIN LTD	5%	A212168	001	Feb 08, 2021	Jan NEWA
AB	TARO PHARMS	5%	A212215	001	May 07, 2021	Apr NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION
CIS-MDP

>D>	SUN PHARM INDNS INC	N/A	N018124	001		Jul CTEC
>A> AP		N/A	N018124	001		Jul CTEC
>D>	MDP-BRACCO					
>D>	@ CARDINAL HEALTH 414	N/A	N018107	001		Jul CTNA
>A>	TECHNETIUM TC-99M MEDRONATE KIT					
>A> AP	CARDINAL HEALTH 414	N/A	N018107	001		Jul CTNA

TELMISARTAN

TABLET;ORAL
TELMISARTAN

AB	CELLTRION	20MG	A078710	001	Jan 08, 2014	Feb CMFD
AB		40MG	A078710	002	Jan 08, 2014	Feb CMFD
AB		80MG	A078710	003	Jan 08, 2014	Feb CMFD

TEMOZOLOMIDE

CAPSULE;ORAL
TEMOZOLOMIDE

@ HERITAGE	5MG	A078879	001	Mar 01, 2010	Feb CAHN
@	20MG	A078879	002	Mar 01, 2010	Feb CAHN
@	100MG	A078879	003	Mar 01, 2010	Feb CAHN
@	140MG	A078879	005	Mar 01, 2010	Feb CAHN
@	180MG	A078879	006	Mar 01, 2010	Feb CAHN
@	250MG	A078879	004	Mar 01, 2010	Feb CAHN
@ WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Jan DISC
@	20MG	A203959	002	Apr 18, 2017	Jan DISC
@	100MG	A203959	003	Apr 18, 2017	Jan DISC
@	140MG	A203959	004	Apr 18, 2017	Jan DISC
@	250MG	A203959	005	Apr 18, 2017	Jan DISC

TEPOTINIB HYDROCHLORIDE

TABLET;ORAL
TEPMETKO

+! EMD SERONO INC EQ 225MG BASE

N214096 001 Feb 03, 2021 Feb NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	May CMFD
AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	May CMFD
AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	May CMFD
AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	May CMFD

TERIFLUONOMIDE

TABLET;ORAL

TERIFLUONOMIDE

@ IMPAX

14MG

A209677 001 Jun 17, 2020 Feb DISC

TESTOSTERONE

GEL;TRANSDERMAL

TESTOSTERONE

AB2	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM PACKET)	A204570	002	Jul 17, 2020	Feb NEWA
AB2		1.62% (40.5MG/2.5GM PACKET)	A204570	003	Jul 17, 2020	Feb NEWA
AB	ALEOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021	Feb NEWA
	SOLUTION, METERED;TRANSDERMAL					
AT	ALEOR DERMACEUTICALS	30MG/1.5ML ACTUATION	A212882	001	Jun 14, 2021	Jun NEWA
@	APOTEX	30MG/1.5ML ACTUATION	A209181	001	Nov 25, 2020	May DISC
AT	DASH PHARMS	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	May CAHN
AT	FEMPHARM	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jan NEWA

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTOSTERONE

@ PFIZER

50MG/ML

A085635 001

Mar CAHN

AO	!	100MG/ML	A085635	002		
AO	!	200MG/ML	A085635	003		

TESTOSTERONE CYPIONATE

@

200MG/ML

A085635 003

Mar CAHN

>A> AO	HIKMA	100MG/ML	A090387	001	Jul 15, 2010	Jul CAHN
>A> AO		200MG/ML	A090387	002	Jul 15, 2010	Jul CAHN
>D> AO	WEST-WARD PHARMS INT	100MG/ML	A090387	001	Jul 15, 2010	Jul CAHN
>D> AO		200MG/ML	A090387	002	Jul 15, 2010	Jul CAHN

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

@ AJANTA PHARMA LTD

12.5MG

A213621 001

Dec 04, 2020 May DISC

@

25MG

A213621 002

Dec 04, 2020 May DISC

TETRACAIN HYDROCHLORIDE

SOLUTION;OPHTHALMIC

TETRACAIN HYDROCHLORIDE

+! BAUSCH LOMB IRELAND 0.5%

N210821 001

Mar 12, 2019 May CAHN

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION

THALLOUS CHLORIDE TL 201

+ @ GE HEALTHCARE 1mCi/ML

N018110 002

Feb 27, 1996 Jun DISC

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	May CTEC
AB	!	450MG	A090430	002	Oct 27, 2010	May CTEC
AB	GLENMARK PHARMS LTD	300MG	A212184	001	Jun 03, 2021	May NEWA
AB		450MG	A212184	002	Jun 03, 2021	May NEWA
>D> AB	! HERITAGE PHARMA	100MG	A089807	001	Apr 30, 1990	Jul DISC
>A>	@	100MG	A089807	001	Apr 30, 1990	Jul DISC
>D> AB	!	200MG	A089808	001	Apr 30, 1990	Jul DISC
>A>	@	200MG	A089808	001	Apr 30, 1990	Jul DISC

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP WEST-WARD PHARMS INT 100MG/ML A080575 001 Apr CMFD

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

MYLAN	10MG	A088004	002	Mar 15, 1983	Jan CTEC
	25MG	A088004	003	Mar 15, 1983	Jan CTEC
	50MG	A088004	004	Mar 15, 1983	Jan CTEC
!	100MG	A088004	001	Nov 18, 1983	Jan CTEC
@ SUN PHARM INDUSTRIES	10MG	A089953	004	Aug 01, 1986	Jan DISC
@	25MG	A089953	003	Aug 01, 1986	Jan DISC
@	50MG	A089953	002	Aug 01, 1986	Jan DISC
@	100MG	A089953	001	Oct 07, 1988	Jan DISC

THIOTEPA

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

THIOTEPA

AP GLAND PHARMA LTD 15MG/VIAL A214222 001 Mar 08, 2021 Feb NEWA

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

TIAGABINE HYDROCHLORIDE

@ WILSHIRE PHARMS INC	2MG	A206857	001	Oct 13, 2017	Jan DISC
@	4MG	A206857	002	Oct 13, 2017	Jan DISC
@	12MG	A206857	003	Oct 13, 2017	Jan DISC
@	16MG	A206857	004	Oct 13, 2017	Jan DISC

TICAGRELOR

TABLET; ORAL

TICAGRELOR

>A> AB	MYLAN	60MG	A208597	001	Jul 09, 2021	Jul NFTG
>A> AB		90MG	A208597	002	Jul 09, 2021	Jul NEWA

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

AP HONG KONG 50MG/VIAL A214020 001 May 13, 2021 May NEWA

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AB	! ALEMBIC PHARMS LTD	EQ 0.25% BASE	A212942	001	Oct 22, 2020	Apr CHRS
AB	!	EQ 0.5% BASE	A212942	002	Oct 22, 2020	Apr CHRS
	TIMOPTIC-XE					
AB	+ VALEANT PHARMS LLC	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Apr CHRS
AB	+	EQ 0.5% BASE	N020330	002	Nov 04, 1993	Apr CHRS
	SOLUTION/DROPS; OPHTHALMIC					
	TIMOLOL MALEATE					
AT	MANKIND PHARMA	EQ 0.25% BASE	A078771	001	Sep 28, 2009	Apr CAHN
AT1		EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr CAHN

TIOPRONIN

TABLET; ORAL

TIOPRONIN

AB TEVA PHARMS USA INC 100MG A214326 001 Apr 26, 2021 Apr NFTG

TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

+! BOEHRINGER INGELHEIM EQ 0.00125MG BASE/INH N021936 002 Sep 15, 2015 Mar CHRS

TIROFIBAN HYDROCHLORIDE

SOLUTION; INTRAVENOUS

AGGRASTAT

+ MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Apr CDFR
@	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998	Apr CDFR

SOLUTION; INTRAVENOUSTIROFIBAN HYDROCHLORIDE

AP GLAND PHARMA LTD EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) A206888 001 Apr 08, 2021 Apr NFTG

TIVOZANIB HYDROCHLORIDECAPSULE; ORALFOTIVDA

+ AVEO PHARMS EQ 0.89MG BASE

+! EQ 1.34MG BASE

N212904 001 Mar 10, 2021 Mar NEWA

N212904 002 Mar 10, 2021 Mar NEWA

TIZANIDINE HYDROCHLORIDECAPSULE; ORALTIZANIDINE HYDROCHLORIDE

@ PAR PHARM INC EQ 2MG BASE
 @ EQ 4MG BASE
 @ EQ 6MG BASE

A207199 001 Mar 14, 2017 Jun DISC
 A207199 002 Mar 14, 2017 Jun DISC
 A207199 003 Mar 14, 2017 Jun DISC

TABLET; ORALTIZANIDINE HYDROCHLORIDE

AB CADILA EQ 2MG BASE A208187 001 Mar 09, 2018 Feb CAHN
 AB EQ 4MG BASE A208187 002 Mar 09, 2018 Feb CAHN
 @ MYLAN EQ 2MG BASE A076354 001 Mar 28, 2003 Jan DISC
 @ EQ 4MG BASE A076354 002 Mar 28, 2003 Feb DISC

TOBRAMYCINSOLUTION; INHALATIONTOBRAMYCIN

AN ALKEM LABS LTD 300MG/5ML A212848 001 Apr 01, 2021 Mar NEWA
 >D> AN AUROBINDO PHARMA LTD 300MG/5ML A210871 001 Jan 22, 2021 Jul DISC
 >A> @ 300MG/5ML A210871 001 Jan 22, 2021 Jul DISC
 AN 300MG/5ML A210871 001 Jan 22, 2021 Jan NEWA

SOLUTION/DROPS; OPHTHALMICTOBRAMYCIN

AT GLAND PHARMA LTD 0.3% A212628 001 Mar 09, 2021 Feb NEWA

TOBRAMYCIN SULFATEINJECTABLE; INJECTIONTOBRAMYCIN SULFATE

AP GLAND PHARMA LTD EQ 10MG BASE/ML A209621 001 Feb 11, 2021 Feb NEWA
 AP EQ 40MG BASE/ML A209621 002 Feb 11, 2021 Feb NEWA
 AP EQ 1.2GM BASE/VIAL A211189 001 May 18, 2021 May NEWA
 TOBRAMYCIN SULFATE (PHARMACY BULK)
 AP ! FRESENIUS KABI USA EQ 40MG BASE/ML A065120 001 Nov 29, 2002 Jan CTEC
 AP GLAND PHARMA LTD EQ 40MG BASE/ML A209346 001 Feb 09, 2021 Jan NEWA

TOFACITINIB CITRATESOLUTION; ORALXELJANZ

+! PFIZER EQ 1MG/ML BASE

N213082 001 Sep 25, 2020 Feb CMS1

TABLET; ORALTOFACITINIB CITRATE

AB AJANTA PHARMA LTD EQ 10MG BASE A212943 001 Jun 01, 2021 May NFTG

TOLCAPONETABLET; ORALTOLCAPONE

@ ALVOGEN 100MG

A207729 001 Jul 29, 2020 Jan DISC

TOLTERODINE TARTRATECAPSULE, EXTENDED RELEASE; ORALTOLTERODINE TARTRATE

AB AJANTA PHARMA LTD 2MG A213397 001 May 19, 2020 Jan CMFD
 AB 4MG A213397 002 May 19, 2020 Jan CMFD
 AB AMTA 2MG A213858 001 Feb 02, 2021 Jan NEWA
 AB 4MG A213858 002 Feb 02, 2021 Jan NEWA
 >D> AB MYLAN 2MG A201486 001 Oct 31, 2013 Jul DISC
 >A> @ 2MG A201486 001 Oct 31, 2013 Jul DISC
 >D> AB 4MG A201486 002 Oct 31, 2013 Jul DISC
 >A> @ 4MG A201486 002 Oct 31, 2013 Jul DISC

TABLET;ORAL

TOLTERODINE TARTRATE

>A> AB	HETERO LABS LTD V	1MG	A204397	001	Aug 02, 2021	Jul NEWA
>A> AB		2MG	A204397	002	Aug 02, 2021	Jul NEWA

TOLVAPTAN

TABLET;ORAL

SAMSCA

AB	+ OTSUKA	15MG	N022275	001	May 19, 2009	Feb CAHN
	+!	30MG	N022275	002	May 19, 2009	Feb CAHN
	+ @	60MG	N022275	003	May 19, 2009	Feb CAHN

TOLVAPTAN

>D> AB	ALKEM LABS LTD	60MG	A211891	002	May 19, 2020	Jul CTEC
>A>		60MG	A211891	002	May 19, 2020	Jul CTEC
>A> AB	HETERO LABS LTD V	30MG	A205646	001	Jul 16, 2021	Jul NEWA

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

AB2	GLENMARK PHARMS LTD	25MG	A210278	001	Feb 01, 2021	Jan NFTG
AB2		50MG	A210278	002	Feb 01, 2021	Jan NFTG
AB2		100MG	A210278	003	Feb 01, 2021	Jan NFTG
AB2		150MG	A210278	004	Feb 01, 2021	Jan NFTG
AB2		200MG	A210278	005	Feb 01, 2021	Jan NFTG
AB1	ZYDUS PHARMS	25MG	A207382	001	Nov 24, 2017	Jan CTEC
AB1		50MG	A207382	002	Nov 24, 2017	Jan CTEC
AB1		100MG	A207382	003	Nov 24, 2017	Jan CTEC
	TROKENDI XR					
AB1	+ SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013	Jan CTEC
AB1	+	50MG	N201635	002	Aug 16, 2013	Jan CTEC
AB1	+	100MG	N201635	003	Aug 16, 2013	Jan CTEC

TORSEMIDE

TABLET;ORAL

SOAANZ

>D>	+ SARFE PHARMS	20MG	N213218	001	Jun 14, 2021	Jul CHRS
>A>	+!	20MG	N213218	001	Jun 14, 2021	Jul CHRS
	+	20MG	N213218	001	Jun 14, 2021	Jun NEWA
>D>	+!	60MG	N213218	002	Jun 14, 2021	Jul CHRS
>A>	+	60MG	N213218	002	Jun 14, 2021	Jul CHRS
	+!	60MG	N213218	002	Jun 14, 2021	Jun NEWA

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

@	GRAVITI PHARMS	50MG	A075968	001	Jun 25, 2002	Apr CAHN
AB	POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Feb CMFD
TABLET, EXTENDED RELEASE;ORAL						
	TRAMADOL HYDROCHLORIDE					
@	ANCHEM PHARMS	100MG	A200491	001	Jun 27, 2012	Apr DISC
@		200MG	A200491	002	Jun 27, 2012	Apr DISC
@		300MG	A200491	003	Jun 27, 2012	Apr DISC

TRANEXAMIC ACID

INJECTABLE;INJECTION

CYKLOKAPRON

AP	+! PFIZER	100MG/ML	N019281	001	Dec 30, 1986	Mar CAHN
	TRANEXAMIC ACID					
AP	CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jun CMFD
AP	PROVEPHARM SAS	100MG/ML	A212676	001	Jul 17, 2019	Jan CAHN
	ZYDUS PHARMS	100MG/ML	A205228	001	Jul 17, 2017	Apr DISC
TABLET;ORAL						
	TRANEXAMIC ACID					
AB	ANI PHARMS	650MG	A203256	001	Jul 25, 2016	Jun CMFD
	@ APOTEX INC	650MG	A202286	001	Jan 27, 2014	Mar DISC

TRANLYLCYPROMINE SULFATE

TABLET;ORAL

TRANLYLCYPROMINE SULFATE

AB	NOVITIUM PHARMA	EQ 10MG BASE	A206856	001	Apr 17, 2018	Apr CAHN
----	-----------------	--------------	---------	-----	--------------	----------

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVOPROST

AT MICRO LABS 0.004% A203767 001 Mar 19, 2021 Mar NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

@ ALVOGEN	50MG	A071636	001	Apr 18, 1988	Jun DISC
@	100MG	A071514	001	Apr 18, 1988	Jun DISC
AB AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Feb CMFD
AB	100MG	A204852	002	Feb 05, 2020	Feb CMFD
AB	150MG	A204852	003	Feb 05, 2020	Feb CMFD
AB	300MG	A204852	004	Feb 05, 2020	Feb CMFD
@ RISING	50MG	A072484	001	Apr 30, 1990	Jan CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

TREPROSTINIL

AP ALEMBIC GLOBAL	1MG/ML	A211574	001	Feb 11, 2021	Feb NEWA
AP	2.5MG/ML	A211574	002	Feb 11, 2021	Feb NEWA
AP	5MG/ML	A211574	003	Feb 11, 2021	Feb NEWA
AP	10MG/ML	A211574	004	Feb 11, 2021	Feb NEWA

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

REMODULIN

@ UNITED THERAP	20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018	Jun DISC
@	50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018	Jun DISC
@	100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018	Jun DISC
@	200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018	Jun DISC

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	Jan CAHN
AT	0.1%	A040671	002	Jun 09, 2006	Jan CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT PERRIGO ISRAEL 0.05% A212460 001 Feb 05, 2021 Jan NEWA

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

>A> @ PERRIGO	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jul CAHN
>D> @ PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jul CAHN

TRIAZOLAM

TABLET;ORAL

HALCION

AB + PFIZER	0.125MG	N017892	003	Apr 26, 1985	Feb CAHN
AB +!	0.25MG	N017892	001	Nov 15, 1982	Feb CAHN
@	0.5MG	N017892	002	Nov 15, 1982	Feb CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

CLOQUIQUE

AB @ CHARTWELL RX	250MG	A209731	001	Oct 21, 2019	Jun DISC
AB	250MG	A209731	001	Oct 21, 2019	Mar CAHN

TRIENTINE HYDROCHLORIDE

AB @ CHARTWELL RX	250MG	A209415	001	Sep 16, 2019	Jun DISC
AB	250MG	A209415	001	Sep 16, 2019	Mar CAHN

TRILACICLIB DIHYDROCHLORIDE

POWDER;INTRAVENOUS

COSELA

+! G1 THERAP EQ 300MG BASE/VIAL N214200 001 Feb 12, 2021 Feb NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TIGAN

+ @ KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	Apr DISC
AB ! SUN PHARM INDUSTRIES	300MG	A076570	001	Aug 28, 2003	Apr CHRS

TROSPiUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
TROSPiUM CHLORIDE

AB AMTA 60MG A214760 001 Apr 30, 2021 Apr NEWA

UMBRALiSiB TOSYLATE

TABLET;ORAL
UKONIQ
+! TG THERAPS EQ 200MG BASE

N213176 001 Feb 05, 2021 Feb NEWA

URSODiOL

CAPSULE;ORAL
URSODiOL
AB STRIDES PHARMA 300MG A210344 001 Jan 22, 2021 Jan NEWA
>A> AB VGYAAN 300MG A214329 001 Jul 28, 2021 Jul NEWA

VALBENAZiNE TOSYLATE

CAPSULE;ORAL
INGREZZA
+ NEUROCRINE EQ 60MG BASE

N209241 003 Apr 23, 2021 May NEWA

VALGANCiCLOViR HYDROCHLORiDE

TABLET;ORAL
VALGANCiCLOViR HYDROCHLORiDE
AB MYLAN EQ 450MG BASE

A205151 001 Mar 03, 2021 Feb NEWA

VALPROiC ACiD

SYRUP;ORAL
VALPROiC ACiD
AA CHARTWELL RX 250MG/5ML

A075782 001 Dec 22, 2000 Mar CMFD

VANCOMYCiN HYDROCHLORiDE

INJECTABLE;INJECTION
VANCOMYCiN HYDROCHLORiDE
@ HIKMA EQ 500MG BASE/VIAL
@ EQ 1GM BASE/VIAL
! HOSPIRA EQ 1.5GM BASE/VIAL

A203300 001 Aug 11, 2020 Feb DISC
A203300 002 Aug 11, 2020 Feb DISC
A062912 003 Jul 10, 2020 May CMFD

VARDENAFiL HYDROCHLORiDE

TABLET;ORAL
LEVITRA
+ @ BAYER HLTHCARE EQ 5MG BASE
+ @ EQ 10MG BASE

N021400 001 Aug 19, 2003 Apr DISC
N021400 002 Aug 19, 2003 Apr DISC

VARENiCLiNE

TABLET;ORAL
>A> VARENiCLiNE
>A> AB PAR PHARM iNC EQ 0.5MG BASE A201785 001 Aug 11, 2021 Jul NFTG
>A> AB EQ 1MG BASE A201785 002 Aug 11, 2021 Jul NFTG

VASOPRESiN

SOLUTION;INTRAVENOUS
VASO STRICT
+! PAR STERiLE PRODUCTS 20UNITS/100ML (0.2UNITS/ML)

N204485 005 Apr 21, 2021 Apr NEWA

VENLAFAXiNE HYDROCHLORiDE

CAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXiNE HYDROCHLORiDE
>A> AB YICHANG HUMANWELL EQ 37.5MG BASE A214654 001 Aug 06, 2021 Jul NEWA
>A> AB EQ 75MG BASE A214654 002 Aug 06, 2021 Jul NEWA
>A> AB EQ 150MG BASE A214654 003 Aug 06, 2021 Jul NEWA

TABLET;ORAL
VENLAFAXiNE HYDROCHLORiDE
@ MYLAN EQ 25MG BASE A077166 001 Jun 13, 2008 Jan DISC
@ EQ 37.5MG BASE A077166 002 Jun 13, 2008 Jan DISC
@ EQ 50MG BASE A077166 003 Jun 13, 2008 Jan DISC
@ EQ 75MG BASE A077166 004 Jun 13, 2008 Jan DISC
@ EQ 100MG BASE A077166 005 Jun 13, 2008 Jan DISC

**TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE**

AB	ALKEM LABS LTD	EQ 37.5MG BASE	A214127	001	Jun 10, 2021	Jun NEWA
AB		EQ 75MG BASE	A214127	002	Jun 10, 2021	Jun NEWA
AB		EQ 150MG BASE	A214127	003	Jun 10, 2021	Jun NEWA
AB		EQ 225MG BASE	A214127	004	Jun 10, 2021	Jun NEWA
AB	APPCO	EQ 150MG BASE	A214609	001	Jun 30, 2021	Jun NEWA
AB		EQ 225MG BASE	A214609	002	Jun 30, 2021	Jun NEWA
AB	DEXCEL PHARMA	EQ 75MG BASE	A213927	001	Jan 21, 2021	Jan NEWA

VERICIGUAT

TABLET;ORAL

VERQUVO

+	MERCK SHARP DOHME	2.5MG	N214377	001	Jan 19, 2021	Jan NEWA
+		5MG	N214377	002	Jan 19, 2021	Jan NEWA
+		10MG	N214377	003	Jan 19, 2021	Jan NEWA

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

AA	ANNORA PHARMA	500MG/PACKET	A213519	001	Jan 26, 2021	Jan NEWA
AA	DEXCEL PHARMA	500MG/PACKET	A214992	001	May 13, 2021	May NEWA
>A> AA	NAVISCI	500MG/PACKET	A213390	001	Jul 29, 2021	Jul NEWA
>A> AA	SPECGX LLC	500MG/PACKET	A212626	001	Jul 28, 2021	Jul NEWA
	TABLET;ORAL					
	VIGABATRIN					
AB	DR REDDYS	500MG	A211539	001	Jan 29, 2021	Jan NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VILAZODONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	10MG	A208209	001	Apr 27, 2021	Apr NEWA
AB		20MG	A208209	002	Apr 27, 2021	Apr NEWA
AB		40MG	A208209	003	Apr 27, 2021	Apr NEWA
AB	INVAGEN PHARMS	10MG	A208200	001	Apr 07, 2021	Mar NEWA
AB		40MG	A208200	002	Apr 07, 2021	Mar NEWA

VILOXAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

QELBREE

+	SUPERNUS PHARMS	EQ 100MG BASE	N211964	001	Apr 02, 2021	Apr NEWA
+		EQ 150MG BASE	N211964	002	Apr 02, 2021	Apr NEWA
+		EQ 200MG BASE	N211964	003	Apr 02, 2021	Apr NEWA

VINBLASTINE SULFATE

INJECTABLE;INJECTION

VINBLASTINE SULFATE

>A>	! HIKMA	10MG/VIAL	A089395	001	Apr 09, 1987	Jul CAHN
>D>	! WEST-WARD PHARMS INT	10MG/VIAL	A089395	001	Apr 09, 1987	Jul CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

@ FRESENIUS KABI USA EQ 10MG BASE/ML

A076849 001 Apr 18, 2005 Jan DISC

VOCLOSPORIN

CAPSULE;ORAL

LUPKYNIS

+	AURINIA	7.9MG

N213716 001 Jan 22, 2021 Jan NEWA

VORICONAZOLE

INJECTABLE;INTRAVENOUS

VORICONAZOLE

AP	ALMAJECT	200MG/VIAL

A206398 001 Mar 23, 2016 Feb CAHN

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE

AP	EXELA PHARMA	EQ 1MG ZINC/ML

A212007 001 May 21, 2021 May NFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

>A> AB	CHARTWELL RX	EQ 20MG BASE	A090348 001 Sep 05, 2012	Jul CAHN
>A> AB		EQ 40MG BASE	A090348 002 Sep 05, 2012	Jul CAHN
>A> AB		EQ 60MG BASE	A090348 003 Sep 05, 2012	Jul CAHN
>A> AB		EQ 80MG BASE	A090348 004 Sep 05, 2012	Jul CAHN
>D> AB	WOCKHARDT LTD	EQ 20MG BASE	A090348 001 Sep 05, 2012	Jul CAHN
>D> AB		EQ 40MG BASE	A090348 002 Sep 05, 2012	Jul CAHN
>D> AB		EQ 60MG BASE	A090348 003 Sep 05, 2012	Jul CAHN
>D> AB		EQ 80MG BASE	A090348 004 Sep 05, 2012	Jul CAHN

ZOLPIDEM TARTRATETABLET, ORALLY DISINTEGRATING;ORAL
TOVALT ODT

+ @ BIOVAIL LABS INTL	5MG	N021412 001 Apr 25, 2007	Apr CRLD
+ @	10MG	N021412 002 Apr 25, 2007	Apr CRLD

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	+ CONCORDIA	25MG	N020789 003 Aug 22, 2003	Mar CAHN
	+ @	50MG	N020789 002 Aug 22, 2003	Mar CAHN
AB	+!	100MG	N020789 001 Mar 27, 2000	Mar CAHN
	ZONISAMIDE			
>A> AB	CADILA	25MG	A077625 001 Oct 16, 2006	Jul CAHN
>A> AB		50MG	A077625 002 Oct 16, 2006	Jul CAHN
>A> AB		100MG	A077625 003 Oct 16, 2006	Jul CAHN
AB	GRANULES	25MG	A077636 003 Jul 27, 2006	Jun CAHN
AB		50MG	A077636 002 Jul 27, 2006	Jun CAHN
AB		100MG	A077636 001 Dec 22, 2005	Jun CAHN
AB	UNICHEM	25MG	A214492 001 Jan 26, 2021	Jan NEWA
AB		50MG	A214492 002 Jan 26, 2021	Jan NEWA
AB		100MG	A214492 003 Jan 26, 2021	Jan NEWA
>D> AB	ZYDUS PHARMS USA	25MG	A077625 001 Oct 16, 2006	Jul CAHN
>D> AB		50MG	A077625 002 Oct 16, 2006	Jul CAHN
>D> AB		100MG	A077625 003 Oct 16, 2006	Jul CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL
ACETAMINOPHEN, ASPIRIN AND CAFFEINE
GRANULES 250MG;250MG;65MG A214039 001 Feb 23, 2021 Feb NEWA

ASPIRIN

CAPSULE;ORAL
VAZALORE
+ PLX PHARMA 81MG N203697 002 Feb 26, 2021 Jun NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL
ASTEPRO ALLERGY
+! BAYER HLTHCARE 0.2055MG/SPRAY N213872 001 Jun 17, 2021 Jun NEWA
CHILDREN'S ASTEPRO ALLERGY
+! BAYER HLTHCARE 0.2055MG/SPRAY N213872 002 Jun 17, 2021 Jun NEWA

BUDESONIDE

SPRAY, METERED;NASAL
RHINOCORT ALLERGY
+! J AND J CONSUMER INC 0.032MG/SPRAY N020746 003 Mar 23, 2015 Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY
APOTEX 10MG A207235 001 Aug 12, 2016 Mar CMFD
@ 10MG A207235 001 Aug 12, 2016 Jan DISC
TABLET;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY
@ CIPLA LTD 5MG A077318 001 Jul 25, 2013 May DISC
@ 10MG A077318 002 Jul 25, 2013 May DISC
TABLET, CHEWABLE;ORAL
CHILDREN'S ZYRTEC ALLERGY
+ @ J AND J CONSUMER INC 2.5MG N021621 007 Nov 30, 2020 Apr DISC

DEXTRMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE
SUN PHARM 30MG;600MG A214781 001 Jul 01, 2021 Jun NEWA
60MG;1.2GM A214781 002 Jul 01, 2021 Jun NEWA

DICLOFENAC SODIUM

GEL;TOPICAL
DICLOFENAC SODIUM
>D> AUROLIFE PHARMA LLC 1% A204306 001 May 06, 2019 May CAHN
PERRIGO 1% A211253 001 May 16, 2019 Jul CAHN
1% A211253 001 May 16, 2019 Jun CAHN
>A> PERRIGO PHARMA INTL 1% A211253 001 May 16, 2019 Jul CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY
TARO 30MG/5ML A208123 001 Nov 09, 2017 Jun CMFD
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES
TARO 30MG/5ML A208123 002 Nov 09, 2017 Jun CMFD
TABLET;ORAL
FEXOFENADINE HYDROCHLORIDE
L PERRIGO CO 60MG A212971 001 Feb 24, 2020 Jun CMFD
180MG A212971 002 Feb 24, 2020 Jun CMFD

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL
FLONASE ALLERGY RELIEF
+ GLAXOSMITHKLINE CONS 0.05MG/SPRAY N205434 001 Jul 23, 2014 Apr CHRS
FLUTICASONE PROPIONATE
! HIKMA 0.05MG/SPRAY A207957 001 May 26, 2016 Apr CHRS

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

GUARDIAN DRUG 100MG/5ML
STRIDES PHARMA 100MG/5MLA210149 001 Aug 17, 2018 Jan CMFD
A211666 001 Feb 22, 2021 Feb NEWA

TABLET;ORAL

IBUPROFEN

@ YICHANG HUMANWELL 200MG

A214003 001 Oct 19, 2020 Apr DISC

ISOPROPYL ALCOHOLSOLUTION;TOPICAL
ZURAGARD>D> + @ ZUREX PHARMA 70% (10.5ML)
>A> + @ 70%N210872 001 Apr 26, 2019 Jul CPOT
N210872 001 Apr 26, 2019 Jul CPOTIVERMECTINLOTION;TOPICAL
IVERMECTIN
TARO 0.5%

A210720 001 May 06, 2020 May CMKT

KETOCONAZOLESHAMPOO;TOPICAL
NIZORAL ANTI-DANDRUFF
+! KRAMER 1%

N020310 001 Oct 10, 1997 Feb CTNA

LEVOSETIRIZINE DIHYDROCHLORIDETABLET;ORAL
LEVOSETIRIZINE DIHYDROCHLORIDE
APOTEX 5MG

A211443 001 Apr 21, 2021 Apr NEWA

LOPERAMIDE HYDROCHLORIDE>A> CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE
STRIDES PHARMA 2MG

A213070 001 Aug 11, 2021 Jul NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONETABLET;ORAL
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
GUARDIAN DRUG 2MG;125MG
HETERO LABS LTD V 2MG;125MGA214541 001 May 27, 2021 May NEWA
A211438 001 Jun 17, 2021 Jun NEWALORATADINESYRUP;ORAL
LORATADINE
HETERO LABS LTD III 1MG/ML

A210409 001 May 07, 2021 Apr NEWA

TABLET;ORAL
LORATADINE
UNIQUE PHARM 10MG

A214684 001 Jan 07, 2021 Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
LORATADINE
@ GLAXOSMITHKLINE 10MG

A075822 001 Feb 10, 2003 Jan DISC

TENSHI 5MG

A212795 001 Sep 18, 2020 Jun CMFD

@ 5MG

A212795 001 Sep 18, 2020 Mar DISC

10MG

A213294 001 Oct 30, 2020 Jun CMFD

@ 10MG

A213294 001 Oct 30, 2020 Mar DISC

MICONAZOLE NITRATE>A> CREAM, INSERT;TOPICAL, VAGINAL
>A> MICONAZOLE NITRATE
>A> PERRIGO R AND D 2%,1.2GM
>A> MONISTAT 1 COMBINATION PACK
>A> +! MEDTECH PRODUCTS 2%,1.2GM
>D> CREAM, SUPPOSITORY;TOPICAL, VAGINAL
>D> MICONAZOLE NITRATE
>D> PERRIGO R AND D 2%,1.2GM
>D> MONISTAT 1 COMBINATION PACK
>D> +! MEDTECH PRODUCTS 2%,1.2GM

A079114 001 Jun 02, 2010 Jul CDFR

N021308 001 Jun 29, 2001 Jul CDFR

A079114 001 Jun 02, 2010 Jul CDFR

N021308 001 Jun 29, 2001 Jul CDFR

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL

>A>	PERRIGO	5%	A091344	001	Apr 28, 2011	Jul CAHN
>D>	PERRIGO ISRAEL	5%	A091344	001	Apr 28, 2011	Jul CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICORETTE

+ GLAXOSMITHKLINE
+!EQ 2MG BASE
EQ 4MG BASEN022360 001 May 18, 2009 Mar CAHN
N022360 002 May 18, 2009 Mar CAHN

>A>	NICOTINE POLACRILEX					
	AUROBINDO PHARMA LTD	EQ 2MG BASE	A213266	001	Aug 03, 2021	Jul NEWA
>A>		EQ 4MG BASE	A213266	002	Aug 03, 2021	Jul NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AKORN
ALEMBIC PHARMS LTD
APOTEX INC
BARR LABS INC
BAUSCH
CIPLA
FDC LTD
MYLAN
USVEQ 0.1% BASE
EQ 0.2% BASE
EQ 0.1% BASE
EQ 0.2% BASE
EQ 0.2% BASE
EQ 0.1% BASE
EQ 0.2% BASE
EQ 0.1% BASE
EQ 0.2% BASE
EQ 0.1% BASEA204532 001 Jan 10, 2017 Jun CMKT
A204723 001 Dec 05, 2017 Jun CMKT
A209919 001 Dec 07, 2018 Feb CMKT
A209420 001 Apr 29, 2019 Jan CMKT
A090918 001 Dec 05, 2017 Jan CMKT
A090848 001 Jul 13, 2015 Feb CMKT
A206046 001 Jul 26, 2017 Jun CAHN
A206087 001 Dec 05, 2017 Mar CMKT
A209282 001 Sep 26, 2019 Feb CMKT
A204392 001 Mar 21, 2018 Feb CMKT
A204620 001 Jun 16, 2020 Jun CAHN
A203152 001 Dec 07, 2015 Apr CMKTOMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

APOTEX

20MG

A210070 001 Feb 11, 2019 May CMFD

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

ANNORA PHARMA

17GM/SCOOPFUL

A214990 001 Apr 14, 2021 Apr NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD
@ WOCKHARDT
ZANTAC 150
+ @ SANOFI US
+ @ ZANTAC 75
+ @ SANOFI USEQ 75MG BASE
EQ 150MG BASE
EQ 75MG BASE
EQ 150MG BASE
EQ 150MG BASE
EQ 75MG BASEA207579 001 Nov 13, 2017 Jun DISC
A207578 001 Nov 13, 2017 Jun DISC
A076760 001 Feb 24, 2006 Jan DISC
N021698 001 Aug 31, 2004 Apr DISC
N021698 002 Mar 13, 2007 Apr DISC
N020520 001 Dec 19, 1995 Apr DISCTRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

>A>	PERRIGO	0.055MG/SPRAY	A078104	002	Nov 14, 2014	Jul CAHN
>D>	PERRIGO ISRAEL	0.055MG/SPRAY	A078104	002	Nov 14, 2014	Jul CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2021

NO JULY 2021 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2021 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	10996208	Apr 30, 2038	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	11000517	Mar 13, 2029	DP U-2513			
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	11000517	Mar 13, 2029	DP U-2513			
<u>ALBUTEROL SULFATE - PROAIR DIGITALER</u>						
N 205636 002	10918816	Dec 14, 2035	DP			
	11000653	Dec 18, 2038	DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344 001	9592195	Dec 05, 2031	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001 >A>	11065213	Aug 23, 2038	DP			
>A>	11077073	Aug 23, 2038	U-2106			
>A>	11077073	Aug 23, 2038	U-2224			
>A>	11077073	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002 >A>	11065213	Aug 23, 2038	DP			
>A>	11077073	Aug 23, 2038	U-2106			
>A>	11077073	Aug 23, 2038	U-2224			
>A>	11077073	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078 001 >A> 11060128		Jun 29, 2032		U-2956		
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	10357567	Jan 12, 2038		U-3163		
>A>	11077192	Jan 12, 2038		U-3163		
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10894039	Oct 06, 2037		U-185		
	10894039	Oct 06, 2037		U-3		
	10952998	Oct 06, 2037		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10959991	Oct 06, 2037		U-158		
	10959991	Oct 06, 2037		U-39		
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	10925835	Jun 14, 2038		U-2410		
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	10925835	Jun 14, 2038		U-2410		
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	10925835	Jun 14, 2038		U-2410		
	10945960	Jun 14, 2038	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 005	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
>A>	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
>A>	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
>A>	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
>A>	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
>A>	11077068	Feb 14, 2022	DP			
<u>APREPITANT - CINVANTI</u>						
N 209296 001	10953018	Sep 18, 2035		U-2161		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10980803	Sep 24, 2033		U-1632		
	10980803	Sep 24, 2033		U-543		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10980803	Sep 24, 2033		U-1632		
	10980803	Sep 24, 2033		U-543		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10980803	Sep 24, 2033		U-1632		
	10980803	Sep 24, 2033		U-543		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10980803	Sep 24, 2033		U-1632		
	10980803	Sep 24, 2033		U-543		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENNU</u>						
N 209381 001	10918723	Sep 10, 2033		U-2310		
<u>ASENAPINE MALEATE - ASENAPINE MALEATE</u>						
A 206098 002					PC	Jun 08, 2021
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 213424 001					CGT	Sep 21, 2021
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	>A> 9200002 >A> 9200002 >A> 9944651 >A> 9944651 >A> 9994575 >A> 9994575	Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034	DS DP U-2726 DS DP U-3168 DS DP U-2726 DS DP U-3168 DS DP U-2726 DS DP U-3168		>A> I-863 >A> I-864 >A> ODE-356	Jun 16, 2024 Jun 16, 2024 Jun 16, 2028
N 212608 002	>A> 9200002 >A> 9200002 >A> 9944651 >A> 9944651 >A> 9994575 >A> 9994575	Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034	DS DP U-2726 DS DP U-3168 DS DP U-2726 DS DP U-3168 DS DP U-2726 DS DP U-3168		>A> I-863 >A> I-864 >A> ODE-356	Jun 16, 2024 Jun 16, 2024 Jun 16, 2028
N 212608 003					>A> ODE-356	Jun 16, 2028
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	>A> 9200002 >A> 9944651 >A> 9994575	Oct 15, 2034 Oct 15, 2034 Oct 15, 2034	DS DP U-3168 DS DP U-3168 DS DP U-3168		>A> I-863 >A> I-864 >A> NCE >A> ODE-356	Jun 16, 2024 Jun 16, 2024 Jan 09, 2025 Jun 16, 2028
N 212608 005	>A> 9200002 >A> 9944651 >A> 9994575	Oct 15, 2034 Oct 15, 2034 Oct 15, 2034	DS DP U-3168 DS DP U-3168 DS DP U-3168		>A> I-863 >A> I-864 >A> NCE >A> ODE-356	Jun 16, 2024 Jun 16, 2024 Jan 09, 2025 Jun 16, 2028
N 202324 001	10869924	Nov 05, 2036		U-3044		
N 202324 002	10869924	Nov 05, 2036		U-3044		
<u>AZACITIDINE - ONUREG</u>						
N 214120 001					ODE-320	Sep 01, 2027
<u>AZACITIDINE - ONUREG</u>						
N 214120 002					ODE-320	Sep 01, 2027
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY</u>						
N 213872 001	>A> 8071073 >A> 8518919 >A> 9919050	Jun 04, 2028 Nov 22, 2025 Nov 22, 2025	DP U-3166 DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	>A> 10392406 >A> 10633397 >A> 10633397 >A> 10759814 >A> 8927710 >A> 8987441	Apr 27, 2036 Apr 27, 2036 Apr 27, 2036 Aug 09, 2037 May 05, 2031 Sep 21, 2031	DS U-2816 U-3000 DS DP DP DS DP		I-811 NCE	Oct 16, 2022 Oct 24, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BALOXAVIR MARBOXIL - XOFLUZA</u> N 210854 003 >A> 9815835		Jun 14, 2030	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u> N 214410 001					NCE	Oct 24, 2023
<u>BEMPEDOIC ACID - NEXLETOL</u> N 211616 001 10941095		Dec 23, 2023		U-2747		
<u>BEMPEDOIC ACID: EZETIMIBE - NEXLIZET</u> N 211617 001 10941095		Dec 23, 2023		U-2746		
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u> N 214094 001					NCE ODE-333	Dec 03, 2025 Dec 03, 2027
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u> N 214094 002					NCE ODE-333	Dec 03, 2025 Dec 03, 2027
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u> N 210251 001					M-82	Feb 24, 2024
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u> N 210557 001 6794489		Jun 28, 2025	DS DP			
<u>BREXANOLONE - ZULRESSO</u> N 211371 001 10940156		Mar 08, 2037		U-2552		
<u>BREXIPRAZOLE - REXULTI</u> N 205422 001 RE48059		Dec 23, 2028	DS			
<u>BREXIPRAZOLE - REXULTI</u> N 205422 002 RE48059		Dec 23, 2028	DS			
<u>BREXIPRAZOLE - REXULTI</u> N 205422 003 RE48059		Dec 23, 2028	DS			
<u>BREXIPRAZOLE - REXULTI</u> N 205422 004 RE48059		Dec 23, 2028	DS			
<u>BREXIPRAZOLE - REXULTI</u> N 205422 005 RE48059		Dec 23, 2028	DS			
<u>BREXIPRAZOLE - REXULTI</u> N 205422 006 RE48059		Dec 23, 2028	DS			
<u>BRIMONIDINE TARTRATE - LUMIFY</u> N 208144 001 >A> 9259425		Jul 14, 2030		U-2222		
<u>BRINCIDOFIVIR - TEMBEWA</u> N 214460 001 9303051		Aug 31, 2031	DS DP U-3165		NP >A> ODE-354	Jun 04, 2024 Jun 04, 2028
<u>BRINCIDOFIVIR - TEMBEWA</u> N 214461 001 10112909		Oct 10, 2034	U-3165		NP	Jun 04, 2024
	10487061	Oct 10, 2034	DP U-3165		>A> ODE-354	Jun 04, 2028
	8962829	Oct 10, 2034	DS DP			
	9303051	Aug 31, 2031	DS DP U-3165			
	9371344	Oct 10, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001					NPP	May 10, 2021
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	11000522	Apr 30, 2032	U-3119			
	11000522	Apr 30, 2032	U-3120			
	11000522	Apr 30, 2032	U-3121			
	11000522	Apr 30, 2032	U-3122			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001 >A> 11033495		Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002 >A> 11033495		Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
<u>BUPIVACAINE - POSIMIR</u>						
N 204803 001	8153149	Sep 15, 2025	DP		NP	Feb 01, 2024
	8153661	Sep 15, 2025	U-3074			
	8753665	Sep 15, 2025	DP U-3074			
	8846072	Sep 15, 2025	DP U-3074			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPRENORPHINE - SUBLOCade</u>						
N 209819 001	11000520	Nov 06, 2035	U-3111			
<u>BUPRENORPHINE - SUBLOCade</u>						
N 209819 002	11000520	Nov 06, 2035	U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	10874661	Sep 18, 2032	DP			
	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001					M-128	Dec 18, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	10927129 8410103	Apr 28, 2026 Apr 28, 2026	DS DP DS DP U-3061		NCE	Jan 21, 2026
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	10927129 6838464 7125879 8080551 8410103	Apr 28, 2026 Feb 26, 2021 Apr 21, 2025 Apr 11, 2023 Apr 28, 2026	DS DP DS DP DS DP U-3059 DS DP DS DP U-3060		NCE	Jan 21, 2026
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	10927129 6838464 7125879 8080551 8410103	Apr 28, 2026 Feb 26, 2021 Apr 21, 2025 Apr 11, 2023 Apr 28, 2026	DS DP DS DP DS DP U-3059 DS DP DS DP U-3060		NCE	Jan 21, 2026
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001					I-854	Jan 22, 2024
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002					I-854	Jan 22, 2024
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003					I-854	Jan 22, 2024
<u>CALCITONIN SALMON - CALCITONIN-SALMON</u>						
A 212416 001					CGT	Nov 10, 2021
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10864181	Mar 15, 2033	U-3017		ODE-231	Jul 21, 2027
<u>CANGRELOL - KENGREAL</u>						
N 204958 001	8680052	Mar 09, 2033	U-2979			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10918608 10918608 10918608 10966939 10966939	Oct 14, 2035 Oct 14, 2035 Oct 14, 2035 Jun 17, 2035 Jun 17, 2035	U-3071 U-3072 U-3073 DP U-2780 DP U-2781		ODE-326 ODE-332	Jul 31, 2027 Jul 31, 2027
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562 001					ODE-345	Jan 22, 2028
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	10287586 10533174 10781450 8524880 8524880 9228187 9416361 9447415 9758783 9758783	Nov 12, 2030 May 04, 2021 Nov 12, 2030 Apr 02, 2026 Apr 02, 2026 Nov 12, 2030 May 04, 2021 Jun 28, 2025 Nov 12, 2030 Nov 12, 2030	DS DP DP U-3089 DS DP U-3087 DS DP U-3088 DS DP DS DS DP U-3088 U-3089		NCE ODE-347	Feb 25, 2026 Feb 25, 2028
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10933053 10933053	Sep 09, 2034 Sep 09, 2034	U-3090 U-3091			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CERITINIB - ZYKADIA</u>						
N 211225 001					ODE*	Apr 29, 2021
					ODE*	May 26, 2024
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 001					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 002					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 003					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 004					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 005					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 214542 001					>A> CGT	Jan 29, 2022
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 214542 002					>A> CGT	Jan 29, 2022
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001 >A> 11040004		Nov 12, 2037		U-2252		
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Mar 06, 2022	DP			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPPIO</u>						
N 209589 001					NPP	Aug 15, 2021
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	10786518	Jul 19, 2038	U-2978			
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001					NCE	Dec 14, 2022
					NP	Jan 10, 2023
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10894012	Feb 07, 2037	U-3014			
	10933060	Feb 07, 2037	U-3014			
	10973811	Feb 07, 2037	U-2226			
	10987347	Feb 07, 2037	U-2225			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					I-852	Jan 14, 2024
					ODE-328	Jan 14, 2028
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					I-852	Jan 14, 2024
					ODE-328	Jan 14, 2028
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002					NCE	Apr 30, 2024
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 001	10993952	Feb 15, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 002	10993952	Feb 15, 2036	DP			
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	10918694	Feb 28, 2037	DP			
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	>A> 7973081 >A> 8298568 >A> 8524779 >A> 9132071 >A> 9220694 >A> 9956289	Jan 27, 2026 Nov 03, 2027 Jan 27, 2026 Jun 02, 2029 Jan 27, 2026 Jan 27, 2026	DP DP DP DP DP DP		>A> ODE-358	Jun 23, 2028
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10905662 8026284 8026284*PED 9173851 9173851*PED 9192590 9192590*PED 9198882 9198882*PED 9233077 9233077*PED	Aug 16, 2036 Sep 22, 2027 Mar 22, 2028 Jun 17, 2034 Dec 17, 2034 Jan 26, 2027 Jul 26, 2027 Jan 26, 2027 Jul 26, 2027 Jun 17, 2034 Dec 17, 2034	U-1399 U-1399 DP U-1399 U-1399 U-1399 U-1399 U-1399 DP		ODE* ODE* PED	Aug 14, 2022 Dec 22, 2024 Feb 14, 2023
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10905662 8026284 8026284*PED 9173851 9173851*PED 9192590 9192590*PED 9198882 9198882*PED 9233077 9233077*PED	Aug 16, 2036 Sep 22, 2027 Mar 22, 2028 Jun 17, 2034 Dec 17, 2034 Jan 26, 2027 Jul 26, 2027 Jan 26, 2027 Jul 26, 2027 Jun 17, 2034 Dec 17, 2034	U-1399 U-1399 DP U-1399 U-1399 U-1399 U-1399 U-1399 DP		ODE* ODE* PED	Aug 14, 2022 Dec 22, 2024 Feb 14, 2023
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10905713 10905714 10912795 10918662 10933089	Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 Jan 15, 2039	DP DP DP DP DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10905713 10905714 10912795 10918662 10933089 >A> 11045438	Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 Mar 15, 2039	DP DP DP DP DP DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912 10028912 10166184 10835492	Sep 29, 2034 Sep 29, 2034 Oct 15, 2032 Oct 15, 2032	DP U-3149 DP U-3150 DP U-3149 U-3150		NPP ODE-350	Mar 30, 2024 Mar 30, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	7850990	Jan 23, 2027	DP U-3147			
	8022279	Sep 14, 2027	DP U-3147			
	8092828	Apr 01, 2029	U-3147			
	8431806	Apr 22, 2025	DP U-3147			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Dec 28, 2021	DS DP U-1931		>A> I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			>A> PED	Dec 21, 2024
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Dec 28, 2021	DS DP U-1931		>A> I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			>A> PED	Dec 21, 2024
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	6087380	Dec 28, 2021	DS DP U-1931		>A> I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			>A> PED	Dec 21, 2024
	7866474	Aug 31, 2027	DP	Y		
	7866474*PED	Mar 02, 2028				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 001	>A> 6087380	Dec 28, 2021	DS DP U-3177		>A> NP	Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178		>A> PED	Dec 21, 2024
	>A> 7932273	Sep 07, 2025	DS DP			
	>A> 7932273*PED	Mar 07, 2026				
	>A> 9925174	Jun 14, 2023	DP			
	>A> 9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 002	>A> 6087380	Dec 28, 2021	DS DP U-3177		>A> NP	Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178		>A> PED	Dec 21, 2024
	>A> 7932273	Sep 07, 2025	DS DP			
	>A> 7932273*PED	Mar 07, 2026				
	>A> 9925174	Jun 14, 2023	DP			
	>A> 9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 003	>A> 6087380	Dec 28, 2021	DS DP U-3177		>A> NP	Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178		>A> PED	Dec 21, 2024
	>A> 7932273	Sep 07, 2025	DS DP			
	>A> 7932273*PED	Mar 07, 2026				
	>A> 9925174	Jun 14, 2023	DP			
	>A> 9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 004	>A> 6087380	Dec 28, 2021	DS DP U-3177		>A> NP	Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178		>A> PED	Dec 21, 2024
	>A> 7932273	Sep 07, 2025	DS DP			
	>A> 7932273*PED	Mar 07, 2026				
	>A> 9925174	Jun 14, 2023	DP			
	>A> 9925174*PED	Dec 14, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 005	>A> 6087380	Dec 28, 2021	DS DP U-3177	>A> NP		Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178	>A> PED		Dec 21, 2024
	>A> 7932273	Sep 07, 2025	DS DP			
	>A> 7932273*PED	Mar 07, 2026				
	>A> 9925174	Jun 14, 2023	DP			
	>A> 9925174*PED	Dec 14, 2023				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 214358 006	>A> 6087380	Dec 28, 2021	DS DP U-3177	>A> NP		Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178	>A> PED		Dec 21, 2024
	>A> 7932273	Sep 07, 2025	DS DP			
	>A> 7932273*PED	Mar 07, 2026				
	>A> 9925174	Jun 14, 2023	DP			
	>A> 9925174*PED	Dec 14, 2023				
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	>A> 9233956	May 04, 2029	U-1811			
	>A> 9233956	May 04, 2029	U-2031			
	>A> 9233956	May 04, 2029	U-2032			
	>A> 9233956	May 04, 2029	U-2296			
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	>A> 9233956	May 04, 2029	U-1811			
	>A> 9233956	May 04, 2029	U-2031			
	>A> 9233956	May 04, 2029	U-2032			
	>A> 9233956	May 04, 2029	U-2296			
DAPAGLIFLOZIN - FARXIGA						
N 202293 001				I-857		Apr 30, 2024
DAPAGLIFLOZIN - FARXIGA						
N 202293 002	10973836	Mar 09, 2040	U-3127	I-857		Apr 30, 2024
DAPTOMYCIN - DAPTOMYCIN						
N 210282 001	>A> 10357535	Sep 11, 2033	DP U-3176			
	>A> 9655946	Sep 11, 2033	DP U-3175			
DAPTOMYCIN - DAPTOMYCIN						
N 210282 002	>A> 10357535	Sep 11, 2033	DP U-3176			
	>A> 9655946	Sep 11, 2033	DP U-3175			
DAROLUTAMIDE - NUBEQA						
N 212099 001	>A> 11046713	Oct 27, 2030	DS			
DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE						
N 214231 001	10442847	Feb 03, 2035	DS DP	NCE		Mar 22, 2026
DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)						
N 214231 002	10442847	Feb 03, 2035	DS DP	NCE		Mar 22, 2026
DEFERIPRONE - DEFERIPRONE						
A 208800 001				PC		Mar 27, 2021
DEFERIPRONE - FERRIPROX						
N 021825 001	7049328	Jun 28, 2021	U-3083	I-859		Apr 30, 2024
DEFERIPRONE - FERRIPROX						
N 021825 002	7049328	Jun 28, 2021	U-3083	I-859		Apr 30, 2024
DEFERIPRONE - FERRIPROX						
N 208030 001	7049328	Jun 28, 2021	U-3083	I-859		Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	>A> 10780055	Oct 25, 2038	DP U-3083		I-859	Apr 30, 2024
	10940115	Oct 25, 2038	DP U-3083			
	10940116	Oct 25, 2038	DP			
	>A> 7049328	Jun 28, 2021	U-3083			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	10973870	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	10973870	Feb 10, 2029	U-1978			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	11020448	May 21, 2029	U-2327			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	10959996	Mar 07, 2036	U-3055		>A> M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
>A>	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
>A>	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			>A> PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	10959996	Mar 07, 2036	U-3055		>A> M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
>A>	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
>A>	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			>A> PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	10959996	Mar 07, 2036	U-3055		>A> M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
>A>	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
>A>	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			>A> PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10799642	May 11, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 001	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 002	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 003	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001					NPP	May 25, 2024
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 001					CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 002					CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317 003					CGT	Sep 26, 2021
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	10842770	Aug 07, 2031	DP U-2998			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	10842770	Aug 07, 2031	DP U-2998			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	10842770	Aug 07, 2031	DP U-2998			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10987364	Jun 28, 2031	DP			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	7732430	Mar 02, 2025	DP U-3152		NCE	Apr 15, 2026
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	10959982	Apr 13, 2037	DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 002					ODE*	May 05, 2024
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Apr 18, 2027	DS			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Apr 18, 2027	DS			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Apr 18, 2027	DS			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10864274	Oct 02, 2034	U-2720			
	7214506	Feb 22, 2026	U-281			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	10881659	Mar 14, 2034	U-2842			
>A>	11045470	Mar 14, 2034	U-2842			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10022352	Apr 09, 2027	DP U-2651		>A> NPP	Jun 08, 2024
	10022352	Apr 09, 2027	DP U-3156		ODE-323	Dec 21, 2027
	10081621	Mar 25, 2031	DP U-2652		>A> ODE-357	Jun 08, 2028
	10081621	Mar 25, 2031	DP U-3032			
	10081621	Mar 25, 2031	DP U-3157			
	10239867	Apr 09, 2027	DS DP U-2653			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10758534	Oct 06, 2035	DS DP U-2645			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	8324242	Aug 05, 2027	U-2645			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-2646			
	8354427	Jul 06, 2026	U-3029			
	8354427	Jul 06, 2026	U-3145			
	8415387	Nov 12, 2027	U-2645			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-2645			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	8629162	Jun 24, 2025	U-2648			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	9012496	Jul 15, 2033	U-2649			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-2650			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 002	10022352	Apr 09, 2027	DP U-3156		>A> NCE	Feb 12, 2023
	10081621	Mar 25, 2031	DP U-3157		>A> NCE	Oct 21, 2024
	10239867	Apr 09, 2027	DS DP U-3158		>A> NPP	Jun 08, 2024
	10646481	Aug 13, 2029	DP		>A> ODE-357	Jun 08, 2028
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-3144			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-3144			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3146			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-3144			
ELIGLUSTAT TARTRATE - CERDELGA						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
ELTROMBOPAG OLAMINE - PROMACTA KIT						
N 207027 001					ODE*	Nov 16, 2025
ELTROMBOPAG OLAMINE - PROMACTA KIT						
N 207027 002					ODE*	Aug 26, 2021
					ODE*	Nov 16, 2025
					PED	Feb 26, 2022
ELUXADOLINE - VIBERZI						
N 206940 001	11007179	Mar 14, 2033	DP			
ELUXADOLINE - VIBERZI						
N 206940 002	11007179	Mar 14, 2033	DP			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	>A> 11033552	May 04, 2027	DP			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	>A> 11033552	May 04, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 001				PC		Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 002				PC		Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 003				PC		Mar 09, 2021
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	11040023	Mar 25, 2036		DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	10960155	Jun 25, 2026		DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034			
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10912781	Oct 23, 2028	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
>A>	11065197	Jun 18, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
>A>	11065197	Jun 18, 2033	DP			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11033551	Sep 29, 2037	U-3129		NCE	Dec 18, 2025
	7300935	Jan 28, 2024	DS		NP	May 26, 2024
	8058280	Jan 28, 2024	DS DP			
	9346822	Feb 17, 2024	U-3129			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001 >A>	11033626	Nov 21, 2032	DP U-2439			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME</u>						
N 209405 001					NDF	Mar 30, 2023
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN</u>						
A 213950 001					CGT	Aug 25, 2021
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE</u>						
A 212706 001					CGT	Jul 17, 2021
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10918649	Jun 21, 2039	DP			
	10925882	Jun 21, 2039	DP			
	10940157	Jun 21, 2039	DP			
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	6824822	Oct 09, 2022	DP			
	6824822*PED	Apr 09, 2023				
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	8431685	Apr 13, 2025	DP U-2597			
	8431685	Apr 13, 2025	DP U-2598			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2597			
	8461105	Apr 13, 2025	DP U-2598			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	U-2588			
	8501698*PED	Dec 20, 2027				
	8895033	Oct 04, 2030	DP U-2589			
	8895033	Oct 04, 2030	DP U-2590			
	8895033	Oct 04, 2030	DP U-2597			
	8895033	Oct 04, 2030	DP U-2600			
	8895033	Oct 04, 2030	DP U-2601			
	8895033	Oct 04, 2030	DP U-2602			
	8895033*PED	Apr 04, 2031				
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-2597			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2597			
	9238076	Apr 15, 2024	DP U-2599			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-2597			
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7456254*PED	Dec 30, 2025				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027		DP U-2588		
	8501698*PED	Dec 20, 2027				
	8906851	Aug 18, 2026		U-2588		
	8906851	Aug 18, 2026		U-2589		
	8906851	Aug 18, 2026		U-2590		
	8906851	Aug 18, 2026		U-2593		
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024		DP U-2588		
	9238076	Apr 15, 2024		DP U-2589		
	9238076	Apr 15, 2024		DP U-2590		
	9238076	Apr 15, 2024		DP U-2599		
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026		U-2588		
	9884092	Aug 18, 2026		U-2589		
	9884092	Aug 18, 2026		U-2590		
	9884092	Aug 18, 2026		U-2593		
	9884092	Aug 18, 2026		U-2594		
	9884092	Aug 18, 2026		U-2595		
	9884092	Aug 18, 2026		U-2596		
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6515117	Oct 04, 2025	DS DP	U-2588	M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	6824822	Oct 09, 2022		DP		
	6824822*PED	Apr 09, 2023				
	7223440	Aug 31, 2021		DP		
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025		DP U-2588		
	7456254	Jun 30, 2025		DP U-2589		
	7456254	Jun 30, 2025		DP U-2590		
	7456254	Jun 30, 2025		DP U-2592		
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024		DP		
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025		DP U-2588		
	7612176	Apr 13, 2025		DP U-2589		
	7612176	Apr 13, 2025		DP U-2590		
	7612176	Apr 13, 2025		DP U-2592		
	7612176*PED	Oct 13, 2025				
	8216180	Jan 12, 2028		DP		
	8216180*PED	Jul 12, 2028				
	8329648	Aug 18, 2026		U-2588		
	8329648	Aug 18, 2026		U-2589		
	8329648	Aug 18, 2026		U-2590		
	8329648	Aug 18, 2026		U-2593		
	8329648	Aug 18, 2026		U-2594		
	8329648	Aug 18, 2026		U-2595		
	8329648	Aug 18, 2026		U-2596		
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028		U-2588		
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025		DP U-2588		
	8431685	Apr 13, 2025		DP U-2589		
	8431685	Apr 13, 2025		DP U-2590		
	8431685	Apr 13, 2025		DP U-2598		
	8431685*PED	Oct 13, 2025				
	8439864	Mar 25, 2028		DP		
	8439864*PED	Sep 25, 2028				
	8461105	Apr 13, 2025		DP U-2588		
	8461105	Apr 13, 2025		DP U-2589		
	8461105	Apr 13, 2025		DP U-2590		
	8461105	Apr 13, 2025		DP U-2598		
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027		DP U-2588		
	8501698*PED	Dec 20, 2027				
	8690837	May 19, 2029		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	8690837*PED	Nov 19, 2029				
	8721615	Jan 18, 2030		DP		
	8721615*PED	Jul 18, 2030				
	8758292	Nov 12, 2027		DP		
	8758292*PED	May 12, 2028				
	8827963	Feb 04, 2029		DP		
	8827963*PED	Aug 04, 2029				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851*PED	Feb 18, 2027				
	8998876	Jan 07, 2030	DP			
	8998876*PED	Jul 07, 2030				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076*PED	Oct 15, 2024				
	9320853	Mar 25, 2028	DP			
	9320853*PED	Sep 25, 2028				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092*PED	Feb 18, 2027				
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 001	10376470	May 01, 2033		DP U-3095		
	9763885	May 01, 2033		DP U-3095		
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 002	10376470	May 01, 2033		DP U-3095		
	9763885	May 01, 2033		DP U-3095		
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 003	10376470	May 01, 2033		DP U-3095		
	9763885	May 01, 2033		DP U-3095		
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 004	10376470	May 01, 2033		DP U-3095		
	9763885	May 01, 2033		DP U-3095		
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	10947183	Dec 20, 2036		DS DP		
	10950331	Sep 28, 2035		U-3098		
>A>	11040018	Aug 02, 2037		U-2861		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028		U-1432		
	7754702	Feb 15, 2028		U-2555		
	7754702	Feb 15, 2028		U-2556		
	7754702	Feb 15, 2028		U-2557		
	8895612	Jan 08, 2027		U-1620		
	8895612	Jan 08, 2027		U-3050		
	8895612	Jan 08, 2027		U-3051		
	8895612	Jan 08, 2027		U-3115		
	8895612	Jan 08, 2027		U-3116		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2024		DS DP		
	7754702	Feb 15, 2028		U-2555		
	7754702	Feb 15, 2028		U-2556		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10624855	Nov 26, 2034	DP			
	10624855*PED	May 26, 2035				
	10682376	Nov 13, 2028	DP			
	10682376*PED	May 13, 2029				
	10695367	Nov 13, 2028	DP			
	10695367*PED	May 13, 2029				
	10925896	Nov 13, 2028	DP			
	10925896*PED	May 13, 2029				
	10925897	Nov 13, 2028	DP			
	10925897*PED	May 13, 2029				
	10933090	Nov 13, 2028	DP			
	10933090*PED	May 13, 2029				
	11013761	Nov 13, 2028	DP			
	11013761*PED	May 13, 2029				
	11013762	Nov 13, 2028	DP			
	11013762*PED	May 13, 2029				
	9561251	Jan 23, 2030	DP U-1468			
	9561251*PED	Jul 23, 2030				
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	8501723	Jun 07, 2027	DP		>A> I-861	Jun 17, 2024
	8501723*PED	Dec 07, 2027			>A> PED	Dec 17, 2024
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	8501723	Jun 07, 2027	DP		>A> I-861	Jun 17, 2024
	8501723*PED	Dec 07, 2027			>A> PED	Dec 17, 2024
<u>FEXINIDAZOLE - FEXINIDAZOLE</u>						
N 214429 001					>A> ODE-359	Jul 16, 2028
<u>FINERENONE - KERENDIA</u>						
N 215341 001	>A> 8436180	Apr 12, 2029	DS DP		>A> NCE	Jul 09, 2026
<u>FINERENONE - KERENDIA</u>						
N 215341 002	>A> 8436180	Apr 12, 2029	DS DP		>A> NCE	Jul 09, 2026
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	10933147	Dec 30, 2035	U-2450			
	10953112	Nov 28, 2026	U-1879			
	10967077	Dec 30, 2035	U-2450			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 003	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 004	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007 >A>	10022510	May 18, 2031	DP			
>A>	10124131	May 18, 2031	DP			
>A>	10195375	Feb 14, 2031	DP			
>A>	10561808	Jan 01, 2032	DP			
>A>	10765820	May 19, 2025	DP			
>A>	7540282	May 06, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	>A> 8651103	Mar 26, 2028	DP			
	>A> 8714149	Feb 25, 2032	DP			
	>A> 8978966	Jan 13, 2032	DP			
	>A> 9216260	Jun 28, 2031	DP			
	>A> 9463288	May 19, 2025	DP			
	>A> 9616024	Sep 01, 2024	DP			
	>A> 9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	11033696	May 20, 2033	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGITALER</u>						
N 208799 004	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FOSCARNET SODIUM - FOSCARNET SODIUM</u>						
A 213001 001					CGT	Dec 28, 2021
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001	7504095	Jan 31, 2025	DP U-3092		NCE	Feb 26, 2026
					ODE-342	Feb 26, 2028
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212642 001					NCE	Dec 01, 2025
					W	Dec 01, 2025
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212643 001					NCE	Dec 01, 2025
					W	Dec 01, 2025
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030	U-2141		D-175	Sep 26, 2022
	10028937	Jun 10, 2030	U-2532		M-259	Apr 10, 2023
	10028937*PED	Dec 10, 2030			NCE	Aug 03, 2022
	10039754	Jun 10, 2030	U-2141		NPP	Apr 30, 2022
	10039754	Jun 10, 2030	U-2532		ODE-232	Apr 30, 2026
	10039754*PED	Dec 10, 2030			ODE-233	Apr 30, 2026
	10286029	Mar 14, 2034	U-2532		PED	Oct 30, 2022
	10286029*PED	Sep 14, 2034			PED	Feb 03, 2023
	8648037	Jan 19, 2032	DS DP U-2141		PED	Mar 26, 2023
	8648037	Jan 19, 2032	DS DP U-2532		PED	Oct 10, 2023
	8648037*PED	Jul 19, 2032			PED	Oct 30, 2026
	8937150	May 18, 2032	DS DP		PED	Oct 30, 2026
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS			
	9321807*PED	Dec 05, 2035				
	9586978	Jun 10, 2030	U-2141			
	9586978	Jun 10, 2030	U-2532			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	9586978*PED	Dec 10, 2030				
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	>A> 10028937	Jun 10, 2030	U-3167			
	>A> 10028937*PED	Dec 10, 2030				
	>A> 10039754	Jun 10, 2030	U-3167			
	>A> 10039754*PED	Dec 10, 2030				
	>A> 10286029	Mar 14, 2034				
	>A> 10286029*PED	Sep 14, 2034	U-3167			
	>A> 8648037	Jan 19, 2032	DS DP U-3167			
	>A> 8648037*PED	Jul 19, 2032				
	>A> 8937150	May 18, 2032	DS DP			
	>A> 8937150*PED	Nov 18, 2032				
	>A> 9321807	Jun 05, 2035	DS DP			
	>A> 9321807*PED	Dec 05, 2035				
	>A> 9586978	Jun 10, 2030	U-3167			
	>A> 9586978*PED	Dec 10, 2030				
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001	10894133	Jan 03, 2038	DP			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001					NPP	Dec 21, 2021
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10940110	Feb 26, 2029	DP U-1773			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10968450	Jun 28, 2025	DS DP			
	10995337	Jun 28, 2025	DP U-2675			
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001	10857159	Nov 30, 2036	DP			
	10857159*PED	May 30, 2037				
	11020407	Nov 30, 2036	DP U-3143			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 001	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 002	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 003	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 004	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>IBREXAFUNGERP CITRATE - BREXFEMME</u>						
N 214900 001	10174074	Jan 19, 2035	DS DP		NCE	Jun 01, 2026
	10370406	Jan 19, 2035	U-3159		GAIN	Jun 01, 2031
	10927142	Jan 19, 2035	DS			
	8188085	Aug 28, 2030	DS DP U-3159			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10961251	Jun 03, 2033	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10918635	Apr 30, 2030	U-1455			
	10918635	Apr 30, 2030	U-172			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIO</u>						
N 214622 001	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	8552002	Aug 25, 2029	DS DP		ODE-353	May 28, 2028
	9067896	Dec 20, 2026	DS			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIO</u>						
N 214622 002	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	8552002	Aug 25, 2029	DS DP		ODE-353	May 28, 2028
	9067896	Dec 20, 2026	DS			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	10980795	Jun 12, 2033	U-1848			
	10993914	Oct 15, 2036	DP			
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001	>A> 10688291	Dec 20, 2034	DP U-1397			
	>A> 8226971	May 06, 2025	DP			
	>A> 8389583	Aug 09, 2029	U-1397			
	>A> 8703828	May 23, 2028	DP			
	>A> 9011897	Feb 08, 2025	DP			
	>A> 9629368	May 23, 2028	U-1397			
	>A> 9844654	Apr 24, 2036	DP U-1397			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001					ODE-338	Dec 21, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003					ODE-338	Dec 21, 2027
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001 >A> 11052075		Dec 04, 2028	DP U-3181			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002 >A> 11052075		Dec 04, 2028	DP U-3181			
<u>IVERMECTIN - IVERMECTIN</u>						
A 210720 001					PC	May 29, 2021
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	11033565	Apr 22, 2024	DP			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10980788	Jun 07, 2039	U-3112			
	10980788	Jun 07, 2039	U-3113			
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025 001 >A> 11077055		Apr 21, 2036	DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10799505	Aug 15, 2036	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
LASMIDITAN SUCCINATE - REYVOW						
N 211280 001 >A> 11053214		Dec 05, 2037	DS DP U-1719			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 002 >A> 11053214		Dec 05, 2037	DS DP U-1719			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 003 >A> 11053214		Dec 05, 2037	DS DP U-1719		>A> NCE	Jan 31, 2025
>A> 7423050		Apr 06, 2025	DS DP U-1719			
>A> 8748459		Mar 27, 2023	U-1719			
LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN						
N 208259 001 10882840		Jul 11, 2026	U-1524			
11021456		Jul 11, 2026	U-1524			
11028081		Jan 27, 2030	U-1524			
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 001				>A> ODE*		Aug 28, 2026
				>A> ODE*		Aug 28, 2026
				>A> ODE*		Aug 28, 2026
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 002				>A> ODE*		Apr 07, 2024
				>A> ODE*		Aug 28, 2026
				>A> ODE*		Aug 28, 2026
				>A> ODE*		Aug 28, 2026
				>A> PED		Oct 07, 2024
LENVATINIB MESYLATE - LENVIMA						
N 206947 001 >A> 7253286		Oct 24, 2025	DS DP			
LENVATINIB MESYLATE - LENVIMA						
N 206947 002 >A> 7253286		Oct 24, 2025	DS DP			
LEUPROLIDE MESYLATE - CAMCEVI KIT						
N 211488 001 >A> 10646572		Jan 16, 2027	DP		NP	May 25, 2024
>A> 9572857		Jan 16, 2027	DP			
>A> 9744207		Jan 16, 2027	DP			
LEVONORGESTREL - MIRENA						
N 021225 001 10987244		Apr 01, 2031	DP			
LEVONORGESTREL - SKYLA						
N 203159 001 10987244		Apr 01, 2031	DP			
LEVONORGESTREL - KYLEENA						
N 208224 001 10987244		Apr 01, 2031	DP			
LIFITEGRAST - XIIDRA						
N 208073 001 >A> 11058677		Dec 18, 2033	DP			
LINAGLIPTIN - TRADJENTA						
N 201280 001 >A> 11033552		May 04, 2027	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001 10973827		Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002 10973827		Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 003 10973827		Apr 02, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001					NPP	Dec 04, 2023
<u>LISDEXAMFETAMINE Dimesylate - VYVANSE</u>						
N 021977 001	>A> 7105486	Feb 24, 2023	U-727			
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP U-842			
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023	U-842			
	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023	DP U-842			
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023	DP U-842			
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7700561	Feb 24, 2023	DP			
	>A> 7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE Dimesylate - VYVANSE</u>						
N 021977 002	>A> 7105486	Feb 24, 2023	U-727			
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP U-842			
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023	U-842			
	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023	DP U-842			
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023	DP U-842			
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7700561	Feb 24, 2023	DP			
	>A> 7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE Dimesylate - VYVANSE</u>						
N 021977 003	>A> 7105486	Feb 24, 2023	U-727			
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP U-842			
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023	U-842			
	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023	DP U-842			
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023	DP U-842			
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7700561	Feb 24, 2023	DP			
	>A> 7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE Dimesylate - VYVANSE</u>						
N 021977 004	>A> 7105486	Feb 24, 2023	U-727			
	>A> 7105486	Feb 24, 2023	U-842			
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP U-842			
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023	U-842			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLYATE - VYVANSE						
N 021977 004	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023		DP	U-842	
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023		DP	U-842	
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7700561	Feb 24, 2023		DP		
	>A> 7700561*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLYATE - VYVANSE						
N 021977 005	>A> 7105486	Feb 24, 2023		U-842		
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023		U-727		
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023		DP	U-842	
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023		U-842		
	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023		DP	U-842	
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023		DP	U-842	
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7700561	Feb 24, 2023		DP		
	>A> 7700561*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLYATE - VYVANSE						
N 021977 006	>A> 7105486	Feb 24, 2023		U-727		
	>A> 7105486	Feb 24, 2023		U-842		
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023		U-727		
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP	U-842		
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023		U-842		
	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023	DP	U-842		
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023	DP	U-842		
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7700561	Feb 24, 2023	DP			
	>A> 7700561*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLYATE - VYVANSE						
N 021977 007	>A> 7223735	Feb 24, 2023	DP			
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7655630	Feb 24, 2023	DS			
	>A> 7655630*PED	Aug 24, 2023				
	>A> 7659253	Feb 24, 2023	DS	DP	U-727	
	>A> 7659253*PED	Aug 24, 2023				
	>A> 7659254	Feb 24, 2023		U-1034		
	>A> 7659254*PED	Aug 24, 2023				
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662787*PED	Aug 24, 2023				
	>A> 7662788	Feb 24, 2023		U-727		
	>A> 7662788*PED	Aug 24, 2023				
	>A> 7671030	Feb 24, 2023	DP	U-727		
	>A> 7671030*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023		U-727		
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP	U-842		
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023		U-842		
	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023	DP			
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687466	Feb 24, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 007	>A> 7687466*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023	DP	U-842		
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7700561	Feb 24, 2023	DP			
	>A> 7700561*PED	Aug 24, 2023				
	>A> 7713936	Feb 24, 2023	U-727			
	>A> 7713936*PED	Aug 24, 2023				
	>A> 7718619	Feb 24, 2023	DP	U-842		
	>A> 7718619*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 001	>A> 7105486	Feb 24, 2023	U-727			
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7655630	Feb 24, 2023	DS	DP		
	>A> 7655630*PED	Aug 24, 2023				
	>A> 7659253	Feb 24, 2023	DS	DP	U-727	
	>A> 7659253*PED	Aug 24, 2023				
	>A> 7659254	Feb 24, 2023	U-727			
	>A> 7659254*PED	Aug 24, 2023				
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662787*PED	Aug 24, 2023				
	>A> 7662788	Feb 24, 2023	U-727			
	>A> 7662788*PED	Aug 24, 2023				
	>A> 7671030	Feb 24, 2023	DP	U-727		
	>A> 7671030*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP	U-727		
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023	U-727			
	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023	DP	U-727		
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687466*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023	DP	U-727		
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7713936	Feb 24, 2023	U-727			
	>A> 7713936*PED	Aug 24, 2023				
	>A> 7718619	Feb 24, 2023	DP	U-727		
	>A> 7723305	Feb 24, 2023	DP	U-727		
	>A> 7723305*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 002	>A> 7105486	Feb 24, 2023	U-727			
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7655630	Feb 24, 2023	DS	DP		
	>A> 7655630*PED	Aug 24, 2023				
	>A> 7659253	Feb 24, 2023	DS	DP	U-727	
	>A> 7659253*PED	Aug 24, 2023				
	>A> 7659254	Feb 24, 2023	U-727			
	>A> 7659254*PED	Aug 24, 2023				
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662787*PED	Aug 24, 2023				
	>A> 7662788	Feb 24, 2023	U-727			
	>A> 7662788*PED	Aug 24, 2023				
	>A> 7671030	Feb 24, 2023	DP	U-727		
	>A> 7671030*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023	U-727			
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP	U-727		
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023	U-727			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 002	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023		DP	U-727	
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687466	Feb 24, 2023		DP		
	>A> 7687466*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023		DP	U-727	
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7713936	Feb 24, 2023			U-727	
	>A> 7713936*PED	Aug 24, 2023				
	>A> 7718619	Feb 24, 2023		DP	U-727	
	>A> 7718619*PED	Aug 24, 2023				
	>A> 7723305	Feb 24, 2023		DP	U-727	
	>A> 7723305*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 003	>A> 7105486	Feb 24, 2023		U-727		
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7223735	Feb 24, 2023		DP		
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7655630	Feb 24, 2023	DS	DP		
	>A> 7655630*PED	Aug 24, 2023				
	>A> 7659253	Feb 24, 2023	DS	DP	U-727	
	>A> 7659253*PED	Aug 24, 2023				
	>A> 7659254	Feb 24, 2023			U-727	
	>A> 7659254*PED	Aug 24, 2023				
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662787*PED	Aug 24, 2023				
	>A> 7662788	Feb 24, 2023			U-727	
	>A> 7662788*PED	Aug 24, 2023				
	>A> 7671030	Feb 24, 2023	DP	U-727		
	>A> 7671030*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023			U-727	
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP	U-727		
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023			U-727	
	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023	DP	U-727		
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687466*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023	DP	U-727		
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7713936	Feb 24, 2023			U-727	
	>A> 7713936*PED	Aug 24, 2023				
	>A> 7718619	Feb 24, 2023	DP	U-727		
	>A> 7718619*PED	Aug 24, 2023				
	>A> 7723305	Feb 24, 2023	DP	U-727		
	>A> 7723305*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 004	>A> 7105486	Feb 24, 2023		U-727		
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7223735	Feb 24, 2023		DP		
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7655630	Feb 24, 2023	DS	DP		
	>A> 7655630*PED	Aug 24, 2023				
	>A> 7659253	Feb 24, 2023	DS	DP	U-727	
	>A> 7659253*PED	Aug 24, 2023				
	>A> 7659254	Feb 24, 2023			U-727	
	>A> 7659254*PED	Aug 24, 2023				
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662787*PED	Aug 24, 2023				
	>A> 7662788	Feb 24, 2023			U-727	
	>A> 7662788*PED	Aug 24, 2023				
	>A> 7671030	Feb 24, 2023	DP	U-727		
	>A> 7671030*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023			U-727	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 004	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP	U-727		
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023		U-727		
	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023	DP	U-727		
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687466*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023	DP	U-727		
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7713936	Feb 24, 2023		U-727		
	>A> 7713936*PED	Aug 24, 2023				
	>A> 7718619	Feb 24, 2023	DP	U-727		
	>A> 7718619*PED	Aug 24, 2023				
	>A> 7723305	Feb 24, 2023	DP	U-727		
	>A> 7723305*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 005	>A> 7105486	Feb 24, 2023		U-727		
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7655630	Feb 24, 2023	DS	DP		
	>A> 7655630*PED	Aug 24, 2023				
	>A> 7659253	Feb 24, 2023	DS	DP	U-727	
	>A> 7659253*PED	Aug 24, 2023				
	>A> 7659254	Feb 24, 2023		U-727		
	>A> 7659254*PED	Aug 24, 2023				
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662787*PED	Aug 24, 2023				
	>A> 7662788	Feb 24, 2023		U-727		
	>A> 7662788*PED	Aug 24, 2023				
	>A> 7671030	Feb 24, 2023	DP	U-727		
	>A> 7671030*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023		U-727		
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP	U-727		
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023		U-727		
	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023	DP	U-727		
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687466*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023	DP	U-727		
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7713936	Feb 24, 2023		U-727		
	>A> 7713936*PED	Aug 24, 2023				
	>A> 7718619	Feb 24, 2023	DP	U-727		
	>A> 7718619*PED	Aug 24, 2023				
	>A> 7723305	Feb 24, 2023	DP	U-727		
	>A> 7723305*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 006	>A> 7105486	Feb 24, 2023		U-727		
	>A> 7105486*PED	Aug 24, 2023				
	>A> 7223735	Feb 24, 2023	DP			
	>A> 7223735*PED	Aug 24, 2023				
	>A> 7655630	Feb 24, 2023	DS	DP		
	>A> 7655630*PED	Aug 24, 2023				
	>A> 7659253	Feb 24, 2023	DS	DP	U-727	
	>A> 7659253*PED	Aug 24, 2023				
	>A> 7659254	Feb 24, 2023		U-727		
	>A> 7659254*PED	Aug 24, 2023				
	>A> 7662787	Feb 24, 2023	DS			
	>A> 7662787*PED	Aug 24, 2023				
	>A> 7662788	Feb 24, 2023	U-727			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATED - VYVANSE</u>						
N 208510 006	>A> 7662788*PED	Aug 24, 2023				
	>A> 7671030	Feb 24, 2023	DP	U-727		
	>A> 7671030*PED	Aug 24, 2023				
	>A> 7671031	Feb 24, 2023		U-727		
	>A> 7671031*PED	Aug 24, 2023				
	>A> 7674774	Feb 24, 2023	DP	U-727		
	>A> 7674774*PED	Aug 24, 2023				
	>A> 7678770	Feb 24, 2023		U-727		
	>A> 7678770*PED	Aug 24, 2023				
	>A> 7678771	Feb 24, 2023	DP	U-727		
	>A> 7678771*PED	Aug 24, 2023				
	>A> 7687466	Feb 24, 2023	DP			
	>A> 7687466*PED	Aug 24, 2023				
	>A> 7687467	Feb 24, 2023	DP	U-727		
	>A> 7687467*PED	Aug 24, 2023				
	>A> 7713936	Feb 24, 2023		U-727		
	>A> 7713936*PED	Aug 24, 2023				
	>A> 7718619	Feb 24, 2023	DP	U-727		
	>A> 7718619*PED	Aug 24, 2023				
	>A> 7723305	Feb 24, 2023	DP	U-727		
	>A> 7723305*PED	Aug 24, 2023				
<u>LISINOPRIL - QBRELIS</u>						
N 208401 001	10940177	Nov 06, 2035	DP			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LORLATINIB - LORBRENA</u>						
N 210868 001	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-349	Mar 03, 2028
	11020376	Jul 27, 2036	DP			
<u>LORLATINIB - LORBRENA</u>						
N 210868 002	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-349	Mar 03, 2028
	11020376	Jul 27, 2036	DP			
<u>LOTEPREDNOL ETABONATE - LOTEPREDNOL ETABONATE</u>						
A 212450 001				CGT		Nov 02, 2021
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	10940108	May 03, 2033	U-2985			
	10945948	May 03, 2033	U-2985			
	10993908	May 03, 2033	U-3117			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001				ODE-339		Nov 23, 2027
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10960009	Dec 03, 2034	U-814			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	10946015	Sep 11, 2026	DP U-1445			
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB (COPACKAGED)</u>						
N 213135 001	11033498	Aug 04, 2037	U-3164			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MANNITOL - BRONCHITOL</u>						
N 202049 001					NP ODE-327	Oct 30, 2023 Oct 30, 2027
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10881663	Mar 08, 2039		U-3038		
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	10285946	Apr 25, 2032	DP		NCE ODE-348	Feb 26, 2026 Feb 26, 2028
	10322182	Apr 25, 2032	DP			
	10543274	Apr 25, 2032		U-3093		
	10869928	Apr 25, 2032	DP			
	6992207	Jun 25, 2022	DS DP	U-3093		
<u>MELPHALAN HYDROCHLORIDE - EVOMEIA</u>						
N 207155 001	10940128	Jun 14, 2030	DP	U-3086		
	11020363	May 28, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	11007206	Aug 08, 2031		U-3128	NCE GAIN	Aug 29, 2022 Aug 29, 2027
	8680136	Aug 29, 2031	DS DP			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	11020361	Dec 22, 2029		U-2843		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 001	10966990	Jun 20, 2038	DP			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 002	10966990	Jun 20, 2038	DP			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10874655	May 30, 2038	U-2371			
	10874656	May 30, 2038	U-2371			
	10874657	May 30, 2038	U-2371			
	10925866	Apr 28, 2028	U-2371			
>A>	11033538	Apr 28, 2028	U-2371			
>A>	RE48608	Feb 12, 2029	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	10946101	Oct 01, 2030	U-1631			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<u>MIRABEGRON - MYRBETRIO GRANULES</u>						
N 213801 001	10058536	Mar 31, 2036	DP U-3108		NP	Mar 25, 2024
	10058536*PED	Oct 01, 2036			PED	Sep 25, 2024
	6346532	Mar 27, 2022	DS			
	6346532*PED	Sep 27, 2022				
	7342117	Nov 04, 2023	DS			
	7342117*PED	May 04, 2024				
	7982049	Nov 04, 2023	DP			
	7982049*PED	May 04, 2024				
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10918615	Aug 12, 2035	DP U-1384			
	10918616	Jun 03, 2035	U-1384			
	10918617	Aug 10, 2035	DP			
	10945985	Aug 14, 2035	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 001					CGT	Aug 10, 2021
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 002					CGT	Aug 10, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022195 001				>A> NPP		Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022195 002				>A> NPP		Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022207 001				>A> NPP		Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022207 002				>A> NPP		Jun 02, 2024
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	10952968	May 13, 2033	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10960155	Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10960155	Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	10722510	Aug 26, 2034	DP U-3110			
	10973814	Aug 26, 2034	DP U-3110			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	10035788	Oct 15, 2028	U-2043			
	10035788	Oct 15, 2028	U-3047			
	10035788	Oct 15, 2028	U-3097			
	7982043	Oct 08, 2025	U-2043			
	7982043	Oct 08, 2025	U-3047			
	7982043	Oct 08, 2025	U-3097			
	8518446	Nov 20, 2030	DP U-2043			
	8518446	Nov 20, 2030	DP U-3047			
	8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031	U-3047			
	8790708	Nov 05, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-3047			
	8790708	Nov 05, 2030	DP U-3097			
	9139558	Oct 15, 2028	U-2043			
	9139558	Oct 15, 2028	U-3047			
	9139558	Oct 15, 2028	U-3097			
	9211291	Mar 24, 2030	U-2043			
	9211291	Mar 24, 2030	U-3097			
	9265784	Aug 04, 2029	U-3047			
	9630946	Oct 15, 2028	U-2043			
	9630946	Oct 15, 2028	U-3047			
	9630946	Oct 15, 2028	U-3097			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10961195	Sep 25, 2035	DS DP			
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 001				ODE-319		Aug 06, 2027
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 002				ODE-319		Aug 06, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
NIRAPARIB TOSYLATE - ZEJULA						
N 208447 001	8071623	Mar 27, 2031	DS DP			
NITAZOXANIDE - NITAZOXANIDE						
A 213820 001					CGT	Jun 05, 2021
NITRIC OXIDE - GENOSYL						
N 202860 001	10124142	Aug 18, 2025	U-3037			
	10814092	Oct 17, 2025	U-3037			
	10926054	Aug 13, 2029	DP			
	7947227	Oct 17, 2026	U-3037			
	8057742	Jan 18, 2026	U-3037			
	8226916	Aug 18, 2025	U-3037			
	8607785	Jul 14, 2030	DP			
	8609028	Aug 18, 2025	U-3037			
	8821801	Aug 18, 2025	DP			
	8944049	Aug 13, 2029	DP			
	9522249	Aug 18, 2025	DP			
	9701538	Jan 28, 2029	DP			
	9956373	Aug 18, 2025	U-3037			
OBETICHOLOIC ACID - OCALIVA						
N 207999 001	RE48286	Nov 16, 2027	DS DP			
OBETICHOLOIC ACID - OCALIVA						
N 207999 002	RE48286	Nov 16, 2027	DS DP			
OCTREOTIDE ACETATE - MYCAPSSA						
N 208232 001 >A> 11052126		Feb 03, 2036	U-2857			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 001	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 002	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 003	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001					NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002					NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003					NCE	Oct 30, 2025
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	8420592	Aug 29, 2029	U-3101		>A> NCE	Aug 06, 2019
	9649352	Jul 16, 2035	DS DP		NP	Mar 12, 2024
	9682061	Apr 26, 2030	U-3101		>A> GAIN	Aug 06, 2024
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	9566252	Nov 02, 2022	U-1370			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEO</u>						
N 212520 001	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031		U-2849		
	10940138	Dec 16, 2039		U-2849		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023		DP		
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023		DP		
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023		DP		
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023		DP		
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023		DP		
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023		DP		
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSTIA</u>						
N 209899 001	10239846	Nov 15, 2030		U-3132	I-860	May 27, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSTIA</u>						
N 209899 002	10239846	Nov 15, 2030		U-3132	I-860	May 27, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSTIA</u>						
N 209899 003	10239846	Nov 15, 2030		U-3132	I-860	May 27, 2024
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Nov 09, 2023	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	RE47739	Mar 05, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	RE47739	Mar 05, 2027	DS DP			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	10035822	Nov 15, 2033	DS			
	10125171	Aug 02, 2033	DS			
	10875893	Nov 15, 2033	DS U-3124			
>A>	11040107	Apr 09, 2038	DP U-3172			
>A>	11040107	Apr 09, 2038	DP U-3173			
>A>	11040107	Apr 09, 2038	DP U-3174			
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	9169307	Nov 18, 2027	DS U-3123			
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027	U-2622			
	10391075	Feb 12, 2027	U-3069			
	8778997	May 07, 2027	U-1627			
	8778997	May 07, 2027	U-2622			
	8778997	May 07, 2027	U-3069			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	10947197	Jun 09, 2037	DS DP U-3130		NCE	May 26, 2026
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3130			
	9861713	Jul 31, 2029	DS DP U-3130			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10953000	Mar 23, 2037	U-1974			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001				ODE-331	Oct 13, 2027	
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002				ODE-331	Oct 13, 2027	
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001				M-14	Nov 20, 2023	
				PED	May 20, 2024	
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002				M-14	Nov 20, 2023	
				PED	May 20, 2024	
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003				M-14	Nov 20, 2023	
				PED	May 20, 2024	
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004				M-14	Nov 20, 2023	
				PED	May 20, 2024	
<u>PONATINIB HYDROCHLORIDE - ICUSIG</u>						
N 203469 001				I-849	Dec 18, 2023	
<u>PONATINIB HYDROCHLORIDE - ICUSIG</u>						
N 203469 002				I-849	Dec 18, 2023	
<u>PONATINIB HYDROCHLORIDE - ICUSIG</u>						
N 203469 003	8114874	Jan 24, 2027	DS DP	I-849	Dec 18, 2023	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
	9029533	Dec 22, 2026		U-1283		
	9029533	Dec 22, 2026		U-1699		
	9029533	Dec 22, 2026		U-1700		
	9029533	Dec 22, 2026		U-1701		
	9029533	Dec 22, 2026		U-836		
	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PONESIMOD - PONVORY</u>						
N 213498 001	10220023	Dec 10, 2035		U-3103		
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	10220023	Dec 10, 2035		U-3103		
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	10220023	Dec 10, 2035		U-3103		
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	10220023	Dec 10, 2035		U-3103		
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	10220023	Dec 10, 2035		U-3103		
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	10220023	Dec 10, 2035		U-3103		
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	10220023	Dec 10, 2035		U-3103		
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	10220023	Dec 10, 2035		U-3103		
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 009	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					NPP >A> ODE-355	May 31, 2024 Jun 17, 2028
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	>A> 9023790	Jul 04, 2031	DP U-1698		NPP >A> ODE-355	May 31, 2024 Jun 17, 2028
	>A> 9023790	Jul 04, 2031	DP U-3160			
	>A> 9023790	Jul 04, 2031	DP U-3171			
	>A> 9358297	Jun 24, 2031	DP U-3160			
	>A> 9358297	Jun 24, 2031	DP U-3171			
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770 001					NP	May 31, 2024
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001					ODE-340 ODE-341	Dec 01, 2027 Dec 01, 2027
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	10350170	Feb 25, 2036	DP		NCE	Dec 18, 2025
	10449191	Sep 29, 2037	U-3020			
	10786501	Sep 29, 2037	U-3020			
	7300935	Jan 28, 2024	DS			
	8058280	Jan 28, 2024	DS DP			
	8735401	Feb 04, 2024	U-3019			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	11007208	Sep 16, 2036	U-2984			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	11007208	Sep 16, 2036	U-2984			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001					NCE	Oct 06, 2025
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11008289	Jul 14, 2030	U-2440			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3068			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	8314117	Feb 22, 2031	DS DP U-2718		>A> I-865	May 27, 2024
	8314117	Feb 22, 2031	DS DP U-3142			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIPRETNINIB - QINLOCK</u>						
N 213973 001	10966966	Aug 12, 2040	U-3153			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001					ODE-334	Aug 07, 2027
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	11013809	Feb 13, 2028	DP U-3135			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	11013809	Feb 13, 2028	DP U-3135			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988 001					PC	Nov 28, 2021
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988 002					PC	Nov 28, 2021
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001 >A> 11058667	9517226	May 09, 2036	U-3170	M-82		Feb 16, 2024
	9937143	Aug 22, 2033	U-3084			
		Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002 >A> 11058667	9517226	May 09, 2036	U-3170	M-82		Feb 16, 2024
	9937143	Aug 22, 2033	U-3084			
		Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003 >A> 11058667	9517226	May 09, 2036	U-3170	M-82		Feb 16, 2024
	9937143	Aug 22, 2033	U-3084			
		Aug 22, 2033	U-3084			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8283380	Mar 21, 2031	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8283380	Mar 21, 2031	U-1993			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001 >A> 10849884	>A> 10849884	Sep 04, 2035	DP U-2583			
	>A> 11000507	Sep 04, 2035	DP U-3169			
	>A> 11000507	Sep 04, 2035	DP U-2583			
	>A> 11000508	Sep 04, 2035	DP U-3169			
	>A> 11000508	Sep 04, 2035	DP U-2583			
	>A> 11020377	Sep 04, 2035	DP U-3169			
	>A> 11020377	Sep 04, 2035	DP U-2583			
	>A> 11020377	Sep 04, 2035	DP U-3169			
<u>SELENIOUS ACID - SELENIOUS ACID</u>						
N 209379 002					NCE	Apr 30, 2024
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584	ODE-346		Dec 18, 2027
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	>A> 11034660	Jul 26, 2032	U-2584			
	>A> 11034660	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	>A> 10519139	Aug 14, 2035	DS DP U-2584		ODE-346	Dec 18, 2027
	>A> 10519139	Aug 14, 2035	DS DP U-2855			
	>A> 10519139	Aug 14, 2035	DS DP U-3018			
	>A> 10544108	Jul 26, 2032	U-2584			
	>A> 10544108	Jul 26, 2032	U-3018			
	>A> 11034660	Jul 26, 2032	U-2584			
	>A> 11034660	Jul 26, 2032	U-3018			
	>A> 8999996	Sep 15, 2032	DS DP			
	>A> 9079865	Jul 26, 2032	U-2584			
	>A> 9079865	Jul 26, 2032	U-2855			
	>A> 9079865	Jul 26, 2032	U-3018			
	>A> 9714226	Jul 26, 2032	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	>A> 10519139	Aug 14, 2035	DS DP U-2584		ODE-346	Dec 18, 2027
	>A> 10519139	Aug 14, 2035	DS DP U-2855			
	>A> 10519139	Aug 14, 2035	DS DP U-3018			
	>A> 10544108	Jul 26, 2032	U-2584			
	>A> 10544108	Jul 26, 2032	U-3018			
	>A> 11034660	Jul 26, 2032	U-2584			
	>A> 11034660	Jul 26, 2032	U-3018			
	>A> 8999996	Sep 15, 2032	DS DP			
	>A> 9079865	Jul 26, 2032	U-2584			
	>A> 9079865	Jul 26, 2032	U-2855			
	>A> 9079865	Jul 26, 2032	U-3018			
	>A> 9714226	Jul 26, 2032	DS DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001					ODE-336	Nov 25, 2027
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 214805 001					>A> CGT	Jan 03, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10864181	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001					ODE*	Aug 28, 2026
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 002					ODE* ODE* PED	Apr 07, 2024 Aug 28, 2026 Oct 07, 2024
<u>SOFOSBUVIR; Velpatasvir - EPCLUSA</u>						
N 208341 001	10086011	Jan 30, 2034	U-1470		D-177	Nov 15, 2022
	10086011*PED	Jul 30, 2034			M-264	Jul 14, 2023
	8575135	Nov 16, 2032	DS DP	U-1470	NPP	Mar 19, 2023
	8575135*PED	May 16, 2033			PED	May 15, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	8735372	Mar 21, 2028	U-1470		PED	Sep 19, 2023
	8735372*PED	Sep 21, 2028			PED	Jan 14, 2024
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9757406	Jan 30, 2034	DP			
	9757406*PED	Jul 30, 2034				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002	10086011	Jan 30, 2034	U-1470		M-264	Jul 14, 2023
	10086011*PED	Jul 30, 2034			NS	Mar 19, 2023
	7964580	Mar 26, 2029	DS DP U-1470		PED	Sep 19, 2023
	7964580*PED	Sep 26, 2029			PED	Jan 14, 2024
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9757406	Jan 30, 2034	DP			
	9757406*PED	Jul 30, 2034				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001	7964580	Mar 26, 2029	DS DP U-1470			
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002	7964580	Mar 26, 2029	DS DP U-1470			
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	10912814	Jun 01, 2037	DP			
	8575135	Nov 16, 2032	DS DP U-2039			
	8575135	Nov 16, 2032	DS DP U-2040			
	8575135*PED	May 16, 2033				
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8735372*PED	Sep 21, 2028				
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	8940718*PED	May 16, 2033				
	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001	9918970	May 18, 2031	DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10912754	Jun 01, 2038	U-3082			
	10940133	Mar 19, 2040	U-3099			
	10959976	Jun 01, 2038	U-3151			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10912754	Jun 01, 2038	U-3082			
	10959976	Jun 01, 2038	U-3151			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10799138	Apr 05, 2039	U-3125			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	11013703	Apr 01, 2034	DP			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001				NCE	May 28, 2026	
				>A> ODE-352	May 28, 2028	
<u>SPINOSAD - NATROBA</u>						
N 022408 001				I-858	Apr 28, 2024	
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10888570	Oct 28, 2036	DP			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10896751	Mar 16, 2030	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001				>A> NPP	Jun 25, 2024	
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002				>A> NPP	Jun 25, 2024	
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001				ODE*	May 24, 2025	
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002				ODE*	May 24, 2025	
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003				ODE*	May 24, 2025	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10888558	Dec 02, 2035		U-2582		
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	10864159	May 28, 2029		DP U-778		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	11007156	Oct 22, 2022		DP U-1178		
	11007156	Oct 22, 2022		DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	11007156	Oct 22, 2022		DP U-1178		
	11007156	Oct 22, 2022		DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	11007156	Oct 22, 2022		DP U-1178		
	11007156	Oct 22, 2022		DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	11007156	Oct 22, 2022		DP U-1178		
	11007156	Oct 22, 2022		DP U-1276		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10610511	Oct 10, 2034	U-2615		I-850	Dec 01, 2023
	10610511	Oct 10, 2034	U-3007		ODE-330	Dec 01, 2027
	10945988	Jan 25, 2033	U-2149			
	10980770	Jan 25, 2033	U-3106			
	10980770	Jan 25, 2033	U-3107			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	10980770	Jan 25, 2033	U-3106		NP	Dec 01, 2023
					ODE-329	Dec 01, 2027
<u>TAVABOROLE - TAVABOROLE</u>						
A 211963 001					PC	Apr 17, 2021
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	>A> 10786511	Dec 19, 2035	DP			
	>A> 11052093	Apr 13, 2032	DS DP U-2736			
	>A> 11052093	Apr 13, 2032	DS DP U-3179			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					NPP	May 19, 2024
<u>TEPOTINIB HYDROCHLORIDE - TEPMETKO</u>						
N 214096 001	8329692	Oct 30, 2029	DS DP		NCE	Feb 03, 2026
	8580781	Mar 19, 2030	DS DP		ODE-325	Feb 03, 2028
	8658643	Jul 04, 2028	U-3077			
	8921357	May 30, 2028	DS DP			
	8927540	Jul 21, 2028	U-3078			
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028	U-3077			
<u>TERIFLUONOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Sep 12, 2026	U-1285		M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	9186346*PED	Aug 04, 2034				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410 6794410*PED 8802735 8802735*PED 9186346 9186346*PED	Sep 12, 2026 Mar 12, 2027 Sep 14, 2030 Mar 14, 2031 Feb 04, 2034 Aug 04, 2034	U-1285 DP U-1786		M-61 PED	Apr 30, 2024 Oct 30, 2024
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10881798 10905827 10912782	Feb 11, 2034 Aug 21, 2031 Feb 19, 2035	DP DP DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10881798 10905827 10912782	Feb 11, 2034 Aug 21, 2031 Feb 19, 2035	DP DP DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10881798 10905827 10912782	Feb 11, 2034 Aug 21, 2031 Feb 19, 2035	DP DP DP U-2418			
<u>THEOPHYLLINE - THEOPHYLLINE</u>						
A 212184 002					CGT	Dec 08, 2021
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					I-851	May 28, 2023
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002					I-851	May 28, 2023
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	10960004 RE46284 RE46284	Feb 03, 2037 Sep 22, 2029 Sep 22, 2029	U-2642 U-1751 U-2503			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	10960004 RE46284 RE46284	Feb 03, 2037 Sep 22, 2029 Sep 22, 2029	U-2642 U-1751 U-2503			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	10323001 10617693 10669236 7300931 7851470 8236799 8980890	Dec 28, 2027 Mar 12, 2038 Sep 07, 2038 Feb 06, 2026 Feb 02, 2029 Dec 28, 2025 Dec 28, 2025	DP U-3015 DS DP DS DP DS DP U-3015 DS DP DS DP		NCE	Dec 14, 2025
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987 7166722	Apr 26, 2022 Nov 16, 2023	DS DP U-3100 DS		NCE	Mar 10, 2026
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987 7166722	Apr 26, 2022 Nov 16, 2023	DS DP U-3100 DS		NCE	Mar 10, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	10905694	Apr 07, 2030	DP			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001					I-856	Mar 31, 2024
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	9498465	May 30, 2033	DP U-1033			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	10085992	Mar 14, 2034	U-3081		NCE	Feb 12, 2026
	10189849	Oct 25, 2031	DS			
	10189850	Oct 25, 2031	DP			
	10927120	Oct 25, 2031	DP			
	10966984	Mar 14, 2034	U-3079			
	10966984	Mar 14, 2034	U-3080			
>A>	11040042	Mar 14, 2034	DP			
	8598186	Oct 25, 2031	DS DP			
	8598197	Oct 25, 2031	DS DP			
	9487530	Mar 14, 2034	U-3079			
	9487530	Mar 14, 2034	U-3080			
	9957276	Oct 25, 2031	DS			
<u>UMBRALISIB TOSYLATE - UKONIQ</u>						
N 213176 001	10072013	Jul 02, 2033	U-3063		NCE	Feb 05, 2026
	10072013	Jul 02, 2033	U-3064		ODE-343	Feb 05, 2028
	10414773	May 26, 2035	DS DP U-3063		ODE-344	Feb 05, 2028
	10414773	May 26, 2035	DS DP U-3064			
	10570142	Jul 02, 2033	DS DP U-3063			
	10570142	Jul 02, 2033	DS DP U-3064			
	10947244	May 26, 2035	U-3063			
	10947244	May 26, 2035	U-3064			
	9150579	Jul 02, 2033	DS DP			
	9669033	Jul 02, 2033	U-3063			
	9669033	Jul 02, 2033	U-3064			
	9969740	May 26, 2035	DS DP U-3063			
	9969740	May 26, 2035	DS DP U-3064			
<u>UPADACITINIB - RINVOQ</u>						
N 211675 001	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10874648	Oct 10, 2037		U-1995		
	10874648	Oct 10, 2037		U-3046		
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037		U-1995		
	10912771	Oct 10, 2037		U-3076		
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040		U-1995		
	10952997	Oct 10, 2037		U-1995		
	10993941	Oct 10, 2037		U-1995		
	11026931	Aug 14, 2039		U-1995		
	11026939	Sep 18, 2038	DP	U-1995		
	11040029	Oct 10, 2037		U-1995		
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10874648	Oct 10, 2037		U-1995		
	10874648	Oct 10, 2037		U-3046		
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037		U-1995		
	10912771	Oct 10, 2037		U-3076		
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040		U-1995		
	10952997	Oct 10, 2037		U-1995		
	10993941	Oct 10, 2037		U-1995		
	11026931	Aug 14, 2039		U-1995		
	11026939	Sep 18, 2038	DP	U-1995		
	11040029	Oct 10, 2037		U-1995		
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	10065952	Oct 28, 2036	DS DP	U-1995	NCE	Apr 11, 2022
	10844058	Oct 28, 2036	DS DP	U-1995		
	10851103	Oct 28, 2036	DS DP	U-1995		
	10851104	Oct 28, 2036	DS	U-1995		
	10857137	Oct 10, 2037		U-1995		
	10857148	Oct 10, 2037		U-1995		
	10874648	Oct 10, 2037		U-1995		
	10874648	Oct 10, 2037		U-3046		
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037		U-1995		
	10912771	Oct 10, 2037		U-3076		
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040		U-1995		
	10952997	Oct 10, 2037		U-1995		
	10993941	Oct 10, 2037		U-1995		
	11026931	Aug 14, 2039		U-1995		
	11026939	Sep 18, 2038	DP	U-1995		
	11040029	Oct 10, 2037		U-1995		
	8039627	Oct 06, 2029	DS DP			
	8357697	Nov 08, 2027		U-1995		
<u>VALSARTAN - DIOVAN</u>						
N 021283 001					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 002					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 004					NPP	Apr 19, 2024
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP	U-3104		
	10959947	Mar 13, 2035	DP	U-3105		
	10959948	Mar 13, 2035	DP	U-3104		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	10993942	Sep 06, 2033	U-3114			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	10993942	Sep 06, 2033	U-3114			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	10993942	Sep 06, 2033	U-3114			
<u>VERICIGUAT - VERQUVO</u>						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VERQUVO</u>						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VERQUVO</u>						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	8247415	Dec 01, 2030	DS DP U-3045		NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
<u>VIGABATRIN - VIGABATRIN</u>						
A 211539 001					CGT	Jul 31, 2021
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033		U-727		
	9662338	Feb 07, 2033	DP			
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	10870676	Aug 31, 2031	DS DP	U-3039	ODE-280	Aug 12, 2027
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9790183	Sep 02, 2025		U-3109		
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	10286036	Dec 07, 2037		U-3056	NCE	Jan 22, 2026
	7332472	Oct 17, 2022	DS DP	U-3056		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004					M-187	Jan 22, 2024
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11020382	Dec 02, 2036		U-3133		
	11020382	Dec 02, 2036		U-3134		
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	DS DP	U-2145		
	10927117	Aug 15, 2037	DS DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41ST Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm